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Abstract 
The bioavailability of the broccoli-derived sulphur-containing compounds, glucoraphanin 
(GR), S-methyl-L-cysteine sulfoxide (SMCSO) and sulforaphane (SF), were quantified 
through a dietary intervention study in humans with the use of soups made with three broccoli 
genotypes that differed in their Myb28 alleles. One genotype was homozygous for the normal 
broccoli Myb28B allele while the other two were either heterozygous or homozygous for a 
Myb28V allele introgressed from the wild species Brassica villosa.  
Phytochemical analysis of the soups confirmed that the presence of one or more Myb28V 
alleles led to higher levels of GR. A randomised, double-blinded, three-phase, crossover study 
was employed to quantify the pharmacokinetics of GR, SF and SMCSO following 
consumption of the soups. A significantly higher plasma concentration and urinary excretion 
of GR, SMCSO and SF and metabolites occurred following consumption of broccoli soup 
derived from the Myb28B/V and Myb28V/V genotypes compared to Myb28B/B genotype. There 
was considerable inter-individual variation in the excretion of these metabolites following 
consumption of the soups, with certain volunteers having consistently higher plasma levels of 
SF and higher levels of SF excretion for each of the different phases of the study. However, 
there was no correlation between plasma and urine levels of SF with SMCSO or GR. 
The use of in vitro models indicated that intact GR and SMCSO may either require a 
transporter to diffuse across the enterocytes or diffuse paracellularly to reach the systemic 
circulation. As an initial investigation to explore the biological activity of SMCSO, 
experiments were undertaken to investigate whether SMCSO could induce nrf2-regulated 
genes within human and mouse liver cells, with the use of SF as a positive control. No gene 
induction was observed with SMCSO and it was concluded that the biological activity of 
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 Summary 
This Chapter introduces the primary focus of the thesis, sulphur-containing compounds from 
broccoli. Current knowledge regarding the synthesis and metabolism of these compounds is 
presented, followed by an overview of their bioavailability and biological activity in vitro and 
in vivo. Lack of knowledge in certain areas provides the rationale for the proposed aims of this 
thesis. 
 
 Cruciferous vegetables: sulphur compounds and their 
metabolism 
Cruciferous is a lay term referring to all species in the family Brassicaceae belonging to the 
order Brassicales. Brassicaceae consist of more than 350 genera and 3000 species [1]. One of 
the genera within this family is Brassica, which includes vegetables consumed worldwide such 
as broccoli, cabbage, cauliflower, mustard and Brussel sprouts. Other more region-specific 
vegetables, mainly consumed in Eastern countries, include Bok choy, kai-lan and kohlrabi are 
also within the Brassica genus. A unique trait shared by the order Brassicales is to synthesise 
glucosinolates. In addition to glucosinolates, Brassicaceae also contains other sulphur 
compounds including S-methyl-L-cysteine sulfoxide (SMCSO) which is also found in other 
plant families [2]. These compounds account for the distinctive taste and smell associated with 
these vegetables.  
 
 Glucosinolates 
To date, 120 glucosinolates have been identified in plants which can be classified into three 
main groups; aliphatic, aromatic, and indolic glucosinolates [1]. The synthesis of the 
glucosinolates from amino acids define which group they are categorised as. Aliphatic 
glucosinolates are mainly derived from methionine but also from isoleucine, leucine, or valine 
whereas aromatic glucosinolates are derived from phenylalanine or tyrosine, and indolic 
glucosinolates are derived from tryptophan [1]. The glucosinolates profile varies amongst the 
Brassica genus, for instance, broccoli predominantly accumulates aliphatic glucosinolates 
including 4-methylsulfinylbutyl glucosinolate (4-MSB, glucoraphanin, GR), 3-
methylsulfinylpropyl glucosinolate (3-MSP, glucoiberin), and 4-methylthiobutyl 
glucosinolate (4-MTB, glucoerucin) [3]. On the other hand, 2-propenyl glucosinolate (PROP, 
sinigrin) is the major glucosinolate in Brussel sprouts and cabbage [4]. All glucosinolates are 
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structurally similar, consisting of a β-D-glucopyranose moiety, a sulfonated oxime groups, and 
a side chain (Figure 1-1 and Table 1-1) [3,5]. Due to the acidic nature of the sulphate groups, 
glucosinolates accumulate in plants as potassium salts [6]. The proportion of glucosinolates 
present in the plant varies amongst the Brassica species and within the same plant at various 
developmental stages and plant organs (heads vs. roots) [7]. The concentration of 
glucosinolates is also influenced by other factors including environmental conditions 
(temperature, pH, moisture) and genetic variations [7]. 
 
Figure 1-1: General structure of glucosinolates. The structure consists of a β-D-
glucopyranose moiety, a sulfonated oxime groups and a variable side chain represented 
as R. Adapted from [1]. 
 
Table 1-1: Structures of the R chain of some of the glucosinolates found in Brassicaceae. 
This includes including aliphatic, indolic and aromatic glucosinolates. Adapted from 
[1,7].  
 
Glucosinolate chemical name Common name R group structure 
Aliphatic glucosinolates 
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 Glucosinolate breakdown products 
Glucosinolates per se are not bioactive compounds but isothiocyanates (ITCs), their 
breakdown product, are biologically active. In comparison to its product, glucosinolates are 
more stable and found in higher levels in plants [1]. The breakdown of glucosinolates to ITCs 
is catalysed either by the plant β-thioglucosidase enzyme, myrosinase, or by our gut bacteria. 
Myrosinase, a glycoprotein, is spatially separated from its substrate, glucosinolates. Upon 
plant damage, the myrosinase comes into contact with glucosinolates thereby catalysing the 
breakdown. The activity of the myrosinase varies between Brassica species. Wilkinson et al. 
demonstrated the activity of myrosinase ranging from 0.3 µmol/min/mg protein to 10.5 
µmol/min/mg protein from 12 cruciferous vegetables [8]. In addition, out of 18 cruciferous 
vegetable seedlings, the activity of myrosinase was highest in Daikon (280 µmol/min/mg of 
protein) [9]. 
Myrosinase appears to bind to the hydroxyl group at the C-2 position of the glucose moiety, 
cleaving the β-glucosyl moiety and releasing a β-D-glucose. In addition, an unstable 
intermediate, thiohydroxamate-O-sulfonate, is produced. Non-enzymatic re-arrangement of 
thiohydroxamate-O-sulfonate generates ITCs and releases other breakdown products 
including glucose and sulphate [1,9]. Hydrolysis of GR, a glucosinolate, results in the 
formation of the ITC, sulforaphane (SF) (Figure 1-2). 
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Figure 1-2: Hydrolysis of glucoraphanin by myrosinase to form SF, nitriles and 
thiocyanates. Re-drawn from [1,10] with permission of Elsevier and Taylor and Francis. 
 
In addition, nitriles and thiocyanates can be produced from the breakdown of glucosinolates 
(Figure 1-2). At pH 6-7, the main products are ITCs. However, under acidic or alkaline 
conditions, the production of nitriles are favoured over ITCs. Furthermore, epithiospecifier 
protein (ESP), a myrosinase co-factor, influences the production of nitriles over ITCs in fresh 
broccoli [11]. Mild cooking can denature the ESP-like protein but maintain an active 
myrosinase [12] as the ESP is not as stable as myrosinase and loses its activity at 60ºC [7]. 
However, further thermal damage such as cooking at high temperatures can denature the 
myrosinase as well as reduce glucosinolate levels [13]. Nevertheless, there is some indication 
that our gut microflora demonstrates thioglucosidase activity and thus is able to convert 
glucosinolates to ITCs. Although the mechanism remains unclear, there is evidence to support 
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in germ-free rats when orally administered with human faecal flora from healthy adult male 
or a single strain of Escherichia coli or Bacteroides [14]. Further work by Shapiro et al. in 
vivo reported an 8.7-fold decrease in the conversion of glucosinolates to ITCs upon inhibition 
of gut microflora by a combination of cleansing and antibiotics [15]. The potential role of the 
gut microflora on the breakdown of glucosinolates to ITCs is an important breakthrough in 
understanding the bioavailability of ITCs from cruciferous vegetables.  
At present, broccoli is purchased by the public either frozen or fresh. While the fresh broccoli 
contains active myrosinase, the frozen broccoli does not. Prior to freezing, broccoli undergoes 
blanching as a pre-treatment step at 80ºC for ˂3 minutes which inactivates myrosinase. It has 
been reported that the process of blanching and boiling affect the levels of glucosinolates [13]. 
Blanching resulted in a 2-37% reduction in the total levels of glucosinolates in a range of 
cruciferous vegetables whereas boiling resulted in a 35.3-72.4% loss of total glucosinolate 
levels [13].  
 
 Development of high-glucoraphanin broccoli varieties 
Compared to a wild type species of B. oleracea, commercially available broccoli (B. oleracea 
var. italica) tends to have lower levels of glucosinolates [16,17]. Through a breeding 
programme at the John Innes Centre (Norwich, UK), a hybrid cross developed by Faulkner et 
al. between B. oleracea var. italica and wild type species B. oleracea resulted in a 10-fold 
enhanced levels of total aliphatic glucosinolates relative to standard edible broccoli, 
comparable to the levels found in the wild type [16]. With promising results, further work was 
undertaken by Mithen et al. in order to naturally enhance the levels of glucosinolates in edible 
B. oleracea [17]. Hybrids were produced by cross-breeding B. oleracea var. italica with B. 
villosa, a wild type species, to introduce three genome segments from B. villosa into the 
genetic background of standard broccoli [17]. Further backcrossing produced three hybrids 
with increased levels of 4-MSB and 3-MSP compared to the commercially available species, 
two of which were commercialised as Beneforté® [18]. Through genomic analysis of the 
hybrids, it was identified that one of the introgression segments from B. villosa found in the 
hybrids contained the Myb28 allele, which encodes for the Myb28 transcription factor. As 
described by others in Arabidopsis thaliana [19], the Myb28 transcription factor is implicated 
in the regulation of glucosinolate biosynthesis. It was demonstrated that these hybrids acquired 
one Myb28 allele from B. villosa and one from standard broccoli thus represented as 
Myb28B/V. The Myb28B/V variety contained increased total sulphur and a 2.5-3-fold enhanced 
levels of GR compared to standard broccoli. However, lower levels of SMCSO were detected 
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in two of the hybrids, presumably due to increased assimilation of sulphate from the soil and 
channelling of sulphur into glucosinolate synthesis [18]. An additional variety possessing two 
Myb28V alleles, accumulating even higher levels of glucosinolates, was developed. 
 
 Sulforaphane 
Compared to the other ITCs including allyl ITC (AITC), benzyl ITC, phenethyl ITC (PEITC), 
SF is the most extensively studied ITC for its health-promoting effects. A considerable amount 
of in vivo and in vitro studies has been undertaken to explore its mechanisms. GR, the most 
abundant glucosinolate in broccoli is the precursor of SF (Figure 1-2). 
 
 Sulforaphane metabolism 
A majority of the studies have investigated the absorption of SF or other ITCs and its 
metabolism via the mercapturic acid pathway, with limited research undertaken to investigate 
the absorption of intact glucosinolates, presumably because possible absorption of intact 
glucosinolates was not considered. However, a small number of studies have measured intact 
GR indicating that GR is absorbed intact [20-22]. 
It was demonstrated that while glucosinolates are stable under acidic conditions of pH 2 in the 
stomach, only approximately 60% of intact glucosinolates reach the colon [7,23]. Following 
conversion of GR to SF in the intestinal lumen, SF is subject to absorption [7]. It is assumed 
that SF rapidly passively diffuses into the enterocytes due to its small molecular weight and 
lipophilicity [24]. Given that SF is an electrophile which can readily react with nucleophiles 
such as proteins, its central carbon reacts with the cysteine sulfhydryl group of glutathione 
(GSH) [25]. This conjugation reaction can occur non-enzymatically but is also stimulated by 
glutathione-S-transferases (GST) [25,26]. Through the use of an intestinal perfusion model, it 
was revealed that apart from the detection of conjugation to GSH, no other conjugates 
(cysteine or N-acetylcysteine) were observed in the enterocytes. This indicates that SF is 
conjugated to GSH in the enterocytes, but breakdown to other conjugates occurs elsewhere 
[27].  
There are 3 families of GSTs; cytosolic GSTs, mitochondrial GSTs, and microsomal GSTs, 
the largest group being cytosolic GSTs which occur as a dimer comprising of 17 subunits 
grouped into 7 classes [28,29]. GSTs have been researched to a great extent due to their 
abilities to conjugate to a wide range of electrophiles maintaining cellular homeostasis [28], 
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including carcinogenic metabolites and several ITCs such as SF, benzyl-ITC, PEITC and 
AITC [25]. Although extensively researched, the conjugation of only 4 cytosolic GSTs 
including M1-1, A1-1, M4-4 and P1-1 were investigated with 14 ITCs [25]. Of the 4 enzymes, 
GST M1-1 presented itself as the most effective catalyst followed by GST P1-1 [25]. However, 
SF proved to be the slowest substrate to be conjugated out of all 14 ITCs tested [25]. Although 
the ITCs were conjugated to GSH non-enzymatically, it was demonstrated that the rate of 
conjugation was augmented in the presence of GSTs.  
In the cells, reversible conjugation can occur rapidly within 30 minutes. Cells exposed to an 
extra-cellular SF concentration of 50-100 µM accumulated 95-98% as SF-Glutathione (SF-
GSH) intracellularly with about 2-5% left as free SF. When the extracellular concentration 
was increased to 500 µM, the intracellular proportion shifted to 82% SF-GSH and 11% free 
SF [30].  
SF can passively diffuse as free SF or can be transported out of cells as a GSH conjugate using 
the multidrug resistance associated protein-1 (MRP-1) and P-glycoprotein-1 (Pgp-1) 
[7,27,31], as revealed by the detection of SF-GSH in the lumen of the jejunum of 6 human 
volunteers following administration of SF from a broccoli extract [27]. In the plasma, due to 
its electrophilic nature, SF can reversibly bind to hydroxyl, sulfhydryl and amino groups of 
proteins such as albumin and glycoprotein enabling distribution around the body [32]. 
However, for SF to diffuse and accumulate in cells, they need to dissociate from proteins as 
only unbound SF compounds such as free SF can passively diffuse. Rapid distribution of ITCs 
around the body was demonstrated by administrating labelled 14C benzyl-ITC to rats. 
Following oral administration, benzyl-ITC was rapidly absorbed in the plasma within 45 
minutes followed by rapid excretion [Franklin, E. R., unpublished, cited in [33]]. In addition 
to the detection of high levels of ITCs in the sites of absorption and elimination such as GI 
tract, kidneys and liver, autoradiographic study in rats described high levels of ITCs in blood 
[Franklin, E. R., unpublished, cited in [33]]. Supporting this, another study in rats 
administrating two ITCs, 14C PEITC and 14C 6-phenylhexyl isothiocyanate (PHITC) 
demonstrated a rapid absorption of 14C PEITC with a peak plasma concentration at 2.9 hours 
but slower absorption of 14C PHITC peaking at 8.9 hours [34]. Following administration of 
14C PEITC, levels were detected in the stomach, small intestine and colon at high 
concentrations compared to lower concentrations in the pancreas and spleen and relatively 
lower in the heart and brain [34]. Peak concentrations are highly influenced by the rate of 
intestinal passage of the dose [34]. 
Following hydrolysis of GR to SF and conjugation in the enterocytes, SF undergoes 
metabolism in the liver. Similar to the conjugation process in the enterocytes, the first step of 
Chapter 1: Introduction 
10 | P a g e  
the elimination process from the body, ITCs undergo conjugation in the liver. The liver, as the 
main site of xenobiotic metabolism, encompasses high levels of GSH and the highest GST 
activity [7]. Following conjugation to SF, SF-GSH undergoes a series of enzymatic reactions 
via the mercapturic acid pathway. Firstly, the γ-glutamyl residue is eliminated by cleavage 
catalysed by γ-glutamyltransferase to produce Sulforaphane-Cysteine-Glycine (SF-Cys-Gly). 
This is followed by cysteinylglycinase catalysing the release of a glycine residue to generate 
Sulforaphane-Cysteine (SF-Cys) (Figure 1-3).  
The final fate of SF is acetylation with N-acetylcysteine catalysed by N-acetyltransferases 
yielding Sulforaphane-N-acetyl-cysteine (SF-NAC) [10], primarily occurring in the kidneys, 
the major organ involved in excretion, due to high N-acetyltransferases activity [7]. In the 
urine, approximately 40-60% of dose consumption is excreted as SF-NAC, the most prevalent 
conjugate in urine excretion [32,35,36]. Dithiocarbamates (DTCs), referring to the mercapturic 
acids SF-GSH, SF-Cys, SF-Cys-Gly, SF-NAC, and SF (Figure 1-3), are measured in the urine 
to assess the bioavailability of ITCs from cruciferous vegetable intake [10]. 
The predominate route of ITC excretion is via the urine, faeces, expiration and bile. Recovery 
of the labelled 14C benzyl-ITC in rats was approximately 92% in the urine, 6% in the faeces, 
0.4% expired in the air and 3.9 % in the bile three days following administration [33]. 
Similarly, another rat study reported 0.1% expired in the air, 89% in the urine, 10% in the 
faeces after 48 hours following administration [7]. Most of the urinary excretion of labelled 
compound occurred within 24 hours. 
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Figure 1-3: Metabolism of sulforaphane via the mercapturic acid pathway. Adapted 
from [37,38] with permission of Oxford University Press and under the terms of the 
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 S-methyl-L-cysteine sulfoxide 
Other than glucosinolates, many cruciferous vegetables have abundant levels of the amino acid 
derivative, 3-methylsulphinyl alanine, SMCSO, first identified to occur naturally in Brassica 
in 1956 [2].Compared to total glucosinolates, accounting for 0.1-0.6% dry weight in Brassica 
vegetables, SMCSO was quantified at higher levels, representing 1-2% of dry weight [2]. 
Other than Brassica vegetables, SMCSO is found in Fabaceae and Alliaceae. SMCSO, a 
secondary metabolite in plants, was implicated in the role of pathogenesis prevention by acting 
as a phytoalexin with anti-microbial activity. In ruminant animals, it was identified as a 
toxicant resulting in severe haemolytic anaemia, known as the ‘kale anaemia factor’ following 
consumption of Brassica crops, however, in humans, it has been associated to have potential 
health benefits but remains unclear due to limited research undertaken. 
 
 S-methyl-L-cysteine sulfoxide synthesis 
Synthesis of SMCSO in plants is largely dependent on the assimilation of inorganic sulphate 
from soil. Inorganic sulphate is converted to 5-adenylsulphate then reduced to sulphite and 
sulphide. The sulphide reacts with O-acetylserine to yield cysteine and acetate. The proposed 
mechanism is the methylation of the cysteine producing S-methyl-L-cysteine followed by 
oxygenation of the sulphur yielding SMCSO [39]. In contrast, others have suggested a reaction 
between serine and methyl mercaptan followed by the oxygenation of sulphur from the 
thiomethyl moiety of methionine [2]. By feeding plants with labelled substrates either [14C]-
serine or [35SO4], it was demonstrated that SMCSO is synthesised via cysteine and via serine 
[2]. 
 
 S-methyl-L-cysteine sulfoxide metabolism 
Like glucosinolates and myrosinase, SMCSO and the enzyme that catalyses its breakdown, 
cysteine β-lyase, are separated in plants. Upon damage to the plant, cysteine β-lyase encounters 
SMCSO and hydrolyses it to yield ammonia, pyruvate and methanesulphenic acid [40]. Given 
that methanesulphenic acid is a highly reactive intermediate, it undergoes further reactions 
depending on various conditions to generate other products [41]. As such, disproportionation 
of methanesulphenic acid results in the formation of methanethiol and methane sulphinic acid 
whereas dimerisation produces S-methyl methanethiosulphinate (dimethyl disulphide 
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sulphoxide, MMTSI) as illustrated in Figure 1-4 [40]. Using an enzymatic model comprising 
incubation of SMCSO and a purified cysteine β-lyase at 35ºC showed an increase in the 
formation of SMCSO-derived products, MMTSI, and pyruvate over 24 hours [41]. However, 
production of S-methyl methanethiosulfonate (dimethyl disulphide sulphone, MMTSO) was 
not detected until the 24-hour time-point at a relatively lower concentration compared to the 
formation of MMTSI (9.55 µM MMTSO vs. 1.72 mM MMTSI at 24 hours) [41]. Further, over 
24 hours, SMCSO levels were significantly reduced by 52% at pH 4.4 and further reduced by 
94% at pH 8.0 while the production of MMTSO increased. This indicates that both pH and 
time influence the degradation of SMCSO and formation of products as well as implicating 
the role of cysteine β-lyase in said breakdown [41]. Disproportionation of MMTSI generates 













Figure 1-4: S-methyl-L-cysteine sulfoxide metabolism by cysteine β-lyase to form 
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In addition to cysteine β-lyase being present in the plants, activity of cysteine β-lyase was 
established within the enteric bacterial population commonly found in the human intestines. 
Of 29 strains, 22 showed high substrate activity. However, the test compounds used in that 
investigation were S-methyl-L-cysteine and other cysteine conjugates, rather than SMCSO 
[42]. Recently, mammalian amino acid transferases including kynurenine aminotransferases 
(KAT I, II and IV) and glutamine transaminase K (GTK) have been identified as enzymes 
exhibiting cysteine β-lyase activity. Based on substrate specificity and subunit composition, it 
was demonstrated that KAT III is identical to the cysteine β-lyase isoform CCBL2, and KAT 
I is identical to the isoform CCBL1 [43] though the substrates used did not include SMCSO. 
Regardless, there are indications that there are enzymes/gut bacteria capable of hydrolysing 
SMCSO. Like myrosinase (the enzyme that catalyses glucosinolates), plant cysteine β-lyase 
could also be denatured when cooked thus relying on the gut bacteria to catalyse the 
breakdown [2]. 
 
 Cruciferous vegetables: the bioavailability of sulphur compounds 
The amount of the ingested dose that is absorbed by the body and reaches the systemic 
circulation is termed as bioavailability of compounds including drugs and dietary nutrients. 
Bioavailability of said compounds is influenced by the food matrix, absorption efficiency of 
individuals, distribution around the body and excretion. Doses that reach the systemic 
circulation after first-pass metabolism via the the liver circulate and reach target tissues [7]. A 
dose that reaches the target tissue is said to be physiologically relevant. However, many in 
vitro studies employ doses of SF that are not achievable in vivo after first-pass metabolism. 
The following sections discuss methods to assess the bioavailability of compounds using in 
vitro models and human intervention studies. While human intervention studies provide an 
insight into the absorption and metabolism of compounds, in vitro models address the transport 
mechanisms used by the compounds. 
 
 Transport and bioavailability of compounds using in vitro 
models  
The permeability of compounds across the biological membrane is a fundamental factor 
considered when developing drugs and determining their pharmacokinetics [44]. The 
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composition of membranes defines the movement of compounds through them. Biological 
membranes consist of a phospholipid bilayer with cholesterol and transporters. In vitro models 
have been developed to mimic such membranes and can be used in the investigation of 
bioavailability of compounds. 
 
 Transport mechanisms across biological membranes 
Three of the main transport mechanisms across membranes are passive transport 
(transcellular), active transport (transcellular) and the paracellular route via tight junctions. 
Passive transport follows the concentration gradient which either permeates across by simple 
diffusion or by non-specific carrier protein-mediated diffusion (facilitated diffusion) or 
filtration. Transport across membranes against the concentration gradient is via active 
transport using a specific transporter. 
Parameters including lipophilicity, molecular weight, and polarity define diffusion of 
compounds [45]. Lipophilicity of compounds is expressed as the octanol/water partition 
coefficient [log10 pc]. A log10 pc <0 means that a compound is hydrophilic (lipophobic), 
whereas a log10 pc >0 means that a compound is hydrophobic (lipophilic). Lipophilic 
molecules tend to passively diffuse across membranes in and out of cells, whereas hydrophilic 
molecules cannot diffuse across the membrane without specific transporters. Polar surface area 
of compounds is another factor considered for intestinal permeability. The polar surface area 
is the total surface area of polar atoms such as nitrogen, oxygen and hydrogen. Compounds 
with a polar surface area of <60 A2 are well absorbed in the gut with 90% absorbed whereas 
compounds with higher polar surface area (<140 A2) correlates with poorer absorption of 
<40% in the gut [46,47]. A polar surface area of 140 A2 is the highest boundary for compounds 
to be considered to be absorbed by gut cells [46]. 
It has generally been assumed that SF passively diffuses into the enterocytes due to its 
lipophilic nature and its small molecular weight of 177.29 g/mol [27]. Given that SF has a 
log10 pc of 0.72 classifying it as a lipophilic molecule implies that it can passively diffuse 
across a membrane [24]. On the other hand, GR is hydrophilic with a log10 pc of -3.8, thus 
potentially requiring a transporter to cross the membrane [24]. The log10 pc of SMCSO has not 
been calculated nor published elsewhere. In terms of the broccoli-derived compounds, SF, GR 
and SMSCO have a polar surface area of 80.7 A2, 236 A2 and 99.6 A2, respectively. Taking 
into consideration their polar surface areas, it can be hypothesised that SMSCO, like SF, could 
be absorbed via passive diffusion (area <140 A2). 
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 In vitro models to study transport mechanisms 
 Human epithelial colorectal adenocarcinoma cells 
The caco-2 cell-line is human epithelial colorectal adenocarcinoma cells. It originates from 
colon cancer and was first developed by Fogh et al. in the 1970s [48-50]. Over 21 days of 
culture, caco-2 cells can differentiate to columnar epithelial cells expressing microvilli, tight 
junctions, and alkaline phosphatase (brush border enzyme), resembling enterocytes [50-52]. 
In addition, caco-2 cells express transporters on both the apical and basolateral membrane [51]. 
While caco-2 cells are a useful model to investigate transport of compounds, there are 
limitations associated with the model. Some of these include (i) higher trans-epithelial 
electrical resistance (TEER) values in comparison to the human intestines; (ii) multilayer 
growth of cells, representing only one of the types cells expressed in human gut, and (iii) lack 
of mucus [47]. It has been observed that data obtained by using the caco-2 models are difficult 
to reproduce due to variation in the experimental conditions between different laboratories in 
terms of culture conditions, passage numbers and type of culturing plates (transwell plates 
with different membrane pore size and area) [50,53]. Furthermore, older passage number 
greatly increases the risk of cells growing in multilayers, as well as affecting TEER and 
markers expressed by enterocytes [50]. For this reason, comparison between data from caco-
2 with older passage and younger passage has to be handled with caution [50].  
 
 Parallel artificial membrane permeability assay 
Commonly used by pharmaceutical companies, the parallel artificial membrane permeability 
assay (PAMPA) was first established by Kansy et al. to investigate the permeability of 
compounds across membranes [54]. It was aimed to be suitable for high throughput and less 
laborious in comparison to culturing and performing transport experiments using caco-2 cells 
[54]. It was designed to correlate with oral permeability as well as provide a stable membrane 
mimicking the phospholipid layer. 
Over the last few years (1998-2008), the PAMPA assay has been developed, most notably by 
modifications to the membrane. Historically, when first introduced, the original Kansy 
PAMPA model required pre-coating of the plates with phospholipids (1-20% lecithin in an 
organic solvent) by users causing significant inter-laboratory and intra-laboratory variations 
[54]. Concerns were also raised in terms of the lipid bilayer composition consisting of 
phosphatidylcholine and alkane or alkylidene that was found responsible of under-/over-
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prediction of oral bioavailability. [55]. Modification to the phospholipids was the practical 
option proposed to overcome these issues [55]. Various modifications were made to the lipid 
composition including a lipid membrane comprising of 2% (w/v) dioleyoylphosphatidyl-
choline (DOPC) in dodecane solution [56], 20% (w/v) dodecane solution in lecithin mixture 
developed by pION Inc [57], a mixture of phosphatidylcholine, phosphatidylethanolamine, 
phosphatidylserine, phosphatidylinositol and cholesterol in an organic solvent to mimic the 
intestinal membrane by Sugano et al. [55]. However, poor predictability of permeability was 
still an issue due to the pre-coating requirement by users and the lipid compositions of 
membranes [58]. This was solved by developing a pre-coated membrane ready to use with a 
lipid-oil-lipid tri-layer, manufactured as the BD Gentest™ PAMPA assay developed by BD 
Bioscience [58], later acquired by Corning®. 
The Gentest™ PAMPA assay is a validated assay comprising of pre-coated plates with a lipid-
oil-lipid bilayer. The formation of the lipid-oil-lipid layer consists of introducing 1 µl 
hexadecane into the polyvinylidene fluoride (PVDF) membrane to form the oil layer coated 
with 40 µg of phospholipids mixture either side of the oil layer. This assay has been optimised 
and validated by Chen et al. [58]. The optimisation of this assay was undertaken by testing a 
wide range of compounds (n=12) that are not actively transported. Data from the Gentest™ 
PAMPA assay was compared with already known permeability coefficient with those obtained 
from the caco-2 model and two different lipid-solution based PAMPA methods (2% (w/v) 
DOPC in dodecane solution and 20% (w/v) dodecane solution in lecithin mixture). It was 
reported that the lipid-solution based PAMPA models have under predicted the permeability 
of some compounds possibly due to excess solution in the membrane. The predictability of the 
permeability of compounds was improved with the Gentest™ PAMPA assay due to its lipid-
oil-lipid membrane. The permeability of compounds from the Gentest™ PAMPA assay 
correlated well with the permeability obtained from the caco-2 model and the human 
absorption data. Thus, the tri-layer mimics the biological membrane and generates 
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 Bioavailability in humans 
 Glucoraphanin and sulforaphane bioavailability in humans 
With a lot of interest regarding SF due to its possible health-promoting effects, it is 
unsurprising that clinical studies have been undertaken to identify the pharmacokinetics of SF 
from dietary sources. The extent of absorption and metabolism are key parameters in defining 
the bioavailability of compounds. Particularly, identifying concentrations of SF achievable in 
vivo is critical for exploring the mechanistic role of SF. A considerable amount of published 
research has been undertaken in vivo and in vitro using a range of SF or GR doses. A summary 
of 16 in vivo studies undertaken measuring mercapturic acids as DTCs or as SF and SF 
conjugates, in plasma and urine following consumption of SF or GR in the form of raw 
broccoli, cooked broccoli, capsules or soups is presented in Table 1-2. At present, in clinical 
studies, the urinary excretion of ITCs and conjugates is used directly as a measure of 
bioavailability of compounds derived from cruciferous vegetable intake [7]. This was 
confirmed as a good measure based on the positive correlation demonstrated between 
cruciferous vegetable intake and urinary excretion of ITCs [59]. However, to gain an insight 
into phase I metabolism of ITCs, a full metabolite analysis of blood, urine and faeces needs to 
be accomplished [7]. 
Initially, the total DTCs were measured using a method, known as cyclocondensation, first 
developed by Zhang et al. [60] and later modified within the same group, that enabled 
quantification via high-performance liquid chromatography (HPLC) or spectroscopy [61]. 
This method provides a quantitative measure of all ITCs present in plasma, urine and other 
samples. However, it does not allow identification of individual metabolites. Since then, a 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed by 
Vermeulen et al. [62] specific to measure N-acetylcysteine conjugates. Janobi et al. established 
a LC-MS/MS method to quantify individual mercapturic acids in plasma and urine samples 
following broccoli consumption [63]. 
The consensus observed from the in vivo studies was rapid absorption and excretion of SF and 
conjugates following direct consumption of SF compared to GR, the precursor. Results have 
consistently reflected that bioavailability of SF is 4-7 times higher upon direct oral 
consumption of SF versus consumption of GR (which must be converted to SF by the gut 
microbiota) [10,32,35,62,64-69]. As highlighted by others, the bioavailability of SF from GR 
is limited to the passage of GR through the gastrointestinal tract to the colon and is reliant on 
the gut microflora for the hydrolysation of GR to SF. Presumably, this takes time, and the gut 
microflora is not as efficient as myrosinase in converting glucosinolates to ITCs, resulting in 
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lower bioavailability. In contrast, bioavailability of SF from direct oral consumption of SF is 
dependent on the diffusion of SF across enterocytes and absorption by the jejunum without the 
dependence on the gut microflora [27]. Supporting this notion, several studies reported higher 
percentage of SF and conjugates recovered in urine (30-80%) following direct oral 
consumption of SF from raw broccoli, capsules, or extracts with intact myrosinase 
[10,32,35,36,38,65-71]. Rapid absorption of SF occurred with levels reaching 0.2-1.9 µM in 
the plasma [64,68,72] at 2-3 hours after oral SF consumption [32,38,68-71]. On the other hand, 
only ≤10% of ingested GR, in the form of cooked broccoli or extracts with inactivated 
myrosinase, was recovered as SF and conjugates [22,32,66-68,71], peaking much later around 
4-6 hours [32,36,65,68,71] with low levels in the plasma of 0.02 µM [68]. In congruence with 
the plasma levels, urinary excretion peaks earlier following direct consumption of SF 
compared to GR [36,64,65,68,69,71]. 
The variation in urinary excretion reported within and amongst all the studies identified in 
Table 1-2 is large irrespective of whether SF or GR was consumed. Fahey et al. reported an 
excretion of 48-96% of ingested SF [70] and excretion of 1-40% of ingested GR [66]. In 
accordance, Conway et al. reported an excretion of 14.2-61.8% and 3.8-24.6% following 
consumption of SF and GR respectively [32]. The variance in the urinary excretion was 
considerably lower following consumption of SF than following consumption of GR [22,70]. 
The variation in the recovery of SF following consumption of GR can be attributed to the 
reliance on the gut microflora, which is diverse and varies from individual to individual. In 
contrast, the variation observed in the recovery of SF following oral SF consumption cannot 
be justified by the gut microflora given that SF is directly absorbed without hydrolysation. 
Effective absorption of SF in an in vivo jejunum was demonstrated with 74% of SF passively 
diffusing [27].  
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Table 1-2: Summary of clinical studies investigating bioavailability of sulforaphane either from consumption of the precursor, glucoraphanin or 
sulforaphane in the form of various matrices 
 
Reference Intervention Findings 
  DTCs measured in 24h urine: 
Fahey et al. (2017) [70] Prostaphane® tablets x 2: 100 µmol SF 
SF preparation in an α-cyclodextrin inclusion (SF-αCD): 200 µmol 
SF 
Prostaphane®:67.4 µmol (71% of dose) 
SF-αCD: 124.6 µmol (62.3% of dose) 
  DTCs measured in 24h urine: 
Fahey et al. (2015) [66] GR-rich BSE extract: 50 µmol, 69 µmol, 230 µmol GR 
Onco-PLEX™ capsules (broccoli seed extract):69 µmol, 230 µmol 
GR 
 
Freeze-dried broccoli sprouts (pre-hydrolysed with active 
myrosinase): 100 µmol GR + 49.6 µmol DTCs  
 
Freeze-dried broccoli sprouts (with active myrosinase, not pre-
hydrolysed): 100 µmol GR + no DTCs 
 
Broccoli seed powder (active myrosinase): 100 µmol GR + No 
DTCs 
 
GR-rich BSE extract: 4.7 μmol (9.4% of 50 µmol dose) 
Onco-PLEX™ capsules: 11.2% of 69 µmol and 9.7% of 
230 µmol 
Freeze-dried broccoli sprouts (pre-hydrolysed with active 
myrosinase): 41.8 µmol (41.8% of GR dose, 84% of DTC 
dose) 
 
Freeze-dried broccoli sprouts (with active myrosinase, not 
pre-hydrolysed): 42.8 μmol (35.1% of dose) 
 
Broccoli seed powder (active myrosinase): 32.6% of dose 
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Reference Intervention Findings 
  SF and conjugates measured: 
Atwell et al. (2015) [72] Broccoli seed extract (BroccoMax™): 224 mg GR  
Placebo: no GR 
Broccoli seed extract (BroccoMax™): Total SF and 
metabolites; 0.27 µM in plasma, 109.7 µmoles in 48h 
urine 
Placebo: 0 µM SF and conjugates in urine and plasma 
  SF and conjugates measured: 
Atwell et al. (2015) [64] Broccoli sprout extract treated with myrosinase: 200 µmol SF 
Fresh broccoli sprout: 200 µmol SF 
Broccoli sprout extract treated with myrosinase: Cmax 0.7 
µM in plasma, AUC: 13.8, Tmax: 3h, 109.7 µmoles in 48h 
urine 
Fresh broccoli sprout: Cmax 1.9 µM in plasma, AUC: 3.0, 
Tmax: 3h, 345.7 µmoles in 48h urine 
  SF and conjugates in 24h urine: 
Oliviero et al. (2014) [67] Broccoli powder with 100% myrosinase activity: 73 µmol GR + 
34.0 µmol SF 
Broccoli florets with 100% myrosinase activity: 73 µmol GR + 11.1 
µmol SF 
Broccoli florets with 80% myrosinase activity: 69 µmol GR + 6.7 
µmol SF 
Broccoli powder with 100% myrosinase activity: 40 µmol 
SF (58% of dose) 
Broccoli florets with 100% myrosinase activity: 23 µmol 
SF (33% of dose) 
Broccoli florets with 80% myrosinase activity: 15 µmol 
SF (22% of dose) 
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Reference Intervention Findings 
Broccoli florets with 2% myrosinase activity: 67 µmol GR + 2.8 
µmol SF 
Broccoli florets with no myrosinase activity: 72 µmol GR + 0.3 
µmol SF 
Broccoli florets with 2% myrosinase activity: 11 µmol SF 
(17% of dose) 
Broccoli florets with no myrosinase activity: 7.1 µmol SF 
(10% of dose) 
  SF and conjugates measured: 
Saha et al. (2012) [68] Fresh broccoli soup: no GR and 23.5 µmoles SF 
Frozen broccoli soup: 42.5 µmoles GR and no SF 
Fresh broccoli soup: Cmax 0.21 µM in plasma, 14 µmol in 
urine (58.5% of dose) 
Frozen broccoli soup: Cmax 0.025 µM in plasma, 2 µmol 
in urine (9.6% of dose) 
  DTCs measured:  
Fahey et al. (2012) [73] Broccoli sprout extract (a): 200 µmol GR 
Broccoli sprout extract (b): 400 µmol GR 
Broccoli sprout extract (a): 23.5 µmol in 24h urine 
(11.8% of dose)  
Broccoli sprout extract (b): 42.1 µmol in 12h urine 
(10.4% of dose) 
  SF-NAC excreted in 24h urine: 
Cramer et al. (2011) [36] Broccoli sprouts with active myrosinase: 74 µmol SF 
Broccoli sprout powder without myrosinase: no SF  
Fresh broccoli sprouts with active myrosinase: 52 µmol 
(74% of dose)  
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Reference Intervention Findings 
Combination of both: 120 µmol SF 
 
Broccoli sprout powder: 22.6 µmol (19% of dose)  
Combination: 93.8 µmol (49% of dose) 
  SF and conjugates measured in 24h urine: 
Clarke et al. (2011) [69] Broccoli sprout with activated myrosinase: 150 µmol GR 
BroccoMax™ pills with inactivated myrosinase: 121 µmol GR 
Broccoli sprouts: 74% of dose  
BroccoMax™ pills: 19% of dose  
  SF and conjugates measured in 24h urine: 
Clarke et al. (2011) [65] Broccoli sprout with activated myrosinase: 218.4 µmol GR 
BroccoMax™ pills with inactivated myrosinase: 220.3 µmol GR  
Broccoli sprout: 192 µmol (96% of dose) 
BroccoMax™ pills: 41.3 µmol (19% of dose) 
  SF and conjugates measured in 12h urine: 
Egner et al. (2011) [22] GR-rich sprout beverage: 800 µmol GR 
SF-rich sprout beverage:150 µmol SF 
GR-rich sprout beverage: 5% of dose  
SF-rich sprout beverage:70% of dose  
  SF and conjugates measured in 24h urine: 
Vermeulen et al. (2008) 
[71] 
Cooked broccoli: 61.4 µmol GR 
Raw broccoli: 9.92 µmol SF 
Cooked broccoli: Cmax, 0.031, Tmax: 6h, 3.4% of dose 
excreted in urine 
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Reference Intervention Findings 
Raw broccoli: Cmax, 0.103, Tmax: 1.6h, 37% of dose 
excreted in urine 
  DTCs measured in 8h urine: 
Shapiro et al. (2006) [10] Broccoli sprout extract: 525 µmol glucosinolates over 7 days 
Broccoli sprout extract: 2,100 µmol glucosinolates over 7 days 
Broccoli sprout extract: 525 µmol ITCs over 7 days 
Broccoli sprout extract: 17.8% of dose 
Broccoli sprout extract: 19.6% of dose 
Broccoli sprout extract: 70.6% of dose 
  DTCs measured in 12h urine: 
Kensler et al. (2005) [74] Broccoli sprout infusions: 400 µmol GR Broccoli sprout infusions: 49µmol (12% of dose) 
  SF and conjugates excreted in 24h urine: 
Gasper et al. (2005) [38] Standard broccoli soup: 101.3 µmol SF 
Super broccoli soup: 344.25 µmol 
Standard broccoli: Cmax: 2.3, Tmax: 1.5h, 82% of dose in 
the urine as SF and conjugates 
Super-broccoli: Cmax: 7.3, Tmax: 2.0h, 55% of dose 
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Reference Intervention Findings 
  Total ITCs excreted in 24h urine: 
Conway et al. (2000) [32] 200g Fresh broccoli: 0.48 µmol GR/g 
200g Steamed broccoli: 0.46 µmol GR/g 
Fresh broccoli: 68.1 µmol (32.3% of dose) 
Steamed broccoli: 20.6 µmol (10.2% of dose) 
This list is not exhaustive and it has been modified from the table from Houghton et al. [75]  with permission of Oxford University Press. 
Abbreviations used: DTC, dithiocarbamate; GR, glucoraphanin; SF, sulforaphane; ITC, isothiocyanate; SF-NAC, sulforaphane-N-acetylcysteine  
The following search terms were used on PubMed: ‘sulforaphane’ and ‘bioavailability’ and ‘humans’. Results were manually curated for relevance. 
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 Genetic polymorphisms in Glutathione-S-transferases 
Considerable variations have been reported from clinical studies in the urinary excretion of 
SF and conjugates. This is highly influenced by the gut microflora, as well as genetic 
predispositions concerning genes involved in phase I and phase II metabolism resulting in 
interindividual variations [7]. Although it is clear that the gut microflora is required for the 
conversion of GR to SF and thus influences the variation in urinary excretion [15], Egner et 
al. observed variations regardless of whether the individuals consumed GR or SF, implying 
that another factor such as genetic polymorphisms could contribute to the interindividual 
variation observed [22]. 
Genetic polymorphisms have been identified in cytosolic GST, a phase I enzyme catalysing 
the conjugation of ITCs with GSH, resulting in the encoding of either an enzyme with reduced 
activity or no production of the enzyme [28]. Deletions in the GSTM1 and GSTT1 gene results 
in the null variants thus those homozygous for GSTM1-null, or GSTT1-null cannot produce 
the enzyme [28], with approximately 50% of the Caucasians homozygous for GSTM1-null 
[76]. Given the crucial role of GSTs in detoxification of electrophiles, it was presumed that 
individuals with polymorphisms in GST genes could be more susceptible to cancers [28]. 
Although this notion was supported by epidemiological studies [77-79], there are 
discrepancies between findings.  
In theory, individuals with the null variants do not produce the GST enzyme. Thus, there is no 
conjugation of ITCs to GSH, and consequently, the excretion of ITCs is slower, exposing 
those individuals to ITCs for a longer period. Lin et al. first reported that subjects with 
GSTM1-null genotype had the lowest adenoma prevalence with high broccoli intake [80]. In 
contrast to the theory that GSTM1-null would retain ITCs and excrete slower, Gasper et al. 
observed a faster and greater urinary excretion of ITCs in individuals with GSTM1-null 
genotype compared to GSTM1-positive genotype [38]. Epidemiological studies from the US 
reported that with high cruciferous vegetable intake GSTM1-positive individuals gain greater 
protection against cancer risk [78,81]. In contrast, Vogtmann et al. reported no inverse 
associations between the risk of colorectal cancer and cruciferous vegetable intake in 
individuals with GST polymorphisms [82]. Similarly, Steck et al. observed no associations 
between breast cancer risk and consumption of cruciferous vegetables when stratified to the 
GST genotype [83]. In agreement, following consumption of GR or SF, no significant 
differences in the urinary excretion of ITCs were observed in two other studies when stratified 
to the GST genotype [22,68] contradicting the findings by Gasper et al. [38]. One limitation 
with regards to the studies discussed above is that most of the studies were retrospectively 
genotyped and therefore not powered for the genotype classification. With contradictory 
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findings from epidemiological and clinical studies, the effect of GST polymorphisms and 
cancer risk with higher cruciferous vegetable intake remains controversial.  
 
 S-methyl-L-cysteine sulfoxide bioavailability in humans 
Inorganic sulphate has been shown to be poorly absorbed despite being needed to produce 
sulphate containing compounds essential for human functions. Thus, most of the sulphate 
required is acquired from protein, mainly via sulphur containing amino acids including 
methionine and cysteine. It is presumed that the degradation and oxidation of the sulphur 
moiety of these amino acids contributes to the sulphate pool, with cysteine being the major 
source. In addition to amino acids, S-substituted cysteine molecules namely SMCSO and S-
carboxymethyl-L-cysteine have been indicated to contribute to the sulphate pool [84]. The 
metabolism of SMCSO has previously been investigated by employing labelled [35S]-SMCSO 
in a human study and measuring radioactivity recovered in urine and faeces. Administration 
of 200 mg labelled [35S]-SMCSO to 4 male volunteers resulted in a 96% recovery of [35S] in 
0-14 days [84]. Excretion of the [35S] over 3 days appeared to occur predominantly via urine, 
with 77% recovered via this route and a significantly smaller amount (1.8%) excreted via 
faeces. Within the first 24 hours, approximately 60% of [35S] was recovered in urine. Of the 
ingested [35S]-SMCSO, 16% and 26% of radioactivity was recovered as inorganic sulphate in 
24 hours and 3 days respectively, supporting the proposed mechanism of S-substituted 
cysteine molecules degrading to sulphate. Presumably, the acute dosing of SMCSO is not 
contributing to sulphate/sulphur containing molecules needed for human functions as a high 
percentage of the ingested [35S]-SMCSO was excreted in urine as [35S] and sulphate [84]. 
Despite the described studies, the metabolism and bioavailability of SMCSO in humans 
remains unclear due to limited research. Further work needs to be carried out to gain an 
understanding into the metabolism of SMCSO and whether products such as MMTSI and 
MMTSO are produced.  
 
 Cruciferous vegetables: health benefits through observational 
and experimental evidence 
Regarding cruciferous vegetables, especially broccoli, as ‘superfood’ has originated from 
observational studies reporting associations between the intake of cruciferous vegetables and 
reduction of chronic disease risks. To elucidate the underlying mechanisms involved for the 
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protective effects associated with cruciferous vegetables, several animal and in vitro studies 
have been performed. The biological activity of two sulphur compounds; SF and SMCSO are 
discussed below. 
 
 Epidemiological evidence for cruciferous vegetable intake and 
chronic diseases 
At present, chronic diseases including cancers, cardiovascular and type 2 diabetes are amongst 
the leading causes of death worldwide. Genetic predisposition highly influences the 
development of these diseases. However, it can still be reduced by lifestyle and dietary 
choices. Exploring the underpinning role of dietary intake with regards to the risks of 
developing chronic diseases is of high priority. It is widely known that the intake of fruit and 
vegetables is implicated with potential health benefits due to the presence of bioactive 
compounds, vitamins, fibre and other mineral elements. In particular, intake of cruciferous 
vegetables has been associated with a reduced risk of several types of cancers, cardiovascular 
diseases [85], and other chronic diseases, evidenced by considerable amount of 
epidemiological studies. Some of these cancers include lung cancer [86-88], breast cancer 
[89,90], prostate cancer [91,92], and colon cancer [93]. However, there are contradictions 
between epidemiological studies in regards to cruciferous vegetable intake and chronic disease 
risks. In the example of lung cancers, only three epidemiological studies demonstrated an 
inverse association between cruciferous vegetable intake and lung cancer risk [86-88], while 
other studies described insignificant associations [94-96]. There is a discrepancy between the 
studies that have reported associations. Feskanich et al. reported 26% lower risks of lung 
cancer (Relative risk= 0.74) in women with the highest intake of cruciferous vegetables (>4.8 
servings/week) and no inverse associations observed in men [87]. Further, Lam et al. reported 
a significant inverse association between the highest intake of cruciferous vegetables and lung 
cancer risk in women (Odds ratio=0.57 Q4 vs. Q1) [88]. On the other hand, Mori et al. reported 
an association between the highest intake of vegetables and a decrease in the risk of lung 
cancers in non-smoking men (Hazard ratio=0.85) [86]. As emphasised by Feskanich et al., 
confounding factors such as smoking have a huge impact on assessing relative risks of 
developing lung cancer [87]. This also supports the recommendation to treat evidence from 
epidemiological studies with caution as dietary intake and other influential factors such as 
smoking vary. Importantly, the intake of cruciferous vegetables differs between the western 
and eastern countries evidenced by the difference reported in literature. Eastern countries such 
as Japan consume on average 83.5 g/day of cruciferous vegetables, 3-fold higher compared to 
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an average consumption of 30.8 g/day in the US [97]. Regardless, the available evidence 
indicates that cruciferous vegetables have health-promoting effects which are associated with 
bioactive phytochemicals, ITCs. 
 
 Biological activity of SF 
SF is an extensively researched ITC studied for its cancer-preventing and other health 
promoting properties based on the indicative data from epidemiological studies. While 
exploring the influence of SF from dietary sources and risks to chronic diseases in vivo using 
mice and humans is important, gaining an insight into the fundamental molecular mechanisms 
is just as significant. Pure commercially available SF has been applied to in vitro models to 
investigate how SF modulates metabolic pathways. SF is able to elicit its health-promoting 
effects notably through the induction of phase II enzymes, cell metabolism, inflammation and 
induction of apoptosis and cell cycle arrest [12]. In addition, there is emerging evidence 
implicating SF in histone modification, inflammation, angiogenesis and metastasis [24]. 
 
 Induction of phase II enzymes and oxidative stress 
Harmful xenobiotics such as carcinogens and electrophiles undergo detoxification, notably by 
conjugation catalysed by phase II enzymes, to generate inactive metabolites. These are 
excreted from the body preventing damage to DNA and proteins. Traditionally, the term 
“phase II enzymes” referred to those with conjugation abilities including GST, and UDP-
glucuronosyltransferase. However, at present, it also includes other enzymes not directly 
involved in conjugation such as NAD(P)H: quinone oxidoreductase, heme oxygenase and 
glutamate cysteine ligase.  
Regulation through the Nrf2-Keap1 pathway is a feature shared by many of the phase II 
enzymes. Nrf2 (nuclear factor erythroid-derived 2-like) is a transcription factor sequestered in 
the cytoplasm of cells by its repressor, Keap1 (Kelch-like ECH-associated protein 1) under 
basal conditions. In the bound form to Keap1, Nrf2 is targeted for ubiquitination and 
proteasomal degradation. Upon modifications of the Keap1 cysteine residues by Nrf2 
agonists, Nrf2 dissociates enabling its translocation into the nucleus. Dissociated Nrf2 forms 
a heterodimer with Maf (small muscle aponeurotic fibrosarcoma protein) promoting its 
binding to a cis-acting antioxidant response element (ARE) located in the upstream region of 
many phase II genes [12,98,99]. Amongst several Nrf2 agonists, SF is known to be a potent 
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inducer. Due to its electrophilic feature, SF reversibly reacts with the thiol groups of the 
cysteine residues on Keap1 forming thionoacyl adducts [12,99-101]. Recently, Hu et al. 
confirmed that SF modifies several cysteine residues [100]. However, it is unclear whether 
modification of cysteine residues results in the dissociation of Nrf2 as work by Eggler et al. 
suggests that modification of Keap1 cysteine residues by SF does not alter its binding ability 
to Nrf2 [102].  
The importance of Nrf2 for basal and inducible expression of phase II enzymes was presented 
in a transcriptional profile of small intestine from wild-type (Nrf2 +/+) and Nrf2-deficient 
(Nrf2 -/-) mice administered with 9 µmol/day of SF for 1 week [99]. Upregulation of a number 
of genes comprising G6PD (glucose-6-phosphate dehydrogenase), malic enzyme and GPx 
(glutathione peroxidase) were observed only in untreated wild-type mice, implying the 
dependence of Nrf2 for basal expression. Further, Nrf2-deficient mice expressed lower levels 
of basal enzyme activities and genetic expression of several genes including NQO1 
(NAD(P)H: quinone oxidoreductase) and GST compared to wild-type mice [99].  
The upregulation of several phase II enzymes induced by SF has been established in vitro and 
in vivo, emphasising the fundamental role of SF on modulating phase II enzymes and thus 
protecting cells from damage. Through a microarray analysis, Agyeman et al. demonstrated 
significant upregulation of phase II genes including AKR1 (alpha-keto reductase), NQO1, 
TXNRD1 (thioredoxin reductase) following treatment of breast epithelial cells (MCF10A) 
with 15 µM SF and/or Keap1 knockdown [103]. AKR1B10 was shown to be the most 
upregulated by a 302.9 and 69.4-fold increase by SF and Keap1 knockdown respectively 
[103]. In congruence, MacLeod et al. reported an upregulation by ≥2-fold of phase II enzymes 
including ARK1, HMOX1 (heme oxygenase-1), GCLC (Glutamate-cysteine ligase catalytic 
subunit) and NQO1 [104]. Further, in vitro work using prostate cancer cells [105], 
osteosarcoma cells [106], pancreatic β-cells [107] and microglia cells [108] demonstrated an 
upregulation of several phase II enzymes by SF. 
Further, a study with wild-type mice (Nrf2 +/+) treated with SF reported upregulated 
expression of NQO1, GST and 6PGDH (6-phosphogluconate dehydrogenase), amongst other 
genes, compared to the untreated wild-type and Nrf2-deficient mice (Nrf2 -/-) [99]. 
Interestingly, enzyme activity of G6PD and malic enzyme were upregulated in wild-type mice 
treated with SF even though the basal gene expression was not upregulated in wild-type mice 
treated with SF. Furthermore, enzyme activity of G6PD was upregulated in Nrf2-deficient 
mice treated with SF indicating that other transcription factors regulate its expression [99].  
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An imbalance in oxidative stress between ROS generation and elimination is linked to cancer 
development as well as other physiological conditions [12]. As many phase II enzymes are 
regulated by Nrf2, it is unsurprising that knockout Nrf2 mice develop lesions and a reduced 
survival rate when exposed to oxidative stress inducers [109-113]. Through the induction of 
phase II enzymes via Nrf2, SF ameliorates oxidative stress-induced physiological conditions. 
SF has the ability to increase the anti-oxidant capacity of cells by inducing anti-oxidant genes 
however it is not regarded as an anti-oxidant [12]. While SF is not classified as a pro-oxidant, 
it functions like a pro-oxidant to a certain extent by initially inducing oxidative stress followed 
by an upregulation of phase II enzymes. This was demonstrated in immortalised human 
hepatocytes exposed to SF for 3-6 hours resulting in a depletion of GSH, followed by an 
upregulation of GSH at 24 hours [114]. Oxidative stress-induced response was attenuated by 
SF in mice through the induction of Nrf2 thereby upregulating the expression of phase II genes 
including NQO1, HMOX1 and GPx [115,116]. This further supports the protective effects of 
SF via the Nrf2-ARE pathway.  
 
 Cell metabolism 
Evidence has emerged on the role of SF in modulating central metabolic pathways. Microarray 
analysis performed on breast cells treated with SF revealed upregulation of 6,378 transcripts, 
with those involved in carbohydrate metabolism and NADH/NADPH (Nicotinamide adenine 
dinucleotide/ Nicotinamide adenine dinucleotide phosphate) generation being the top 
pathways elevated [103]. Exposure to SF resulted in an increase in the expression of several 
genes including key enzymes involved in the pentose phosphate pathway (PGD 
(Phosphogluconate dehydrogenase), G6PD, TALDO (transaldolase), TKT (transketolase)), 
and enzymes implicated in the glycolysis pathway (PGAM1 (Phosphoglycerate Mutase) ; HK1 
(Hexokinase-1)  and HDK1 (hexokinase domain containing 1)) [103]. These are also genes 
positively regulated by Nrf2-ARE pathway [117], possibly explaining the elevation observed 
when cells are subject to SF. Exposure to SF increases metabolism through glycolysis and the 
pentose phosphate pathway. The glycolysis pathway produces NADH, a cofactor that donates 
electrons to enzymes involved in xenobiotic metabolism. Likewise, NADPH, another cofactor 
involved in xenobiotic metabolism and anti-oxidant systems such as regeneration of GSH, is 
generated from the pentose phosphate pathway [103,117]. Congruently, SF increased the rate 
of the pentose phosphate pathway after 15 hours in astroglia cells [118]. Further, a recent 
three-phase study with a standard broccoli, high-glucoraphanin, and pea intervention reported 
an elimination of the differences observed pre-intervention in the TCA cycle intermediates in 
two genotypes following the broccoli intervention. Armah et al. suggested that a broccoli 
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intervention normalised the TCA cycle metabolism supporting the effect of SF on cellular 
metabolism [119]. There is supporting evidence to suggest SF can alter metabolism largely 
through the regulation of Nrf2 but further studies need to be focused on the implications of 
these metabolic changes. 
 
 Inflammation 
In addition, SF modulates inflammatory responses by inhibiting lipopolysachcharide (LPS)-
mediated cytokine secretion. A transcription factor, NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) and LPS, a glycolipid, are key mediators of inflammation. LPS 
induces the secretion of pro-inflammatory cytokines including interleukin (IL)-1β, tumor 
necrosis factor (TNF)-α and IL-6 [12]. SF was shown to inhibit the translocation of the NF-
κB to the nucleus as well as decreasing the pro-inflammatory cytokines (IL-1β and TNF-α) 
and increasing the anti-inflammatory cytokines (IL-4 and IL-10) in pancreatic β-cell lines 
[107]. Other in vitro studies have demonstrated a decrease in the elevated pro-inflammatory 
cytokines (IL-1β, TNF-α and IL-6) induced by stimuli and increased anti-inflammatory 
cytokines (TGF-β) [115,120,121]. This is mainly occurring through the depletion in the 
translocation of NF-κB [115]. A considerable amount of evidence has shown the anti-
inflammatory effects of SF attenuating inflammation induced responses (Figure 1-5). 
 
Figure 1-5: Suppression of pro-inflammatory cytokines by SF. SF inhibits inflammation 
by either modifying the cysteine residue of the Toll-Like receptor-4 (TLR4) and by 
inhibiting the translocation of NF-κB from the cytoplasm to the nucleus [120].  
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 Induction of cell cycle arrest and apoptosis by SF 
The cell cycle is regulated by cyclin-dependent kinase (CDK), CDK inhibitors, and cyclins. 
This occurs through five stages of the cycle, G0, G1, S, G2 and M [12]. G0 phase is the 
quiescence phase where cells leave the cycle to stop dividing, G1 is the period of growth where 
cells increase their metabolic activity, S phase where DNA is duplicated, G2 is the step where 
cells prepare to divide and finally M phase is where mitosis occurs. CDK and cyclins facilitate 
the progression of cells from one phase to the other. SF has the ability to induce cell cycle 
arrest thus inhibiting cell growth in various cell lines. SF induces a cell cycle arrest at G2/M 
phase as demonstrated by in vitro studies. A decrease in the percentage of cells in the G0/G1 
phase and an increase in the G2/M phase was observed in lung cells exposed to 1 µg/ml (~5-6 
µM) SF for 48 hours [122], prostate cells subject to 10 µM SF for 24 hours [123], bladder cell 
exposed to 20 µM SF for 48 hours [124], leukemia cells at 48-hour treatment with SF [125] 
and keloid fibroblasts exposed to 10-20 µM for 48 hours [126]. It is proposed that the 
accumulation of cells in the G2/M phase is a result of a cell cycle arrest induced by SF [127]. 
This inhibits cells transitioning to the G1 phase halting cell growth associated with reduced 
cell proliferation. 
Apoptosis is a regulated programmed cell death fundamental in maintaining cellular 
homeostasis by eliminating dead cells. In certain scenarios, such as autoimmune diseases and 
some cancers, apoptosis is no longer properly regulated leading to aberrant death of cells [12]. 
There are two possible apoptosis mechanisms; caspase-dependent pathway and caspase-
independent pathway. Caspase-dependent pathway is cell death mediated by a group of 
cysteine proteases known as caspases. They are synthesised as pro-caspases and become 
activated to caspases upon cleavage of specific aspartate residues [12]. Activated caspases 
lead to the cleavage of DNA characterised by apoptotic bodies and cell shrinkage. In contrast, 
cell death can also occur without the activation of caspases, via the release of the 
mitochondrial protein apoptosis-inducing factor (AIF). 
Early reports of inhibition of proliferation and induction of apoptosis mediated by SF were 
evidenced by a decrease in viability of colon cancer cells subjected to 15 µM SF [128]. Thus 
far, a considerable number of in vitro studies have reported apoptosis induced by SF in various 
cell lines including lungs [122], cervical [127], liver [127], prostate [123] and bladder [124]. 
Even though SF inhibited proliferation of the lung adenocarcinoma cell line, no effect was 
observed in normal lung cells [122]. A growth inhibition of 82% and 73% was demonstrated 
in cervical and liver cells following exposure to 20 µM SF for 48 hours [127] and 75% growth 
inhibition of prostate cells treated for 48 hours with 10 µM SF [123]. 
Chapter 1: Introduction 
34 | P a g e  
SF was implicated in the activation of the intrinsic pathway, extrinsic pathway, and the 
caspase-independent pathway [12]. Activation of the intrinsic pathway involves release of 
cytochrome c from mitochondria induced by Bax and Bak resulting in the activation of 
caspase-9 and consequently activating caspase-3 [12]. Downregulation of anti-apoptotic 
proteins (Bcl-2 and BclXL) and upregulation of pro-apoptotic proteins (Bax and Bak) involved 
in the intrinsic pathway is a key target in treating tumours. Overexpression of Bcl-2 is a classic 
feature of non-small cell lung cancer patients resulting in apoptotic resistance in cells [122]. 
SF was shown to downregulate Bcl-2 in lung cancer cells at a concentration of 1 µg/ml for 72 
hours [122], in cervical cancer cells and in liver cells for 48 hours [127]. Whereas, 
upregulation of Bax and increased activation of caspase-3 was demonstrated in lung cells 
treated with 1 µg/ml SF for 72 hours [122]. In another study, upregulation of Bax in cervical 
cancer cells subject to SF for 48 hours was reported but not in liver cancer cells [127]. 
Upregulation of caspase-3 but no changes in caspase-9 was observed in cervical cancer cells 
and liver cancer cells [122,127]. Similarly, in bladder cells treated with SF, activity of caspase-
3 was reported, but no activated caspase-9 was detected [124]. Activation of the extrinsic 
pathway comprises of activation of caspase-8 leading to the activation of caspase-3. SF 
significantly increased the activity of caspase-3 and caspase-8 in leukemia cells subject to 8 
µM SF for 24-48 hours [125] and in prostate cells treated with 40 µM SF for 24 hours [129]. 
In many studies, the apoptotic effects of SF were demonstrated with ≥ 15 µM SF ( IC50 of cell 
growth [122,127,129]). Given that these concentrations of SF does not reach the plasma 
following intake of commercially available broccoli by the general population, it is not 
physiologically relevant. 
 
 Biological activity of SMCSO 
The combination of glucosinolates and SMCSO could contribute to the health benefits 
associated with cruciferous vegetables intake. In comparison to SF, SMCSO has not been 
extensively researched for its health benefits. However, it has been associated with anti-
carcinogenic, anti-diabetic and cardiovascular effects using mice studies and in vitro work. 
 
 Anti-carcinogenic effects modulated by SMCSO 
To establish whether SMCSO could be a chemopreventative agent, the effect of SMCSO and 
its metabolite MMTSI (Figure 1-4) was investigated by Marks et al. in a genotoxicity induced 
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mice model [41]. Genotoxicity was induced in mice by 8-fold with the treatment of 
benzo[a]pyrene, a tobacco carcinogen (0.75 mmol kg-1 body weight) resulting in the formation 
of micronucleated polychromatic erythrocytes. Mice that were pre-treated with either SMCSO 
(0.5 mmol kg-1 body weight) or MMTSI (0.05 mmol kg-1 body) presented lower levels of 
micronucleated polychromatic erythrocytes, diminished by 31% and by 33% respectively. 
These data indicated early signs that SMCSO and its metabolite, MMTSI could exhibit anti-
carcinogenic effects. However, it is imperative to note that the metabolites derived from 
SMCSO such as MMTSI proved to be extremely toxic at high concentrations (1.0 mmol) 
evidenced by the death of 6 out of 7 mice [41]. Other in vitro studies have shown induction of 
apoptosis by thiosulfinates such as MMTSI leading to the inhibition of cell growth [130,131]. 
A crude extract of thiosulfinates largely made up of MMTSI demonstrated inhibitory effects 
on the growth of prostate cancer cells (RC-58T, DU-145, LNCap, PC-3), breast cancer cells 
(MCF-7) and liver cancer cells (HepG2) through the induction of apoptosis [130-132]. 
Mediation of apoptosis by thiosulfinates occurred via caspase-dependent and caspase-
independent pathways. Thiosulfinates increased levels of caspase-3, caspase-8 and caspase-9 
as well as increasing the levels of the pro-apoptotic protein Bax and decreasing the levels of 
the anti-apoptotic protein Bcl-2 in RC-58T cells [130] and in PC-3 cells [131]. Besides the 
activation of the caspase-dependent pathway, thiosulfinates induced the translocation of the 
AIF into the nucleus resulting in DNA fragmentation in RC-58T cells [130] and in PC-3 cells 
[131]. Furthermore, MMTSO, another SMCSO derived metabolite (Figure 1-4), was reported 
to have chemopreventative effects in animal studies. Administration of MMTSO attenuated 
the development of aberrant crypt foci (lesions leading to colorectal cancer) induced by 
azoxymethane, a carcinogen [133]. Concurring with the work by Morishita et al. [133], co-
administration of MMTSO and sulindac (an anti-inflammatory drug) in another study by 
Reddy et al. repressed the incidence of invasive adenocarcinomas [134]. SMCSO and its 
secondary metabolites, MMTSI and MMTSO have been demonstrated as promising 
chemopreventative agents. However further work is required in this area, especially the effect 
of these sulphur compounds in vivo.  
 
 Anti-diabetic and cardiovascular effects mediated by 
SMCSO 
SMCSO has shown possible regulation of cholesterol in animal studies. Augmented 
cholesterol levels in the plasma and liver of rats induced by a hypercholesterolemic diet was 
suppressed following a diet with SMCSO [135,136]. In agreement, Kumari and Augusti. 
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reported that the treatment of SMCSO suppressed the elevated cholesterol levels in rats 
induced by a hypercholesterolemic diet [137]. In addition to the cholesterol levels, SMCSO 
treatment reduced the triglyceride, phospholipid and free fatty acid levels [137]. Another study 
by Kumari et al. found a depletion in the blood and urine glucose levels of diabetic rats 
following a two month SMCSO treatment [138]. Interestingly, increased bile acid excretion 
was observed following administration of SMCSO to rats [136,137]. The proposed 
mechanism for the lipid-lowering effects of SMCSO is through increased lipid catabolism and 
bile acid excretion [2]. Presumably, SMCSO, via its cysteine moiety, increases the activity of 
cholesterol 7α-hydroxylase, the rate-limiting enzyme responsible for bile acid synthesis from 
cholesterol [16,137]. This was supported by the increased activity of cholesterol 7α-
hydroxylase detected in rats fed with SMCSO [136]. Possibilities for SMCSO to be used as 
anti-diabetic or anti-lipidemic agent have been demonstrated from the animal studies. Further 
work is necessary to confirm these effects using in vitro models and in vivo as well as to 
elucidate the mechanisms involved for said effects. 
 
 Thesis aims 
A considerable amount of research has been undertaken to support the epidemiological 
evidence presenting an association between consumption of cruciferous vegetables and a 
reduction in the risk of chronic diseases. Much of this extensive research has employed human, 
animal and in vitro studies to investigate the effects of SF however many uncertainties remain. 
Further, SMCSO has been implicated to exhibit potential health benefits. However, the 
underlying mechanisms have not been extensively researched. As there are areas of SF and 
SMCSO research that remain unexplored, this thesis will address the bioavailability and 
bioactivity of sulphur-containing compounds with a series of aims as follows: 
1. To date, a considerable number of in vivo studies have been conducted to assess the 
bioavailability of SF through the consumption of SF or its precursor, GR through a variety 
of matrices such as soups, florets, pills and extracts. The main limitation with most of 
these studies is the use of doses of SF/GR that may not be achievable in a day to day basis 
by the general population and are too high to encourage compliance during studies. 
Therefore, novel broccoli varieties with increasing levels of GR (Myb28B/V and Myb28V/V) 
were previously developed at the John Innes Centre and manufactured into soups. 
Therefore, the aim of Chapter 2 is to quantify the levels of sulphur compounds in the 
three types of soups to confirm that the increasing levels of GR observed in the broccoli 
florets is preserved in the soups. 
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2. The three types of soups produced by a leading food manufacturer as a portion size of 
300g (comparable to commercially available soup portion sizes), enables compliance and 
is achievable in vivo. The aim of Chapter 3 is therefore to quantify the bioavailability of 
sulphur-containing compounds including GR, SF and SMCSO in plasma and urine by 
means of undertaking a human intervention study. 
3. The quantification of SF in biological samples has been reported, but limited studies have 
shown the quantification of GR and SMCSO in such samples. The presence of SMCSO 
and GR in plasma and urine poses an interesting question regarding their permeability. 
Previous reports assume that SF can passively diffuse through the enterocytes from the 
gut lumen into the blood circulation. However, the transport of GR and SMCSO remain 
unexplored. Therefore, Chapter 4 aims to investigate the potential transport and the 
mechanism of these compounds using an artificial model (PAMPA) and a human colon 
model (caco-2). 
4. Many of the health benefits reported with cruciferous vegetable intake has been primarily 
associated with SF. However, Brassica vegetables also contain high levels of SMCSO and 
early animal studies have indicated the possible anti-carcinogenic, anti-diabetic and anti-
lipidemic effects of by SMCSO. Therefore, the aim of Chapter 5 is to elucidate whether 
SMCSO, like SF, could exert changes to the expression of Nrf-2 regulated genes via the 
expression analysis of 10 genes following exposure of liver cells (HepG2) to SMCSO, SF, 
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 Summary 
Two high-glucoraphanin broccoli varieties were previously developed by cross-breeding 
standard commercially available broccoli, Brassica oleracea var.italica, with a wild broccoli 
species, Brassica villosa. This induced the introgression of several segments from Brassica 
villosa into the genome of standard broccoli, including a key transcription factor implicated in 
glucosinolate biosynthesis. Subsequently, broccoli soups were manufactured using these 
broccoli varieties to deliver high levels of sulphur-containing bioactives, GR and SMCSO in 
vivo. The soups were analysed to confirm whether the high levels of bioactives from the 
broccoli plant were retained during the soup production process. Analysis confirmed the soups 
accumulated increased levels of GR and SMCSO compared to standard broccoli soup. The 
development of these high-GR broccoli soups is of great importance to investigate the 
bioavailability and biological activity of sulphur-containing compounds from the novel 
broccoli varieties.  
 
 Introduction 
Cruciferous vegetables including Brassica oleracea accumulate phytochemicals including 
glucosinolates and SMCSO. Glucosinolates uniquely accumulate in these plants at high levels 
as a defensive mechanism against pests and insects. Hence, glucosinolates and SMCSO have 
been associated with health-promoting effects because they may provide a defensive 
mechanism against carcinogens in the human body [2]. For this reason, developing cultivars 
with naturally enhanced levels of GR was a promising breakthrough. In the 1990s, pioneering 
research at the John Innes Centre (Norwich, UK) resulted in the development of cultivars by 
cross-breeding wild type broccoli Brassica villosa and commercially available broccoli. Due 
to the introgression of a novel Myb28V allele from Brassica villosa, a transcription factor 
regulating glucosinolate biosynthesis, the two novel varieties (Myb28B/V and Myb28V/V) 
accumulate enhanced GR levels compared to standard broccoli (Myb28B/B) [16,18]. The 
consumption of GR from 1 portion of Myb28B/V florets is equivalent to ~ 3 portions of standard 
broccoli and 1 portion of Myb28V/V florets is equivalent to ~6 portions of standard broccoli 
(unpublished data). This provided a valuable dietary tool for clinical studies as many studies 
have employed doses of SF or GR not achievable in the general population.  
Food matrix influences the palatability, compliance and absorption of dietary compounds. 
Dietary intervention studies summarised in Chapter 1 used various matrices including pills, 
powder, raw or cooked florets, and soups. These matrices deliver problems concerned with 
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tolerance, diet compliance, and replication of cooking methods for long-term dietary studies 
and household cooking. Although pills made with pure SF seem to be an appealing idea to 
promote intake of SF especially for those who do not consume broccoli as their normal diet, it 
was not well tolerated by participants in a recent study [70]. In addition, synthesised SF is not 
stable at fridge/room temperatures and degrades easily. Although Fahey et al. developed a 
stabilised encapsulated SF [70], and drug company Evgen (Liverpool, UK) have developed 
Sulforadex®, a stabilised SF pill, it is a complex procedure. Homogenising florets to get an 
extract or powder may preserve the myrosinase and enable higher bioavailability of SF. 
However, it is not a food matrix that is palatable and it is laborious for long-term clinical 
studies/household cooking. Raw broccoli/lightly cooked broccoli is not appetising to the 
general population and it would be difficult to replicate cooking methods in households to 
ensure consistency. Soups used in previous studies represent a good food matrix, however 
previous studies have cooked broccoli in water and homogenised [38,68]. Again, this is not a 
palatable food source and compliance to diet may be low. Hence, there was scope to develop 
a food matrix that is palatable, ensures compliance, suitable for cooking in general households 
and clinical trials. Consequently, in collaboration with other companies including Monsanto®, 
A.P. East Anglia Ltd, Bakkavor Ltd, a leading food manufacturer, and Norbert Dentressangle, 
soups were developed according to a commercial broccoli and stilton recipe (Figure 2-1). 
Three soups using the genotypes (Myb28B/B, Myb28B/V and Myb28V/V) were manufactured into 
freezable 300g portions. This provided a trouble-free dietary intervention suitable for long-
term dietary interventions and cooking by volunteers in their households, unlike soups 
produced by other studies. With the potential to deliver enhanced levels of glucosinolates in 
human intervention studies, these palatable broccoli variety soups represent a feasible means 
of compliance in long-term dietary studies. 
 
Figure 2-1: Collaborators involved in the process of developing broccoli soups using 
three genotypes. Broccoli cultivar seeds provided by Monsanto®, broccoli floreted and 
frozen by A.P. East Anglia Ltd, produced into broccoli and stilton soups by Bakkavor 
Ltd and stored in a food-grade long-term storage facility by Norbert Dentressangle. 
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This chapter explores whether the soup production, using the three broccoli varieties, 
Myb28B/B (standard broccoli), Myb28B/V, and Myb28V/V, preserved the high GR content and 
other sulphur containing bioactives. The main aim was to analyse the levels of glucosinolates, 
SMCSO, mineral elements and amino acids of the soups to establish whether the presence of 
one or more Myb28V alleles results in enhanced levels of glucosinolates and other compounds. 
 
 Materials and Methods 
 Materials  
The following were purchased from Sigma® (UK); sinigrin hydrate, internal standard for GR 
(Cat. # 85440), DL-NorLeucine, internal standard for SMCSO (Cat # N1398), sulfate 
(TraceCERT®, 1000 mg/L) (Cat. # 90071), O-(carboxymethyl)hydroxylamine 
hemihydrochloride (OCMHA) (Cat. # C13408), sulfatase (Type H-1 from Helix pomatia) 
(Cat. # S9626), heptafluorobutyric (Cat. # 52411) and ammonium acetate (Cat. # 73594). 
Sulfatase was purified by passing through columns with DEAE Sephadex A25 (Cat. # 17-
0170-01) and SP Sephadex C25 (Cat. # 17-0123-01) obtained from Amersham Biosciences 
(Sweden) as described previously [68]. The following was purchased from Cayman Chemical 
(Michigan, USA); S-methyl-L-cysteine sulfoxide (SMCSO) (CAS 6853-87-8) (purity ≥98%) 
(Cat # 17600) and GR (CAS 21414-41-5) (purity ≥95%) (Cat # 10009445). SF (CAS 4478-
93-7) (purity > 98%) (Cat. # S8045) was purchased from LKT Laboratories (St. Paul, USA). 
Dulbecco's phosphate-buffered saline (DPBS) (Gibco®) 10X with no calcium and no 
magnesium was purchased from Thermo Fisher Scientific (Cat. # 14200059). Acetic acid was 
purchased from Biosolve (Cat. # 01074131).  
All solvents and other chemicals used were of high-performance liquid chromatography 
(HPLC) grade with a purity of ≥95%, Acetonitrile (Cat. # 10407440) and methanol (Cat. # 
10674922) purchased from Fischer Scientific. Only pure water from Milli-Q® Integral Water 
Purification System (Millipore Advantage) was used to dissolve chemicals. 
Broccoli cultivars were grown in Spain and made into broccoli and stilton soup by Bakkavor 
Group Limited. Soups produced from each cultivar were freeze-dried and powdered using a 
food mixer. The freeze-dried samples were stored at -80ºC for SMCSO analysis and at room 
temperature for GR and sulphate analysis. Dr Shikha Saha (QIB analytical chemist) freeze-
dried soup samples, performed the extraction and quantification of glucosinolates, SMCSO 
and sulphate. Analysis of mineral elements and amino acids were undertaken by Eurofin. 
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 Glucosinolate analysis by high-performance liquid 
chromatography 
 Extraction of glucosinolates from samples 
Glucosinolates were extracted and quantified using a method described by Magrath et al. [139] 
and Shikha et al. [68] involving the conversion of glucosinolates to desulfoglucosinolates. Hot 
aqueous 70% methanol (10 ml) was added to 50 mg freeze-dried powder. Following the 
addition of known amounts of sinigrin (internal standard), samples were vortexed and then 
incubated at 70ºC for 20-30 mins. After samples were cooled and centrifuged at 4000 x g for 
10 mins at room temperature. After centrifugation, the supernatant (3 ml) was passed through 
an ion exchange column. Once the samples had passed through, the columns were washed 
with water (2 x 0.5 ml) and 0.02 M sodium acetate (2 x 0.5 ml). Purified sulfatase (75 µl) was 
applied to the column and incubated overnight at room temperature for desulfonation reaction 
of glucosinolates. Following an overnight incubation at room temperature, the 
desulfoglucosinolates were eluted by sequential addition of 0.5, 0.5 and 0.25 ml water and 
collected into the autosampler vials and analysed by HPLC. 
 
 High-performance liquid chromatography set-up and 
quantification of glucosinolates  
Desulfoglucosinolates were analysed using a Waters Spherisorb ODS2 (250 × 4.6 mm , 5 µM 
particle size) connected to an Agilent Technologies HPLC system model 1100 (Agilent 
Technologies, Waldbronn, Germany) equipped with a binary pump, degasser, cool 
autosampler, column oven and diode array detector. Ultrapure water and acetonitrile were used 
as solvents with a flow rate of 1 ml/min, and a gradient of an increasing proportion of 
acetonitrile from 5% to 100% over 25 minutes was applied, prior to re-equilibration to 5% for 
7 minutes. Desulphoglucosinolate quantification was achieved, using absorbance at 229 nm, 
by comparison with the peak area ratio of the internal standard (sinigrin), and the relevant 
desulphoglucosinolate ultraviolet (UV) light relative response factor.  
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 Amino acid analysis by high-performance liquid 
chromatography 
Freeze dried samples were sent to Eurofins UK (Eurofins Food Testing UK Ltd, i54 Business 
Park, Valiant Way, Wolverhampton, WV9 5 GB) for analysis of amino acids using an 
accredited HPLC method. All amino acids apart from cysteine, methionine and tyrosine, can 
be detected in their oxidised or unoxidized sample. However, cysteine and methionine must 
be oxidised to cysteic acid and methionine sulphone respectively, and tyrosine can only be 
analysed in the unoxidized sample. Oxidation of amino acids was carried out at 0ºC with a 
solution of performic acid/phenol mixture for 16 hours. Excess oxidation reagent was 
decomposed with sodium disulfite. Prior to analysis, oxidised or unoxidized samples were 
hydrolysed with hydrochloric acid for 23 hours and the hydrolysate was adjusted to pH 2.2 
prior to running the samples on the HPLC. Internal standard and citrate buffer were added to 
the hydrolysate and filtered through a 0.2 µM filter. Amino acids were separated by ion 
exchange chromatography. The product from the reaction of the amino acids with ninhydrin 
was detected at 570 nm (440 nm for proline). 
 
 S-methyl-L-cysteine sulfoxide analysis by ultra-performance 
liquid chromatography-tandem mass spectrometry 
 Extraction of S-methyl-L-cysteine sulfoxide from samples 
Extraction of SMCSO from freeze-dried soup samples was undertaken as described by 
Bernaert N et al. [140]. Freeze-dried powder (45-50 mg) was diluted with 1.1 mg/ml of 
OCMHA (O-(carboxymethyl)hydroxylamine hemihydrochloride). The addition of OCMHA 
inhibits the allinase activity to stop the breakdown of SMCSO. The solution was placed on a 
horizontal shaker for 10 minutes and centrifuged at 4000 x g for 10 minutes. The supernatant 
was further diluted by 10-fold with the addition of 0.1% formic acid in Milli-Q® water into 
autosampler vials and analysed by UPLC-MS/MS. 
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 UPLC-MS/MS set-up and quantification of S-methyl-L-
cysteine sulfoxide  
A 1 mg/ml SMCSO stock was prepared in Milli-Q® water and a serial dilution was produced 
in the same matrix as the samples that were run. Serial dilutions were prepared prior to each 
run to generate a 4-6 point standard curve ranging from 0 μg/ml to 50 μg/ml. Analysis was 
performed using an Agilent 6490 Triple Quad LC-MS mass spectrometer equipped with a 4ºC 
autosampler, a degasser, binary pump, column oven, diode array detector and 6490 mass 
spectrometer. The column temperature and auto sampler were maintained at 20°C and 4°C 
respectively. 
Samples were injected at 2 µl eluted at a flow rate of 0.3 ml/min on an Agilent SB-AQ 1.8 uM 
(100 x 2.1mm) C18 column. Separation was carried out using 10 mM ammonium acetate + 
0.05% heptafluorobutyric acid in water (mobile phase A) and 10 mM ammonium acetate + 
0.05% heptafluorobutyric acid in 90% methanol (mobile phase B). The gradient started at 2 % 
mobile phase B increasing over 2 mins to 5% mobile phase B and finally re-equilibrated to 
2% mobile phase B for 2 mins. The LC eluent flow was sprayed into the mass spectrometer 
interface without splitting. SMCSO ion was monitored using mass spectrometry multiple 
reaction monitoring mode (MRM) in positive polarity with electrospray ionization (ESI) 
source. The source parameters were; a gas temperature at 200˚C with a gas flow of 16 l/minute, 
a sheath gas temperature at 300˚C with a sheath gas flow of 11 l/minute, a nebuliser pressure 
of 50 psi and capillary voltage at 3500V. The quantification was performed using matrix match 
calibration curve. Identification was achieved based on retention time and product ions 
monitored summarized in Table 2-1. 
 
Table 2-1: Summary of the monitored product ions of SMCSO and the optimised MS 













SMCSO 0.98 152.19 87.9 4 4 Positive 
SMCSO 0.98 152.19 69.9 16 4 Positive 
SMCSO 0.98 152.19 42.1 20 4 Positive 
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 Sulphate analysis by liquid chromatography- mass 
spectrometry 
 Extraction of sulphate from samples  
Analysis of sulphate was carried out as described elsewhere [141]. Milli-Q® water (1 ml) was 
added to 25g of washed and grounded PVPP (polyvinylpolypyrrolidone) and stored at 4ºC 
overnight. Powdered soup samples (20-30 mg) added to the solution of PVPP in water was 
vortexed briefly followed by shaking for 1 hour at 4ºC. Samples were then incubated at 95ºC 
for 15 mins and centrifuged at 4000 x g 4ºC for 15 mins. The supernatant was filtered using a 
PVDF 0.45 μm syringe filter into autosampler vials and analysed on an 1100 series Agilent 
Single Quad LC-MS mass spectrometer. 
 
 LC-MS set up and quantification of sulphate 
Samples were eluted at 0.8 ml/min using an AcclaimTM TrinityTM P1 3 μm (3 x 50 mm) column 
and separated using 200 mM ammonium acetate with acetic acid, pH4 (mobile phase A) and 
60% acetonitrile/40% ultrapure water (mobile phase B). The gradient started at 5 % mobile 
phase A increasing over 15 min to 90% solvent A and finally re-equilibrated to 5% solvent A 
for 5 min. The LC eluent flow was sprayed into the mass spectrometer interface without 
splitting. Sulfate was monitored using mass spectrometry in selective ion monitor mode (m/z 
= 97) in negative polarity with (ESI). The quantification was performed using matrix match 
calibration curve of the standard. Identification was achieved on the basis of retention time of 
the standard. 
 
 Data analysis from liquid chromatography-tandem mass 
spectrometry 
Data files are exported and analysed on Agilent MassHunter Quantitative analysis 
B.06.00/Build 6.0.388.0 (Agilent Technologies©). The software manually integrates the peak 
area for the metabolites which is then exported as an Excel document. The concentration of 
the metabolites was calculated using the equation of the standard curve and the peak area of 
the metabolites.  
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 Mineral elements analysis by inductively- coupled conductive 
plasma optical emission spectrometry 
Freeze dried broccoli soup samples were sent to Eurofins UK (Eurofins Food Testing UK Ltd, 
i54 Business Park, Valiant Way, Wolverhampton, WV9 5 GB) for analysis of mineral 
elements including sodium, potassium, sulphur, calcium, magnesium, phosphorus, iron and 
zinc. Analysis of mineral elements was undertaken using inductively coupled plasma optical 
emission spectrometry (ICP-OES). Samples were first digested using microwave assisted 
accelerated digestion by adding concentrated nitric acid to 1 g of homogenised sample. 
Digested samples were then analysed on an Agilent 700 series ICP-OES. Limits of detection 
and quantification were provided by Eurofins UK (Table 2-2). 
Table 2-2: Limit of detection and quantification of mineral elements analysed by 
inductively coupled plasma optical emission spectrometry  
 
List of Minerals LOD LOQ 
Calcium 0.0001g/100g 0.0005g/100g 
Phosphorus 0.00004g/100g 0.0002g/100g 
Iron 0.2 mg/kg 1 mg/kg 
Zinc 0.4 mg/kg 2 mg/kg 
Sodium 0.0002g/100g 0.001g/100g 
Potassium 0.001g/100g 0.005g/100g 
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 Results 
 Increasing levels of glucoraphanin in soups with the presence 
of one or more Myb28V alleles 
To assess whether the presence of one or more Myb28V alleles influenced the concentration 
of glucosinolates in the soups, freeze-dried samples were analysed using HPLC (Figure 2-2). 
Amongst the glucosinolates derived from broccoli, the predominant glucosinolate is 4-MSB, 
GR as illustrated in Figure 2-3. The second major glucosinolate detected is 3-MSP, 
glucoiberin, followed by indoles (IND), 4-methoxyindole glucosinolate (4-MIND), hydroxy-
indolyl methyl glucosinolate (OH-IND) and 1-methoxyindole glucosinolate (1-MIND). The 
level of 4-MSB is approximately 5-fold higher compared to MSP in the Myb28B/B broccoli 
soup. The presence of one or two Myb28V alleles significantly increased the concentration of 
4-MSB and 4-MIND (p˂0.0001). Myb28V/V and Myb28B/V broccoli soups accumulate a 
statistically significant ~5-fold and ~3-fold elevated levels of 4-MSB respectively compared 
to Myb28B/B broccoli soup (Myb28V/V, 452 µmoles; Myb28B/V, 280 µmoles; vs. Myb28B/B, 84 
µmoles; p<0.0001). Similarly, the presence of one or more Myb28V alleles resulted in a 
singificant ~2-fold and ~4-fold enhanced levels of 4-MIND respectively compared to 
Myb28B/B broccoli soup (Myb28V/V, 49.1 µmoles; Myb28B/V, 27.5 µmoles; vs. Myb28B/B, 13.5 
µmoles; p<0.0001). Significant increase in the levels of 3-MSP was observed in the Myb28B/V 
soups (p˂0.0001) but not in Myb28V/V soups compared to Myb28B/B. On the contrary, levels 
of IND were significantly lower in the Myb28B/V soups (p˂0.0001) compared to Myb28V/V and 
Myb28B/B. Whereas, the levels of OHIND were only significant in the Myb28V/V soups 
(p˂0.01). No significant differences were detected in the levels of 1-MIND between the three 
varieties. No glucosinolate breakdown products was detected in the soups confirming that the 
soups only contain glucosinolates. 
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Figure 2-2: Chromatogram of glucosinolates profile in standard soup.  An example of a 
chromatogram from the analysis of standard soup using HPLC system and absorbance 
measured at 229 nm. Quantification was relative to the internal standard peak sinigrin. 
Glucosinolates quantified include 3-MSP, 4-MSB, IND, 1-MIND and 4-MIND as shown 
in the chromatogram. 
 
Figure 2-3: Concentration of glucosinolates in three varieties of broccoli soups. Freeze-
dried soup samples were analysed and quantified for glucosinolates using HPLC. 
Glucosinolates measured includes 3-MSP, 4-MSB, IND, OHIND, 1-MIND and 4-MIND. 
Data is represented as mean ± SD (n=10, Myb28B/B, Myb28B/V soups; n=4, Myb28V/V 
soups), ‘n’ varies due to differing stability of the broccoli lines. Statistical analysis of the 
data was undertaken by two-way ANOVA with Dunnett’s multiple comparisons test (** 
p˂0.01 and *** p˂0.0001 vs. Myb28B/B broccoli soup). 
DAD1 A, Sig=229 
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Parent ion 
 Increasing levels of S-methyl-L-cysteine sulfoxide in soups 
with the presence of one or more Myb28V alleles 
To evaluate whether the presence of one or more Myb28V alleles impacts on the concentration 
of SMCSO in the soups, freeze-dried samples were analysed for SMCSO using UPLC-
MS/MS. Spectrum from the UPLC-MS/MS shows the fragmentation of the parent ion to 
daughter ions (Figure 2-4), of which the daughter ion (m/z = 87.9) was quantified in samples 
(Figure 2-5). As evidenced by Figure 2-6, the presence of one or more Myb28V alleles 
resulted in significantly higher levels of SMCSO by ~1.4-1.5-fold compared to Myb28B/B 
broccoli soup (Myb28V/V, 1454 µmoles; Myb28B/V, 1514 µmoles vs. Myb28B/B, 1030 µmoles; 
p˂0.001). However, no significant differences were observed between the soups made with 






















Figure 2-4: Mass spectrum of the fragmentation of the SMCSO parent ion to produce 
daughter ions. An example of a chromatogram from the analysis of standard soup using 
UPLC-MS/MS system in the multiple reaction monitoring (A) and structures of the 
fragmentation ions produced from the parent ions (B). 
 
m/z = 152.2  m/z = 87.9  m/z = 69.9  m/z= 42.1  
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Figure 2-5: Chromatogram of the SMCSO daughter ion (m/z = 87.9) quantified in 
broccoli soup. An example of a chromatogram from the analysis of standard soup using 
UPLC-MS/MS system. Fragmentation of the daughter ion (m/z = 87.9) from parent ion 
(m/z = 152.2 ) was extracted using MRM mode from the ESI-MS positive mode. 
 
 
Figure 2-6: Concentration of SMCSO in three varieties of broccoli soups. Freeze-dried 
soup samples were analysed and quantified for SMCSO using UPLC-MS/MS. Data is 
represented as mean ± SD (n=3). Statistical analysis of the data was undertaken by one-
way ANOVA with Dunnett’s multiple comparisons test (*** p˂0.001 vs. Myb28B/B 
broccoli soup). 
 
+ MRM 152.1900 > 87.9000 
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Parent ion 
 Sulphate levels in soups with the presence of one more Myb28V 
alleles 
Sulphate levels were measured in soups made with three varieties using LC-MS to determine 
whether the levels would vary with the three varieties. LC-MS spectrum illustrates the 
production of daughter ions from the parent ion (Figure 2-7). The daughter ion (m/z= 80.0) 
was quantified in samples (Figure 2-8). The three broccoli varieties accumulated high levels 
of sulphate. The levels in Myb28B/V were significantly reduced compared to Myb28B/B 
(Myb28B/V, 445 µmoles vs. Myb28B/B, 531 µmoles; p<0.05) whereas, the levels between 
Myb28V/V and Myb28B/B were not significantly different (Myb28V/V, 555 µmoles vs. 



















Figure 2-7: Mass spectrum of the fragmentation of the sulphate parent ion to produce 
daughter ion. An example of a chromatogram from the analysis of standard soup using 
LC-MS system in the SIM mode (A) and structures of the daughter fragmentation ion 
produced from the parent ion (B).  
 
 
m/z= 97.0  m/z= 80.0 
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Figure 2-8: Chromatogram of the sulphate daughter ion (m/z = 80.0) quantified in 
broccoli soup. An example of a chromatogram from the analysis of standard soup using 
LC-MS system. Fragmentation of the daughter ion (m/z = 80.0) from parent ion (m/z = 
97.0) was extracted using SIM mode from the ESI-MS negative mode. 
 
 
Figure 2-9: Concentration of sulphate in three varieties of broccoli soups. Freeze-dried 
soup samples were analysed and quantified for sulphate using LC-MS. Data is 
represented as mean ± SD (n=3, Myb28B/B, Myb28V/V soups; n=2 Myb28B/V soup). 
Statitical analysis of the data was undertaken by one-way ANOVA with Dunnett’s 
multiple comparisons test (* p˂0.05 vs. Myb28B/B broccoli soup). 
 
 
-MRM 97.0 > 80.0 
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 Increased levels of potassium, sulphur and iron in the presence 
of one or more Myb28V alleles 
In order to establish whether the presence of one or more Myb28V alleles effects the 
concentration of mineral elements, soups made with three broccoli varieties were quantified 
using ICP-OES (Figure 2-10). The soups had enhanced levels of sodium and potassium 
compared to other mineral elements. Potassium levels in Myb28V/V broccoli soup is 
significantly higher compared to Myb28B/B broccoli soup (p<0.001). No significant changes 
were observed in the levels of magnesium, phosphorus and zinc between the three broccoli 
varieties. Interestingly a significant decrease in calcium was detected in the presence of one or 
more Myb28V alleles (p<0.05). In contrast, the levels of sulphur and iron significantly 
increased in the presence of one or more Myb28V alleles (p<0.001). Sulphur levels increased 
by ~1-fold and ~2-fold in the Myb28B/V broccoli soup and Myb28V/V broccoli soup 
respectively, compared to Myb28B/B broccoli soup. Whereas the presence of one or two 
Myb28V alleles enhanced the levels of iron by ~2-fold compared to Myb28B/B broccoli soup.  
A 
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B 
 
Figure 2-10: Concentration of mineral elements in three varieties of broccoli soups. 
Freeze-dried soup samples were analysed and quantified using ICP- OES. The following 
mineral elements were quantified; sodium, potassium, calcium, magnesium, phosphorus 
and sulphur in g/100g dry weight (A) and iron and zinc in mg/100g dry weight (B). Data 
is represented as mean ± SD (n=2). Statistical analysis of the data was undertaken by 
two-way ANOVA with Dunnett’s multiple comparisons test (* p˂0.05, ** p˂0.01 and *** 
p˂0.001 vs Myb28B/B broccoli soup). 
 
 Increased levels of amino acids in the presence of one or more 
Myb28V alleles 
Eighteen amino acids were analysed in the soups using HPLC to explore the levels of amino 
acids in the presence of one or more Myb28V alleles (Figure 2-11). Foremost is glutamic acid, 
found in high levels in all three broccoli varieties compared to all 18 amino acids. No 
significant differences were observed in the levels of phenylalanine, threonine, tyrosine, 
cysteine and cystine, methionine, or tryptophan. Interestingly, the levels of alanine, glycine, 
histidine, lysine, isoleucine, leucine, serine, and valine were only significantly increased in the 
presence of one Myb28V allele (p<0.05). In contrast, the presence of one or more Myb28V 
alleles resulted in significant increased levels of arginine, aspartic acid, glutamic acid, and 
proline relative to Myb28B/B broccoli soup (p<0.0001). There is approximately a 1.3-1.4-fold 
difference in the levels of glutamic acid in the presence of one or more Myb28V alleles 
respectively compared to Myb28B/B broccoli soup. 
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Figure 2-11: Concentration of amino acids in three varieties of broccoli soups. Freeze-
dried soup samples were analysed and quantified using HPLC. Data is represented as 
mean ± SD (n=2). Statistical analysis of the data was undertaken by two-way ANOVA 




Broccoli varieties containing one or two Myb28V alleles were developed by conventional 
cross-breeding with enhanced levels of 4-MSB, the precursor of the bioactive ITC, SF. These 
broccoli varieties were made into soups for use in long-term human intervention studies. The 
three varieties of broccoli soups were analysed and quantified for glucosinolates, SMCSO, 
sulphate, mineral elements and amino acids. This chapter investigated the hypothesis that the 
presence of one or more Myb28V alleles would result in enhanced levels of GR and SMCSO 
being carried into the resultant soups. 
The example of the chromatogram obtained from the analysis of glucosinolates from Myb28B/B 
soups, demonstrated that the highest peak observed is 2-propenylglucosinolate (sinigrin) 
followed by 4-MSB and 1-MIND. The high peak of sinigrin is a result of spiking samples with 
sinigrin, the internal standard for glucosinolates analysis. As hypothesised, the presence of one 
or two Myb28V alleles significantly increased the levels of 4-MSB in the broccoli soups 
compared to Myb28B/B broccoli soup by ~3-fold and ~5-fold, respectively (Myb28B/V, 280 
µmoles; Myb28V/V, 452 µmoles; vs. Myb28B/B, 84 µmoles; p<0.0001). The levels of 4-MSB 
in the broccoli plant were measured as a 6-fold and 3-fold increase with the Myb28V/V and 
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Myb28B/V broccoli genotypes respectively (unpublished data; Myb28V/V, 31.30 µmoles/100 g 
fresh weight; Myb28B/V; 17.60 µmoles/100 g fresh weight vs. Myb28B/B, 5.40 µmoles/100 g 
fresh weight). The variation in the fold levels of GR between Myb28B/B and Myb28V/V in the 
soups and broccoli plant is due to variation in the 4-MSB levels in different Myb28V/V batches. 
The increase in the GR levels with the presence of one or more Myb28V alleles corroborates 
the implication of Myb28 transcription factor in glucosinolate biosynthesis. In addition, the 
levels of 4-MIND were also elevated in the broccoli soups containing one or two Myb28V 
alleles compared to Myb28B/B broccoli soup. As the levels of 4-MSP is enhanced in the soups 
in the presence of one or two Myb28V alleles and it is an aliphatic glucosinolate derived from 
mainly methionine, it was presumed that the methionine levels might be significantly different 
between the three varieties. However, as illustrated in Figure 2-11, methionine levels in the 
soups were not significantly different between the three varieties while the other amino acids 
used to synthesis aliphatic glucosinolates, valine and leucine, were significantly upregulated 
in Myb28B/V broccoli soups but not in Myb28V/V broccoli soups (p<0.05). Similarly, even 
though tryptophan-derived indolic glucosinolate, 4-MIND was elevated in Myb28B/V and 
Myb28V/V broccoli soups, tryptophan levels were not different between the three soup varieties 
as represented in Figure 2-11. Further, significant difference was observed in the levels of 
several amino acids in the presence one or more Myb28V allele compared to Myb28B/B 
(p˂0.05). This is probably due to the variation in growing conditions such as soil nutrient 
content. In agreement with Traka et al. [18], the presence of one or two Myb28V alleles resulted 
in increased total sulphur levels (Figure 2-10 A) and no changes in sulphate (Figure 2-9) 
compared to Myb28B/B. It is likely that the presence of Myb28V allele increases sulphate 
assimilation, providing sulphur for glucosinolate biosynthesis resulting in enhanced levels of 
4-MSB in Myb28B/V and Myb28V/V broccoli soups as proposed by Traka et al. [18]. Levels of 
4-MSB were enhanced by ~3-fold in the Myb28B/V broccoli soup compared to Myb28B/B 
broccoli soup which is comparable to that reported previously in the florets [18]. In contrast 
to the lower SMCSO concentration reported in the florets of Myb28B/V compared to Myb28B/B 
previously [18], the current analysis of the soups demonstrated increased levels of SMCSO in 
the presence of one or more Myb28V alleles compared to Myb28B/B broccoli soup (Myb28V/V, 
1454 µmoles; Myb28B/V, 1514 µmoles vs. Myb28B/B, 1030 µmoles; p˂0.001). It is predicted 
that this could be a consequence of the soup production. The aim was to produce a food product 
that could deliver high levels of sulphur-containing bioactives in vivo and be used in future 
long-term intervention studies. These results confirm that increasing GR levels in the broccoli 
varieties is translated into increasing GR levels within the soups and that the processing does 
not affect the content. This is important for the development of a consistent dietary 
intervention.  
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Due to technical limitations with the internal standard D-NorLeucine for SMCSO, 
quantification was undertaken without the internal standard. An unknown interfering peak was 
appearing at the same retention time as D-NorLeucine (internal standard for SMCSO). The 
internal standard is crucial to allow monitoring and correction for signal fluctuation in the 
samples. However, the signal from the system suitability and calibration curve were 
monitored. 
 Conclusion 
Through a breeding programme initiated at the John Innes Centre, two high-glucoraphanin 
trait broccoli varieties, heterozygous and homozygous for the Myb28V allele from Brassica 
villosa, were developed. These high-glucoraphanin varieties (Myb28B/V and Myb28V/V) and 
standard commercially available broccoli (Myb28B/B) were manufactured into soups. Analysis 
confirmed that the presence of one or two Myb28V alleles resulted in a ~3-fold and ~5-fold 
enhanced levels of 4-MSB (GR) in the soups (Myb28V/V, 452 µmoles; Myb28B/V, 280 µmoles; 
vs. Myb28B/B, 84 µmoles). Further, the Myb28B/V and Myb28V/V soups accumulated increased 
levels of SMCSO compared to Myb28B/B broccoli soups (Myb28V/V, 1454 µmoles; Myb28B/V, 
1514 µmoles vs. Myb28B/B, 1030 µmoles). Consequently, a human intervention study was 
undertaken following on from this work to gain an insight into the bioavailability of GR and 
SMCSO from these soups containing increased levels of GR and SMCSO. In addition, the 
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 Summary 
Novel broccoli varieties that were heterozygous or homozygous for the wild-type broccoli, 
Brassica villosa allele Myb28V were developed at the John Innes Centre. The levels of sulphur-
containing bioactives such as GR and SMCSO were considerably higher compared to broccoli 
genotypes that were homozygous for the standard broccoli allele Myb28B. As a practical 
means of delivering enhanced levels of bioactives, the three broccoli varieties (Myb28B/B, 
Myb28B/V and Myb28V/V) were manufactured into broccoli and stilton soups that retained the 
increased levels as described in Chapter 2. The aim of the work presented in this Chapter was 
to undertake a human intervention study to assess the pharmacokinetics of GR and other 
sulphur-containing bioactives (SF and SMCSO) from consumption of the soups. The presence 
of one or two Myb28V alleles resulted in significantly higher plasma concentrations and a 
greater urinary excretion of GR, SF and SMCSO compared to standard broccoli. The results 
from this study have provided information on the levels of sulphur-containing compounds 
achievable in vivo. 
 
 Introduction 
The previous Chapter demonstrated the enhanced concentration of GR and SMCSO in the 
novel varieties Myb28B/V and Myb28V/V compared to Myb28B/B (standard broccoli). The soups 
made from these varieties accumulated a ~5-fold (Myb28V/V) and ~3-fold (Myb28B/V) increase 
in GR content compared to those made with Myb28B/B. Likewise, elevated levels of SMCSO, 
relative to Myb28B/B broccoli, were quantified in the Myb28B/V and Myb28V/V soups. In this 
project, a human study was designed and undertaken to investigate whether these enhanced 
levels are bioavailable. Bioavailability describes the amount of a nutrient from the 
consumption dose that is absorbed into the systemic circulation, distributed to target tissues, 
and is excreted.  
A considerable amount of epidemiological evidence suggests that consumption of cruciferous 
vegetables such as broccoli is associated with a reduction in the risk of chronic diseases. This 
is mainly attributed to ITCs which exhibit health-promoting properties. To date, SF is the most 
extensively studied ITC in in vivo and in vitro models. SF is generated enzymatically by the 
hydrolysis of GR, the most abundant glucosinolate in broccoli. This reaction is catalysed by a 
plant enzyme called myrosinase that is denatured by thermal degradation through cooking at 
high temperatures. However microbial thioglucosidase, present in the gut, can also catalyse 
the reaction [12] (Figure 1-2, Chapter 1). There is also evidence of the production of SF from 
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another isothiocyanate (4-methylthiobutyl isothiocyanate, erucin) and its precursor 
glucoerucin, commonly found in rocket salads. Like its analogue GR, glucoerucin is 
enzymatically converted by myrosinase to the ITC, erucin. Erucin and SF can undergo 
conversion by oxidation/reduction [142]. It is now well established that the health benefits 
associated with the consumption of cruciferous vegetables are the outcome of the biological 
activity of ITCs. SF is a potent inducer of Nrf2, a transcription factor causing the up-regulation 
of many phase II detoxification enzymes [65]. Recent work has also demonstrated the potential 
biological activity of erucin, including induction of phase 2 detoxification enzymes in rats 
[143] and inhibition of proliferating cells by p53 and p21 [144]. However, the potency of 
erucin is less than that of SF [145]. Following conversion of SF from GR by our gut microbial 
thioglucosidase, SF is absorbed by the enterocytes. Subsequently, SF is conjugated to 
glutathione, undergoes further metabolism via the mercapturic acid pathway and is excreted 
as a N-acetylcysteine conjugate [38] (Figure 1-3, Chapter 1). In addition to glucosinolates, 
Brassica vegetables such as broccoli contain high levels of another sulphur compound, 
SMCSO. Limited research has been conducted on SMCSO, but it has been reported that it may 
potentially have health benefits such as anti-carcinogenic, anti-diabetic and cardiovascular 
effects [2]. Therefore, this study aimed to assess the bioavailability of SMCSO as levels 
achievable in vivo will aid in investigating its biological activity at physiologically relevant 
concentrations.  
Several studies have been undertaken to quantify the pharmacokinetics of SF using various 
doses of SF and GR. As previously reported, SF is more bioavailable from a direct intake of 
SF than from an intake of GR [22,38,66,69,71]. However, broccoli is often consumed cooked 
rather than raw, in which more SF would be present because the myrosinase will still be active. 
For this reason, novel broccoli varieties with enhanced levels of GR were developed to deliver 
increased concentrations of GR to the gut. This will be the first study to investigate the 
bioavailability of SMCSO and SF from these novel broccoli soups. Two other studies 
previously published by our group investigated the bioavailability of SF from different 
broccoli-rich “soups” [38,68]. However, the soups used in those studies were produced by the 
study scientists cooking broccoli in water and homogenising the cooked broccoli using a 
blender. To achieve palatable soups, a commercially available recipe was chosen and its 
production carried out by a leading international food manufacturer based in Lincolnshire 
(UK). The food manufacturer Bakkavor®, has produced broccoli and stilton soups for the 
purpose of this study using three broccoli varieties. This is a practical way to achieve increased 
GR levels in the diet as well as facilitating compliance from participants in long-term 
interventional studies. The bioavailability of SF from a high-glucosinolate variety, standard 
broccoli soup and water was previously assessed in a randomised, three-phase crossover study 
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(REC reference E/10/2003) [38]. Additional information on SF bioavailability following 
consumption of soups made from fresh and frozen plant material were reported by Saha et al. 
[68]. Both studies were very informative for the conception of the present study specifically 
designed to compare the bioavailability of SF from three broccoli varieties. While the other 
two studies have provided information about the bioavailability from simple soups, the current 
study is distinct due to the use of soups that closely approximate commercially available 
broccoli soups with increasing levels of GR. A double-blinded, randomised, cross-over design 
that is regarded as the gold standard trial for evaluating the bioavailability of interventions was 
chosen for the purpose of the research described in this Chapter with soups containing GR as 
in the study (LREC 2003/082) undertaken by Saha et al. [68].  
This Chapter describes the design of the human study and the analysis of biological samples, 
i.e. urine and plasma, to determine the bioavailability of GR, SMCSO and SF using UPLC-
MS/MS and LC-MS/MS. Based on the enhanced levels of bioactives measured in the broccoli 
soups (Myb28B/V and Myb28V/V), it is hypothesised that higher levels of sulphur compounds 
(GR, SF, and SMCSO) will be delivered to the systemic circulation and excreted in the urine 
following consumption of these soups. 
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 Materials and Methods 
 Materials 
BD Vacutainer® EDTA (purple capped) (Cat # 367839) and trace-free (blue capped) (Cat # 
368381) blood collection tubes were purchased from Becton, Dickinson and Company (New 
Jersey, USA). DNeasy® blood & tissue kit (Cat # 69504) and RNase (100 mg/ml) (Cat # 
19101) were acquired from Qiagen. The following were purchased from Thermo Fischer 
Scientific; DPBS (Gibco®) 10X with no calcium and no magnesium (Cat. # 14200059), 
NanoDrop™ 1000 spectrophotometer, TaqMan®Drug Metabolism SNP Genotyping Assays 
(Cat # 4362691) and TaqMan® Universal Master Mix II without uracil-N-glycosylase (UNG) 
(Cat # 4440047) and Thermo Scientific™ insert vials (Cat # 10798345). Real-time Polymerase 
Chain Reaction (RT-PCR) was performed using the Applied Biosystems (AB) StepOnePlus™ 
machine.  
 
 Study design 
The study was designed as a randomised, double-blinded, three-phase crossover trial carried 
out at the Human Nutrition Unit (HNU) at the Quadram Institute Bioscience (QIB), formerly 
known as the Institute of Food Research (Figure 3-1). Each phase involved a 48-hour pre-
intervention diet restriction, a study day involving a 9-hour stay at the HNU and a sample 
collection the following morning (24 hours post soup consumption) followed by a washout 
period of 2 weeks. Participants (n=10) were required to follow a glucosinolate-free diet as well 
as avoiding alcohol, spicy food and garlic (for SMCSO) for 48 hours prior to each study day 
until the collection of the 24-hour sample for each phase. This dietary restriction was required 
to ensure that glucosinolates from other food sources did not have an impact on the study 
results. During each study day, eleven blood samples (10 ml) were collected after the 
consumption of the soups at the following timepoints: 0, 30, 45, 60, 90, 120, 180, 240, 360, 
480 minutes and 24-hour. Six urine samples were collected at the following timepoints: 0, 0-
2, 2-4, 4-6, 6-8, 8-24 hours. Using an electronic randomization generator 
(www.randomization.com), a randomisation sequence was generated prior to the start of the 
intervention allocation. Blinding was undertaken by an independent person. The study lasted 
from September 2014-August 2015.  
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Figure 3-1: Study outline 
 
 Ethics approval 
Prior to commencing the human study, approval was obtained from the institute’s Human 
Research Governance Committee (HRGC) (reference IFR06/2014) and the NRES East of 
England Norfolk Ethics Committee (REC reference 14/EE/1121) (Figure 3-2). The attendance 
to both meetings has been crucial for obtaining ethical approval in a time-effective manner. 
Following ethical approval, the study was registered on ClinicalTrials.gov (NCT02300324). 
All documents submitted to the REC can be found in Appendix I including the study protocol, 
study letters, ethical approval letters and subsequent amendments approvals. 
Participant (n=10) 
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6 Urine samples 
11 Blood samples 







profiling of ITC 
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Figure 3-2: Flowchart of ethics approval process 
 
 Study recruitment 
Ten apparently healthy men and women aged 18-65 years old were recruited onto the study. 
The recruitment strategy was mainly based on the use of the HNU volunteer database 
maintained by the HNU senior research nurse. The database consists of name and contact 
details of local people who have previously participated in studies or those who have registered 
interest in taking part in studies. Other recruitment resources included study advertisement 
around the Norwich Research Park and on the QIB website (Annex 3, Appendix I). Interested 
participants who met the basic inclusion criteria were sent additional information about the 
study (Annex 2, Appendix I). Further to this, interested participants were invited to the HNU 
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 Study inclusion/exclusion criteria 
The basic eligibility criteria are listed in Table 3-1. Participants who were eligible to take part 
based on the basic inclusion/exclusion criteria underwent further eligibility assessment, prior 
to which they signed informed consent forms (Annex 6, Appendix I). Eligibility assessments 
included anthropometric measurements (blood pressure, pulse, weight, height and Body Mass 
Index (BMI), a screening questionnaire assessing previous medical history and clinical 
laboratory analysis of urine and blood (screening for full blood count, urea and electrolytes 
and glycated haemoglobin, HbA1c). This assessment was carried out at the HNU by a senior 
nurse, and the screening results were reviewed by the HNU medical doctor. Participants’ GP 
were informed of their patients’ involvement into this study and they received copies of 
screening results to take further action in case of unexpected clinical findings.   
Table 3-1: Eligibility criteria  
Criteria Included Excluded 
Aged between 18-65 years old ✓  
Non-smoker ✓  
Living within 40 miles of Norwich ✓  
BMI between 20 and 35 kg/m2 ✓  
Like broccoli and stilton soups. ✓  
Unwilling/unable to provide urine and blood samples,  ✕ 
Clinical screening results were outside the standard 
range indicating a health problem 
 ✕ 
Veins unsuitable for cannulation  ✕ 
Known history of fainting when blood samples were 
taken/or during any clinical procedures 
 ✕ 
Women who were or have been pregnant within the last 
12 months/who were breastfeeding 
 ✕ 
Diagnosed with any long-term medical condition (e.g. 
diabetes, haemophilia, cardiovascular disease, glaucoma, 
anaemia) 
 ✕ 
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Criteria Included Excluded 
Requiring short or long term medication that may affect 
the study outcome, (including having used antibiotics 
within the previous one month) 
 ✕ 
Taking dietary supplements/ herbal remedies which may 
affect the study outcome - unless the participant were 
willing to discontinue taking them for 1 month prior to 
starting study 
 ✕ 
Allergic to members of the brassica family or the 
ingredients of the broccoli and stilton soups 
 ✕ 
Participation in another dietary intervention/ blood 
sampling study 
 ✕ 
Blood donors who have last donated in the last 16 weeks  ✕ 
Depressed or elevated blood pressure measurements 
(<90/50 or 95/55 if symptomatic or >160/100) 
 ✕ 
Unable to provide GP contact details/written informed 
consent and unable to complete the study diet. 
 ✕ 
 
 Study diet 
Participants were randomly allocated to one of the three types of broccoli soups at each phase: 
(i) 300g Myb28B/B broccoli (standard broccoli) and stilton soup (providing 84 μmoles GR & 
1031 μmoles SMCSO /300g soup), (ii) 300g Myb28B/V broccoli (Beneforte®) and stilton soup 
(providing 280 μmoles GR & 1514 μmoles /300g soup), (iii) 300g Myb28V/V broccoli and 
stilton soup (providing 452 μmoles GR & 1454 μmoles /300g soup), as reported in Figure 2-3 
and Figure 2-6 (Chapter 2). The frozen soups were manufactured by Bakkavor, a leading 
international producer of freshly prepared foods. The study diet was heated in the microwave 
at the HNU for approximately six minutes on the morning of the study phases following a 
standard operating procedure strictly implemented by the study team for avoiding variability 
in the cooking process. All three types of soups appeared the same and had the same flavour 
enabling us to use them for a double-blinded study.  
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 Sample preparation 
Blood samples (10 ml) were collected via a cannula in EDTA tubes and trace free tubes at 0, 
30, 45, 60, 90, 120, 180, 240, 360, 480 mins and 24-hour. Immediately after collection, blood 
samples were centrifuged at 1000 x g for 15 minutes at room temperature for plasma 
separation. Plasma samples were aliquoted and stored at -80°C. Six urine samples were 
collected at 0, 0-2, 2-4, 4-6, 6-8 and 8-24 hours. The total volume of urine was recorded and 
sub-samples aliquoted and stored at -80°C.  
 
 Extraction of DNA from whole blood samples 
Genomic DNA was extracted from whole blood samples using DNeasy® blood & tissue kit 
from Qiagen per manufacturer’s instructions. Samples were lysed with 20 µl proteinase K to 
100 µl anticoagulated blood and made up to 220 µl with DPBS. To obtain RNA-free genomic 
DNA, 4 µl RNase was added to degrade RNA. Buffer AL (supplied with the kit) was added to 
the samples and incubated at 56°C for 10 minutes to provide an optimum buffer for lysis 
conditions. This was followed by the addition of 100% ethanol and vortexing to mix the 
samples. Samples were pipetted into DNeasy spin columns and centrifuged at 8000 rpm for 1 
minute. Buffer AW1 was added to the DNeasy membrane inserted in a new column and 
centrifuged at 8000 rpm for 1 minute. Flow through was discarded followed by the addition 
of buffer AW2 and centrifuging at 8000 rpm for 3 minutes. DNA was eluted by adding buffer 
AE to the DNeasy membrane in a new column and centrifuging samples at 8000 rpm for 1 
minute. To obtain maximum DNA yield, samples were eluted twice. Quantification was 
determined by using the NanoDrop™. 
 
 Quantification of the extracted DNA from whole blood 
samples 
To determine the quantity and quality of DNA in the samples, a UV/VIS spectrophotometer 
(NanoDrop™) capable of measuring at 220 nm-750 nm was used. The spectrophotometer was 
normalised with 1 μl buffer AE as DNA was eluted in buffer AE. After which, 1 μl of the 
samples were pipetted on the pedestal of the spectrophotometer. Absorbance was measured at 
260 nm, and 280 nm as nucleic acids including DNA absorb at 260 nm whereas proteins and 
phenols absorb at 280 nm. Using these absorbance values, the software calculates two 
Chapter 3: Human study 
68 | P a g e  
parameters that define purity of the DNA; the A260/280 and the A230/260. A 260/280 ratio 
of 1.8 indicates that the samples are ‘pure’ DNA, however, this is not a confirmation. A 
230/260 ratio of 1.8-2.2 is a good indication of a low probability of contaminants present in 
the samples as contaminants absorb at 230 nm. 
 
 Real-time PCR to genotype blood samples 
Real-Time polymerase chain reaction (RT-PCR) of GSTM1 gene was undertaken using the 
AB StepOnePlusTM machine as reported by Cotton et al. [146]. The Corbett robot was provided 
with the master mix with the assay and DNA to prepare samples in a 96-well plate for the RT-
PCR process. TaqMan® Drug Metabolism SNP Genotyping Assay for GSTM1 (assay ID: 
C4420299720) was used. The assay includes the forward and reverse primers, two TaqMan® 
minor groove binder probes labelled at the 5’ end of oligos with a reporter dye and a 
nonfluorescent quencher at the 3’ end. The probes are labelled either with VIC® or FAM™ to 
distinguish between the two alleles. The master mix included a DNA polymerase enzyme 
(AmpliTaq Gold® DNA Polymerase), salts, buffer, and an internal reference (ROX™) to 
amplify the DNA. Each reaction consisting of  20 µl were run the AB StepOnePlusTM. RT-
PCR reactions comprised of the conversion of RNA to cDNA catalysed by the reverse 
transcriptase at 48°C for 30 minutes, activation of DNA polymerase enzyme at 95°C for 10 
minutes followed by denaturation of the DNA at 95°C for 15 seconds and primer annealing 
and extension of DNA at 60°C for 1 minute. 
 
 Analysis of sulforaphane and conjugates, glucoraphanin and 
S-methyl-L-cysteine sulfoxide  
Plasma (n=10) and urine samples (n=10) obtained from the study were analysed for SF and its 
conjugates; SF-GSH, SF-Cys-Gly, SF-Cys and SF-NAC using a validated LC-MS/MS method 
as described in Al Janobi et al. with minor modifications [63]. In addition, sulforaphane-nitrile 
(SF-N) and Erucin-N-acetylcysteine (ERN-NAC) were also measured by using the same 
method. 
Dr Shikha Saha (QIB analytical chemist) developed a method to quantify GR (GR) and 
glucoerucin in urine and plasma samples. Quantification of SMCSO in the human study 
samples used the method described in section 2.3.4.2, Chapter 2. 
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 Reagents and standards 
SF (CAS 4478-93-7) (purity>98%) (Cat. # S8045) was purchased from LKT Laboratories (St. 
Paul, USA). SMCSO (CAS 853-87-8) (purity ≥98%) (Cat # 17600) and GR (CAS 21414-41-
5) (purity ≥95%) (Cat # 10009445) were purchased from Cayman Chemical (Michigan, USA). 
Glucoerucin (CAS 21973-56-8) (purity≥97%) (Cat # 2280.1) was purchased from Carl Roth® 
(Karlsruhe, Germany). Dr Paul Needs (QIB chemist) synthesised the internal standard for SF 
N-butylthiocarbamoyl cysteine (B-ITC), SF conjugates including SF, SF-GSH, SF-Cys-Gly, 
SF-Cys, SF-NAC and ERN-NAC as published in [147] and SF-N as described by Zabala et 
al. [148]. The internal standard sinigrin for GR (Cat. # 85440) was purchased from Sigma-
Aldrich®. Blank plasma from healthy participants with the same diet restriction described in 
section 3.3.2 was ordered from Sera Laboratories International Ltd to make standard curves. 
Trichloroacetic acid (TCA)  (Cat # 63399) and ammonium acetate (Cat. # 73594) was 
purchased from Sigma-Aldrich®. Hypergrade solvents were used for the LC-MS/MS. UV 
spectrometer was used to measure extinction coefficient. Agilent 6490 Triple Quad LC-
MS/MS purchased from Agilent Technologies was used for analysis of SF and metabolites, 
GR and SMCSO in urine and plasma samples. 
 Plasma and urine extraction  
Plasma samples were extracted on ice by adding 20 µl of pre-cooled 50% TCA and 10 µl of 
internal standard (B-ITC or Sinigrin) to 100 µl of plasma sample. The samples were vortexed 
for 30 seconds followed by centrifugation at 17,000 x g at 4°C for 10 minutes. The supernatant 
was transferred into Thermo Scientific™ insert vials and analysed on the LC-MS/MS. 
Using 0.2 μM filters, urine samples were filtered and extracted by the addition of 890 μl of 
either ammonium acetate buffer for SF or 0.5% formic acid for GR or 5% TCA for SMCSO 
to 100 μl of the filtered urine samples. Samples were vortexed for 30 seconds then centrifuged 
for 10 minutes at 17,000 x g at 4°C. The supernatant was transferred into Agilent vials and 
analysed on the LC-MS/MS system. 
 
 Measuring the extinction coefficient of sulforaphane and its 
conjugates 
SF and SF-GSH were diluted in water while the other conjugates were diluted in methanol to 
1 mg/ml. All compounds were further diluted in methanol to measure the absorption using a 
UV spectrometer. The extinction coefficient (M−1cm−1) was calculated using the absorbance 
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values at 270 nm (and at 240 nm for SF) as follows; SF-Cys (8711), SF-Cys-Gly (4721), SF-
GSH (5825), SF-NAC (7927) and SF (871), ERN-NAC (7854) comparable to published 
extinction coefficient [69,102,149]. 
 
 LC-MS/MS analysis of sulforaphane and its metabolites 
SF and metabolites were identified and quantified by LC-MS/MS. A serial dilution was 
conducted in either blank urine or plasma relevant to the sample run to minimise matrix effect. 
For plasma samples, the standards used were SF, SF-GSH and ITC-mix (SF-Cys, SF-Cys-Gly, 
SF-NAC, ERN-NAC) and the standards used for urine samples were SF, ITC-mix (SF-Cys, 
SF-Cys-Gly, SF-NAC, ERN-NAC, SF-GSH) diluted to generate a 10-point standard curve. 
The standard curve ranged from 0–10 µg/ml for SF and ITC-mix and 0–40 µg/ml for SF-GSH. 
Quality control consisting of pooled urine and blood samples and system suitability samples 
were run to check that the instrument operated without any issues. 
The LC-MS/MS was set on a flow rate of 0.3 ml/min. The column used for the analysis was a 
HPLC Phenomenex® Luna 3u C18 (2) 100A 100 x 2.1 mm with a Phenomenex® C18 (2) 100A. 
The column temperature and autosampler were maintained at 40°C and 4°C respectively. 
Samples were injected at 5 μl, ‘system suitability’ was injected at 1 μl, and blank was injected 
at 20 µl. Separation of metabolites was carried out with 0.1% ammonium acetate in deionised 
water titrated with 0.1% acetic acid until pH 4 was reached (mobile phase A) and 0.1% acetic 
acid in acetonitrile (mobile phase B). The LC eluent flow was sprayed into the mass 
spectrometer interface without splitting. SF and SF conjugates ions were monitored using mass 
spectrometry in MRM mode in positive polarity with ESI source. The source parameters were; 
a gas temperature at 200˚C with a gas flow of 12 l/minute, a sheath gas temperature at 400˚C 
with a sheath gas flow of 12 l/minute, a nebuliser pressure of 60 psi and capillary voltage at 
4000V.  
The standard curve was used to calculate the concentration of the samples relative to the 
internal standard. For quantitative analysis in urine, the sample volume was considered to 
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Table 3-2: Summary of the monitored product ions of SF and SF conjugates and the 















SF 7.1 178.01 136.0 10 5 Positive 
SF 7.1 178.01 119.1 10 5 Positive 
SF 7.1 178.01 114.1 10 5 Positive 
SF-GSH 6.2 485.01 178.9 22 5 Positive 
SF-GSH 6.2 485.01 113.9 38 5 Positive 
SF-Cys-Gly 3.4 356.01 114.0 18 5 Positive 
SF-Cys-Gly 3.4 356.01 75.9 24 5 Positive 
SF-Cys 3.2 299.01 136.1 12 5 Positive 
SF-Cys 3.2 299.01 114.0 10 5 Positive 
SF-NAC 6.4 341.01 177.8 20 5 Positive 
SF-NAC 6.4 341.01 114.0 18 5 Positive 
ERN-NAC 7.9 325.01 164.0 10 5 Positive 
ERN-NAC 7.9 325.01 122.0 14 5 Positive 
ERN-NAC 7.9 325.01 102.9 18 5 Positive 
SF-N 2.7 146.01 60.9 10 5 Positive 
SF-N 2.7 146.01 55.0 22 5 Positive 
B-ITC 9.2 279.01 122.0 10 5 Positive 
 
 UPLC-MS/MS analysis of glucoraphanin  
GR and its reduced analog (glucoerucin) were analysed by UPLC-MS/MS in all study samples. 
GR stock (1 mg/ml) and glucoerucin (1 mg/ml) were diluted to a 9-point standard curve 
ranging from 0-2 µg/ml for urine and ranging from 0-0.25 µg/ml for plasma. Samples were 
injected at 5µl and eluted at a flow rate of 0.3 ml/min. GR was separated with 0.2% formic 
acid in water (mobile phase A) and 0.2% formic acid in acetonitrile (mobile phase B) using a 
Kinetex® 1.7 µm XB-C18 100 Å 100 x 2.1 mm UPLC column. The gradient started at 5% 
mobile phase B increasing over 7 mins to 80% mobile phase B and finally re-equilibrating to 
5 % mobile phase B for 2 mins. 
The LC eluent flow was sprayed into the mass spectrometer interface without splitting. GR 
ion and sinigrin ion was monitored using mass spectrometry MRM mode in negative polarity 
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with ES. The source parameters were the same as SMCSO analysis in section 2.3.4.2, Chapter 
2. The quantification was performed using matrix match calibration curve. Identification and 
quantification of the GR peak was on the basis of retention time and peak area through the use 
of calibration standards relative to sinigrin. 
Table 3-3: Summary of the monitored product ions of GR and glucoerucin and the 















GR 2.0 436.42 372 18 4 Negative 
GR 2.0 436.42 96.9 22 4 Negative 
Glucoerucin 5.5 419.99 96.8 22 4 Negative 
Glucoerucin 5.5 419.99 74.8 34 4 Negative 
Sinigrin 2.3 357.99 96.9 22 4 Negative 
Sinigrin 2.3 357.99 74.8 34 4 Negative 
 
 UPLC-MS/MS analysis of S-methyl-L-cysteine sulfoxide  
The UPLC-MS/MS set up is the same as the method in section 2.3.4.2, Chapter 2. Blood and 
urine samples were analysed for measuring SMCSO by using a novel UPLC-MS/MS method. 
A 10-point standard curve ranging from 0-20 µg/ml for urine and ranging from 0-10 µg/ml 
was generated by diluting 1 mg/ml SMCSO stock. Using an Agilent SB-AQ 1.8 uM (100 x 
2.1mm) C18 column with an Agilent Zorbax guard column, SMCSO was separated in plasma 
with 10 mM ammonium acetate + 0.05% heptafluorobutyric acid in water (mobile phase A) 
and 10 mM ammonium acetate + 0.05% heptafluorobutyric acid in 90% methanol (mobile 
phase B). Analysis of urine samples was undertaken with 0.1% formic acid in water (mobile 
phase A) and 0.1% formic acid in acetonitrile (mobile phase B).  
 
 Inductively coupled plasma-mass spectrometry to quantify 
trace elements in plasma samples  
Plasma samples (0.5 ml) collected in BD Vacutainer® trace free blood collection tubes were 
sent to Dr Scott Young at the University of Nottingham to analyse 29 trace elements by 
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inductively coupled plasma-mass spectrometry (ICP-MS). Samples were run on a Thermo-
Fisher Scientific iCAP-Q equipped with collision cell technology with kinetic energy 
discrimination. The analysis of the samples was undertaken as published in Hurst et al. [150]. 
The collision gas used for most elements was helium except for the use of hydrogen for 
selenium. A multi-element calibration standards including silver, aluminium, arsenic, barium, 
cadmium, cobalt, chromium, caesium, copper, iron, manganese, molybdenum, nickel, lead, 
rubidium, selenium, strontium, uranium, vanadium and zinc in the range 0 – 50 µg/L were 
purchased. Additional calibration standards were created comprising of calcium, magnesium, 
sodium and potassium ranging from 0-30 mg/L and phosphorus, sulphur and boron at 10 mg/L. 
Samples were diluted 1:20 with a solution consisting of 0.1% non-ionic surfactant Triton X-
100, an anti-foam reagent, 1% HNO3, 2% methanol and an internal standard mix including 
scandium (10 µg/L), rhodium (5 µg/L) and iridium (2 µg/L). 
Seronorm™ trace elements whole blood L-1 and L-2 were run as quality control to check 
instrument run without any issues. Quantification of samples from the instrument was also 
undertaken by Dr Scott Young using a Qtegra™ software by Thermo-Fisher Scientific. See 
Appendix II for results from ICP-MS. 
 
 Data Analysis 
 Sample size 
Power calculation was performed by the statistician Dr Jack Dainty (UEA senior statistician) 
in order to determine the sample size for the study. To detect a significant (p<0.05) difference 
in mean total urinary thiol excretion of 18 μmoles between consumption of Myb28B/B (standard 
broccoli) and stilton soup and Myb28B/V (Beneforte®) broccoli and stilton soup, the study 
required ten participants giving a power of 80%. The SD of the differences between the two 
groups was estimated to be 17 μmoles. The basis for this calculation was preliminary 
unpublished data from 65 subjects from the ENGAGE study (REC 12/EE/0483) (data not 
published). 
 
 Statistical analysis 
Statistical analysis was undertaken by Dr Jack Dainty (UEA senior statistician) and Dr Henri 
Tapp (QIB senior statistician). Response variables were modelled using sequential analysis of 
variance (ANOVA). These are linear models that account for the non-independence of the type 
Chapter 3: Human study 
74 | P a g e  
of data that were generated in this cross-over study (i.e. data that come from the same 
participants after different interventions). The aim of the analysis was to examine whether the 
intervention(s) had any effect on the various outcome measures (e.g. urinary excretion of total 
thiol conjugates, pharmacokinetic parameters generated from the time course of plasma 
samples). The four explanatory variables employed comprised the following: concentration 
prior to meal, volunteer identification code, sequence in which the soups were consumed, and 
either soup Myb28B/B, Myb28B/V or Myb28V/V. Standard model diagnostics were applied such 
as transformations of the response or removal of potential outliers. Significance levels for 
multiple comparisons are based on Tukey’s honest significant difference.  
 
 Pharmacokinetic analysis 
The plasma data from the study was imported into GraphPad Prism version 7.02 for Windows, 
(GraphPad Software, La Jolla California USA, www.graphpad.com). Prism was used to 
calculate area under the curve (AUC), Tmax (time of maximum concentration), Cmax (maximum 
concentration) as pharmacokinetic parameters. The percentage excreted from the initial dose 
was calculated for the urine samples as a biomarker of SF and metabolite, SMCSO and GR 
recovery. 
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 Results 
 Participant recruitment 
Eighty-seven potential participants expressed interest in taking part in the study. These 
potential participants were sent a participant information sheet to provide them more 
information about the study. Following this, 43 expressed an interest to come for a study talk 
at the HNU. Out of 24 participants that were subsequently screened, 11 participants were 
included into the study. The other 13 potential participants were excluded for various medical 
reasons as shown in Figure 3-3. One participant was excluded during the study thus of the 11 
















Figure 3-3: Flowchart presenting participant recruitment 
Initial interest in study (n=87) 
Interest in study talk (n=43) 
Completed study talk (n=34) 
Eligibility screening (n=24) Dropped out prior to screening (n=11) 
Excluded (n=13) due to: 
 BMI <20 
 Anaemia 
 Blood pressure over 160/100 
 Inaccessible veins 
 Urine results outside the range 
 Hepatitis 
 HbA1c  42 (pre-diabetic range) 
 Blood results outside the range 
 Medications 
Dropped out prior to study talk (n=9) 
Randomisation (n=11) 
Excluded (n=1) 
Completion of all phases (n=10) 
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 Participant anthropometric measurements and their 
genotypes 
Recruited participants had the following anthropometric characteristics as summarised in 
Table 3-4. Out of 10 participants, 6 were GSTM1-positive, and 4 were GSTM1-null. The 
occurrence of GSTM1-null genotype in this small study sample (n=10) is 40% which is within 
the range of 39-62% for Caucasians as published by Cotton et al. [146]. 
Table 3-4: Baseline characteristics of participants involved in the study. 
Participant ID Age (years) Height (cm) Weight (kg) BMI (kg/m²) 
B02 24 161.8 67.2 25.7 
B03 23 172.1 80.3 27.1 
B07 61 158.9 61.3 24.3 
B09 24 178.8 69.7 22 
B15 59 173.5 66.3 22.0 
B16 26 192.1 87.2 24.0 
B20 45 179.7 97.6 30.2 
B22 43 168.9 87.7 30.7 
B23 62 162.0 61.0 23.2 
B24 62 160.8 57.8 22.4 
Mean ± SD 42.9 ± 17.4 170.9 ± 10.6 73.6 ± 13.6 25.2 ± 3.2 
 
 Bioavailability of sulforaphane and its conjugates following 
consumption of soups made with three broccoli genotypes 
To determine the pharmacokinetics of SF and mercapturic acid metabolites from the broccoli 
soups, blood and urine samples collected from participants were analysed using LC-MS/MS. 
Prior to consumption of the soups, baseline plasma and urine samples were collected to check 
compliance to the glucosinolate diet restriction. Following consumption of the soups, SF and 
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metabolites were detected in both the plasma and urine samples. The concentration of SF and 
metabolites detected in the baseline samples was subtracted from subsequent time points to 
confirm that the concentration of SF and metabolites observed is a result of the broccoli 
genotypes. After consumption of all three types of soups, the concentration of SF and 
metabolites in the plasma was detectable within 30 minutes (Figure 3-4). Following 
consumption of Myb28B/B broccoli soups, the levels of SF and metabolites peaked at 6 hours 
(Figure 3-4) subsequently declining to 0.02 ± 0.01 µM within 24 hours (Table 3-5). On the 
contrary, after consumption of the soups with the Myb28B/V and Myb28V/V broccoli genotypes, 
the levels of SF and metabolites peaked later, at 8 hours, (Figure 3-4) subsequently decreasing 
to 0.07 ± 0.06 μM and 0.09 ± 0.05 μM respectively (Table 3-5). There is a dose-dependent 
increase in the levels of SF and metabolites detected in the plasma at 8 hours following 
consumption of soups with Myb28B/V and Myb28V/V broccoli genotypes compared to 
Myb28B/B broccoli soup (Figure 3-4).  
 
Figure 3-4: The plasma concentration of SF and metabolites (µM) following consumption 
of the three types of broccoli soups. Plasma samples were collected over 24 hours 
following consumption of Myb28B/B (84 μmoles GR /300g soup), Myb28B/V (280 μmoles 
GR /300g soup) and Myb28V/V (452 μmoles GR /300g soup). The samples were analysed 
for SF and metabolites including SF-GSH, SF-Cys, SF-Cys-Gly and SF-NAC using LC-
MS/MS. Data (n=10) is represented as mean ± SD.  
 
The pharmacokinetics of the broccoli soups are represented as the AUC, Cmax, Tmax, and 
percentage of excretion, as reported in Table 3-5. The levels of SF and metabolites reach a ~4 
and ~2-fold significant increase in the plasma following consumption of the soups with the 
Myb28V/V (p<0.0001) and Myb28B/V (p<0.01) broccoli genotypes, respectively, compared to 
Myb28B/B broccoli expressed as the AUC and Cmax (Table 3-5). 
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Table 3-5: Summary table of the levels of SF and metabolites in plasma and urine after consumption of soups stratified by soups made with different 
broccoli genotypes 
 Myb28B/B broccoli 
and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
p-value for broccoli and stilton soup 
 







SF and metabolites in 
plasma 
       
AUC (μmol.h/l) 1.99 ± 1.31 4.92 ± 3.77 8.08± 6.60 <0.0001 ˂0.01 <0.0001 0.0905 
Cmax (μmol/l) 0.17 ± 0.12 0.37 ± 0.26 0.61 ± 0.40 ≤0.0001 ˂0.01 ≤0.0001 0.0683 
Tmax (h) 6.10 ± 2.23 7.40 ± 0.97 9.20 ± 5.27 ˂0.05 0.5258 ˂0.05 0.2301 
Concentration at 24 
hours (μmol/l)  
0.02 ± 0.01 0.07 ± 0.06 0.09 ± 0.05 <0.0001 ˂0.01 <0.0001 0.1797 
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 Myb28B/B broccoli 
and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
p-value for broccoli and stilton soup 
 







SF and metabolites in 
urine 
Total excreted in 24 
hours (μmoles) 
8.74 ± 4.95 23.14 ± 16.17 39.98 ± 26.22 <0.001 ˂0.05 <0.001 ˂0.01 
Percentage excreted 24 
hours after ingestion % 
10.40 ± 5.90 8.26 ± 5.78 8.85 ± 5.80 0.5727    
Analysis modelled using sequential analysis of variance (ANOVA) by Dr Henri Tapp/Dr Jack Dainty. The variables underwent log transformation 
except for plasma concentration at 24 hours, which underwent a square root transformation. Significance level for multiple comparisons was analysed 
using Tukey’s honest significance test. ‘SF metabolites’ refers to SF, SF-GSH, SF-Cys, SF-Cys-Gly and SF-NAC in plasma and SF, SF-NAC, SF-Cys, 
ERN-NAC and SF-Cys-Gly in urine. 
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The urinary excretion of SF and metabolites was detected within the first hour, peaked at 6-8 
hours, and subsequently declined. SF and metabolites is slowly excreted in the first 0-6 hours 
followed by rapid excretion at 6-8 hours following consumption of the Myb28B/B broccoli 
soups, and rapid excretion 6-24 hours following consumption of the soups with Myb28B/V and 
Myb28V/V broccoli genotypes (Figure 3-5 A). The amount of SF and metabolites excreted in 
the urine may not have reached a plateau following consumption of the soups with Myb28B/B 
broccoli, Myb28B/V and Myb28V/V broccoli genotypes (Figure 3-5 A). Compared to the 
Myb28B/B broccoli, the cumulative amount of SF and metabolites excreted in the urine is 
significantly higher by ~5-fold 24 hours following consumption of the soups with Myb28V/V 
(39.98 ± 26.22 vs. 8.74 ± 4.95 µmoles, p<0.001) and significantly higher by ~3-fold following 
consumption of the soups with Myb28B/V (23.14 ± 16.17 vs. 8.74 ± 4.95 µmoles, p˂0.05) 
(Figure 3-5 A-B). Plasma and urine results have provided strong evidence that the presence 
of one or two Myb28V alleles enhances the pharmacokinetics of dietary compounds delivered 
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A Cumulative excretion of SF and metabolites 
 
 
B Total urinary excretion of SF and metabolites 
 
Figure 3-5: Urinary excretion of SF and metabolites (µmoles) in 24 hours following 
consumption of the three types of broccoli soups.  The cumulative excretion of SF and 
metabolites (A) and the total urinary excretion of SF and metabolites (B) measured in 
urine samples collected over 24 hours after consumption of Myb28B/B (84 μmoles GR 
/300g soup), Myb28B/V (280 μmoles GR /300g soup) and Myb28V/V (452 μmoles GR /300g 
soup). Samples were analysed for SF and metabolites including ERN-NAC, SF-Cys, SF-
Cys-Gly, and SF-NAC using LC-MS/MS. Data (n=10) is represented as mean ± SD. Total 
urinary excretion data underwent log root transformation followed by analysis by one-
way ANOVA with Tukey’s honest significance test (*p<0.05 and *** p˂0.001 vs. My28B/B 
broccoli soup). 
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Plasma samples were analysed for the following SF metabolites; SF, SF-GSH, SF-Cys, SF-
Cys-Gly, SF-NAC and ERN-NAC. The SF conjugates found in the plasma were, in order of 
the percentage of the total conjugates in 24 hours, SF = SF-GSH > SF-Cys-Gly > SF-Cys > 
SF-NAC, as represented in (Table 3-6). ERN-NAC was not detected in the plasma samples. 
Whereas ERN-NAC was detected in the urine samples but SF-GSH was not detected. The 
percentage of urinary excretion of SF and conjugates in 24 hours were as follows, SF-NAC > 
ERN-NAC > SF-Cys > SF > SF-Cys-Gly (Table 3-6). 
Table 3-6: Summary table of the percentage of individual SF metabolite in plasma and 
urine after consumption of soups with increasing levels of GR 
 
Myb28B/B broccoli 
and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
 
Mean ± SD (%) Mean ± SD (%) Mean ± SD (%) 
Metabolites in plasma 
over 24-hours   
SF 32.20 ± 17.29 34.59 ± 14.67 36.58 ± 14.35 
SF-GSH 34.57 ± 21.74 33.01 ± 23.80 30.45 ± 21.21 
SF-CYS 8.93 ± 9.93 5.54 ± 3.53 8.77 ± 8.80 
SF-CYS-GLY 21.60 ± 11.81 22.22 ± 10.27 20.23 ± 7.38 
SF-NAC 2.70 ± 1.79 4.63 ± 4.29 3.97 ± 2.84 
Metabolites in 24-
hour urine excretion   
SF 8.53 ± 5.57 5.66 ± 3.04 5.41 ± 2.20 
SF-NAC 57.78 ± 11.73 49.46 ± 14.08 51.26 ± 11.07 
SF-CYS 18.29 ± 6.18 19.15 ± 9.20 21.08 ± 5.61 
ERN-NAC 20.93 ± 9.04 25.30 ± 16.73 21.15 ± 13.51 
SF-CYS-GLY 0.48 ± 0.90 0.44 ± 0.72 1.11 ± 2.74 
Data (n=10) is represented as mean ± SD. The percentage was calculated as the 
concentration of each individual metabolite (µM) of the total concentration of SF and 
metabolites (µM). 
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In order to explore the role of the GSTM1 genotype on the metabolism of SF, data collected 
from the urine and plasma samples were stratified according to the genotypes (Table 3-7). 
There was no significance on the plasma pharmacokinetics (AUC, Cmax, Tmax) and the urinary 
excretion between GSTM1-null and GSTM1-positive participants as reported in Table 3-7. 
However, the study was not powered in such a way that one could definitively say that there 
is no effect.  
Table 3-7: Summary table of the SF metabolites in plasma and urine after consumption 









Mean ± SD Mean ± SD 
SF and metabolites in plasma  
AUC (μmol.h/L)  
Myb28B/B broccoli and stilton soup  1.45 ± 0.68 2.79 ± 1.72 0.2186 
Myb28B/V broccoli and stilton soup 4.05 ± 2.75 6.22 ± 5.13 0.4815 
Myb28V/V broccoli and stilton soup 7.39 ± 3.41 9.12 ± 10.43 0.7670 
Cmax (μmol/L)    
Myb28B/B broccoli and stilton soup  0.12 ± 0.06 0.25 ± 0.15 0.1882 
Myb28B/V broccoli and stilton soup 0.32 ± 0.22 0.43 ± 0.33 0.5839 
Myb28V/V broccoli and stilton soup 0.63 ± 0.29 0.58 ± 0.58 0.8866 
Tmax (h)    
Myb28B/B broccoli and stilton soup  5.50 ± 2.66 7.0 ± 1.15 0.2614 
Myb28B/V broccoli and stilton soup 7.33 ± 1.03 7.50 ± 1.00 0.8065 
Myb28V/V broccoli and stilton soup 10.33 ± 6.74 12.00 ± 8.00 0.7436 
Total SF and metabolites in urine 
(μmoles) 
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Mean ± SD Mean ± SD 
Myb28B/B broccoli and stilton soup  10.28 ± 4.86 6.42 ± 4.73 0.2541 
Myb28B/V broccoli and stilton soup 25.47 ± 16.28 19.64 ± 17.77 0.6179 
Myb28V/V broccoli and stilton soup 47.86 ± 23.92 28.17 ± 28.27 0.2972 
Percentage excreted 24 hours after 
ingestion %   
 
Myb28B/B broccoli and stilton soup  12.23 ± 5.78 7.65 ± 5.64 0.2541 
Myb28B/V broccoli and stilton soup 9.09 ± 5.81 7.01 ± 6.35 0.6180 
Myb28V/V broccoli and stilton soup 10.59 ± 5.29 6.23 ± 6.26 0.2972 
Data was analysed using unpaired t-test with Welch’s correction. ‘SF metabolites’ refers 
to SF, SF-GSH, SF-Cys, SF-Cys-Gly and SF-NAC in plasma and SF, SF-NAC, SF-Cys, 
ERN-NAC and SF-Cys-Gly in urine. 
 
 Bioavailability of intact glucoraphanin following consumption 
of soups made with three broccoli genotypes 
Plasma and urine samples collected from participants were analysed by UPLC-MS/MS to 
assess the bioavailability of intact GR. Following consumption of the soups, intact GR was 
detected in both plasma and urine samples. To our knowledge, this is the first human study to 
report the detection and quantification unmetabolized GR in plasma and urine. The 
concentration of GR detected in the baseline samples were subtracted from subsequent time 
points to confirm that the concentration of GR observed is because of the broccoli genotypes. 
In addition, glucoerucin was found in the urine samples but not detected in the plasma samples. 
After consumption of all three types of soups, the concentration of GR in the plasma was 
detectable within 30 minutes (Figure 3-6). The levels of GR peaked at 2 hours and then within 
24 hours decreased to trace levels following consumption of all three types of soups (Table 
3-8). At 2 hours after the participants consumed the soups with the Myb28V/V and Myb28B/V 
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broccoli genotypes, higher levels of GR were detected in the plasma in a dose-dependent 
manner compared to Myb28B/B broccoli soups. 
 
Figure 3-6: The plasma concentrations of unmetabolised GR (µM) following 
consumption of the three types of broccoli soups. Plasma samples were collected over 24 
hours following consumption of Myb28B/B (84 μmoles GR /300g soup), Myb28B/V (280 
μmoles GR /300g soup) and Myb28V/V (452 μmoles GR /300g soup). The samples were 
analysed for GR by UPLC-MS/MS. Data (n=10) is represented as mean ± SD.  
 
The pharmacokinetics parameter including AUC, Cmax, Tmax, and percentage of excretion are 
all reported in Table 3-8. Significant ~5-fold and ~3-fold enhanced levels of GR were 
delivered to the plasma following consumption of soups enriched with GR (Myb28V/V and 
Myb28B/V broccoli soups respectively, p<0.0001) in contrast to Myb28B/B broccoli soup 
consumption as represented by the AUC.  
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Table 3-8: Summary table of the levels of unmetabolised GR in plasma and urine after consumption of soups stratified by soups made with different 
broccoli genotypes 
 Myb28B/B broccoli 
and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
p-value for broccoli genotypes 
 







GR in plasma         
AUC (μmol.h/l) 0.05 ± 0.05 0.15 ± 0.08 0.24 ± 0.11 <0.0001 <0.0001 <0.0001 <0.05 
Cmax (μmol/l) 0.01 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 <0.0001 <0.0001 <0.0001 <0.01 
Tmax (h) 2.20 ± 1.16 2.23 ± 0.90 2.25 ± 0.95 0.8006    
Concentration at 
24 hours (μmol/l) 
˂0.1 ˂0.1 ˂0.1 0.8389    
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 Myb28B/B broccoli 
and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
p-value for broccoli genotypes 
 










       
Total excreted in 
24 hours 
(μmoles) 
0.54 ± 0.29 1.44 ± 0.66 2.12 ± 0.98 <0.0001 <0.0001 <0.0001 <0.05 
Percentage 
excreted 24 hours 
after ingestion % 
0.64 ± 0.34 0.51 ± 0.24 0.47 ± 0.22 0.6053    
Analysis modelled using sequential analysis of variance (ANOVA) by Dr Henri Tapp. The variables including AUC, total excreted and percentage 
excreted underwent a square root transformation, Cmax and Tmax underwent a log transformation. Concentration at 24 hours underwent a 
transformation of (y + 9.5463e-05)^-1. Significance level for mutliple comaprisons was analysed using Tukey’s honest significance test.  
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GR and glucoerucin were excreted via urine within 2 hours after consumption of all three types 
of soups. The levels of GR and glucoerucin rapidly increased at 2-4 hours followed by a 
decline in the levels. The cumulative amount of GR and glucoerucin demonstrates a rapid 
excretion of these compounds from 0-8 hours, and then reaches a plateau following 
consumption of all three types of soups which is consistent with the trace levels measured at 
8-24-hour urine samples (Figure 3-7 A). A similar dose-dependent trend to that observed in 
the plasma is also demonstrated in the urine excretion (Figure 3-7 A-B). Compared to 
Myb28B/B broccoli, ~4-fold and ~3-fold greater cumulative amount of GR and glucoerucin 
was significantly excreted in the urine following consumption of the soups with Myb28V/V 
broccoli genotype (2.12 ± 0.98 vs. 0.54 ± 0.29 µmoles, p<0.0001) and Myb28B/V broccoli 
genotype respectively (1.44 ± 0.66 vs. 0.54 ± 0.29 µmoles, p<0.0001) (Figure 3-7 A-B). These 
data convincingly demonstrate that the presence of one or two Myb28V alleles delivers 
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A Cumulative excretion of GR and glucoerucin 
 
 
B Total urinary excretion of GR and glucoerucin 
 
Figure 3-7: Urinary excretion of unmetabolised GR and glucoerucin (µmoles) in 24 hours 
following consumption of the three types of broccoli soups. The cumulative excretion of 
GR and glucoerucin (A) and the total urinary excretion of GR and glucoerucin (B) 
measured in urine samples were collected over 24 hours after consumption of Myb28B/B 
(84 μmoles GR/300g soup), Myb28B/V (280 μmoles GR /300g soup) and Myb28V/V (452 
μmoles GR/300g soup). The samples were analysed for GR and glucoerucin by UPLC-
MS/MS. Data (n=10) is represented as mean ± SD. Total urinary excretion data 
underwent square root transformation followed by analysis by one-way ANOVA with 
Tukey’s honest significance test (*** p˂0.0001 vs. My28B/B broccoli soup). 
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Glucoerucin, a product of the enzymatic conversion of GR by gut bacteria, was determined in 
the urine and plasma samples of participants who consumed the three soups. The levels of 
glucoerucin were undetectable in the plasma samples after consuming all three types of soups. 
In contrast, it was quantifiable in the urine samples collected from the participants. The 
percentage of GR and glucoerucin individually excreted in the urine is represented in Table 
3-9. There was no significant difference in the percentage of GR or glucoerucin excreted 
following consumption of the three soups. However, excretion of GR was the major 
contributor to the total excretion in the urine. The percentage of GR excreted was twice the 
percentage of glucoerucin excreted following consumption of all three types of soups. 
Table 3-9: Summary table of the individual percentage of GR and glucoerucin excreted 
in urine following consumption of soups made with different broccoli genotypes 
 Myb28B/B broccoli 
and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
 Mean ± SD (%) Mean ± SD (%) Mean ± SD (%) 
Urine metabolites    
GR 66.7 ± 11.02 60.7 ± 8.83 64.7 ± 13.24 
Glucoerucin 33.3 ± 11.02 39.3 ± 8.83 38.6 ± 9.64 
Data (n=10) is represented as mean ± SD. The percentage was calculated as the individual 
concentration of glucoraphanin and glucoerucin (µM) of the total concentration of 
glucoraphanin and glucoerucin (µM). 
To assess whether the GSTM1 genotype affects the bioavailability of GR, urine and plasma 
data were stratified per the participants’ genotypes (Table 3-10). There was no significant 
difference with the plasma pharmacokinetics (AUC, Cmax, Tmax) and the urinary excretion 
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Table 3-10: Summary table of unmetabolised GR in plasma and urine after consumption 









Mean ± SD Mean ± SD  
GR in plasma  
AUC (μmol.h/l)  
Myb28B/B broccoli and stilton soup  0.07 ± 0.06 0.03 ± 0.01 0.2390 
Myb28B/V broccoli and stilton soup 0.18 ± 0.09 0.12 ± 0.03 0.1488 
Myb28V/V broccoli and stilton soup 0.27 ± 0.12 0.20 ± 0.08 0.3559 
Cmax (μmol/l)    
Myb28B/B broccoli and stilton soup  0.01 ± 0.01 0.01 ± 0.00 0.4689 
Myb28B/V broccoli and stilton soup 0.03 ± 0.01 0.03 ± 0.01 0.9463 
Myb28V/V broccoli and stilton soup 0.04 ± 0.01 0.05 ± 0.03 0.3866 
Tmax (h)    
Myb28B/B broccoli and stilton soup  2.25 ± 1.48 2.13 ± 0.63 0.8591 
Myb28B/V broccoli and stilton soup 1.88 ± 0.74 2.75 ± 0.96 0.1788 
Myb28V/V broccoli and stilton soup 2.50 ± 1.18 1.88 ± 0.25 0.2597 
Total GR and glucoerucin in 
urine (μmoles)  
 
Myb28B/B broccoli and stilton soup  0.53 ± 0.27 0.56 ± 0.36 0.9005 
Myb28B/V broccoli and stilton soup 1.51 ± 0.46 1.34 ± 0.98 0.7583 
Myb28V/V broccoli and stilton soup 2.11 ± 0.55 2.13 ± 1.53 0.9777 
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Mean ± SD Mean ± SD  
Percentage excreted 24 hours after 
ingestion % 
Myb28B/B broccoli and stilton soup  0.63 ± 0.32 0.66 ± 0.43 0.9004 
Myb28B/V broccoli and stilton soup 0.16 ± 0.348 0.35 ± 0.164 0.7583 
Myb28V/V broccoli and stilton soup 0.47 ± 0.12 0.47 ± 0.34 0.9777 
Data (n=10) was analysed using unpaired t-test with Welch’s correction.  
 
 Bioavailability of S-methyl-L-cysteine sulfoxide following 
consumption of soups made with three broccoli genotypes  
To assess the bioavailability of SMCSO, plasma and urine samples collected from participants 
were analysed for SMCSO using a new validated UPLC-MS/MS method. All baseline samples 
collected prior to consumption of the soups detected SMCSO as SMCSO is present in some 
non-Brassica vegetables e.g. onions. Participants were only required to restrict glucosinolate-
containing foods and garlic. This was considered and baseline levels were subtracted from all 
the subsequent samples. Following consumption of the soups, SMCSO was detected in both 
plasma and urine samples. To our knowledge, this is the first human study to report SMCSO 
detection and quantification in plasma and urine using UPLC-MS/MS.  
SMCSO was detected in the plasma within 30 minutes of consumption of all three types of 
soups (Figure 3-8). Subsequently, there is a steady increase in the levels of SMCSO in the 
plasma and peaks between 1.5-2 hours following consumption of Myb28B/B broccoli soups 
and soup with the Myb28V/V broccoli genotypes. After consumption of the soup with Myb28B/V 
broccoli genotype, the levels peak slightly earlier at 1 hour post-consumption. Consequently, 
the levels of SMCSO gradually decrease over the 24 hours after soup consumption but do not 
relapse to baseline levels. At 24 hours after consumption of the Myb28B/B broccoli soup, 
Myb28B/V broccoli soup, and Myb28V/V broccoli soup, SMCSO was quantified at 2.18 ± 1.53 
µM, 3.57 ± 1.52 µM and 4.66 ± 1.52 µM respectively. There is an increase in the plasma levels 
of SMCSO following consumption of the soups with Myb28B/V broccoli genotype and 
Myb28V/V broccoli genotype compared to Myb28B/B broccoli soup (Figure 3-8). In contrast to 
Chapter 3: Human study 
93 | P a g e  
GR and SF, the presence of one or two Myb28V alleles results in similar levels of SMCSO in 
plasma but increased levels compared to Myb28B/B.  
 
Figure 3-8: The plasma concentrations of SMCSO (µM) following consumption of the 
three types of broccoli soups. Plasma samples were collected over 24 hours following 
consumption Myb28B/B (84 μmoles GR & 1031 μmoles SMCSO /300g soup), Myb28B/V 
(280 μmoles GR & 1514 μmoles SMCSO /300g soup) and Myb28V/V (452 μmoles GR & 
1454 μmoles SMCSO /300g soup). The samples were analysed for SMCSO by UPLC-
MS/MS. Data (n=10) is represented as mean ± SD. 
 
The pharmacokinetics of SMCSO from the broccoli soups are represented as the AUC, Cmax, 
Tmax, and percentage of excretion as reported in Table 3-11. There is a significant increase in 
the plasma levels of SMCSO by ~2-fold following consumption of the soups with the 
Myb28B/V and Myb28V/V broccoli genotypes (p<0.0001) compared to Myb28B/B broccoli as 
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and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
p-value for broccoli genotypes 







SMCSO in plasma         
AUC (μmol.h/l) 130.85 ± 51.49 195.34 ± 40.42 217.53 ± 43.22 <0.01 ≤0.0001 ˂0.0001 0.2793 
Cmax (μmol/l) 16.93 ± 3.79 26.94 ± 7.70 28.03 ± 5.39 <0.01 ˂0.0001 ˂0.0001 0.6122 
Tmax (h) 1.78 ± 0.63 1.38 ± 0.54 1.70 ± 0.35 0.2548    
Concentration at 24 
hours (μmol/l) 
2.18 ± 1.53 3.57 ± 1.52 4.66 ± 1.52 <0.01 0.1360 ˂0.01 0.1273 
 
 
       
Chapter 3: Human study 
95 | P a g e  
 
Myb28B/B broccoli 
and stilton soup 
Myb28B/V broccoli 
and stilton soup 
Myb28V/V broccoli 
and stilton soup 
p-value for broccoli genotypes 







SMCSO in urine 
Total excreted in 24 
hours (μmoles) 
68.16 ± 23.98 104.71 ± 46.16 109.27 ± 34.50 <0.01 <0.05 <0.01 0.6820 
Percentage excreted 
24 hours after 
ingestion % 
6.61 ± 2.33 6.92 ± 3.05 7.52 ± 2.37 0.4501    
Analysis modelled using sequential analysis of variance (ANOVA) by Dr Henri Tapp. The variables including Cmax, total excreted and percentage 
excreted underwent a log transformation. Significance level for multipe comparisons was analysed using Tukey’s honest significance test. 
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The excretion of SMCSO via urine commenced within 2 hours and peaked at 2-4 hours with 
consumption of all three types of soups. The cumulative excretion of SMCSO rapidly increases 
between 0-8 hours and then continues at a steady rate. Thus, excretion does not reach a plateau 
in any of the three types of soups (Figure 3-9 A). The cumulative amount of SMCSO excreted 
in the urine 24 hours following soup consumption is significantly higher by ~1.6-fold with 
Myb28V/V (109.27 ± 34.50 vs. 68.16 ± 23.98 µmoles, p<0.01) and significantly higher by ~1.5-
fold with Myb28B/V (104.71 ± 46.16 vs. 68.16 ± 23.98 µmoles, p<0.05) compared to Myb28B/B 
broccoli (Figure 3-9 A-B). No significant difference was observed between the two enhanced 
broccoli types in terms of the excretion of SMCSO in the urine (Figure 3-9 A-B).  
The urine excretion (Figure 3-9 A-B) and plasma levels of SMCSO (Figure 3-8) depict that 
the occurrence of one or two Myb28V alleles in the broccoli genotypes results in increased 
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A Cumulative excretion of SMCSO 
 
  
B Total urinary excretion of SMCSO 
 
Figure 3-9: Urinary excretion of SMCSO following consumption of the three types of 
broccoli soups. The cumulative excretion of SMCSO (A) and the total urinary excretion 
of SMCSO (B) measured in urine samples collected over 24 hours after consumption of 
Myb28B/B (84 μmoles GR & 1031 μmoles SMCSO /300g soup), Myb28B/V (280 μmoles GR 
& 1514 μmoles SMCSO /300g soup) and Myb28V/V (452 μmoles GR & 1454 SMCSO 
μmoles /300g soup). The samples were analysed for SMCSO using UPLC-MS/MS. Data 
(n=10) is represented as mean ± SD. Data underwent log transformation followed by 
analysis by one-way ANOVA with Tukey’s honest significance test (* p<0.05 and 
**p<0.01 vs. My28B/B broccoli soup). 
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Pharmacokinetic parameters of SMCSO were stratified by GSTM1 genotype to determine its 
influence on the bioavailability of SMCSO. The analysis indicated no statistically significant 
difference between GSTM1-null and GSTM1-positive participants on the plasma 
pharmacokinetics (AUC, Cmax, Tmax) and the urinary excretion (Table 3-12). 
Table 3-12: Summary table of SMCSO in plasma and urine after consumption of soups 









Mean ± SD Mean ± SD  
SMCSO in plasma  
AUC (μmol.h/l)  
Myb28B/B broccoli and stilton soup  152.72 ± 52.45 98.06 ± 31.26 0.0732 
Myb28B/V broccoli and stilton soup 209.03 ± 44.68 174.80 ± 25.22 0.1617 
Myb28V/V broccoli and stilton soup 231.03 ± 44.91 197.28 ± 36.49 0.2303 
Cmax (μmol/l)    
Myb28B/B broccoli and stilton soup  17.64 ± 2.96 15.88 ± 5.09 0.5627 
Myb28B/V broccoli and stilton soup 29.83 ± 7.53 22.62 ± 6.45 0.1478 
Myb28V/V broccoli and stilton soup 29.14 ± 5.28 26.36 ± 5.88 0.4747 
Tmax (h)    
Myb28B/B broccoli and stilton soup  1.75 ± 0.42 1.81 ± 0.94 0.9072 
Myb28B/V broccoli and stilton soup 1.38 ± 0.54 1.38 ± 0.63 0.9999 
Myb28V/V broccoli and stilton soup 1.75 ± 0.42 1.63 ± 0.25 0.5711 
Total SMCSO in urine (μmoles)   
Myb28B/B broccoli and stilton soup  68.2 ± 25.52 68.2 ± 25.29 0.9995 
Myb28B/V broccoli and stilton soup 110.8 ± 51.6 95.5 ± 42.11 0.6221 
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Mean ± SD Mean ± SD  
Myb28V/V broccoli and stilton soup 106.0 ± 17.04 114.2 ± 55.07 0.7885 
Percentage excreted 24 hours 
after ingestion %   
 
Myb28B/B broccoli and stilton soup  6.61 ± 2.48 6.62 ± 2.45 0.9995 
Myb28B/V broccoli and stilton soup 7.32 ± 3.41 6.31 ± 2.78 0.6221 
Myb28V/V broccoli and stilton soup 7.29 ± 1.17 7.86 ± 3.79 0.7885 
Data represented as mean ± SD and analysed using unpaired t-test with Welch’s 
correction. 
 Comparison of the bioavailability of sulforaphane, 
glucoraphanin and S-methyl-L-cysteine sulfoxide in plasma 
following consumption of soups made with three broccoli genotypes 
To compare the bioavailability of the three compounds; GR, SF and SMCSO, data were 
collated as represented in Figure 3-10. Following consumption of the soups, SMCSO and GR 
levels peaked much earlier at approximately 2 hours and started to decline, whereas SF peaked 
at 6-8 hours. Twenty-four hours after soup consumption, levels of SF and GR measured in the 
plasma were negligible. On the other hand, SMCSO levels were quantified at higher levels of 
2.2-4.7 µM. A similar trend in GR, SMCSO and SF across 24 hours in plasma was observed 
following consumption of all three types of soups. The major distinction between the 
consumption of the three types of soups is the levels achieved in the plasma. Consumption of 
the soup with the Myb28V/V broccoli genotype accumulates enhanced levels of all three 
compounds compared to after consumption of the soup with Myb28B/V broccoli genotype and 
Myb28B/B broccoli. There was a dose-dependent increase in the levels of GR, SMCSO and SF 
and metabolites. A crucial finding is the augmented levels of SMCSO measured in the plasma, 
ranging from 15.1-26.6 µM, compared to SF (0.2-0.6 µM) following consumption of the 
soups. This is ~44-75-fold greater than the SF levels achieved in the plasma. Intact GR levels 
detected are much lower than those of SF in plasma. 
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A Levels in the plasma after consumption of Myb28B/B broccoli soup 
 
B Levels in the plasma after consumption of Myb28B/V broccoli soup 
 
C Levels in the plasma after consumption of Myb28V/V broccoli soup 
 
Figure 3-10: The plasma concentrations of GR, SF, and SMCSO (µM) following 
consumption of soups made with three broccoli genotypes. Blood samples collected from 
participants were analysed for metabolites. GR and SF concentration are plotted on the 
left y-axis and SMCSO is plotted on the right y-axis. SF metabolites measured in the 
plasma includes SF, SF-GSH, SF-Cys, SF-Cys-Gly and SF-NAC. The levels of 
metabolites in the plasma following consumption of standard broccoli soup, Myb28B/B 
(84 μmoles GR & 1031 μmoles SMCSO /300g soup) (A); Myb28B/V (280 μmoles GR & 
1514 μmoles SMCSO /300g soup) (B) and Myb28V/V (452 μmoles GR & 1454 μmoles 
SMCSO /300g soup) (C). Data (n=10) is represented as mean ± SD. 
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 Comparison of the bioavailability of sulforaphane, 
glucoraphanin and S-methyl-L-cysteine sulfoxide in urine following 
consumption of soups made with three broccoli genotypes 
Data from the bioavailability of the three compounds were compared as illustrated in Figure 
3-11. Following consumption of the soups, the excretion of SMCSO and GR rapidly increases 
at 0-4 hours whereas SF does not increase until at 6-8 hours post consumption. While the 
cumulative excretion of GR reaches a plateau after 8 hours of excretion, SF and SMCSO do 
not plateau even after 24 hours, following consumption of all three types of soups. The levels 
of GR and SF excreted increase in a dose-dependent manner following consumption of soups 
made with Myb28V/V broccoli genotype versus those made with Myb28B/V broccoli and 
Myb28B/B broccoli. Comparable levels of SMCSO were excreted in the urine following 
consumption of the soups made with Myb28V/V broccoli genotype and Myb28B/V broccoli 
genotype, with both being greater than levels excreted following consumption of Myb28B/B 
broccoli. The fundamental difference in the levels of excreted metabolites in the urine 
following soup consumption is that the levels of GR excreted are considerably lower than 
those of SF and SMCSO. The levels of SMCSO excreted are notably higher than those of SF 
and GR. At 24 hours, SMCSO excretion ranges from 68.2-109.3 µmoles as opposed to 9.0-
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A Levels in the urine after consumption of Myb28B/B broccoli soup 
 
B Levels in the urine after consumption of Myb28B/V broccoli soup 
 
C  Levels in the urine after consumption of Myb28V/V broccoli soup 
 
Figure 3-11: Cumulative urinary excretion of GR, SF, and SMCSO (µmoles) following 
consumption of soups made with three broccoli genotypes. Urine samples collected from 
participants were analysed for metabolites. GR and SF concentration are plotted on the 
left y-axis and SMCSO is plotted on the right y-axis. SF metabolites measured in the 
urine includes SF, ERN-NAC, SF-Cys, SF-Cys-Gly, and SF-NAC. GR levels shows also 
include glucoerucin levels. The levels of metabolites in the urine following consumption 
of standard broccoli soup, Myb28B/B (84 μmoles GR & 1031 μmoles SMCSO /300g soup) 
(A); Myb28B/V (280 μmoles GR & 1514 μmoles SMCSO /300g soup) (B) and Myb28V/V 
(452 μmoles GR & 1454 μmoles SMCSO/300g soup) (C). Data is represented as mean + 
SD (n=10). 
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 Comparison of the percentage of sulforaphane, glucoraphanin 
and S-methyl-L-cysteine sulfoxide excreted in the urine following 
consumption of soups made with three broccoli genotypes 
The SF and GR data are represented here as the percentage of the ingested dose of GR that is 
excreted. However, SMCSO is expressed as the percentage of the ingested SMCSO. There is 
a considerable variation in the percentage of SF and metabolites excreted following 
consumption of the three types of soups compared to the percentage of GR and SMCSO 
excreted. The percentage of SF and metabolites excreted ranges from 2.5-23.1%, 2.2-18.1% 
and 0.2-18.9% following consumption of Myb28B/B, Myb28B/V and Myb28V/V broccoli soups, 
respectively (Figure 3-12 A). In contrast, the percentage of GR and metabolites excreted 
ranges from 0.2-1.0% following consumption of Myb28B/B, Myb28B/V and Myb28V/V broccoli 
soups, respectively (Figure 3-12 B). The percentage of SMCSO excreted ranges from 3.3-
10.7%, 3.4-12.3%, 2.5-11.0% following consumption of Myb28B/B, Myb28B/V and Myb28V/V 
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A Percentage of SF and metabolites excreted 
 
B Percentage of GR and glucoerucin excreted 
 
C Percentage of SMCSO excreted 
 
Figure 3-12: Percentage of SF, GR, and SMCSO excreted in the urine following 
consumption of soups made with three broccoli genotypes. Urine samples collected from 
participants were analysed for metabolites. SF metabolites measured in the urine 
includes SF, ERN-NAC, SF-Cys, SF-Cys-Gly, and SF-NAC. GR levels shown also include 
glucoerucin levels. The percentage of SF and metabolites (A), GR and glucoerucin (B) 
and SMCSO (C) excreted of the ingested dose of GR and SMCSO in the broccoli soups, 
Myb28B/B (84 μmoles GR & 1031 μmoles SMCSO /300g soup) (A); Myb28B/V (280 μmoles 
GR & 1514 μmoles SMCSO /300g soup) (B) and Myb28V/V (452 μmoles GR & 1454 
μmoles SMCSO/300g soup). 
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In order to assess whether an individual would excrete similar percentages of metabolites 
following consumption of Myb28B/B and Myb28V/V, correlation graphs were plotted for SF and 
its metabolites, GR and glucoerucin, and SMCSO. A strong statistically significant positive 
correlation was observed in the percentage of SF and metabolites excreted between 
consumption of Myb28B/B and Myb28V/V (p<0.0001) (Figure 3-13 A). Additionally, a 
moderate statistically significant positive correlation was observed in the percentage of 
SMCSO excreted between consumption of Myb28B/B and Myb28V/V (p<0.05) (Figure 3-13 C). 
In contrast, no significant correlation was observed in the percentage of GR and glucoerucin 
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A Urine excretion of SF and metabolites 
 
B Urine excretion of GR and glucoerucin 
 
C Urine excretion of SMCSO 
 
Figure 3-13: Correlation of the percentage of SF, GR, and SMCSO excreted in the urine 
following consumption of Myb28B/B and Myb28V/V soups.  Urine samples collected from 
participants were analysed for metabolites. SF metabolites measured in the urine (n=10) 
includes SF, ERN-NAC, SF-Cys, SF-Cys-Gly, and SF-NAC. GR levels shown also include 
glucoerucin levels. The graphs represent the correlation of the percentage of SF and 
metabolites (A), GR and glucoerucin (B) and SMCSO (C) excreted of the ingested dose 
of GR and SMCSO in the broccoli soups between Myb28B/B (84 μmoles GR & 1031 
μmoles SMCSO /300g soup) and Myb28V/V (452 μmoles GR & 1454μmoles SMCSO/300g 
soup).  
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To evaluate whether there is a correlation between the percentage excretion of the three 
metabolites following consumption of the three types of soups, correlation graphs were plotted 
for SF vs. SMCSO, SF vs. GR and GR vs. SMCSO. There was no statistically significant 
correlation between the percentage of SF and SMCSO excreted following consumption of the 
three types of soups (Figure 3-14). Similarly, there was no statistically significant correlation 
between the percentage of GR and SF excreted following consumption of the three types of 
soups (Figure 3-15). Although not statistically significant, there is a moderate relationship 
between the percentage of GR and SMCSO excreted following consumption of Myb28B/B and 
Myb28V/V soups (Figure 3-16). Following consumption of Myb28B/V soup, a non-statistically 
significant weak correlation was observed between the percentage of GR and SMCSO 
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A Percentage urinary excretion after consumption of Myb28B/B broccoli soup 
 
B Percentage urinary excretion after consumption of Myb28B/V broccoli soup  
 
C Percentage urinary excretion after consumption of Myb28V/V broccoli soup  
 
Figure 3-14: Correlation of the percentage of SF and SMCSO excreted in the urine 
following consumption of all three types of soups.  Urine samples collected from 
participants were analysed for metabolites. SF metabolites measured in the urine (n=10) 
includes SF, ERN-NAC, SF-Cys, SF-Cys-Gly, and SF-NAC. The graphs represent the 
correlation between the percentage of SMCSO and SF excreted of the ingested dose 
following consumption of Myb28B/B (84 μmoles GR & 1031 μmoles SMCSO /300g soup) 
(A), Myb28B/V (280 μmoles GR & 1514 μmoles SMCSO /300g soup) (B) and Myb28V/V 
(452 μmoles GR & 1454 μmoles SMCSO /300g soup) (C).  
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A Percentage urinary excretion after consumption of Myb28B/B broccoli soup 
 
B Percentage urinary excretion after consumption of Myb28B/V broccoli soup  
 
C Percentage urinary excretion after consumption of Myb28V/V broccoli soup  
 
Figure 3-15: Correlation of the percentage of SF and GR excreted in the urine following 
consumption of all three types of soups.  Urine samples collected from participants were 
analysed for metabolites. SF metabolites measured in the urine (n=10) includes SF, ERN-
NAC, SF-Cys, SF-Cys-Gly, and SF-NAC. GR levels includes glucoerucin. The graphs 
represent the correlation between the percentage of GR and SF excreted of the ingested 
dose following consumption of Myb28B/B (84 μmoles GR & 1031 μmoles SMCSO /300g 
soup) (A), Myb28B/V (280 μmoles GR & 1514 μmoles SMCSO /300g soup) (B) and 
Myb28V/V (452 μmoles GR & 1454 μmoles SMCSO /300g soup) (C).  
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A Percentage urinary excretion after consumption of Myb28B/B broccoli soup 
 
B Percentage urinary excretion after consumption of Myb28B/V broccoli soup  
 
C Percentage urinary excretion after consumption of Myb28V/V broccoli soup  
 
Figure 3-16: Correlation of the percentage of SMCSO and GR excreted in the urine 
following consumption of all three types of soups. Urine samples (n=10) collected from 
participants were analysed for metabolites. GR levels includes glucoerucin. The graphs 
represent the correlation between the percentage of GR and SMCSO excreted of the 
ingested dose following consumption of Myb28B/B (84 μmoles GR & 1031 μmoles SMCSO 
/300g soup) (A), Myb28B/V (280 μmoles GR & 1514 μmoles SMCSO /300g soup) (B) and 
Myb28V/V (452 μmoles GR & 1454 μmoles SMCSO /300g soup) (C).  
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 Discussion 
The aim of this work was to investigate the bioavailability of sulphur-containing compounds 
from enriched broccoli soups made with three broccoli genotypes. To accomplish this, 10 
apparently healthy participants were recruited into a double-blind, three-phase, crossover, 
randomised intervention trial with three soups made with different broccoli genotypes. The 
three types of broccoli consist of standard broccoli (Myb28B/B) and two novel varieties; 
Myb28B/V and Myb28V/V. As reported in Chapter 2 the presence of one or more Myb28V allele 
resulted in elevated levels of GR and SMCSO in the soups. The Myb28V/V soups accumulate 
452 μmoles GR; 1454 μmoles SMCSO, Myb28B/V soups accumulate 280 μmoles GR; 1514 
μmoles SMCSO compared to standard broccoli soup/Myb28B/B (84 μmoles GR;1031 μmoles 
SMCSO). The objective was to assess whether the enhanced levels of GR and SMCSO in the 
soups would be bioavailable resulting in enhanced levels absorbed and delivered to the plasma. 
Participants consumed each of the three types of soups in a random sequence, following which 
plasma and urine samples were collected at various time-points and quantitatively analysed 
for SF, GR and SMCSO using LC-MS/MS and UPLC-MS/MS. 
Bioavailability of SF and metabolites from the intake of cruciferous vegetables including 
raw/cooked broccoli has been widely demonstrated by many human intervention studies. 
Further, Gasper et al. described increased absorption of SF following consumption of a high-
glucosinolate soup, with the AUC and Cmax in the plasma being 3-fold greater than that 
resulting from the consumption of standard broccoli [38]. The present study confirmed that 
the intake of increasing GR levels with the three broccoli genotypes delivered increasing 
concentrations of GR to the gut as demonstrated by a dose-dependent curve for SF (Figure 
3-4) and GR (Figure 3-6). Consumption of the Myb28V/V broccoli soup, containing 5 times 
more GR, led to an AUC for SF 4 times that of Myb28B/B broccoli. Similarly, Myb28B/V 
broccoli soup containing 3 times more GR resulted in an AUC for SF of 2 times that of 
Myb28B/B broccoli. In addition, both the Myb28V/V and Myb28B/V broccoli soups comprised 
levels of SMCSO 1.4 times that of Myb28B/B broccoli resulting in an AUC of 2 times that of 
Myb28B/B, respectively. The enhanced levels of GR and SMCSO from the soups are 
bioavailable as indicated by the elevated levels of SF, GR and SMCSO in plasma. 
As a result of the soup production process, the myrosinase enzyme was inactivated thus there 
was no presence of SF in the soups ingested. Following consumption of the three types of 
soups, intact SMCSO and GR was rapidly absorbed at 30 minutes and peaked approximately 
at 2 hours in the plasma (Figure 3-6; Figure 3-8). On the other hand, even though SF was 
detected at 30 minutes, it did not peak until 6 hours with Myb28B/B broccoli soup and 8 hours 
with Myb28B/V and Myb28V/V broccoli soups which is comparable to the Tmax= 6 hours 
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reported by previous studies [68,69,71]. This is much later compared to GR and SMCSO 
presumably because time is required for the GR to reach the gut where it is hydrolysed to SF 
by the gut microbial thioglucosidase [15] followed by absorption through the enterocytes. The 
study by Gasper et al. demonstrated a Tmax of 1.5-2 hours following ingestion of SF as the 
broccoli soups were produced without denaturing the myrosinase [38]. Evidently, SF was 
delivered to the gut and rapidly absorbed, peaking earlier at 2 hours without the pre-
requirement of conversion by the microbial thioglucosidase. Given that this is the first human 
study intervention to report the detection of intact GR and SMCSO in plasma, the 
pharmacokinetics of these dietary compounds are unknown. However, it can be assumed that 
GR and SMCSO are absorbed in their native forms, without conversion by the gut bacteria, 
peaking in the plasma at 2 hours. Although this is the first study to report intact GR in human 
plasma, other studies have described measuring intact GR in the plasma of dogs and rats [21]. 
This suggests that GR is hydrolysed by our microbial thioglucosidase as well as absorbed 
intact through the enterocytes. 
The present study has reported a plasma Cmax of 0.2 µM for SF following consumption of soup 
containing 84 µmoles GR (Myb28B/B broccoli). Increasing the GR levels in the soups resulted 
in higher Cmax of 0.4 µM and 0.6 µM following consumption of Myb28B/V and Myb28V/V 
broccoli soups, respectively. Despite providing participants soups with only ½ the amount of 
GR compared to the current study, Saha et al. reported that considerably less SF was detected 
with a Cmax of 0.025 µM SF [68]. Similarly, Vermeulen and colleagues showed a Cmax of 0.031 
µM following consumption of 61.4 µmoles [71]. One of the potential reasons for the difference 
in the levels of measured SF across these interventions could be the use of a different column 
and LC-MS/MS system. The present study used a Luna 3u C18 presenting better separation 
than the Zorbax SB-Aq column used in the study by Saha et al. as well as the use of an Agilent 
6490 Triple Quad LC-MS/MS [68]. Other explanations include the use of a different food 
matrix as the soups used in this study were rich in fat and other nutrients which could have 
aided absorption of GR. The Cmax of intact GR was ˂0.1 µM following consumption of all 
three types of soups which is less in comparison to SF in plasma. On the other hand, elevated 
levels of SMCSO in the plasma were achieved. A Cmax of 16.9 µM, 26.9 µM and 28.0 µM was 
measured following consumption of Myb28B/B, Myb28B/V and Myb28V/V broccoli soups, 
respectively. In comparison to the levels of SF, this is considerably higher and could possibly 
be explained by the high levels of SMCSO present in the soups compared to the other dietary 
compound GR.  
The prevalence of the SF conjugates in plasma in the current study is not in accordance with 
previous reports. SF and SF-GSH were the primary metabolites measured in the plasma 
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followed by SF-Cys-Gly. However, Saha et al. ranked the metabolites in the following order; 
SF, SF-Cys-Gly, SF-Cys, SF-GSH and SF-NAC [68] whereas Clarke et al. ordered them as 
SF-Cys-Gly, SF-NAC, SF-Cys, SF-GSH, SF following consumption of GR [69]. Gasper et al. 
reported a higher percentage of SF succeeded by SF-Cys, SF-Cys-Gly, SF-NAC and SF-GSH 
in that order following consumption of SF [38].  
The discrepancy observed in the concentrations of SF, in addition to individual SF conjugates, 
could be justified by the intra-individual variations, potentially influenced by age, diet, gender, 
gut microbiota and other characteristics [22]. Gut microbiota variation amongst individuals, 
resulting in a deviation in the amount of SF hydrolysed from its precursor GR, is a plausible 
explanation [151], especially as greater variations have previously been reported in the 
excretion of SF following consumption of GR compared to direct consumption of SF 
[22,151,152].  
This study has also reported that increasing levels of GR in soups resulted in increased levels 
of total SF (Figure 3-5 B) and GR excreted in the urine (Figure 3-7 B) in a dose-dependent 
manner. Likewise, the Myb28B/V and Myb28V/V broccoli soups with higher SMCSO levels led 
to greater urinary excretion concentration compared to Myb28B/B broccoli (Figure 3-9 B). As 
the levels of SMCSO did not significantly differ between Myb28B/V and Myb28V/V broccoli 
soups, the urinary output also did not significantly differ. While another study has reported the 
detection of SMCSO in urine using NMR [153], this was not quantifiable and thus the present 
study is the first to report the bioavailability of SMCSO in humans. One human intervention 
study employing radiolabelled [35S]-SMCSO was undertaken in 4 healthy males and quantified 
recovered [35S] [84], however, this approach did not discriminate between [35S] contained 
within SMCSO and that incorporated into metabolites, whereas this study specifically 
quantified SMCSO. Urinary excretion of intact GR has been discovered by others in human 
[14] and rats [20] although one study was not able to detect GR in human urine following 
consumption of broccoli sprouts [22]. 
GR and SMCSO are rapidly excreted at 0-4 hours (Figure 3-7; Figure 3-9) but SF is excreted 
much later (Figure 3-5), emphasising the role of gut microbiota in the hydrolysis of GR to SF. 
Consumption of the three types of soups resulted in a peak urinary excretion of SF at 6-8 hours, 
comparable to findings by others [65,69]. Consistent with other findings, the most abundant 
metabolite excreted in urine was SF-NAC [38,68,69]. Approximately 4-6% of ingested GR 
was excreted as SF-NAC which represented 49-58% of the total ITC recovered in urine (Table 
3-6), as demonstrated by Conaway et al. [32]. Erucin-NAC was the second major metabolite 
excreted with consumption of all three types of soups (Table 3-6). Erucin enzymatically 
derived from glucoerucin by myrosinase was reported to be excreted in the urine of rats 
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[20,147] and humans [65,69] following consumptions of cruciferous vegetables [65,69]. 
Reduction of SF’s sulfinyl group results in the interconversion between SF and erucin [68,69]. 
This was confirmed by the excretion of erucin in urine following consumption of broccoli 
without glucoerucin [68,154]. In the present study, glucoerucin was not detected in the 
broccoli soups confirming the interconversion between SF and erucin. Excretion of SF-NAC 
was ~2-fold greater than erucin-NAC, similar to the 3-fold difference reported by Saha et al. 
[68]. The current study has reported that 2% of the ingested GR was excreted as ERN-NAC 
in accordance with the findings described by Saha et al. [68].  
The current study measured a high percentage of SF-NAC followed by ERN-NAC, SF-Cys, 
SF and SF-Cys-Gly excreted in the urine in congruence with the study by Saha et al. [68]. The 
present study recovered ~10%, ~8% and ~9% of the ingested dose as SF and its metabolites 
in the urine following consumption of Myb28B/B, Myb28B/V and Myb28V/V broccoli soups 
respectively (Table 3-5), consistent with published literature [32,66,67]. In contrast, Saha et 
al. [68] and Egner et al. [22] reported 5% excretion as SF of the ingested GR dose. Inclusion 
of the excretion of erucin-NAC in the total amount of SF excreted, which accounts for 2%, 
could be a plausible explanation as could the use of a more sensitive LC-MS/MS method than 
previously used by Saha et al. [68]. Approximately 7-8% of ingested SMCSO (Table 3-11) 
was excreted in urine following consumption of the soups which was inconsistent with the 
recovery of 60.2% of labelled [35S] following consumption of [35S]-SMCSO in the study by 
Waring et al. [84]. As noted earlier, however, that result should be viewed with caution as 
Waring et al. quantified the total [35S], not SMCSO specifically, therefore also measuring 
metabolites derived from SMCSO [84]. Therefore, the discrepancy observed could be due to 
the metabolism of SMCSO to other metabolites which has not been quantified in this study 
[2]. The metabolism of SMCSO in humans remains unclear and is imperative in understanding 
the potential biological mechanisms of SMCSO. As glucoerucin is a reduced analogue of GR 
converted by gut microbiota [20,68,142], its excretion was also taken into account when 
calculating the excretion of GR following soup consumption. Of the ingested dose, ˂1% was 
excreted as GR and glucoerucin which is to a certain extent comparable to the 5% reported in 
rats [20] and 3% reported in humans by Egner et al. [22]. The difference can be justified by 
taking into consideration individual variations and sample size as Egner et al. recruited 50 
participants as opposed to the 10 participants recruited for this study [22]. However, 17% of 
the ingested dose has been excreted as GR in mice [142], this being considerably more than 
the amount excreted reported by the other studies. 
Despite the enhanced levels of SMCSO, relative to GR, in the soups, the bioavailability of 
these compounds was to a certain extent comparable. Although the SMCSO plasma Cmax of 
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28 µM was higher compared to SF plasma Cmax of 0.6 µM, the percentage recovery was similar 
with ~9% SF and ~8% SMCSO recovered in the urine. This can be rationalised by the fact that 
SF is represented by data comprising SF and its metabolites, whereas the metabolites of 
SMCSO have not been quantified and are therefore not represented in the bioavailability of 
SMCSO. Interestingly, there is only a ~3-fold difference in the levels of SMCSO and GR in 
Myb28V/V soup (1454 µmoles SMCSO and 452 µmoles of GR). However, the plasma 
concentration of SMCSO is ~47-fold higher than SF (28 µM SMCSO and 0.6 µM SF). Given 
that SMCSO is abundant in other species such as allium, participants were requested to 
exclude garlic 48 hours prior to the study day and during the study day but onions were not 
excluded. Consequently, baseline sample detection of SMCSO was subtracted from 
subsequent time points to ensure that the SMCSO quantified is a result of the soup intake as 
opposed to other dietary sources of SMCSO. Regardless, the levels of SMCSO is considerably 
higher than the SF plasma levels despite the differing soup levels. 
Inter-individual variation in the urine excretion of SF and metabolites following consumption 
of GR and SF has been well documented. The current study presents a range of SF excretion 
between 2.5-23.1%, 2.2-18.1% and 0.2-18.9% following consumption of Myb28B/B, Myb28B/V 
and Myb28V/V (Figure 3-12). This is comparable to the SF recovery reported by others, e.g. 1-
40% [70] and 3.8- 24.6% [32] following consumption of GR. The variation observed in the 
percentage of intact GR and SMCSO excreted is not unreasonably large compared to the 
percentage of SF recovered (Figure 3-12). This further supports the notion that the inter-
individual variation observed is influenced by the gut microflora as uptake of SF is dependent 
on the gut microbiota conversion from GR whereas the uptake of unmetabolised GR and 
SMCSO is not.  
Interestingly, there is a strong, statistically significant, correlation in the urine excretion of SF 
following consumption of Myb28B/B and Myb28V/V (p<0.0001) suggesting that the variation 
observed is due to inter-individual variation, possibly influenced by the gut microflora (Figure 
3-13 A). A correlation was not observed between the GR and glucoerucin excreted following 
consumption of each soup, indicating that any variation is unlikely to be due to characteristics 
unique to the participants, e.g. gut microbiota (Figure 3-13 B). However, it appears that there 
is inter-individual variation in the percentage of SMCSO excretion following consumption of 
Myb28B/B and Myb28V/V evidenced by the moderate significant correlation (p<0.05) (Figure 
3-13 C). Given that intact SMCSO was measured as requiring no metabolism by the gut 
microflora, the variation observed is presumably influenced by another participant-unique 
factor.  
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Inter-individual differences do not result in the variation observed with the percentage of 
SMCSO or GR excreted compared to the percentage of SF excreted in the urine (Figure 3-14; 
Figure 3-15). On the other hand, there is a non-significant moderate correlation between the 
percentage of SMCSO and GR excreted (Figure 3-16). This indicates that the urinary 
excretion of both compounds is potentially influenced by the same factor but not due to gut 
microbiota as seen with SF excretion. 
Blood samples from participants were genotyped for GSTM1 as it was previously suggested 
that the genotype influenced the metabolism, absorption, and excretion of SF [38]. Individuals 
with GSTM1-null genotypes excreted higher amounts of SF according to the study by Gasper 
et al. [38] and Steck et al. [155]. However, the current study revealed no significant difference 
in the metabolism of SF (Table 3-7) as shown by others [22,68]. It was previously assumed 
that upon consumption of SF as opposed to GR, the GSTM1 genotype played a significant role 
in the metabolism of SF. However, the influence of the GSTM1 genotype on SF metabolism 
remains controversial irrespective of whether SF or GR is consumed [22,68]. Further, the 
GSTM1 genotype influence on the metabolism of GR (Table 3-10) and SMCSO (Table 3-12) 
also demonstrated no significant difference following consumption of three types of soups. 
One of the principle strengths of this study was the fact that the subjects acted as their own 
control. This means that the inter-individual variability in response to the dietary intervention 
is accounted for. Lack of faecal collection was one of the major limitations of this study. 
Presumably, these compounds are excreted via faeces in humans as reported in mice [142]. To 
gain a complete understanding of the bioavailability of SF, GR and SMCSO, urine, blood as 
well as faecal samples would prove useful. Additionally, a longer period of urine collection of 
up to 48-72 hours would be essential in further work as the 24 hours samples in this study still 
showed excretion of SF and SMCSO. The cumulative excretion of SF and SMCSO illustrated 
that the excretion did not reach a plateau at 24 hours post-soup consumption (Figure 3-5; 
Figure 3-9). The rationale to design the study with 24-hour urine collection was based on the 
findings that SF and conjugates were excreted by 24 hours in other studies [142]. No previous 
data about SMSCO pharmacokinetic in humans were available. This study has provided new 
and invaluable pharmacokinetic information on GR, SMCSO and SF and on the bioavailability 
of these compounds from the novel soups. 
It is important to note that while SF and metabolites and GR were quantified relative to the 
internal standard, quantification of SMCSO was not relative to an internal standard as 
mentioned in section 2.5, Chapter 2.  
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 Conclusion 
For the first time, this study has demonstrated the use of novel soups with increasing levels of 
GR led to increased levels of SF and metabolites that reflected the ingested levels. 
Consumption of increased levels of GR and SMCSO led to elevated AUC, Cmax, and total 
amount excreted for SF, GR and SMCSO. However, with only ~9% of SF and ~8% of SMCSO 
recovered in urine, it is reasonable to state that the bioavailability of SF and SMCSO is low. 
Though, it is important to note that the metabolism of SMCSO in humans remains unclear and 
this study only investigated the bioavailability on intact SMCSO, not its metabolites. 
Nevertheless, the present study has provided an insight into physiologically relevant 
concentrations of GR, SMCSO and SF to be used for cell treatments. Furthermore, this is the 
first human intervention study to investigate the bioavailability of intact GR in plasma and of 
SMCSO in plasma and urine. On the basis of these results, it can be hypothesised that intact 
GR and SMCSO are absorbed into the enterocytes either via passive diffusion or via 
transporters. This poses the question of how these compounds are absorbed in their native form 
given that GR is a large molecule, with a molecular weight of 437.50, and that SMCSO could 
potentially be charged in the physiological environment. With very limited evidence available 
on the transport of these compounds, in vitro models will be used to investigate the transport 
of GR and SMCSO. In conclusion, this study has provided conclusive evidence for the 
suitability of these novel soups with increasing GR levels for future human intervention studies 














CHAPTER 4  
Transport of sulforaphane, glucoraphanin, 
and S-methyl-L-cysteine sulfoxide using in 
vitro models 
Chapter 4: Transport study 
119 | P a g e  
 Summary 
The human intervention study presented in Chapter 3 is the first to indicate the transport of 
GR and SMCSO across the enterocytes into the systemic circulation. SF is widely accepted to 
passively diffuse across enterocytes however the transport mechanism of GR and SMCSO has 
not been previously reported. Given the limited literature on the transport of these compounds, 
the purpose of the experimental work presented in this Chapter was to investigate the 
mechanism of this transport across the enterocytes. Two in vitro models, caco-2 cells and the 
PAMPA assay, were used to determine whether GR and SMCSO permeate across the 
membrane via passive diffusion and/or active transport. SF was used as a positive control 
under the assumption that it can passively diffuse while glucose was used as negative control 
given that it is known to require a transporter. For the first time, evidence from the caco-2 
model and the PAMPA assay indicates that GR and SMCSO may transfer across the 
membrane via active transporters. Further work is required to discover the transporters 
involved.  
 Introduction 
Several human intervention studies have reported recovery of SF and its metabolites in plasma 
and urine following broccoli consumption [22,32,38,68]. The results from the BOBS human 
intervention study described in Chapter 3 have shown for the first time that intact GR and 
SMCSO can transfer across across the gut, and be recovered in plasma and urine of human 
participants who have consumed broccoli-rich soups. It is has been reported by others that SF 
is likely to passively diffuse across the membrane of the enterocytes [27,156], but there is 
limited literature on the mechanism of transport of other broccoli-derived phytochemicals 
including GR and SMCSO. Transport of GR and SMCSO across the enterocytes could be 
either via passive diffusion, paracellularly via tight junctions, or by active transport. 
To explore the transport mechanism of GR and SMCSO, two in vitro models were used to 
mimic the intestinal wall. This Chapter describes the use of a cell model (caco-2) and a cell-
free system (PAMPA assay) to explore the potential mechanisms of transport that are 
responsible for the absorption of GR and SMSCO in vivo. At present, the caco-2 (human colon 
adenocarcinoma) cell line is the most well-established model to investigate intestinal 
permeability. While caco-2 cells give an insight into transport via passive diffusion, active 
transport, and paracellular diffusion, the PAMPA assay is an artificial membrane which only 
permits passive diffusion of compounds. It was envisaged that the combination of both models 
would give an insight into the transport mechanism of GR and SMCSO.  
Chapter 4: Transport study 
120 | P a g e  
SF is reported to passively diffuse across the membrane, and it appeared to be well absorbed 
(absorption rate: 74 ± 29%) by the enterocytes as reported in an in vivo study using human 
jejunum [27]. Although the accumulation of SF in cells have been reported, implying that it 
can enter cells, to our knowledge the diffusion of SF has not been previously tested using in 
vitro models such as the PAMPA assay or caco-2 cells transport experiments. The hypothesis 
is that SF passively diffuses, given its lipophilicity (log10 pc of 0.72) [24] and small molecular 
weight (mw=177.29 g/mol) [27], and thus such experiments aim to confirm the concept. 
Furthermore, due to the assumption that SF can passively diffuse, it was used as a positive 
control for both in vitro models while glucose was used as a negative control since it is known 
to require a transporter [157]. 
Given that there is no literature on the transport mechanism of GR and SMCSO, the work 
described in this Chapter sought to investigate for the first time their potential transport 
mechanism across the gut membrane. The combination of a large molecular weight of 437.49 
g/mol and a partition coefficient (log10 pc) of -3.8 [24], making it hydrophilic, leads to the 
hypothesis that GR cannot passively diffuse across the membrane and thus requires a 
transporter. There is limited literature regarding the partition coefficient of SMCSO so it is not 
known whether it would be hydrophilic or hydrophobic. Based on its polar surface area which 
is <140 A2, and its molecular weight of 151.2 g/mol, one might suggest that SMCSO may 
passively diffuse across the membrane. However, due to the structural similarity with the 
amino acid L-cysteine, it was hypothesised that SMCSO would require a transporter to 
permeate across the membrane. 
In this Chapter, transport of broccoli-derived compounds (SF, GR and SMCSO) were 
investigated using two in vitro models; caco-2 cells and PAMPA assay. Exploring the transport 
of these compounds is of great importance facilitating the understanding of fundamental 
mechanisms involved in the bioavailability of bioactives from broccoli.   
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 Materials and Methods 
 Materials  
Human colon adenocarcinoma cell line (caco-2) (Cat # ATCC® HTB-37™ and Essential 
Minimum Eagle’s Medium (EMEM) (Cat # ATCC-30-2003) containing Earle’s balanced salt 
solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1500 mg/l 
sodium bicarbonate was obtained from the ATCC. The following were purchased from 
Thermo Fischer Scientific; heat-inactivated fetal bovine serum (FBS) (Gibco™) (Cat # 10270-
106), Penicillin-Streptomycin 10,000 U/ml (Cat # 15140122), DPBS (Gibco®) 10X with no 
calcium and no magnesium (Cat. # 14200059) and Hank’s Balanced Salt Solution (HBSS) 
10X with calcium, magnesium and no phenol red (Cat # 14065049). DPBS and HBSS were 
diluted to 1X in sterile water for use on cells. Amphotericin B (Cat # A2942), Corning® 
Transwell® polycarbonate membrane cell culture inserts (12 mm transwell with 0.4 μM pore) 
(Cat # CLS3401), Lucifer Yellow CH dipotassium salt (Cat # L0144), Corning ® 96 well black 
plate with clear bottoms, and glucose assay kit (Cat # GAGO20) were purchased from Sigma®. 
Corning® Gentest™ pre-coated PAMPA assay plates were purchased from Corning® (Cat # 
353015). Only autoclaved glassware was used, and all items were sterilised with 70% ethanol 
prior to using in the laminar flow cabinet. T75 flasks were purchased from Starstedt (Cat # 
83.3911.002). The epithelial Volt/Ohm meter (EVOM2) to measure the transepithelial 
electrical resistance was acquired from the world precision instrument (WPI) (Florida, USA). 
FLUOstar® Omega 96-well plate reader was obtained from BMG labtech.  
 
 Cell culture  
Caco-2 cells between passage 44 and 55 were cultured in 75cm² flasks in EMEM 
supplemented with 10% heat-inactivated FBS, 1% penicillin-streptomycin and 0.1% 
amphotericin B. The cells were routinely cultured in a humidified atmosphere containing 5% 
CO2 at 37 °C and were grown to 80% confluency on 75 cm² flasks.  
 
 Caco-2 culture conditions 
Caco-2 cells were cultured on pore inserts in transwell wells (Corning® Transwell® 
polycarbonate membrane, 12 mm with 0.4 μM pore inserts) to enable them to grow in a 
monolayer with the formation of tight junctions and characterise the apical and basolateral 
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membranes (Figure 4-1). The matrix above and below the pore membrane is the apical 
chamber (AP) and basolateral chamber (BL), respectively. Prior to seeding cells, the transwell 
plates were equilibrated with the addition of fresh medium to the AP and BL chamber and 
incubated for 1 hour. Cells were then seeded at a density of 2 x 104 cells/cm2 and cultured for 
21-25 days with media replaced every other day. One well without cells was used as a control 
for each plate. Media was first removed from the BL followed by removal from the AP 
chamber. Pre-warmed media was then added to the AP chamber (0.5 ml) and then to the BL 
chamber (1.5 ml). This process was followed carefully because the order of the medium 
replacement is critical in maintaining the hydrostatic pressure to reduce the risk of cells lifting 
off from the membrane. 
Figure 4-1: Illustration of the apical chamber and the basolateral chamber of the 
transwell plates. 
 
 Assessment of cell monolayer integrity  
When performing transport experiments, it is crucial to assess the integrity of the monolayer 
to ensure the cells have formed tight junctions to characterise gut cells. This is to ensure that 
transport experiments provide reliable results on the movement of compounds via transporters, 
passive diffusion, and tight junctions as opposed to movement through ‘gaps’ between the 
cells. Two parameters were used to examine the integrity of the monolayers; TEER and Lucifer 
yellow leakage. 
 
 Trans-epithelial electrical resistance (TEER) 
The Epithelial Volt/Ohm meter (EVOM2) supplied with an electrode ‘STX2’ quantitatively 
measures the integrity of a monolayer. The transepithelial electrical resistance (TEER) is 
measured across a monolayer by placing the shorter end of the electrode in the transwell insert 
and the longer end of the electrode in the well. Current is passed through the transcellular (cells 
growing on the membrane) and paracellular routes (between the tight junctions). The 
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transcellular pathway presents a high resistance due to the AP and BL membrane of cells 
whereas the resistance through the tight junctions will vary and thus governs the TEER values 
[158,159]. A good monolayer is defined by formation of tight junctions which results in high 
TEER values. 
TEER (Ohms) is calculated as below: 
Equation 4-1: RCell Monolayer (Ω)= RTotal (Ω)- Rcell-free control (Ω) 
Equation 4-2: RCorrected Cell Monolayer (Ω.cm2)= Rcell monolayer (Ω) x Area of membrane (cm2) 
Although TEER is a widely used parameter to determine the monolayer integrity, it also poses 
limitations such as variations in the readings. This can be affected by the position of the 
electrode, temperature, media, pH, the transwell inserts used and seeding density of cells [160]. 
To ensure minimal variables such as temperature were introduced when TEER was measured, 
plates were taken out of the incubator and placed in the flow cabinet for 15 mins along with 
the pre-warmed media for temperature equilibrations, and TEER was measured after media 
was replaced [158]. TEER was measured after replacing media every two days for 21 days. 
As a safeguard, another procedure to assess the monolayer integrity was used due to the 
variations presented from the use of TEER.  
 
 Permeability of Lucifer yellow 
The permeability of Lucifer yellow is a less commonly used method to establish the integrity 
of the monolayer [51,161]. Lucifer yellow is a fluorescent marker which diffuses through the 
paracellular route via tight junctions as its primary method of transport; it does not diffuse 
through the transcellular route due to its high molecular weight of 444.29 g/mol [162]. The 
permeability of Lucifer yellow is influenced by intact tight junctions thus low permeability of 
Lucifer yellow represents a good monolayer. In this case, it was used to verify the TEER values 
to eliminate erroneous TEER values due to limitations discussed above. The Lucifer yellow 
permeability assay was performed according to the Sigma® protocol. After the transport 
experiments were conducted, Lucifer yellow (1 mg/ml) was diluted to 0.1 mg/ml in HBSS 
buffer (transport experiment buffer) and added to the AP chambers (0.5 ml). HBSS was added 
to the BL chambers (1.5 ml). The transwell plates were incubated at 37°C for 60 minutes. 
Lucifer yellow permeability was measured by collecting 200 μl samples from the BL chamber 
of each transwell into a black plate and measuring excitation at 485 nm and emission at 520 
nm in a fluorescent plate reader. Fluorescence was also measured for HBSS (blank) and 0.1 
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mg/ml Lucifer yellow in the same black plate. Permeability of Lucifer yellow is calculated 
using the following equation:  
Equation 4-3: % permeability= 
.  /   
  100 
Less than 3% permeability of Lucifer yellow is considered a good monolayer as advised in the 
Sigma® protocol. Data were analysed from experiments performed in wells with a Lucifer 
yellow permeability of ˂3%. 
 
 Treatment with test compounds: sulforaphane, 
glucoraphanin and S-methy-L-cysteine 
SF (CAS 4478-93-7) (purity > 98%) (Cat. # S8045) was purchased from LKT Laboratories 
(St. Paul, USA). SF stock solution (100 mM) in DMSO was used to obtain a final concentration 
in the media of 10 µM. SMCSO (CAS 6853-87-8) (purity ≥98%) (Cat # 17600) and GR (CAS 
21414-41-5) (≥95%) (Cat # 10009445) were purchased from Cayman Chemical (Michigan, 
USA). Stock solutions (1 mg/ml) of GR and SMCSO were diluted in DPBS to obtain final 
concentrations of 100-200 μM. An aliquot (100 μl) of each final concentration of SF, GR and 
SMCSO was stored at -20°C for analysis to calculate % of transport from initial dose. 
After 21 days of culture, transport experiments of SF, GR, SMCSO were performed at low 
temperature (4°C) and at physiological temperature (37°C).  
For experiments at 4°C, media in the AP and BL chambers of the transwell plates were 
replaced with HBSS and transferred to the fridge (4°C) for 2 hours. This allowed the 
elimination of active transport processes and equilibration of cells. After 2 hours, HBSS was 
aspirated from the BL chambers followed by the AP chambers. Cells in the AP chambers were 
exposed to 0.5 ml of SF (10 µM), GR (100-200 µM) or SMCSO(100-200 µM). The BL 
chambers were replaced with 1.5 ml of HBSS. Transwell plates were incubated for 30, 60 and 
120 minutes. After the given incubation period, samples were collected from the AP and BL 
chambers and transferred into eppendorf tubes for storage at -20°C until analysis by LC-
MS/MS.  
For the experiments at 37°C, the media from the AP and BL chambers were replaced with 
HBSS and incubated at 37°C for 15 mins. Cells were treated with the same concentrations of 
SF, GR and SMSCO used for the experiments at 4ºC. The BL chambers were loaded with 1.5 
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ml of HBSS. After the incubation time, samples from the AP and BL chambers were 
transferred into eppendorf tubes and stored at -20°C until analysis by LC-MS/MS. 
 
 Parallel artificial membrane permeability assay 
PAMPA is a regularly used assay in the pharmaceutical industry. The assay investigates the 
permeability of compounds via passive diffusion and can be used as a high-throughput 
screening of many drug compounds. The assay is a 96-well plate consisting of one plate with 
filter membrane (acceptor plate) which sits on top of the other plate (donor plate) as illustrated 
in Figure 4-2. The artificial membrane has been designed to mimic the physiological lipid 
layer but as it is not biological, it has no active transporters thus only passive diffusion of 
compounds can be explored. This is an efficient way to screen drugs for their permeability 
coefficient as drugs with high permeability will be able to cross the blood-brain barrier and 
various lipid layers to reach their targets.  
 
Figure 4-2. Diagram of the parallel artificial membrane permeability assay. Re-drawn 
from BD biosciences [58]. 
Various concentrations of glucose (200 μM, 1 mM and 10 mM) were added to the PAMPA 
assay plates as a negative control because it should not be able to pass through the lipid-oil-
lipid membrane from the donor well to the acceptor well. Glucose is known to use active 
transporters to permeate across a membrane as it is large molecule [163]. Final concentrations 
of glucose were obtained by diluting an aqueous stock solution of 2 mg/ml solution in DPBS. 
Given that SF has a small molecular weight and is lipophilic, it was used as a positive control 
because it is likely to passively diffuse [156]. SF was tested at the final concentration of 1 μM, 
5 μM and 10 µM. 
Treatment with GR and SMSCO was carried out at the concentrations described below. GR 
stock solution of 1 mM was diluted in DPBS to 5 μM and 1 μM. Further dilution of 1 μM by 
1:20 resulted in 0.05 μM. Final concentrations of SMCSO at 100 μM, 200 μM and 300 μM 
were prepared by diluting a stock solution of 1 mM. 
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The Corning Gentest™ PAMPA plate was stored at -20°C and thawed out at room temperature 
for 30 minutes before use. Once defrosted, plates must be used within 24 hours. The final 
concentrations of tested compounds (glucose, SF, GR, SMCSO) (300 µl) were dispersed into 
the receiver plate, donor plate and 200 μl of DPBS was added to the filter plate (acceptor 
plate). The filter plate is slowly positioned on top of the receiver plate and placed at room 
temperature for 5 hours. Post-incubation time, solutions from both plates were transferred into 
labelled eppendorf tubes and stored at -20°C until analysis by LC-MS/MS. 
 Analysis of sulforaphane, glucoraphanin and S-methyl-L-
cysteine sulfoxide  
 Reagents and standards 
HPLC columns (Luna 3u C18 (2) 100 A and Kinetex® XB-C18 100 Å) were purchased from 
Phenomenex®. Agilent SB-AQ 1.8 uM (100 x 2.1mm) C18 column was purchased from 
Agilent Technologies. All reagents used for LC-MS/MS were prepared following 
manufacture’s advice. Water was obtained from a Milli-Q® Integral Water Purification System 
(Millipore Ltd). B-ITC used as the internal standard was synthesised by Dr Paul Needs (QIB 
chemist). The following were purchased from Sigma®; sinigrin (Cat. # 85440), ammonium 
acetate (Cat. # 73594) and TCA (Cat # 63399 ). TCA was diluted to 50% in deionised water 
and stored at 4°C. Agilent 6490 Triple Quad LC-MS mass spectrometer was used for the 
analysis.  
 Sample extraction 
The extraction process is the same as the one describe in section 3.3.11.2, Chapter 3. Samples 
were thawed out, and extraction process was carried out on ice by adding 20 μl of pre-cooled 
50% TCA, 10 μl of the internal standard (B-ITC for SF, sinigrin for GR) to 100 μl of samples, 
followed by vortexing for 10 minutes at 17,000 x g at 4°C. The supernatants were transferred 
into insert vials and run on the LC-MS/MS for SF and UPLC-MS/MS for GR and SMCSO. 
 
 LC-MS/MS and UPLC-MS/MS setup  
The LC-MS/MS and UPLC-MS/MS set up and monitoring of ions is the same as section 
3.3.11.4, 3.3.11.5 and 3.3.11.6, Chapter 3. Analysis was performed using an Agilent 6490 
Triple Quad LC-MS mass spectrometer equipped with a degasser, binary pump, 4ºC 
autosampler, column oven, diode array detector and 6490 mass spectrometer. Samples were 
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eluted at a flow rate of 0.3 ml/min. Separation of SF, GR and SMCSO was carried out using 
HPLC columns Luna 3u C18 (2) 100 A, Kinetex® XB-C18 100 Å and Agilent SB-AQ 1.8 uM 
(100 x 2.1mm) C18 column respectively. The column temperature and auto sampler were 
maintained at 20°C and 4°C respectively. Samples were injected at 5 μl and separation carried 
out solvent A and solvent B. 
Separation of SF was carried out with 0.1% ammonium acetate in deionised water titrated with 
0.1% acetic acid until pH 4 was reached (mobile phase A) and 0.1% acetic acid in acetonitrile 
(mobile phase B). Separation of GR was using separated with 0.2% formic acid in water 
(mobile phase A) and 0.2% formic acid in acetonitrile (mobile phase B). Separation of SMCSO 
was using 10 mM ammonium acetate + 0.05% heptafluorobutyric acid in water (mobile phase 
A) and 10 mM ammonium acetate + 0.05% heptafluorobutyric acid in 90% methanol (mobile 
phase B). 
The LC eluent flow was sprayed into the mass spectrometer interface without splitting. SF, 
GR and SMCSO ion were monitored using mass spectrometry in MRM mode in positive 
polarity (GR in negative polarity) with ESI. The quantification was performed using matrix 
match calibration curve. Identification and quantification of the SF, SMCSO and GR peak 
were based on retention time and peak area using calibration standards. 
 
 Identification and quantification of SF, GR and SMCSO 
SF stock (1 mg/ml) was prepared in Milli-Q® water, and a serial dilution was produced in the 
same matrix as the samples that were run (e.g. HBSS for caco-2 transport experiments and 
DPBS for PAMPA assay). All serial dilutions were prepared fresh directly before each run. 
An 11-point standard curve ranging from 0-10 μM SF was generated as the highest 
concentration used for the treatments was 10 μM.  
GR stock (1 mg/ml) was prepared in Milli-Q® prior to the run. For the caco-2 experiments, a 
12-point standard curve from 0-200 μM was constructed by diluting the GR stock solution (1 
mg/ml). For the PAMPA assay, lower concentrations were used so a 10-point standard curve 
ranging from 0-11 μM was prepared. 
SMCSO stock solution (1mg/ml) was diluted to produce an 11-12-point standard curve 
ranging from 0-200 μM and 0-331 μM for analysis of caco-2 and PAMPA assay samples, 
respectively.  
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 Analysis of glucose using a glucose detection assay kit 
Glucose was quantified using a Sigma® glucose assay kit stored at 2-8°C. The purpose of the 
kit is to determine the quantity of glucose in various non-biological and biological samples. It 
comprises of a glucose oxidase/peroxidase reagent, o-Dianisidine reagent, and 1 mg/ml 
glucose solution in 0.1% benzoic acid. The glucose oxidase/peroxidase capsule contains 500 
units of glucose oxidase (Aspergillus niger), 100 purpurogallin units of peroxidase 
(horseradish) and buffer salts. The oxidase/peroxidase reagent is made up with 39.2 ml of 
deionised water (Milli-Q®) in an amber bottle and is stable at 2-8°C for one month or at -20°C 
for 6 months. The vial containing 5 mg of o-Dianisidine dihydrochloride powder was dissolved 
with 1 ml of deionised water and inverted to mix contents. It can be stored for 3 months at 2-
8°C and should be protected from light. To formulate the assay reagent, 0.8 ml of reconstituted 
o-Dianisidine dihydrochloride was pipetted to the amber bottle with glucose 
oxidase/peroxidase reagent and inverted. This should be kept away from light and stored at 2-
8°C to keep it stable for 1 month. Sulfuric acid was prepared by Dr Paul Needs (QIB chemist). 
As sulfuric acid is a diprotic acid, a 12 N solution of sulfuric acid in water is equivalent to 6 
M as explained in Equation 4-4. Stock solution of sulfuric acid will contain 18.38 M (36.76 
N) in 1 L (Equation 4-5). To dilute 36.76 N to 12 N, 326.44 ml of 36.76 N sulphuric acid was 
slowly added to 1 L of deionised water (Equation 4-6). Sulfuric acid solution can be stored at 
room temperature. 
Equation 4-4: Molar concentration = Normality  Equivalence Factor 
Molar concentration = 12 N  0.5 (equivalence factor for sulfuric acid) 
Molar concentration = 6 M 
Equation 4-5: Molarity= 
 %  
 




 10  




  1000 326.44   1   
The principle of the assay kit is based on an enzymatic reaction producing a colour change in 
the presence of glucose which is then measured using a plate reader. Gluconic acid and 
hydrogen peroxide accumulate upon the addition of the enzyme glucose oxidase to the glucose 
samples. The reduced form of o-Dianisidine is colourless, oxidation by hydrogen peroxide 
Chapter 4: Transport study 
129 | P a g e  
catalysed by peroxidase results in an oxidised o-Dianisidine, a brown coloured product. 
Incubation of the coloured product with sulfuric acid at 37°C in a water bath for 30 minutes 
develops a stable pink coloured product which is influenced by the glucose concentration 
(Equation 4-9). The concentration of glucose in samples is determined from the standard 
curve generated using glucose samples of known concentrations.  
Equation 4-7: D-Glucose + H2O + O2 → D-Gluconic Acid + H202 catalysed by glucose 
oxidase 
Equation 4-8: H2O2 + Reduced o-Dianisidine (colourless) → Oxidised o-Dianisidine (brown) 
catalysed by peroxidase 
Equation 4-9: Oxidised o-Dianisidine (brown) → Oxidised o-Dianisidine (pink) in addition 
to sulfuric acid 
Samples from PAMPA assay were defrosted and diluted with deionised water to contain 20-
80 μg/ml. All samples and standard curve were pipetted into glass test tubes for the reactions. 
The concentrations of glucose added to the PAMPA donor plate were 200 μM (36.03 μg/ml), 
1 mM (180.16 μg/ml), 10 mM (1801.60 μg/ml). Only the wells treated with 200 μM were 
within the range of glucose detection. The wells treated with 1 mM and 10 mM were diluted 
in deionised water by a factor of 1:5 and 1:50 respectively to give a glucose concentration of 
36.03 μg/ml. Samples collected from both the donor plate and acceptor plate were diluted for 
consistency. The glucose detection assay was carried out as stated by Sigma®’s protocol with 
modifications. The main adjustment to the protocol was the change in the volume of samples 
and reagents added. This was a consequence of low volume of samples obtained from the 
PAMPA assay. A dilution of the 1 mg/ml glucose standard was undertaken to give a final 
concentration of 0-80 μg/ml in 200 μl in glass test tubes. The reaction commenced with the 
addition of 400 μl of assay reagent prepared previously followed by mixing of the test tubes. 
A 30-60 second interval was allowed between subsequent tubes prior to the addition of assay 
reagent. Tubes were placed in a water bath set at 37°C to react for 30 minutes. The reaction 
was terminated by pipetting 200 μl of sulfuric acid with an interval of 30-60 seconds between 
each tube. At this stage, a colour change from brown to pink was observed in the presence of 
glucose while samples without glucose remained colourless. To measure the absorbance, 200 
μl of samples were transferred into a clear 96-well plate and measured at a wavelength of 540 
nm against the blank sample (0 μg/ml) on the FLUOstar® Omega plate reader. Concentrations 
of the samples were interpolated from the standard curve. 
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 Measurement of percentage of transport and apparent 
permeability coefficient  
The percentage of transport (%) from the AP to the BL chamber was calculated from the initial 
concentration of compounds added to the AP chamber as shown in Equation 4-10. The 
apparent permeability coefficient (Papp) was calculated using Equation 4-11 [164]:. 
Equation 4-10: percentage of transport (%)=   100 
Cf= Final concentration in the BL chamber (µM) 
C0= Initial concentration added to the APchamber (µM) 
Equation 4-11:  /
  
    
V= Volume in the BL chamber (1.5 ml) 
A= area of the transwell (1.12 cm2) 
 = change in the concentration of compound in the BL chamber over incubation time 
 
 Results 
 Assessment of membrane integrity in caco-2 cells by 
measuring the trans-epithelial electrical resistance 
To assess the integrity of the caco-2 monolayer, caco-2 cells were grown on 12-well transwell 
plates, and TEER was measured using the Epithelial Volt/Ohm meter (EVOM2) after media 
was replaced every two days as described in section 4.3.2.2.1. TEER from 3 repeated 
measurements from each well were recorded for 21 days and corrected from the cell-free 
control well (Figure 4-1). This value was corrected for the area of the membrane (Equation 
4-2). The average TEER values of 24 wells (from two 12-well transwell plates) with standard 
deviation was plotted as illustrated in Figure 4-3. During the first 4 days of seeding the TEER 
values were low, almost the same as the TEER value from the blank well. After day 4, TEER 
values increased up to day 8. Thereafter, the TEER values stabilised until day 21, when the 
last measurement was obtained. Therefore, subsequent transport experiments were undertaken 
on day 21 of culturing cells on transwells. Wells with TEER values of <500 Ω.cm2 were 
omitted from transport experiments. 
Chapter 4: Transport study 
131 | P a g e  
 
Figure 4-3: TEER values measured on caco-2 cells grown on 12-well transwell plates for 
21 days. TEER values (Ohms) were measured after replacing media every two days. The 
values were subtracted from the cell-free control well and multiplied to correct for the 
membrane area of 1.12 cm². Data are represented as mean ± SD (n=22). 
 
 Assessment of membrane integrity in caco-2 cells by 
measuring Lucifer yellow fluorescence 
To confirm membrane integrity independently, transwell plates were incubated with a 
fluorescent paracellular marker (Lucifer yellow), after treatment with tests compounds (SF. 
GR, SMCSO). Permeability of Lucifer yellow was calculated using Equation 4-3, and 
percentage values <3% were indicative of a good cell monolayer in accordance with 
manufacturer’s instruction (Sigma®). As illustrated in Figure 4-4, Lucifer yellow permeability 
(%) (n=43 wells) was in the range of 0.02-2.8% with an average of 0.47 ± 0.60%. Each well 
containing cells had a Lucifer yellow permeability (%) ˂3% confirming a good membrane 
integrity as already demonstrated by TEER values. As expected, cell-free control wells showed 
much higher permeability values (n=4; 17.03 ± 2.98%).  
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Figure 4-4: Percentage permeability of Lucifer yellow in transwell plates after treatment 
with test compounds. Fluorescence values were measured at excitation of 485 nm and 
emission of 520 nm on a FLUOstar® Omega plate reader. Lucifer yellow permeability 
(%) was calculated by correcting for the HBSS blank and 0.1 mg/ml Lucifer yellow. All 
values are represented as mean ± SD (n=47 wells). 
 
 Effect of temperature on sulforaphane transport through 
caco-2 monolayer  
SF has been widely regarded as a small compound capable of passively diffusing through the 
monolayer. Caco-2 cells were exposed to SF (10 μM) at different temperature conditions (4°C 
and 37°C) to confirm that SF does use passive diffusion rather than active transport. It is well 
established that active transport is halted at 4°C, and thus by exposing SF-treated cells to this 
temperature its movement will only occur via passive diffusion. Results obtained by LC-
MS/MS analysis of SF concentrations in AP and BL samples showed an increase of SF 
transport over time at both 4°C and 37°C (Figure 4-5). Transport of SF (%) at physiological 
temperature (37°C) was 1.44 ± 0.05%, 1.84 ±0.51% and 2.92 ± 0.47% at 30, 60, and 120 
minutes, respectively. SF transport (%) at 4°C was lower as only 0.61 ± 0.05%, 1.05 ± 0.13%, 
and 1.83 ± 0.15% at the same time intervals. Results obtained did show a significantly reduced 
transport of SF at 4ºC compared to the physiological temperature 37ºC at 30 minutes 
(p<0.0001) and at 120 minutes (p <0.05).  
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Figure 4-5: Percentage of SF transport from the AP to the BL chamber in caco-2 grown 
in transwells.  Cells were treated with SF at the concentration of 10 μM and incubated 
at both 4°C, and 37°C. Diffusion of SF was quantified over time at 30, 60 and 120 mins. 
All values are represented as mean ± SD (n=3). Data points at 30 minutes have small 
errors hence the bars are not visible. Statistical analysis was undertaken by one-way 
ANOVA with Dunnett’s multiple comparisons test (** p<0.01 and *** p<0.001 vs. 0 
minutes). 
 Effect of temperature on glucoraphanin transport through 
caco-2 monolayer  
To date, there is no literature on the transport of GR; results obtained from the human 
intervention study (BOBS study) described in Chapter 3, revealed that unmetabolised GR 
can be detected in plasma and urine after consumption of GR-enriched food product. The 
transport of GR (100-200 µM) and the potential effect of different temperature conditions was 
evaluated by undertaking the transport experiments in caco-2 cells grown in transwells at 4°C 
and 37°C. Data obtained by UPLC-MS/MS analysis of samples showed that GR transport 
increases with time at both concentrations at 37°C (Figure 4-6 A-B). Treatment of caco-2 
cells with 100 μM GR at 37°C resulted in 0.28 ± 0.18%, 0.33 ±0.16 and 0.72 ± 0.22% at 30, 
60, and 120 minutes respectively. In comparison, at 4°C only 0.03 ± 0.01%, 0.06 ± 0.03% and 
0.06 ± 0.02% of the 100 μM GR diffused through the monolayer at 30, 60, and 120 minutes 
(Figure 4-6 A). This difference in the percentage of 100µM GR transport induced by 
temperature change is significant at 60 and 120 minutes (p<0.01). The same trend was 
observed with caco-2 cells exposed to 200 μM GR where cells incubated at 37°C accumulated 
a significantly higher percentage of GR in the BL chamber compared to cells at 4°C (p<0.01 
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at 30 minutes, p˂0.0001 at 60 and 120 minutes) (Figure 4-6 B). Following exposure of cells 
to 100 μM and 200 μM GR treatment, a similar trend was observed with an increase in the 
permeation of GR from the AP to BL chamber with increasing time. However, there was a 
significant increase in the accumulation of GR in the BL when caco-2 cells were subjected to 
200 μM versus 100 μM at 60 (p˂0.01) and 120 minutes (p˂0.05). The higher the concentration 
of GR dispersed in the AP chamber, the greater the recovery of GR in the BL chamber. 
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Caco-2 cells treated with 100 µM GR 
A 
 
Caco-2 cells treated with 200 µM GR 
B 
 
Figure 4-6: Percentage of GR transport from the AP to the BL chamber in caco-2 grown 
in transwells.  Cells were treated with GR at the concentration of 100 µM (A) or 200 µM 
(B) and incubated at both 4°C and 37°C. The permeability of GR was measured over 
time at 30, 60, and 120 minutes. All values are represented as mean ± SD (n=6, 37°C 
experiments; n=3, 4°C experiments). Outliers were excluded when appropriate. 
Statistical analysis was performed by one-way ANOVA with Dunnett’s multiple 
comparisons test (*p<0.05, ** p˂0.01 and *** p≤0.0001 vs. 0 minutes). 
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 Effect of temperature on S-methyl-L-cysteine sulfoxide 
transport through caco-2 monolayer  
Thus far, there are no reports on the transport of SMCSO. Unmetabolised SMCSO was 
detected in plasma and urine after consumption of GR and SMCSO enriched soups as 
described in Chapter 3. Consequently, the transport of SMCSO (100-200 µM) across the 
caco-2 monolayer was investigated at two temperatures. Transport experiments were 
undertaken in caco-2 cells grown in transwells at 4°C, and 37°C. Analysis by UPLC-MS/MS 
showed that SMCSO increases with time at both concentrations at 37°C (Figure 4-7). 
Treatment of caco-2 cells with 100 μM SMCSO at 37°C resulted in 0.31 ± 0.16%, 0.45 ± 
0.55%, 0.74 ± 0.39% at 30, 60, and 120 minutes respectively (Figure 4-7 A). The temperature 
did not induce a significant change in the percentage of 100 µM SMCSO transport at 4°C at 
30 and 60 minutes (0.35 ± 0.50% at 30 and 0.60 ± 0.53% at 60 minutes). The percentage of 
SMCSO transported across the monolayer at 30 and 60 minutes is comparable to 37ºC. 
However, at 120 minutes, the percentage of SMCSO transport is significantly reduced at 4ºC 
compared to 37ºC (0.11 ± 0.02%, 4ºC vs. 0.74 ± 0.39% at 37ºC, p˂0.0001) (Figure 4-7 A). 
On the other hand, caco-2 cells exposed to 200 μM SMCSO incubated at 37ºC accumulated a 
significantly higher percentage of SMCSO in the BL chamber compared to cells at 4°C 
(p˂0.05 at 30 minutes, p˂0.01 at 60 and 120 minutes) (Figure 4-7 B). A similar trend to that 
observed with the percentage of 200 µM GR at 37º C and 4ºC (Figure 4-6). Caco-2 cells 
exposed to 100 μM and 200 μM SMCSO treatment at 37ºC demonstrated a similar trend in 
the increase of SMCSO transport from the AP to BL chamber with increasing time. However, 
unlike the permeation of GR at 37ºC (Figure 4-6), the accumulation of SMCSO in the BL 
chamber is not significantly different in cells subject to 100 µM or 200 µM SMCSO. A similar 
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Caco-2 cells treated with 100 µM SMCSO 
A 
 




Figure 4-7: Percentage of SMCSO transport from the AP to the BL chamber in caco-2 
grown in transwells.  Cells were treated with SMCSO at the concentration of 100 µM 
(A) or 200 µM (B) and incubated at both 4°C and 37°C. The permeability of SMCSO 
was measured over time at 30, 60, and 120 minutes. All values are represented as mean 
± SD (n=9, 37°C experiments; n=3, 4°C experiments). Outliers were excluded when 
appropriate. Statistical analysis was performed by one-way ANOVA with Dunnett’s 
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 Apparent permeability coefficient of sulforaphane, 
glucoraphanin and S-methyl-L-cysteine sulfoxide  
The permeability coefficient of all three compounds in caco-2 cells incubated at 4ºC and 37ºC 
was calculated at 30 minutes to elucidate whether SF reported to passively diffuse, has a higher 
permeability coefficient compared to SMCSO and GR (Table 4-1). SF (10 µM) displayed a 
higher permeability coefficient compared to 100-200 µM of GR and SMCSO by ~4-fold and 
~5-fold respectively at 37ºC. Whereas, at 4ºC, the permeability coefficient of SF (10 µM), GR 
(100-200 µM) and SMCSO (200 µM) decreased compared to 37ºC, albeit with no difference 
in the permeability coefficient observed with 100 µM SMCSO. However, even at 4ºC the 
permeability coefficient of SF was higher than GR and SMCSO. Results obtained indicate 
that SF is more permeable than GR and SMCSO at both a physiological temperature (37ºC) 
and at 4ºC and that the temperature influences the permeability of compounds. 
Table 4-1: Permeability coefficient (Papp) of SF, GR and SMCSO in caco-2 cells 
incubated at 4ºC and 37ºC. 
Treatment group Papp AP→BL (x 10-6cm/s) n 
Incubation at 37ºC,30 minutes 
10 µM SF  10.73 ± 0.38  3 
100 µM GR  2.72 ± 1.83 5 
200 µM GR  3.02 ± 1.34 5 
100 µM SMCSO  2.33 ± 1.17 9 
200 µM SMCSO  1.76 ± 0.71 8 
Incubation at 4ºC, 30 minutes 
10 µM SF  4.53 ± 0.39 3 
100 µM GR  0.25 ± 0.06 3 
200 µM GR  0.39 ± 0.24 3 
100 µM SMCSO  2.62 ± 3.71 2 
200 µM SMCSO  0.46 ± 0.47 3 
Data presented as mean ± SD, ‘n’ represents biological replicates, >n=3 indicates 
independent experiments. Outliers were excluded when appropriate. 
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 Permeability of Lucifer yellow does not correlate with the 
permeability of sulforaphane, glucoraphanin and S-methyl-L-
cysteine sulfoxide 
The permeability of Lucifer yellow, a paracellular marker was assessed across the caco-2 
monolayer to evaluate the monolayer integrity. A permeability of ˂3% was indicative of a 
satisfactory monolayer for transport experiments as reported in the protocol by Sigma®. 
However, the transport of the test compounds (SF, GR and SMCSO) was ˂3%. To elucidate 
whether the permeability of Lucifer yellow and the test compounds are related, correlation 
graphs were drawn as illustrated in Figure 4-8. There is no correlation between SF or SMCSO 
permeability and Lucifer yellow permeability. Although significant (p<0.05), there is a weak 
negative correlation between Lucifer yellow and GR permeability. The graphs show that there 
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Figure 4-8: Correlation of Lucifer yellow permeability and SF, GR or S-methyl-L-
cysteine permeability across caco-2 cells.  Permeability (%) was calculated as the amount 
recovered in the BL chamber from the added concentration of Lucifer yellow/test 
compounds in the AP chamber. The relationship is illustrated between the permeability 
of Lucifer yellow and SF (A), permeability of Lucifer yellow and GR (B) and 
permeability of Lucifer yellow and SMCSO (C). 
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 Sulforaphane transport occurs via passive diffusion through 
an artificial membrane  
Several reports indicated that SF passively diffuses through biological membranes due to its 
chemical structure. To confirm that SF uses this mechanism of transport, an artificial 
membrane presenting no transporters (PAMPA assay) was exposed to a range of SF 
concentrations for 5 hours. The donor plate was treated with 1 μM (n=8 wells), 5 μM (n=8 
wells), 10 μM SF (n=8 wells) and acceptor plate with DPBS. Chromatograms of samples 
analysed by LC-MS/MS are illustrated in (Figure 4-9). As expected, SF peaks were detected 
in all donor plate samples loaded with various concentrations of SF. On the other hand, even 
though the acceptor plate was treated with DPBS only, peaks of SF were identified in all 
acceptor plate samples indicating transport via passive diffusion. SF peaks detected in the 
samples had the same retention time of 7.1 minutes such as the SF standard run at the same 
time.  
Donor plate treated with SF (1-10 µM) 
A 
 
Acceptor plate treated with DPBS 
B 
 
Figure 4-9: LC-MS/MS chromatograms of SF transport from the donor to the acceptor 
plate through an artificial membrane using PAMPA . Donor plates were treated with SF 
(1-10 µM) (A), and acceptor plates were treated with DPBS (B). Permeability of SF was 
measured using LC-MS/MS after 5 hours of incubation at room temperature.  
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 Glucoraphanin does not passively diffuse through an artificial 
membrane  
Unlike SF, there is no literature on the transport of GR. To investigate whether GR can 
passively diffuse, the PAMPA assay was used in the same experimental conditions described 
in section 4.4.3. The donor plate was treated with 0.05 µM (n=8 wells), 1 µM (n=8 wells), 5 
μM GR (n=8 wells) and the acceptor plate with DPBS. The incubation time was 5 hours as 
described for the experiments with SF. UPLC-MS/MS chromatograms are presented in Figure 
4-10. GR peaks with a retention time of 2.0 minutes were identified in all the donor plate 
samples loaded with various GR concentrations (Figure 4-10 A and B). Due to the difference 
in scale, the peak observed with 0.05 µM GR treatment is not visible in Figure 4-10 A. As 
such, this peak is redrawn in Figure 4-10 B. The retention time of GR detected in the assay 
samples was identical to the GR standard. On the other hand, samples from the acceptor plate 
revealed no GR peaks (Figure 4-10 C). Unlike the assay with SF treatment, peaks were only 
detected in the donor plate which was treated with GR, and no peaks were detected in the 
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Donor plate treated with GR (0.05-5 µM) 
A 
 
Donor plate treated with 0.05µM GR 
B 
 
Acceptor plate treated with DPBS 
C 
 
Figure 4-10: UPLC-MS/MS chromatograms of GR transport from the donor to the 
acceptor plate through an artificial membrane using PAMPA. Donor plates were treated 
with GR (0.05-1 µM) (A), and acceptor plates were treated with DPBS (C). GR peak 
detected in the donor wells treated with 0.05 µM GR (B). Permeability of GR was 
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 SMCSO does not passively diffuse through an artificial 
membrane  
There is no previous report showing the mechanism of transport of SMSCO through biological 
membranes. The PAMPA assay was carried out to explore whether SMCSO can passively 
diffuse. As described for the experiments undertaken with SF and GR, donor plate was treated 
with a wide range SMCSO concentrations (100-300 µM) and the acceptor plate with DPBS 
for 5 hours. UPLC-MS/MS chromatograms of SMSCO are shown in Figure 4-10. Data 
obtained revealed that SMCSO, like GR, does not passively diffuse as confirmed from the 
absence of SMCSO peaks in acceptor plate samples (Figure 4-10 B). However, SMCSO peaks 
with a retention time of 0.98 were detected in all samples from the donor plate loaded with 
SMCSO (Figure 4-10 B); the same retention time was observed by using a synthetic standard. 
Donor plate treated with SMCSO (100-300 µM) 
A 
 
Acceptor plate treated with DPBS 
B 
 
Figure 4-11: UPLC-MS/MS chromatograms of SMCSO transport from the donor to the 
acceptor plate through an articifical membrane using PAMPA. Donor plates were 
treated with SMCSO (100-300 µM) (A), and acceptor plates were treated with DPBS (C). 
Permeability of SMCSO was measured using UPLC-MS/MS after 5 hours of incubation 
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 The use of glucose as a negative control for the parallel 
artificial membrane permeability assay 
To ensure that the PAMPA assay was a suitable experimental tool for studying passive 
diffusion, glucose was used as a control because of its well-known transport mechanism based 
on specific transporters [157]. The PAMPA assay was carried out following the same 
experimental conditions used for the tests compounds (SF, GR, SMCSO). However, a 
different method based on absorbance readings was used for measuring glucose in assay 
samples. As Table 4-2 shows, no samples from the acceptor plate detected any glucose. A 
glucose concentration of 201.79 μM, 0.85 mM and 9.18 mM was determined in donor plate 
samples treated with 200 μM, 1 mM and 10 mM. The concentration of glucose was 
underestimated (0.9 mM and 9.2 mM) in donor plate samples treated with 1 mM and 10 mM 
whereas the glucose concentration was overestimated in the donor plate samples treated with 
200 µM (Table 4-2). This may be due to technical problems related to the processing of many 
samples at the same time. Despite the technical problem, the assay confirmed that glucose 
does not passively diffuse corroborated with the absence of glucose in the acceptor samples.  
Table 4-2: Glucose concentrations as measured by an absorbance-based method in 
samples from the donor and acceptor plates.  
Donor plates were treated with glucose (0.2-10 mM), and acceptor plates were treated 
with DPBS. Permeability of glucose was measured using an absorbance-based method 
after 5 hours of incubation at room temperature. Data represented as mean ± SD (n=8 
wells, 200 µM and 1 mM glucose; n=16 wells, 10 mM glucose). 
 
Glucose concentration detected 
Mean ± SD  n 
Donor wells treated with 200 µM glucose 201.79 ± 7.06 μM 8 
Acceptor plate treated with DPBS  0 8 
Donor wells treated with 1 mM glucose 0.85 ± 0.13 mM 8 
Acceptor plate treated with DPBS 0 8 
Donor wells treated with 10 mM glucose 9.18 ± 1.58 mM 15 
Acceptor plate treated with DPBS 0 16 
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 Discussion 
This study aimed to investigate the transport mechanisms of the dietary compounds SF, GR 
and SMCSO using established in vitro models (caco-2 and the PAMPA assay). Previous 
reports have indicated that SF passively diffuses through membranes due to its low molecular 
weight and high lipophilicity [24]. For this reason, SF has been used as a positive control in 
both in vitro models described in this Chapter. To date, there has been no study published on 
the mechanisms of transport used by GR and SMCSO. Due to the high molecular weight and 
polar surface area of GR, it was predicted that GR would require a transporter to cross the 
membrane. Although SMCSO has a low molecular weight and a polar surface area comparable 
to that of SF, it was hypothesised that SMCSO would also require a transporter due to its 
structural similarity with L-cysteine.  
Prior to the transport experiments, the monolayer integrity was assessed by measuring TEER 
and permeability of Lucifer yellow. Measurement of TEER is the leading method extensively 
used to assess the integrity of the caco-2 monolayer. Over 21 days of culture, the TEER values 
increased, eventually plateauing, indicating that tight junctions had developed to a satisfactory 
degree to follow with the transport experiments. TEER values reached >1000 Ω.cm2 on day 8 
post-seeding, in congruence with previously published literature that reported that caco-2 
monolayer density is established around day 6-7 [52]. While a lot of studies report lower 
TEER values, in the range of 450-500 Ω.cm2 [160,165,166], this is likely due to the low 
passage number cells used in those cases. TEER values are generally higher for cells at older 
passage numbers [50,53]. In this study, cells at a passage number of 44-55 were used hence 
the TEER was >1000 Ω.cm2 in accordance with the study by Ishida et al. who used cells at 
passage number 40 and recorded TEER values of 900 Ω.cm2 [167]. Wells with TEER values 
of <500 Ω.cm2 were omitted from transport experiments as it indicated that tight junctions 
were not fully developed. To further confirm the integrity of the cell monolayer, the 
fluorescence probe Lucifer yellow was used in all experiments described in this Chapter. 
Lucifer yellow permeability of ˂3% is indicative of a monolayer with intact tight junctions. A 
high permeability of Lucifer yellow, a paracellular marker, implies that the tight junctions are 
not intact in the monolayer and hence transport of compounds would be due to ‘gaps’ in the 
monolayer. While most wells used in the transport experiments exhibited a permeability of 
<3% (Figure 4-8), some wells displayed a permeability of >3% such as those in the GR 
experiments (Figure 4-8 B). Although Lucifer yellow implied poorly formed tight junctions, 
TEER values, the more widely used method indicated othewise. Therefore, these wells were 
still included on the basis of the TEER values indicating that it was a good monolayer. 
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The effect of temperature on the transport of the test compounds across the cell monolayer 
was investigated at 37°C and at 4°C. This was undertaken to differentiate between passive 
diffusion (not energy-dependent) and active transport (energy-dependent). At 4°C active 
transport is halted due to less energy production, a key requirement for functional transporters 
[44,164,167-170]. The percentage of transport of 10 μM SF increases over time at 37°C and 
4°C (Figure 4-5). This implies that even when active transport is halted at 4°C, there is 
transport of SF occurring at a similar trend to the transport at 37°C but at a reduced rate. Two 
possible reasons for transport to occur at 4°C are either the transport of SF through unsealed 
tight junctions or via passive diffusion which is not energy-dependent. Given that the integrity 
of the monolayer was verified using TEER, the only plausible explanation is that SF passively 
diffuses across the membrane. Data obtained from this study represent the first experimental 
evidence of transport across caco-2 grown in transwells supporting the assumption that SF 
passively diffuses across membrane [27,156]. As observed with SF, the percentage of GR 
transport increases over time at 37°C. However, there is negligible transport of 100 μM and 
200 μM GR at 4°C (Figure 4-6) in contrast to the percentage of SF transport at 4°C. In this 
case, the low percentage of GR transport at 4°C suggests that the diffusion of GR may require 
active transport to permeate across the membrane. Similarly, the percentage of SMCSO 
transport increases over time at 37°C. However, there is negligible transport of 200 µM 
SMCSO at 4°C. Transport of 100 µM SMCSO at 4ºC is erratic as it does not follow the trend 
observed with SF or GR at 4ºC or 37ºC. This may be due to technical issues as the lowest limit 
of detection of SMCSO by the UPLC-MS/MS is 0.19 µM. At 4ºC, the concentration of 
SMCSO might be ˂0.19 µM thus resulting in irregular detection of SMCSO reflected by the 
standard deviation bars. Taking into consideration the data from the transport of 200 µM 
SMCSO at 4ºC indicates that like GR, SMCSO may require an active transport. Incubating 
caco-2 cells at 4°C is not a commonly used procedure but has been applied previously by 
others to distinguish between passive diffusion and active transport [44,167-172]. The major 
concern with reducing the temperature is the consequent changes to the physical properties of 
the cells such as decreasing membrane fluidity [173].  
Permeability of compounds can be determined by calculating the apparent permeability 
coefficient (Papp). In congruence with Song et al., incubation at 4ºC compared to 37ºC reduced 
the Papp for SF, GR (100-200 µM) and SMCSO (200 µM) bar SMCSO (100 µM) [169]. 
Artursson and Karlsson demonstrated that well absorbed drugs had a Papp of >1 x 10-6 cm/s 
[174] while, Yee, S. reported that a Papp ˂1 x 10-6 cm/s, 1-10 x 10-6 cm/s, and >10 x 10-6 cm/s 
correlates with a human oral absorption of 0-20%, 20-70%, and 70-100% respectively [175]. 
In this study, at 37ºC GR and SMCSO had a Papp >1 x 10-6 cm/s, suggesting that these 
compounds are moderately absorbed, while SF is well absorbed (70-100%) as a result of a Papp 
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>10 x 10-6 cm/s. In agreement with this, a SF absorption of 74 ± 29% was reported in human 
enterocytes using perfused jejunum segment by Petri et al. [27]. While the permeability 
coefficient does not distinguish whether a compound can passively diffuse or require active 
transport, it can aid classification of compounds according to their permeability. Given the 
similarity in the Papp between GR and SMCSO, it suggests that both compounds might use 
similar transport routes, e.g. active transport, whereas SF, which is more permeable based on 
the Papp, passively diffuses. 
To further investigate the mechanism of transport of the tested dietary compounds, a cell-free 
model was selected to obtain additional information that would complement the data obtained 
from culturing caco-2 cells. LC-MS/MS analysis of samples obtained from the PAMPA assay 
showed that peaks of SF were detected in the donor plate and acceptor plate. The donor plate 
was treated with SF, thus it was expected to detect peaks. The presence of peaks in the acceptor 
plate implies that SF passively diffused across the membrane. This data corroborates the data 
from the caco-2 cells signifying that SF can passively diffuse as indicated in the literature 
[27,156]. On the other hand, GR and SMCSO were detected in the samples from the donor 
plate but not detected in the samples from the acceptor plate. This indicates that GR and 
SMCSO cannot passively diffuse which supports the data from the caco-2 model. Glucose, 
known to require active transport, was used as a control for the PAMPA assay and was added 
to the donor plate. As expected, glucose could not be detected in the samples from the acceptor 
plate but was detected in the samples from the donor plate where it was added and thus has 
validated the use of the PAMPA assay for the work presented in this Chapter.  
It is important to note that the percentage movement of all three compounds (SF, SMCSO and 
GR) was lower than the percentage of Lucifer yellow permeating across the membrane, 
suggesting that the transport of the compounds may have been due to impaired tight junctions, 
allowing diffusion through the ‘gaps’ in the monolayer rather than via active transport. 
However, there is no correlation between the permeability of Lucifer yellow and that of the 
test compounds (SF, GR and SMCSO) (Figure 4-8), suggesting that the movement of the test 
compounds is due to a factor unrelated to that allowing the movement of Lucifer yellow. Thus 
transport of compounds may not be due to gaps. There are inconsistencies regarding the 
Lucifer yellow flux calculations as Debebe et al. excluded wells with a Lucifer yellow 
permeability of >2% [176]. Whereas, others [172,177-180] have calculated the apparent 
coefficient permeability (Papp) of Lucifer yellow as described by Lea, T. [50] and Hubatsch et 
al. [49]. The permeability of SF, GR and SMCSO is less than that of Lucifer yellow and 
therefore Lucifer yellow may not be a suitable assay. However, the TEER values alone are a 
suitable evaluation of the monolayer integrity thus we can still hypothesise. Given that 
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unmetabolized GR and SMCSO were detected in the plasma following consumption of soups, 
their transport by some means remains a plausible theory. 
 Conclusion 
The findings from this study for the first time confirm experimentally that SF can passively 
diffuse using caco-2 and the PAMPA model. The data suggests that GR and SMCSO may 
require a transporter to permeate across the membrane, given the negligible transport of these 
compounds across the caco-2 monolayer at 4°C and lack of evidence for diffusion through the 
PAMPA membrane. The use of appropriate control (glucose and SF) and well-established 
analytical methods such as LC-MS/MS methods were used to investigate the hypothesis. For 
the first time, the work described in this Chapter indicates the potential involvement of a 
transporter in the influx of broccoli-derived compounds GR and SMCSO, however it is clear 
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 Summary 
Phytochemical analysis of the broccoli-rich food product described in Chapter 2 has revealed 
that SMCSO is present at significantly higher levels compared to GR. Following consumption 
of these soups, high levels of SMCSO were measured in plasma and urine of healthy 
participants (Chapter 3). SMCSO has recently drawn interest due to its potential protective 
effects including anti-carcinogenic, anti-diabetic and cardiovascular effects. As SF exhibits 
these biological effects by inducing a transcription factor Nrf2, and up-regulating anti-oxidant 
genes, it was postulated that the putative biological effects of SMCSO could also be similar. 
The purpose of this Chapter was to investigate whether SMCSO can up-regulate anti-oxidant 
genes through the induction of Nrf2 in human liver cells (HepG2). Interestingly, while SF up-
regulated several Nrf2-regulated genes as predicted, SMCSO had opposing effects. However, 
this may not be biologically significant as fold changes induced by SMCSO are relatively low 
compared to the fold change elicited by SF. This data provides convincing evidence that Nrf2 
induction is not a key molecular mechanism of SMCSO biological profile. 
 
 Introduction 
Cruciferous vegetables have high levels of sulphur compounds such as glucosinolates 
[1,2,181]. These vegetables also accumulate another sulphur compound, SMCSO in 
significantly higher levels compared to glucosinolates [2] as reported in Chapter 2 which are 
bioavailable as demonstrated from the in vivo work described in Chapter 3. Even though, the 
in vitro work using caco-2 cells (Chapter 4) suggested that ˂0.6% of SMCSO may diffuse 
through tight junctions or be actively transported, high levels of SMCSO were delivered to 
the plasma (17-28 µM) as reported in Chapter 3. In addition, the high levels of SMCSO in 
cruciferous vegetables poses the question of its influence on human health and whether this is 
comparable to the most studied phytochemical delivered from cruciferous vegetables, SF.  
SF is a phytochemical extensively researched for its putative health benefits through the 
induction of phase II enzymes and its anti-carcinogenic activities [12]. Induction of 
transcription factor Nrf2 by SF facilitates its translocation from the cytoplasm into the nucleus 
[99]. Nrf2 binds to the ARE with a sequence of 5’-A/G TGA C/T NNN GC A/G-3’in the 
promoter region of several genes thereby inducing up-regulation of phase II enzymes [99]. It 
has been shown that SF stimulates the up-regulation of phase II genes such as GCLC and 
NQO1 in several cell lines and mice models [99,103,108,117,125,182-184]. Through the up-
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regulation of Nrf2-regulated genes, SF has been shown to modulate the central metabolic 
pathways and thus exert its chemo-preventative and anti-oxidant-like properties. 
Previously published literature has regarded SMCSO as a bioactive phytochemical with 
positive health effects, including anti-diabetic, anti-carcinogenic, cardiovascular, and 
antioxidant-like effects [2]. The mechanism of action by which SMCSO achieves this is 
unknown. SMCSO’s anti-oxidant effects have been mainly associated to its metabolite 
MMTSI and MMTSO [2]. MMTSI and MMTSO are formed from the dimerization of a highly 
reactive intermediate (methanesulphenic acid) produced by the enzymatic breakdown of 
SMCSO by cysteine β-lyase (Figure 1-4, Chapter 1). It was proposed that the MMTSI 
induced apoptosis in PC3 [131] as well as in DU-145 cells [130] via induction of the caspase-
dependent and caspase-independent cascade. Its anti-diabetic and cardiovascular effects were 
associated with the reduction of cholesterol levels in the plasma of rats that were fed a high 
cholesterol diet with the addition of SMCSO [135,137]. The proposed mechanism for the 
reduction of cholesterol was via the induction of the hepatic cholesterol 7-α hydroxylase 
activity [136,137]. This enzyme catalyses the conversion of cholesterol into bile acids for 
excretion. This theory was supported by an increased faecal excretion of bile acids in mice on 
the cholesterol and SMCSO diet compared to a cholesterol alone diet [136,137]. However, it 
is worth remembering that mice and human metabolism may differ in this regard. While 
research has been undertaken to investigate the potential health benefits, exploration into the 
underpinning mechanism such as transcriptional regulation by SMCSO remains unexplored 
[11, 12, 14-16, 18]. 
Given that SF, also derived from cruciferous vegetables, induces transcriptional changes via 
Nrf2, the rationale question was developed of whether SMCSO could induce Nrf2 and thereby 
up-regulate Nrf2-regulated genes like SF. On the basis of the putative health effects of 
SMCSO, it was hypothesised that SMCSO could induce Nrf2 and up-regulate phase II 
enzymes. To accomplish this objective, 10 genes positively regulated by SF and containing a 
putative ARE in their promoter region were selected. The following genes were selected; 
NQO1, TXNRD1, UGT1A1 (UDP-glucuronosyltransferase family 1 member A1) ), HMOX1, 
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Table 5-1: Selection of 10 Nrf2-regulated genes, positively induced by SF, listed with 
their functions 
 
Gene Gene name Function [117] 
NQO1a,b NAD(P)H quinone dehydrogenase 1 Detoxification of 
xenobiotics 
TXNRD1a,b Thioredoxin reductase 1 Part of thioredoxin 
system 




HMOX1a,b Heme oxygenase 1 Heme and Iron 
Metabolism 
GCLCa,b Glutamate-cysteine ligase catalytic subunit Antioxidant enzymes 
AKR1B1b Aldo-keto reductase family 1 member B Phase I enzyme 
PGDb 6-phosphogluconate dehydrogenase 
Carbohydrate 
metabolism enzymes 
G6PDb Glucose-6-phosphate 1 dehydrogenase 
TALDO1a,b Transaldolase 1 
TKTa Transketolase isoform 1 
a contains putative ARE [99,183], b induced by SF [103,106,108,125,182-184] 
This Chapter explores this hypothesis by analysing the expression of an array of genes 
positively-regulated by Nrf2 in a human hepatocellular carcinoma (HepG2) exposed to 
physiologically relevant concentrations of SMCSO and SF. HepG2 is an extensively used 
model to investigate liver metabolism and primary site of detoxification of xenobiotics. 
However, potential regulation of these genes by SMCSO might not exclusively implicate Nrf2 
as a key transcription factor as these genes can be regulated by other inducers/signalling 
pathways. 
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 Materials and Methods 
 Materials 
Human hepatocellular carcinoma cell line (HepG2) (ATCC® HB-8065™) and EMEM 
containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 
mM sodium pyruvate, 1500 mg/L sodium bicarbonate (Cat # ATCC-30-2003) were purchased 
from ATCC. The following were obtained from Thermo Fischer Scientific; heat-inactivated 
FBS (Gibco™) (Cat # 10270-106), DPBS (Gibco®) 10X with no calcium and no magnesium 
(Cat. # 14200059) and penicillin-streptomycin (10,000 units/ml) (Cat # 15140122). T75 flasks 
were purchased from Starstedt (Cat # 83.3911.002). CellTiter-Blue® was purchased from 
Promega (Cat # G8080). RNeasy® mini kit (Cat # 74014) supplied with RLT, RW1, RPE 
buffer, RNeasy® mini spin column, RNase-free water and QIAshredder™ (purchased 
additionally) (Cat # 79654) was acquired from Qiagen. NanoDrop™ 1000 spectrophotometer 
was purchased from Thermo Fisher Scientific. Primers were obtained from Integrated DNA 
Technologies® (IDT). Precision one step master mix with ROX (Cat # OneStepPLUS-R) was 
acquired from primer design. AB StepOnePlus™ was purchased from Applied Biosystems™. 
 
 Culturing HepG2 
HepG2 from passage 16-20 were routinely cultured in 75cm² flasks and maintained in a 
humidified atmosphere containing 5% CO2 at 37°C. EMEM supplemented with 10% FBS, 
and 1% penicillin-streptomycin was replaced 3-4 times a week. Cells were grown to 80% 
confluency in a 75cm² flasks before subculturing as described in section Chapter 4.  
 
 Cell viability of HepG2 cells treated with S-methyl-L-cysteine 
sulfoxide measured by CellTiter-Blue®  
To measure cell viability, the CellTiter-Blue® viability assay was used, in which the end-
product can be measured by fluorescence or absorbance. Firstly, HepG2 cells were seeded in 
a 96-well plate for 24 hours to allow cells to attach. SMCSO stock (CAS 6853-87-8) (purity 
≥98%) (Cat # 17600) was purchased from Cayman Chemical (Michigan, USA) and 
reconstituted in water to prepare a 1 mg/ml stock solution that was stored at -20°C. Cells were 
exposed to 1-3000 μM of SMCSO in EMEM + 10% FBS for 24 hours. Water was used as 
vehicle control. As per the manufacturer’s instruction, 40 μl of CellTiter-Blue® was pipetted 
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directly to the cells in the 96-well plate and incubated at 37°C for 30, 60, 120, 180 and 240 
minutes. At each time point, plates were shaken for 10 seconds prior to measuring excitation 
at 560 nm, and emission at 590 nm on a fluorescent plate reader (FLUOstar® Omega plate 
reader). Background correction was performed by subtracting fluorescence values measured 
in cell-free wells containing culture medium. The principle of the assay is based on the ability 
of live cells to reduce resazurin (a blue indicator dye) to resorufin, a pink fluorescent product. 
Dead cells do not have the capacity to reduce resazurin due to loss of metabolic activity and 
thus fluorescent signal is not emitted. 
 
Resazurin (dark blue and not highly fluorescent) 
 
 
Resorufin (pink and highly fluorescent) 
 
Figure 5-1: The principle of the cell viability assay. Viable cells are capable of reducing 
resazurin, a dark blue indicator dye to resorufin, a highly fluorescent product which 
excites at 560 nm and emits at 590 nm. Dead cells are not capable of reducing resazurin 
as a result of loss in metabolic activity. 
 
 Treatment of cells with sulforaphane and S-methyl-L-cysteine 
sulfoxide 
HepG2 cells were cultured in 6-well plates until 80% confluency prior to treatment with SF 
and SMCSO. SF was diluted to a stock solution of 100 mM in DMSO stored at -20ºC. Cells 
were subject to 10 μM, 100 μM and 300 μM SMCSO and 2 µM, 5 µM and 10 μM SF, based 
on the data from the human study which reported plasma concentrations of 30 µM SMCSO 
and 1 µM SF. Prior to the treatment of cells, 100 mM SF stock solution was diluted to 1 mM 
and further diluted to obtain a final concentration of 2 μM, 5 µM and 10 µM SF. SMCSO was 
diluted to 1 mM and further diluted to give final concentrations of 10 μM, 100 µΜ, 300 μM 
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and 1000 µM SMCSO. Cells were exposed to SF (0-10 μM) and SMCSO (0-1000 µM 
SMCSO) for 2, 6 and 24 hours at 37°C. In addition, cells were also subject to co-treatment of 
10 µM SF and 300 µM SMCSO for 24 hours. DMSO was used as a vehicle control for SF and 
water was used as a vehicle control for SMCSO. 
 
 RNA extraction  
Following treatment of cells with the dietary bioactives (SF, SMSCO), RNA was extracted 
using the RNeasy® mini kit, following the manufacturer’s instructions. HepG2 cells were 
washed twice with cold DPBS. To lyse the cells, 350 μl of RLT buffer was added per well, 
and cells were harvested using cell scrapers. Subsequently, cell lysate was pipetted into 
QIAshredder™ spin columns and centrifuged for 2 minutes at 13,000 rpm. The QIAshredder 
spin columns consist of a biopolymer filter which homogenises cell lysate, disrupts high 
molecular weight DNA, filters out insoluble material, and reduces viscosity of the lysates. The 
addition of 350 μl of 70% ethanol to the lysate enables selective binding of RNA to the RNeasy 
membrane of the spin columns at the following step. The 700 μl sample was pipetted and 
transferred to the RNeasy spin column. Following centrifugation of the RNeasy spin column 
at 13,000 rpm for 15 seconds, the flow-through was discarded. Contaminants were washed 
away three times. The first wash comprised of adding 700 μl RW1 buffer to the spin column 
and centrifuging at 13,000 rpm for 15 seconds. This was repeated for the second wash. The 
third wash involved the addition of 500 μl of buffer RPE and centrifuging for 2 minutes at 
13,000 rpm. The three-wash step efficiently washes contaminants. The RNA was eluted in 30 
μl nuclease-free water and quantified using the NanoDrop™. 
 
 RNA quantification 
To determine the quantity and quality of RNA in the samples, a UV/VIS spectrophotometer 
(NanoDrop™) capable of measuring at 220 nm-750 nm was used. The spectrophotometer 
readings were normalised by using 1 μl nuclease-free water. After which, 1 μl of the samples 
were pipetted on the pedestal of the spectrophotometer. Absorbance was measured at 260 nm, 
and 280 nm as in section 3.3.9. 
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 Gene expression analysis by real-time PCR 
RT-PCR was used to analyse the expression of genes in HepG2 cells treated with SF and 
SMCSO using the AB StepOnePlus™ machine. The Corbett robot was provided with probes, 
master mix and RNA to prepare samples in a 96-well plate for the RT-PCR process. The 
probes at a concentration of 2.5 nmoles were labelled at the 5’ end of oligos with the 
fluorescent dye 6-Carboxyfluorescein (5’6-FAM™), at the 3’end with a quencher 3' Iowa 
Black® FQ (3’IBFQ) and with an internal quencher ZEN™. Double quenchers (ZEN/3’IBFQ) 
benefits by increasing signal and reducing background noise. The pre-designed primers 
purchased at a concentration of 5 nmoles are listed in Table 5-2. A master mix master mix 
consisting of a TAQ polymerase, buffer, MgCl2, Moloney murine leukaemia virus reverse-
transcriptase enzyme was acquired to enable a one-step RT-PCR reaction. RT-PCR reactions 
comprised of the conversion of RNA to cDNA catalysed by the reverse transcriptase at 48°C 
for 30 minutes, activation of DNA polymerase enzyme at 95°C for 10 minutes followed by 
denaturation of the DNA at 95°C for 15 seconds and primer annealing and extension of DNA 
at 60°C for 1 minutes. 
 
Table 5-2: List of human genes purchased from IDT® for RT-PCR.  PrimeTime® pre-
designed standard qPCR assay was purchased consisting of a forward primer, reverse 
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 Isolation of primary hepatocytes from wild-type mice 
Primary hepatocytes isolated from healthy wild-type mice (BL6 C57) were provided by the 
research group led by Dr Naiara Beraza (QIB research leader). Briefly, mouse liver was 
perfused with a buffer containing collagenase I (Worthington, USA). Cells were washed and 
cultured in minimum essential media in 6-well plates pre-coated with rat collagen type I (BD 
Biosciences). Following 24-hour incubation, the hepatocytes were subject to 10 µM SF and 
300 µM SMCSO for 2 hours. Subsequently, RNA was extracted and gene expression analysis 
was undertaken as described in section 5.3.5, 5.3.6 and 5.3.7. The expression of two genes; 
HMOX1 and G6PDx (X-linked) was quantified relative to the Polr2a, mouse housekeeping 
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Table 5-3: List of mouse genes purchased from IDT® for RT-PCR.  PrimeTime® pre-
designed standard qPCR assay was purchased consisting of a forward primer, reverse 






































Chapter 5: Gene expression study 
161 | P a g e  
 Results 
 S-methyl-L-cysteine sulfoxide does not affect HepG2 cell 
viability  
To determine the viability of HepG2 cells in response to various concentrations of SMCSO, 
cells were seeded on a 96 well-plate and exposed to SMCSO (0-3000 μM) for 24 hours. 
Examination under the microscope pre- and post-SMCSO treatment presented no apparent 
changes to cell morphology. Following the addition of CellTiter-blue® reagent, cells were 
incubated at 37°C, and fluorescence was measured at 30, 60, 120, 180 and 240 minutes. Over 
the time-course, metabolically active cells reduced resazurin (a blue dye) to resorufin 
(fluorescent product). Fluorescence values were blank corrected against EMEM + 10% FBS 
to minimise the signal from the media. There was no significant change in the viability of 
HepG2 with increasing SMCSO concentration (Figure 5-2). 
 
 
Figure 5-2: Viability of HepG2 cells treated with 0-3000 μM SMCSO for 24 hours. Cells 
were subject to vehicle control (water) and SMCSO for 24 hours. CellTiter-blue® reagent 
was added to the cells and emission at 560 nm, and excitation at 590 nm measured using 
a FLUOstar® Omega plate reader. Data (n=6) represented as mean ± SD for 240 minutes 
of incubation with CellTiter-blue® reagent.   
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 Modulation of Nrf2-regulated genes by a short-term treatment 
of HepG2 cells with sulforaphane and S-methyl-L-cysteine sulfoxide  
To elucidate whether SMCSO could induce Nrf2 and up-regulate phase II enzymes like SF, 
as reported in the literature, HepG2 cells were exposed to SMCSO (0-300 μM) and SF (0-10 
μM) for 2 and 6 hours. An array of 10 genes positively regulated by Nrf2 was analysed using 
RNA extracted from HepG2 cells. The NanoDrop™ spectrophotometer indicated that the 
quality of RNA was suitable for gene expression analysis using RT-PCR, based on the 260/280 
and 230/260 ratios of 2.0 and 1.8-2.2, respectively. The expression of the following genes was 
quantified relative to the expression of 18S (housekeeping gene); NQO1, HMOX1, GCLC, 
TXNRD1, UGT1A1, AKR1B1, PGD, G6PD, TALDO1, and TKT (Figure 5-3). Exposure of 
HepG2 cells to a range of concentrations of SF (0-10 µM) for 2 hours resulted in no change 
to the expression of the Nrf2-regulated genes except for UGT1A1 and AKR1B1. A significant 
decrease was demonstrated in the expression of UGT1A1 at 5 μM and 10 μM SF (p<0.05) 
(Figure 5-3 I), and in AKR1B1 expression at 2 μM, 5 μM and 10 μM SF (p<0.05) (Figure 5-3 
K). Contrastingly, a significant up-regulation was observed following treatment for 6 hours 
with SF at 10 μM for HMOX1 (Figure 5-3 C), GCLC (Figure 5-3E), TXNRD1 (Figure 5-3G), 
G6PD (Figure 5-3 O), TALDO1 (Figure 5-3 Q) and TKT (Figure 5-3 S) (p<0.05), while no 
change was observed in the expression of NQO1 (Figure 5-3 A), UGT1A1, AKR1B1 or PGD 
(Figure 5-3 M). Out of all the 10 genes analysed, the up-regulation of HMOX1 and TXNRD1 
revealed the highest fold increase of ~4 vs. control after 6 hours at 10 μM SF while the other 
genes showed a ~1-3-fold increase. In contrast to SF, SMCSO showed a dose-dependent 
down-regulation of the Nrf2-regulated genes including NQO1 (Figure 5-3 B), HMOX1 
(Figure 5-3 D), TXNRD1 (Figure 5-3 H), AKR1B1 (Figure 5-3 L) and G6PD (Figure 5-3 P) 
at 2 hours. A significant decrease in the expression of NQO1, HMOX1, TXNRD1, UGT1A1 
(Figure 5-3 J), AKR1B1, G6PD and TKT (Figure 5-3 T) was observed at 300 μM as early as 
2 hours (p<0.05). This effect was abolished at 6 hours for all the genes except for G6PD which 
was significantly down-regulated by SMCSO at 100 μM and 300 μM (p<0.05). No change in 
the expression of GCLC (Figure 5-3 F), PGD (Figure 5-3 N) or TALDO1 (Figure 5-3 R) was 
detected in response to SMCSO. Results obtained from this study indicated that the expression 
of targeted genes was considerably lower following treatment with SMCSO compared to SF. 
Interestingly, most of the analysed genes were down-regulated by SMCSO. A down-
regulation of ~0.4-fold in the expression of AKR1B1 was the largest decrease observed at 2 
hours (300 μM SMSCO). In summary, the gene expression analysis reported in this Chapter 
has demonstrated that SF increased the expression of Nrf2-regulated genes at 10 μM whereas 
SMCSO reduced their expression at 300 μM.  
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Figure 5-3: Expression of 10 Nrf2-regulated genes in HepG2 cells subject to SF or 
SMCSO. Cells were incubated with either vehicle control (DMSO) and 2-10 µM SF or 
vehicle control (water) and 10-300 µM SMCSO for 24 hours. Isolated RNA was used to 
perform RT-PCR to quantify 10 genes normalised to 18S including NQO1 (A-B), 
HMOX1 (C-D), GCLC (E-F), TXNRD1 (G-H), UGT1A1 (I-J), AKR1B1 (K-L), PGD (M-
N), G6PD (O-P), TALDO1 (Q-R), TKT (S-T). Data represented as average (n=3) ± SD. 
Statistical analysis was carried out by one-way ANOVA with Dunnett’s multiple 
comparisons test (*p˂0.05, ** p˂0.01 and*** p˂0.001 vs. control). 
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 Modulation of Nrf2-regulated genes by a 24-hour treatment of 
HepG2 cells with S-methyl-L-cysteine sulfoxide  
In order to examine the expression of Nrf2-regulated genes as a result of chronic exposure to 
SMCSO, HepG2 cells were treated with SMCSO (0-300 μM) for 24 hours. RNA was analysed 
for 10 Nrf2-regulated genes. The expression of Nrf2-regulated genes comprising of NQO1, 
HMOX1, GCLC, TXNRD1, UGT1A1, AKR1B1, PGD, G6PD, TALDO1, and TKT were 
normalised to β-actin (housekeeping gene) (Figure 5-4). HepG2 treated with SMCSO (0-1000 
µM) for 24 hours exhibited no changes in the expression of the following genes; HMOX1 
(Figure 5-4 B), UGT1A1 (Figure 5-4 E), AKR1B1 (Figure 5-4 F), PGD (Figure 5-4 G), 
G6PD (Figure 5-4 H) and TALDO1 (Figure 5-4 I). A significant up-regulation of NQO1 
(Figure 5-4 A), GCLC (Figure 5-4 C), TXNRD1 (Figure 5-4 D) and TKT (Figure 5-4 J) 
genes was induced by 300 µM SMCSO (p<0.05). NQO1 and GCLC genes were significantly 
induced by all SMCSO concentrations (p<0.05). The highest fold increase (~1.3-fold up-
regulation) was observed for GCLC following treatment for 24 hours with SMCSO at the 
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Figure 5-4: Expression of 10 Nrf2-regulated genes in HepG2 cells subject to SMCSO.  
Cells were incubated with vehicle control (water) and 10-1000 µM SMCSO for 24 hours. 
Isolated RNA was used to perform RT-PCR to quantify 10 genes normalised to β-actin 
including NQO1 (A), HMOX1 (B), GCLC (C), TXNRD1 (D), UGT1A1 (E), AKR1B1 (F), 
PGD (G), G6PD (H), TALDO1 (I), TKT (J). Data (n=3) represented as mean ± SD. 
Statistical analysis was carried out by one-way ANOVA with Dunnett’s multiple 
comparisons test (*p˂0.05, ** p˂0.01 and *** p˂0.001 vs. control). 
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 Synergetic effects of sulforaphane and S-methyl-L-cysteine 
sulfoxide on Nrf2-regulated genes in HepG2 cells 
To assess whether both sulphur compounds had a synergetic effect on the induction of Nrf2-
regulated genes, HepG2 cells were subject to co-treatment with 10 μM SF and 300 μM 
SMCSO for 24 hours. Using RT-PCR, 10 Nrf-2 regulated genes were quantified relative to β-
actin (housekeeping gene) including NQO1, HMOX1, GCLC, TXNRD1, UGT1A1, AKR1B1, 
PGD, G6PD, TALDO1, and TKT (Figure 5-5). SMCSO treatment for 24 hours did not 
significantly change the expression of any of the genes. Following stimulation with 10 µM SF 
and co-treatment with SF and SMCSO, 6 out 10 genes were significantly up-regulated in both 
cases, including NQO1 (Figure 5-5 A), GCLC (Figure 5-5 C), TXNRD1 (Figure 5-5 D), 
UGT1A1 (Figure 5-5 E), PGD (Figure 5-5 G) and TALDO1 (Figure 5-5 I) (p<0.001). Both 
HMOX1 (Figure 5-5 B) and AKR1B1 (Figure 5-5 F) showed no significant changes in 
response to 10 µM SF or co-treatment with SF and SMCSO. TKT (Figure 5-5 J) was 
significantly up-regulated only by the co-treatment (p<0.01), while G6PD was induced by SF 
alone (Figure 5-5 H). In the case of G6PD, the co-treatment with SF and SMCSO did not 
induce the up-regulation observed following treatment with SF alone. A~4-fold up-regulation 
in the expression of TXNRD1 represented the highest fold increase following SF treatment 
alone. Both TXNRD1 and PGD exhibited a ~4-fold increase in response to co-treatment with 
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Figure 5-5: Expression of 10 Nrf2-regulated genes in HepG2 cells exposed to exposed to 
SMCSO, SF and co-treatment with SMCSO and SF for 24 hours. Cells were incubated 
with vehicle control (DMSO), SF (10 µM), SMCSO (300 μM) and co-treatment with 
SMCSO (300 μM) and SF (10 µM). RNA was used to perform RT-PCR to quantify 10 
genes normalised to β-actin including NQO1 (A), HMOX1 (B), GCLC (C), TXNRD1 (D), 
UGT1A1 (E), AKR1B1 (F), PGD (G), G6PD (H), TALDO1 (I), TKT (J). Data (n=3) 
represented as mean ± SD. Statistical analysis was carried out by one-way ANOVA with 
Dunnett’s multiple comparisons test (**p<0.01 and *** p<0.001 vs. control). 
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 SMCSO did not affect cysteine β-lyase in HepG2 
Gene expression analysis was carried out in order to identify whether SMCSO was able to 
induce the transcription of cysteine β-lyase (CCBL1 and CCBL2), the enzyme that may 
catalyse the breakdown of SMCSO in humans. HepG2 cells were exposed to SMCSO (0-1000 
µM) for 2, 6 and 24 hours before undertaking RT-PCR analysis (Figure 5-6). The expression 
of two cysteine β-lyase isoforms, CCBL1 and CCBL2, showed no significant changes 
following stimulation of SMCSO in doses ranging from 0-300 µM at any time points (Figure 
5-6 A-D). Additionally, HepG2 cells were exposed to higher concentration of SMCSO (1000 
µM) for 24 hours, eliciting no changes in the expression of CCBL1 or CCBL2 (Figure 5-6 C-
D). Further, cells were incubated with SF (10 µM), SMCSO (300 µM), and a co-treatment 
with SF (10 µM) and SMCSO (300 µM) for 24 hours to establish whether SF alone or in 
combination with SMCSO could potentially regulate the expression of CCBL1 and CCBL2. 
As reported by Figure 5-6 E-F, no changes in the expression of CCBL1 and CCBL2 genes 
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Figure 5-6: Expression of CCBL1 and CCBL2 in HepG2 cells exposed to SMCSO, SF and 
co-treatment with SMCSO and SF. RNA was used to perform RT-PCR to quantify 
CCBL1 and CCBL2 genes that were normalised to 18S or β-actin. HepG2 cells were 
incubated with 0-300 µM SMCSO for 2 and 6 hours (A-B), 0-1000 µM SMCSO for 24 
hours (C-D), SF (10 µM), SMCSO (300 µM), co-treatment with SF (10 µM) and SMCSO 
(300 µM) for 24 hours (E-F). Data (n=3) represented as mean ± SD. Statistical analysis 
was performed by one-way ANOVA with Dunnett’s multiple comparisons test (treated 
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 SMCSO does not induce expression of Nrf2-regulated genes in 
primary hepatocytes isolated from wild-type mice 
Isolated primary hepatocytes from wild-type mice were subject to 10 µM SF and 300 µM 
SMCSO for 2 hours to assess the effect of SMCSO on Nrf2-regulated gene expressions. 
Extracted RNA was analysed for the expression of two genes; HMOX1 and G6PDx. A 
significant up-regulation of HMOX1 gene expression by ~2-fold was observed in the 
hepatocytes treated with 10 µM SF (p<0.0001) (Figure 5-7 A). However, no changes in the 
expression of G6PDx was observed following exposure to SF (Figure 5-7 B). SMCSO (300 






Figure 5-7: Expression of HMOX1 and G6PDx in primary hepatocytes isolated from 
wild-type mice subject to SF and SMCSO. RNA was used to perform RT-PCR to 
quantify HMOX1 (A) and G6PDx (B) normalised to Polr2a. Primary hepatocytes were 
incubated with vehicle controls (DMSO, water), SF (10 µM), and SMCSO (300 μM) for 
2 hours. Data (n=3) represented as mean ± SD. Statistical analysis was performed by one-
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 Discussion 
The experimental work described in this Chapter was designed to examine the potential 
biological effects of SMCSO at the level of gene expression in HepG2 cells. The human 
hepatocellular carcinoma cell line (HepG2) was selected to represent the liver, where 
fundamental detoxification of xenobiotics occurs. To address the question of whether SMCSO 
can induce Nrf2 and consequently up-regulate Nrf2-regulated genes like SF, an array of ten 
Nrf2-regulated genes were analysed in HepG2 cells exposed to SMCSO and SF. Due to its 
potential health benefits as reported in the literature, it was hypothesised that SMCSO could 
induce Nrf2 and up-regulate Nrf2-regulated genes. 
This is the first study to report the viability of cells in response to SMCSO. However, as 
evidenced by Figure 5-2, no significant changes in the viability of HepG2 subject to 1-3000 
μM SMCSO was observed, indicating that SMCSO does not have a potent toxic effect on cells. 
However, MMTSI, a secondary breakdown product of SMCSO, demonstrated a dose-
dependent decrease in cell viability and cell proliferation in PC3 cells (IC50:165.63 μM) [131], 
in DU-145 cells (IC50:183.63 μM) [131], and in HepG2 cells (183.64 μM)[132].  
The human intervention study undertaken as part of this PhD project (Chapter 3) revealed 
that approximately 30 μM SMCSO and 1 µM SF reach the systemic circulation after 
consuming Myb28V/V broccoli soup. Plasma levels of these dietary bioactives are achieved 
post first-pass metabolism in the liver. Therefore, the concentrations that the liver is exposed 
to must be considerably higher than those in the plasma. For this reason, HepG2 cells were 
exposed to >30 μM SMCSO (10 μM, 100 μM and 300 μM SMCSO) and >1 µM SF (2 µM, 5 
µM and10 μM SF). In the case of SMCSO, the concentrations were shown not to affect 
viability of HepG2 cells (Figure 5-2), with regards to SF, it has been reported by others that 
concentrations of 15-20 µM SF reduces cell viability [127,145]. In this work, HepG2 cells 
were treated with concentrations ≤10 µM SF. 
Genes positively up-regulated by Nrf2; NQO1, UGT1A1, AKR1B1, TXNRD1, GCLC, 
HMOX1, G6PD, TKT, TALDO1, and PGD, were analysed in HepG2 cells stimulated with SF 
and SMCSO [117]. Two housekeeping genes, 18S and β-actin (ACTB), were used to normalise 
the quantification of the Nrf2 genes. The primary choice for the housekeeping gene was 18S 
due to its ubiquitous expression and the fact that its expression would be unchanged when 
stimulated by SMCSO and SF, given that it is a component of 40S ribosomal RNA [185,186]. 
Another housekeeping gene, GAPDH (glyceraldehyde-3-phosphate dehydrogenase), was 
reported to be suitable for normalisation in HepG2. However, given that SF modulates central 
metabolic pathways including glycolysis, in which GAPDH is involved, it was deemed to be 
Chapter 5: Gene expression study 
178 | P a g e  
unsuitable for this study. Gene expression data described in Figure 5-3 were normalised to 
18S, however, high variation between samples was observed in subsequent work when 
normalising to this gene. Chua et al. demonstrated that 18S had the least stable expression of 
12 housekeeping genes, which could justify the variations seen in the data [186]. As a result, 
β-actin, a cytoskeleton component, was selected to normalise later work as represented by 
Figure 5-4, Figure 5-5, Figure 5-6. It should be noted that β-actin was ranked 7 out of 12 
genes for its stability. Despite this, variation among samples was small.  
The expression of 10 Nrf2-regulated genes and two non Nrf2-regulated genes (CCBL1 and 
CCBL2) was compared following exposure to SF and SMCSO at different time points as 
summarised in Table 5-4. As previously published elsewhere in various cell lines including 
murine microglia cells, osteosarcoma cells, mice insulinoma cells, breast cancer cells, and 
colorectal adenocarcinoma cells [103,106-108,182-184], SF resulted in the induction of 
several Nrf2-regulated genes in the current study. In contrast, SMCSO did not result in a 
considerable up-regulation of Nrf2-regulated genes relative to SF. 
Table 5-4: Summary of the changes in the expression of genes analysed in HepG2 cells 
exposed to SF (10 µM) or SMCSO (300 µM) for 2, 6 and 24 hours 
 
Gene name SF SMCSO 
 2 hours 6 hours 24 hours 2 hours 6 hours 24 hours 
NQO1 - - Up Down - Up 
HMOX1 - Up - Down - - 
GCLC - Up Up - - Up 
TXNRD1 - Up Up Down - Up 
UGT1A1 Down - Up Down - - 
AKR1B1 Down - - Down - - 
PGD - - Up - - - 
G6PD - Up Up Down Down - 
TALDO - Up Up - - - 
TKT - Up - Down - Up 
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Gene name SF SMCSO 
 2 hours 6 hours 24 hours 2 hours 6 hours 24 hours 
CCBL1 - - - - - - 
CCBL2 - - - - - - 
Up denotes up-regulation of genes, Down denotes down-regulation of genes and – 
represents no significant changes.  
Exposure of HepG2 cells to 300 µM SMCSO for 2 hours resulted in a down-regulation in 
several genes including NQO1, HMOX1, TXNRD1, UGT1A1, AKR1B1, G6PD, and TKT. 
However, these genes were no longer down-regulated after 6 hours, apart from G6PD. 
Following exposure to SMCSO (300 µM) for 24 hours, an induction was demonstrated in few 
genes including NQO1, GCLC, TXNRD1 and TKT. On the contrary, although no up-regulation 
of Nrf2-regulated genes was observed with 2-hour treatment of SF, several genes including 
HMOX1, GCLC, TXNRD1, G6PD, TALDO1 and TKT were significantly up-regulated at 6 
hours (p<0.05), in accordance with published work [107,108,183,184]. Similarly, SF induced 
several genes at 24 hours, as previously reported by Agyeman et al. [103]. Some of these 
genes, such as GCLC, TXNRD1, G6PD and TALDO1, remained induced from the 6-hour 
incubation with SF. Interestingly, others including NQO1, UGT1A1 and PGD were not up-
regulated at 2 or 6 hours, in congruence with other studies [103,108,182]. HMOX1 and TKT 
were up-regulated by treatment with SF for 6-hours but not with 24-hour stimulation. This 
concurs with Townsend and Johnson, as up-regulation of HMOX1 in microglia cells was only 
observed between 3-9 hours but abolished at 24 hours exposure [108]. A similar time-
dependent effect on TKT was also reported by Agyeman et al. [103] and Chorley et al. [183]. 
Despite published work reporting up-regulation of AKR1B1 in response to 15 µM SF 
stimulation in breast cells for 24 hours [103], the current work presented in this Chapter 
showed no up-regulation of AKR1B1 at 2, 6, or 24 hours. 
The study described in this Chapter aimed to further understand the effects of both dietary 
bioactives alone (SF or SMCSO) and in combination (SF and SMCSO) on gene expression by 
using the same in vitro model. HepG2 cells exposed to SF and co-treatment with SF and 
SMCSO demonstrated a significant up-regulation in the gene expression of NQO1, GCLC, 
TXNRD1, UGT1A1, PGD, and TALDO1 (p<0.001) (Figure 5-5). Given that no up-regulation 
was observed following exposure to SMCSO alone, these data clearly suggest that the 
induction observed in the co-treatment is associated with the bioactivity of SF as opposed to 
SMCSO. It should be noted that 300 µM SMCSO showed statistically significant up-
regulation of NQO1, GCLC, TXNRD1, and TKT (p<0.05) (Figure 5-4) when compared to its 
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control vehicle (water). However, when compared to the control vehicle for SF (DMSO) as 
illustrated in Figure 5-5, 300 µM SMCSO was not significant for any of those genes. 
Retrospectively a control vehicle of water and DMSO should have been used when comparing 
SF, SMCSO and the co-treatment. Regardless, the up-regulation observed with 300 µM 
SMCSO at 24 hours was relatively small. Further, SMCSO did not elicit any changes in the 
expression of HMOX1 and G6PDx in primary hepatocytes, whereas an up-regulation of 
HMOX1 was demonstrated with SF treatment. 
It is important to highlight that the fold change in the up-regulation and down-regulation of 
genes observed with SMCSO treatment is relatively low compared to SF. For example, the 
highest up-regulation was a fold-change of ~4 for HMOX1 in response to 10 µM SF for 6 
hours. Whereas, the largest fold-change observed with SMCSO (300 µM) treatment was ~1.3-
fold for GCLC, which is considerably lower in comparison to the induction of genes by SF. 
This suggests that even though the up-regulations observed with SMCSO were statistically 
significant (p<0.05); it might not necessarily be biologically relevant. A plausible explanation 
could be an initial metabolic stress on the cells resulting in the down-regulation of these genes. 
Subsequently, the cells recover by switching on a response to counteract the metabolic stress, 
evidenced by a lack of change in the expression of all the genes at 6 hours other than G6PD. 
This could support the role of SMCSO as a pro-oxidant like SF [114,187]. Taking into 
consideration the results obtained by using both an immortalised cell line (HepG2) and 
primary hepatocytes, this study provides the first in vitro evidence that SMSCO has the 
opposite effect on Nrf2-regulated genes in comparison to the well-studied ITC, SF.  
Although SMCSO demonstrated no up-regulation of Nrf2-regulated genes; it does not 
necessarily imply that SMCSO does not exert any biological activities. Discussed below are 
three hypothetical scenarios that could support the role of SMCSO as a bioactive compound 
with health benefits.  
Firstly, the work presented in this Chapter is specifically focused on Nrf2-regulated genes and 
SMCSO could be able to regulate other metabolic or signalling pathways. As such, Kumari 
and Augusti reported reduced enzyme activity of G6PD in the liver of cholesterol-fed mice 
receiving SMCSO treatment compared to mice fed only with cholesterol [137]. This supports 
the down-regulation of G6PD expression observed with SMCSO exposure at 2 hours in this 
Chapter (Figure 5-3) as well as the up-regulation observed with SF treatment alone at 24 
hours, which was eliminated with the co-treatment of SF and SMCSO. However, no change 
in G6PDx was observed in primary hepatocytes from mice in the current study. Perhaps, 
SMCSO could influence protein expression and enzyme activity of G6PD metabolic enzymes 
but not their gene expression. Reducing G6PD could have biological relevance by decreasing 
Chapter 5: Gene expression study 
181 | P a g e  
de novo fatty acid synthesis. NADPH, a product generated from the reaction catalysed by 
G6PD, is a co-factor for the fatty acid synthesis enzyme (FASN; fatty acid synthase) [188]. 
Therefore, SMSCO-induced reduction of G6PD enzyme activity could lead to a decrease of 
NADPH generation and de novo fatty acid synthesis that could play a key role for its potential 
use as an anti-diabetic agent possessing lipid-lowering effects. This is crucial for ameliorating 
cardiovascular diseases, as reported by Edmands et al. [2] and Kumari and Augusti [137].  
Secondly, there is a distinct discrepancy between the recovery of SMCSO in urine reported in 
Chapter 4 (~7-8% of administered SMCSO recovered) and that reported by Waring et al. 
(60% labelled [35S] recovered in urine after consumption of [35S]-SMCSO) [84]. Therefore, 
another explanation could be that the biological effects of SMCSO may be attributed to its 
secondary breakdown products, MMTSI and MMTSO (Figure 1-4, Chapter 1). SMCSO 
undergoes hydrolysis, catalysed by either the plant cysteine β-lyase or our own gut microbiota 
presenting cysteine β-lyase activity or by human cysteine β-lyase, to produce a highly reactive 
intermediate, methanesulphenic acid [42]. This undergoes dimerization to generate MMTSI 
and MMTSO. It has been previously reported that MMTSI and MMTSO have 
chemopreventative effects such as inhibiting proliferation of cells and inducing apoptosis 
[130-134]. It has been proposed that cysteine β-lyase could be inactivated by these SMCSO 
products [189]. However, results reported in this Chapter demonstrated no changes in the 
expression of CCBL1 or CCBL2 in HepG2 cells subject to SMCSO alone at different time 
points. It could be hypothesised that SMCSO is an inert compound and further work needs to 
be undertaken to understand its metabolism in cells and humans. To date SMCSO metabolic 
pathway and the bioactivity of its metabolites remain unclear.  
Finally, another factor to consider is the thermal degradation of SMCSO. Kubec et al. 
described SMCSO as ‘thermoabile’ compared to other amino acid containing compounds, 
given that its decomposition into sulphur and volatile compounds was detected at 80ºC [190]. 
Further, it was noted that water content as well as time also influenced the degradation of 
SMCSO [190]. Marks et al. demonstrated the formation of MMTSI and MMTSO over 24 
hours at 35ºC in the presence of cysteine β-lyase [41]. Therefore, it is possible that the 
incubation of cells at 37ºC and the composition of culture medium may influence its 
degradation. As a result, the up-regulation observed at 24 hours may occur as a result of cells 
being exposed to the secondary metabolites of SMCSO rather than SMCSO itself. 
Nonetheless, if SMCSO undergoes thermal degradation at 37ºC, cells may be subject to lower 
concentrations than those intended. 
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 Conclusion 
The experimental work described in this Chapter aimed to elucidate the effect of SMCSO on 
hepatic gene expression in vitro. Results obtained clearly indicate that SMCSO does not affect 
Nrf2-regulated genes. The data in this Chapter are in accordance with published work showing 
the effects of SF in upregulating several Nrf2-regulated genes. On the other hand, SMCSO has 
the opposite effect, causing down-regulation of several genes at 2 hours followed by up-
regulation at 24 hours, albeit with a small fold decrease that may not be biologically 
significant. To date there is very little published data on SMCSO biological profile, and this 
is the first in vitro study investigating the effect of SMCSO on gene expression. This warrants 
further work to investigate the metabolism of SMCSO in cells and humans as well as underpin 
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 Summary of the thesis findings 
The emphasis of the work described in this thesis was on assessing the bioavailability of 
sulphur-containing bioactives (SF, GR and SMCSO) through a multidisciplinary approach 
based on the use of in vivo and in vitro models. A broccoli-rich food formulation was 
specifically developed for this study by using novel broccoli varieties Myb28B/V and Myb28V/V 
(Chapter 2) were tested in an interventional trial in human participants. A three-phase, 
double-blinded, randomised crossover design, often considered the gold standard for clinical 
trials, was chosen as one of the experimental tool for investigating the bioavailability of 
broccoli-delivered phytochemicals. Bioavailability was assessed in plasma and urine samples 
of participants following consumption of the broccoli-rich soups (Chapter 3). A higher 
plasma concentration and greater urinary excretion of SF, GR, and SMCSO was achieved 
following consumption of soups made with the Myb28B/V and Myb28V/V broccoli varieties. 
This lead to the investigation into transport mechanism of SF, GR, and SMCSO using two 
established in vitro models, caco-2 cells and the PAMPA assay (Chapter 4). It was shown 
that SF can passively diffuse across the enterocytes whereas neither GR nor SMCSO can 
passively diffuse. However, the results were not indicative of a specific transport mechanisms, 
leaving open the possibility that GR and SMCSO may use an active transporter or diffuse 
paracellularly. Further studies are required to confirm either mechanism. Subsequently, the 
biological effects of SMCSO were investigated in an immortalised hepatic cell line of human 
origin (HepG2). No changes in the expression of Nrf2-regulated genes were observed, in 
contrast with SF which upregulated several genes upon exposure for 6 and 24 hours (Chapter 
5). Further exploration into other potential mechanisms will provide insight into the biological 
targets of SMCSO. Given the increased levels of bioactives measured in vivo following 
consumption of the novel broccoli soups, this food formulation represents a new tool for 
delivering enhanced levels of sulphur-containing bioactives in an effective and practical way. 
This is a promising tool to be used in large clinical trials to assess the health benefits of 
bioactives delivered by cruciferous vegetables, ensuring good compliance to the trial 
intervention.  
 
 Accomplishment of the thesis aims: 
The overall aim of this thesis was to investigate the bioavailability and bioactivity of sulphur- 
containing compounds as described in Chapter 1.  
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The bioavailability of SF, an ITC derived from broccoli, has already been well established. 
Despite the use of various food matrices including pills, soups, florets, and extracts, there is 
still a substantial need for the development of a new food product easier to consume by the 
general population. Broccoli soups with increasing levels of GR and high levels of SMCSO, 
as described in Chapter 2, are a good example. Through the collaboration of several 
companies including Monsanto®, A.P. East Anglia Ltd, Bakkavor Ltd, and Norbert 
Dentressangle, broccoli and stilton soups were produced using three broccoli genotypes, 
Myb28B/B, Myb28B/V and Myb28V/V. Two of these, Myb28B/V and Myb28V/V are novel broccoli 
varieties developed by scientists at the John Innes Centre. The aim of the work presented in 
Chapter 2 was to quantify the levels of sulphur-containing compounds to ensure that the soup 
production retained the increased levels of GR and SMCSO from the florets of the Myb28B/V 
and Myb28V/V broccoli varieties. The broccoli soups made with the broccoli varieties 
containing one or two Myb28V alleles indeed resulted in increased levels of GR (280 μmoles 
and 452 μmoles respectively) and SMCSO (1514 μmoles and 1454 μmoles respectively) 
compared to standard broccoli (84 μmoles GR and 1031 μmoles SMCSO). This has provided 
a dietary intervention that is both palatable and a practical means of delivering increased levels 
of bioactives for use in long-term clinical studies.  
Prior to commencing a long-term study assessing biological and clinical endpoints, it is 
imperative to identify levels of dietary bioactives that are physiologically achievable in vivo 
to translate it into in vitro studies investigating their mechanisms of action. This warranted 
further exploration into the bioavailability of the bioactives from the broccoli-rich soups 
developed for the purpose of this study. Consequently, a human intervention study was 
undertaken to assess whether these increased levels of bioactives were ‘bioavailable’ in human 
subjects (Chapter 3). Healthy participants (n=10) were recruited into a double-blind, three-
phase, crossover study (ClinicalTrials.gov NCT02300324). At each phase, following 
consumption of one of the three types of broccoli and stilton soups, blood and urine samples 
were collected for 24 hours. A significantly higher plasma concentration of SF and 
metabolites, GR and SMCSO was observed following consumption of soups with the presence 
of one or two Myb28V alleles. Similarly, a greater amount of these metabolites was excreted 
in the urine following consumption of soups with the presence of one or two Myb28V alleles. 
This study for the first time not only demonstrated that the increased levels of GR and SMCSO 
were bioavailable from the new food product, but also showed that intact GR and SMCSO 
were quantifiable in plasma and urine. As well as confirming that the soups are a suitable 
dietary tool for long-term interventional studies, the results drew attention to the findings that 
intact GR and SMCSO were identified in plasma. This indicated that GR and SMCSO are able 
to permeate across the enterocytes to reach the systemic circulation.  
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Figure 6-1: Schematic illustration of main findings of the bioavailability of sulphur-
containing compounds from BOBS study and their potential transport mechanisms. 
 
The above findings posed the question of how these bioactives were transported across the 
enterocytes. Therefore, the transport mechanisms of these compounds were investigated by 
using two in vitro models, caco-2 cells and the PAMPA assay (Chapter 4). The purpose of 
both models was to differentiate between permeation of compounds via passive diffusion and 
via active transporters. Given that the caco-2 model differentiates into polarised enterocytes 
expressing active transporters, it enables permeation of compounds transcellularly via active 
transporters or via passive diffusion, as well as paracellularly through the tight junctions. On 
the other hand, the PAMPA assay is an artificial membrane (cell-free membrane) with no 
active transporters or tight junctions thus passive diffusion is the exclusive means of 
permeation across the membrane. The use of the PAMPA assay confirmed that while SF can 
passively diffuse through biological membranes, GR and SMCSO cannot. Caco-2 cells were 
incubated at different temperature conditions (4ºC and 37ºC) to discriminate between passive 
diffusion and active transport of compounds on the basis that transporters are deactivated at 
4ºC, permitting transport of compounds either through tight junctions or via diffusion. 
Although the diffusion of SF was reduced at 4ºC, mainly due to reducing the rate of diffusion, 
the transport of SF at 4ºC and 37ºC indicated that SF can passively diffuse, supporting the 
results from the PAMPA assay. However, in the case of GR and SMCSO (apart from 100 µM 
SMCSO), the transport of said compounds at 4ºC was negligible compared to that at 37ºC. 
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This indicated that both compounds may require active transporters or can permeate 
paracellularly. Nonetheless, these results are not conclusive due to the high percentage of 
Lucifer yellow recovery (independent paracellular marker to assess monolayer integrity) 
compared to the low permeability of GR and SMCSO. Irrespective of the data from the caco-
2 cells, the presence of GR and SMCSO in plasma and urine imply that these compounds 
permeate across the enterocytes, either via active transport or through tight junctions. 
Interestingly, the levels of SMCSO measured in the plasma were considerably higher than the 
levels of GR and SF. Taking into account the high levels of this dietary bioactive in the 
systemic circulation and its potential association with human health benefits as demonstrated 
by previous studies, the hypothesis that SMCSO exhibits anti-oxidant properties was further 
investigated. In order to accomplish this, expression of anti-oxidant genes regulated by Nrf2 
was explored in human HepG2 liver cells exposed to SF, a known Nrf2 inducer, and SMCSO 
(Chapter 5). To date, there is no experimental evidence of the effects of SMCSO on the Nrf2 
signalling pathway. The overall aim was to investigate whether SMCSO induced Nrf2-
regulated genes in a similar way to the well-known Nrf2 inducer SF. HepG2 cells were 
exposed to SMCSO (0-300 µM) and SF (10 µM) for 2, 6 and 24 hours, and Nrf2-regulated 
gene expression was quantified. While SF upregulated the expression of several Nrf2-
regulated genes at 6 and 24 hours, SMCSO did not show the same effect. It must be noted that 
while SMCSO was able to upregulate certain genes after treatment for 24 hours, this may not 
be biologically significant given the small fold-change. Further, SMCSO did not affect the 
expression of the two Nrf2-regulated genes measured in primary hepatocytes from wild-type 
mice. It is possible that SMCSO may exert its biological activity through a different 
mechanism of action rather than the induction of Nrf2-regulated gene expression. It could also 
be hypothesised that SMCSO activity require its metabolic transformation into active products. 
The primary aims of the work described in this thesis were successfully completed, and 
interesting findings from the human intervention study have generated new research questions 
that go beyond the scope of the current study. Firstly, this study clearly supports the use of 
broccoli soups made with different broccoli genotypes as an effective dietary intervention for 
delivering higher doses of bioactives and minimising compliance issues in long-term 
interventional trials. In addition, it has shed some light into the bioavailability of other sulphur-
containing bioactives, SMCSO and GR. Although the matter of whether SMCSO is a bioactive 
phytochemical has not been resolved in this thesis, preliminary work has demonstrated that 
SMCSO has a different bioactivity in terms of Nrf2-mediated pathways compared to the well-
studied SF. Further work is essential to understand the molecular mechanisms by which 
SMCSO could exert health-promoting activities. This will definitely help our understanding 
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of the health benefits associated with the human consumption of broccoli and other plant 
material rich in sulphur-containing compounds. 
 Congruence of findings to published literature and implications 
of research 
Although there are other broccoli-rich food matrices used as a SF/GR intervention tool, the 
use of a commercially available soup recipe and novel broccoli varieties with increased levels 
of bioactives represents a novel delivery formulation potentially useful in interventional trial. 
The development of this food product requires minimal effort by both the study scientists and 
the participants involved in the studies. However, a well-controlled platform, where scientists 
work closely with industrial partners, is crucial for the development of a high-quality product. 
As this is a new dietary tool with increasing levels of GR, its pharmacokinetic profile was 
investigated (BOBS study). When comparing human intervention studies that have either 
administered SF or GR, it very clear that the plasma levels and urinary excretion of SF are 
considerably higher following direct intake of SF rather than the precursor, GR (Table 6-1). 
This is presumably because SF is readily absorbed by the enterocytes, whereas GR requires 
conversion to SF by the gut microbiota prior to absorption. This is reflected with a Tmax of 1.5-
2 hours observed in plasma following consumption of SF [38,64,68,71] compared to a Tmax of 
6-7 hours observed following consumption of GR [68,71]. In terms of the BOBS study, as the 
soups only contained GR, the Tmax observed following consumption of Myb28B/B and 
Myb28B/V was 6-7 hours, comparable to those reported following consumption of GR. 
However, following consumption of Myb28V/V broccoli soup, a Tmax of 9.20 hours was 
observed, slightly later than previously reported. This result is due to the Tmax of 24 hours for 
one of the study participants. The Cmax reported in previous studies following consumption of 
SF rather than GR is considerably higher, especially in the study by Gasper et al. possibly due 
the intake of super broccoli soup which contains 3-fold higher levels of SF than standard 
broccoli [38]. Nonetheless, they observed a Cmax following consumption of standard broccoli 
soup more than ~10-fold higher than in a study undertaken by Vermeulen et al. [71], despite 
that the administered dose of SF levels was very similar. Likewise, despite participants in the 
BOBS study consuming twice the GR levels administered by Saha et al., the Cmax reported in 
this study is ~8-fold higher (0.2 µM vs. 0.025 µM) [68]. Similarly, the Cmax following 
consumption of GR reported by Vermeulen et al. is considerably lower than the Cmax reported 
in the BOBS study (0.031 µM vs. 0.2 µM respectively) [71]. Several factors could have 
influenced the discrepancies observed between the BOBS study and previous reports [68,71] 
including individual variability, analytical tools and food matrices. For examples, the use of 
HPLC column for analysing the study samples and the presence of fat in the intervention soups 
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may have contributed to the higher levels of bioactives measured in the BOBS study. In 
accordance with the data reported by Gasper et al. [38] increasing GR intake resulted in 
increased levels of SF in the plasma and the percentage of excretion excreted in the urine are 
to a certain extent similar between studies following consumption of GR or SF. The percentage 
of excretion following GR consumption is approximately 7.6-10.7% which is comparable to 
previous studies [22,32,67,68,70] (Table 6-2). 
Table 6-1: Comparison of the pharmacokinetics (Cmax, Tmax, AUC) following GR or SF 
consumption between the current study presented (BOBS) and other published 
intervention studies 
 
  Pharmacokinetics 







(reported in this 
thesis) 
Myb28B/B broccoli soup (standard 
broccoli) (84 μmoles GR) 
Myb28B/V broccoli soup (280 μmoles 
GR) 
Myb28V/V broccoli soup (452 μmoles 
GR) 
0.2 6.1 2.0 
0.4 7.4 4.9 
0.6 9.20 8.0 
Gasper et al. [38] 
Standard broccoli soup (95.1-107.5 
µmol/l SF) 
2.3 1.5 10.7-13.0 
Super broccoli soup (342.7-342.8 µmol/l 
SF) 
7.3 2.0 35.0-40.2 
Saha et al. [68] 
Frozen broccoli soup (42.5 µmoles GR) 0.025 6.0 0.144-
0.414 
Fresh broccoli soup (23.5 µmoles SF) 0.21 2.0 1.26-1.27 
Vermeulen et al. 
[71] 
Cooked broccoli (61.4µmol GR) 0.031 6.0 0.286 
Raw broccoli (9.92 µmol SF) 0.103 1.6 0.495 
Atwell et al. [64] 
Sprout extract treated with myrosinase 
(200 µmol SF) 
0.7 3.0 13.8 
Fresh broccoli sprout (200 µmol SF) 1.9 3.0 3.0 
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Table 6-2: Comparison of the percentage of SF and metabolites excreted following 






(reported in this 
thesis) 
Myb28B/B broccoli soup (standard broccoli) 
Myb28B/V broccoli soup 




Gasper et al. [38] 
Standard broccoli soup (95.1-107.5 µmol/L SF) 82 
Super broccoli soup (342.7-342.8 µmol/L SF) 55 
Saha et al. [68] 
Frozen broccoli soup (42.5 µmoles GR) 9.6 
Fresh broccoli soup (23.5 µmoles SF) 58.5 
Vermeulen et al. 
[71] 
Cooked broccoli (61.4µmol) 3.4 
Raw broccoli (9.92 µmol) 37 
Fahey et al. [70] 
Prostaphane® tablets (100 µmol SF) 71 
SF preparation in an α-cyclodextrin inclusion 
(200 µmol SF) 
62.3 
Egner et al.[22] 
GR-rich beverage (800 µmol GR) 5 
SF-rich beverage (150 µmol SF) 70 
Clarke et al. [69] 
Broccoli sprout with myrosinase (150 µmol GR) 74 
BroccoMax™ pills (121 µmol GR) 19 
Clarke et al. [65] 
Broccoli sprout with myrosinase (218.4 µmol 
GR) 
96 
BroccoMax™ pills (220.3 µmol GR) 19 
Fahey et al. [73] Broccoli sprout extract (200 µmol GR) 11.8 
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 Broccoli sprout extract ( 400 µmol GR) 10.4 
 
Oliviero et al. [67] 
Broccoli powder with 100% myrosinase activity 
(73 µmol GR + 34.0 µmol SF) 
58 
Broccoli florets with 100% myrosinase activity 
(73 µmol GR + 11.1 µmol SF) 
33 
Broccoli florets with 80% myrosinase activity (69 
µmol GR + 6.7 µmol SF) 
22 
Broccoli florets with 2% myrosinase activity (67 
µmol GR + 2.8 µmol SF) 
17 
Broccoli florets with no myrosinase activity (72 
µmol GR + 0.3 µmol SF) 
10 
Shapiro et al. [10] 
Sprout extract (525 µmol glucosinolates over 7 
days) 
17.8 
Sprout extract (2,100 µmol glucosinolates over 7 
days) 
19.6 
Sprout extract (525 µmol ITCs over 7 days) 70.6 
Kensler et al. [74] Sprout infusion (400µmol GR) 12 
Conway et al. [32] 
Fresh broccoli (0.48µmol GR/g) 32.3 
Steamed broccoli (0.46 µmol GR/g) 10.2 
 
It is well-established that SF is bioavailable from the intake of SF or GR; however, for the 
first-time, this study has reported the presence of intact GR and SMCSO in the systemic 
circulation. Due to limited literature, the pharmacokinetics of GR and SMCSO are unknown. 
The general observation is that increasing GR levels in the soups resulted in increasing levels 
of GR and SF in the plasma in a dose-dependent manner (Table 6-3), as previously reported 
by Gasper et al. [38]. While Myb28B/V and Myb28V/V broccoli soups delivered higher levels of 
SMCSO in the plasma compared to Myb28B/B broccoli soup, there was no significant 
difference in the SMCSO levels between the two novel varieties. In comparison to SF and 
SMCSO, the plasma concentration and percentage excretion of GR was considerably lower. 
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Presumably this is because most of the intact GR is converted to SF and only a small amount 
is absorbed as intact GR. The amount of SF absorbed and excreted is dependent on the 
conversion efficiency of GR to SF. In accordance with published data, ˂1% was excreted as 
intact GR and approximately 9-11% as SF and metabolites, in congruence with other studies 
(Table 6-2). However, this leaves ~88% unaccounted for. It is possible that this lost proportion 
may have been excreted, as intact GR and as SF and metabolites, in faeces, accumulated in 
tissues, or be excreted over the course of 48-72 hours (not measured in this study) (Figure 
6-2). Although, a previous study in rats detected no intact GR in faeces [20]. 
Table 6-3: Comparison of the plasma Cmax and the percentage of sulphur-containing 
bioactives excreted in BOBS study following consumption of three types of broccoli soups 









  Mean ± SD Mean ± SD Mean ± SD 
Plasma Cmax GR 0.01 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 
SF 0.17 ± 0.12 0.37 ± 0.26 0.61 ± 0.40 




GR 0.64 ± 0.34 0.51 ± 0.24 0.47 ± 0.22 
SF 10.75 ± 7.48 7.68 ± 5.98 8.99 ± 6.27 
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Figure 6-2: Schematic illustration of the percentage recovery from the intake of GR in 
the soups in BOBS study. While the black solid lines represent the findings from BOBS 
study, the blue dotted lines represent speculations about the unaccounted 88%. 
 
The plasma concentration and urinary excretion of SMCSO was considerably higher than SF. 
Though the percentage of SMCSO excretion is to a certain extent similar to SF (Table 6-3), it 
does not appear to align with evidence from the only published study regarding the 
bioavailability of SMCSO [84]. Of the administered SMCSO dose, 6-8% was recovered in the 
urine with 92% unaccounted for. Perhaps SMCSO accumulates in tissues, or is excreted in 
faeces or urine over 48-72 hours (Figure 6-3). Data from another intervention study (SAP 
study) using the same soup intervention indicate accumulation of SMCSO in prostate and 
adipose tissues (Unpublished data from Mr. Jack Coode-Bate, MD research). Most 
importantly, these results lead to three main hypotheses, discussed below, including; 




Excreted in urine 
as intact GR and 
glucoerucin 
9-11% 
Excreted in urine as SF 
and metabolites 
88% ? 
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metabolism of SMCSO by cysteine β-lyase, metabolism of SMCSO by gut microbiota, and 
thermal degradation of SMCSO. These hypotheses arose from the large discrepancy between 
the 6-7% SMCSO excreted in this study and 60% 35S of the administered 35S-SMCSO excreted 
in the study by Waring et al. [84]. Although the study by Waring et al. recovered 35S as 
opposed to SMCSO, a key distinction, the findings suggest that SMCSO undergoes further 
metabolism [84]. In addition, Waring et al. reported 16% of the 35S-SMCSO excreted as 
sulphate, further supporting the concept of SMCSO undergoing further metabolism in humans, 
as the 35S from the SMCSO has been incorporated into metabolites derived from SMCSO and 
excreted in the urine [84]. Thus, the low percentage of recovery reported by the BOBS study 
could be due to the fact that SMCSO metabolites were not measured. 
 
 
Figure 6-3: Schematic illustration of the percentage recovery of from the intake of 
SMCSO in the soups in BOBS study. While the black solid lines represent the findings 
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As illustrated in Figure 6-4, SMCSO in the plant undergoes breakdown through the activity 
of plant cysteine β-lyase to generate an intermediate which undergoes further metabolism to 
generate MMTSI and MMTSO. This was confirmed using an enzymatic model consisting of 
SMCSO and purified cysteine β-lyase at 35ºC resulting in the generation of MMTSO, MMTSI, 
pyruvate and dimethyl trisulphide over 24-hours [41]. In addition, two human enzymes 
CCBL1 and CCBL2 were recently identified as presenting cysteine β-lyase activity, 














Figure 6-4: SMCSO metabolism by cysteine β-lyase to form breakdown products.  Re-
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Nonetheless, metabolism of SMCSO in humans remains unclear due to limited research. An 
alternative metabolism route is via the gut microbiota. There are indications that SMCSO can 
undergo metabolism by the gut microbiota, as reported by Schwiertz et al. [42] and Dr Lee 
Kellingray (unpublished data from PhD thesis); however, the underpinning reactions and 
metabolite formation from this conversion remain unclear. 
One final point to consider is that the process of cooking the soups in the microwave may 
result in thermal degradation of SMCSO and thus the actual amount administered may be 
much less than assumed. Further, physiological temperatures of 37ºC may also result in 
degradation of SMCSO, thus resulting in a lower amount reaching the gut. This has not been 
investigated as of yet but may be a significant factor. 
There is very little evidence on the biological activity of SMCSO. In the current study, SMCSO 
presented no changes in Nrf2-regulated genes or viability of cells in HepG2. This could be due 
to the fact that SMCSO is an inactive phytochemical in its form like GR. It is possible that 
either MMTSI or MMTSO or other unknown metabolites from the breakdown of SMCSO in 
human exhibit biological activity as opposed to SMCSO. There is clear evidence to warrant 
further investigation to elucidate the metabolism of SMCSO by the gut microbiota and the 
biological activity of its metabolites. 
Chapter 4 has provided novel data on the potential mechanisms of transport of GR and SMCSO 
through cell-free models and human intestinal cells. However, further work is required to 
elucidate their transport mechanism at the molecular level. The current work corroborates the 
widely-accepted hypothesis that SF passively diffuses across the enterocytes and confirms that 
neither GR or SMCSO are able to do likewise. However, as reported in Table 6-4, the transport 
of all three compounds were low in comparison to the independent paracellular marker, 
Lucifer yellow. This suggests that the transport was either through ‘gaps’ in the monolayer 
due to poorly formed tight junctions, via diffusion or active transport. It is unlikely that GR 
and SMSCO were passing through ‘gaps’ because all experiments were carried out using high 
quality cell monolayers as confirmed by the measured TEER values; however, it cannot be 
excluded because a 100% monolayer is not realistically achievable in laboratory conditions. 
On the other hand, the low permeability of GR and SMCSO could be justified by their inability 
to diffuse through the gap junctions that allow the diffusion only to certain compounds on the 
basis of on molecular weight, size, charge, structure and interactions of with the gap junction 
protein [191]. Lucifer yellow is known to permeate through the tight junctions [192], however, 
data obtained from the transport experiments of the tests compounds and Lucifer yellow 
permeability did not show any correlation suggesting that the transport of test compounds was 
not related to the transport of Lucifer yellow. 
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Furthermore, it was hypothesised that GR and SMCSO could permeate across membranes via 
active transport using membrane transporters. Taking into consideration the structural 
characteristics of GR, it could be hypothesised that GR might permeate across cell membranes 
using glucose transporters, either GLUT-2 or SGLT1, due to the presence of a glucose moiety 
in its structure. Similarly, given that SMCSO is derived from amino acids, it was hypothesised 
that it may permeate using amino acid transporters. This theory is further supported by Song 
et al. who investigated the transport of S-methyl-L-methionine, derived from Brassicaceae 
[164]. The authors have demonstrated that SGLT1 and Pgp-1 were not involved in the 
transport of S-methyl-L-methionine, but amino acid transporters were suggested as potentially 
responsible for its transport. 
Once passively diffused across the enterocytes, given its electrophilic nature, SF binds to other 
proteins but most importantly conjugates to glutathione. Approximately 95-98% of SF was 
reported to accumulate as SF-GSH intracellularly and 2-5% as free SF of the initial dose used 
for the treatment of mouse liver cells [30]. This corroborates the findings from the study 
presented in Chapter 4 as ~3% of the SF added to the apical chamber was measured in the 
basolateral. Free SF can passively diffuse out or it can be exported as SF-GSH conjugate using 
MRP-1 and Pgp-1 transporter [7,27,31]; however, SF-GSH was not measured in the study 
described in Chapter 4 due to technical limitations. Interestingly, the low percentage of GR 
and SMCSO transport observed in vitro supports the data from obtained from the human 
intervention study (BOBS study).  
Table 6-4: Transport of test compounds from the AP chamber to the BL chamber at 120 
minutes, 37ºC. 
 
 Test compounds 
 SF GR SMCSO 
 Mean ± SD Mean ± SD Mean ± SD 
Percentage of transport 
from AP→BL 
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 Limitations to the research 
While specifically designed in vivo studies provide pharmacokinetic information such as the 
absorption, metabolism, distribution and excretion of dietary food/drugs, it is crucially 
important to carry out in vitro studies in order to elucidate their molecular mechanism of 
action. As in vitro studies are undertaken using isolated cells from their biological 
environment, they may behave differently under laboratory conditions. Consequently, it is 
difficult to translate data from in vitro studies into in vivo due to the complexity of human 
biology. Hence, the experimental work described in this thesis was carried out by using a 
combination of in vivo and in vitro models to provide information on the bioavailability of 
SMCSO, GR and SF in humans, and further mechanistic understanding in cultured cells. The 
main limitation of the research looking at the health benefits of broccoli-rich diets is the use 
of high concentrations of GR or SF that are not achievable in habitual diet by the general 
population. However, in this study, novel soups with higher levels of glucosinolates were 
successfully developed. 
However, there are limitations to the research presented in this thesis. On reflection, given that 
there is a possibility that SMCSO could undergo possible thermal degradation, analysing sub-
samples from soups after heating prior to participant consumption would have been valuable 
in determining the levels of SMCSO consumed by participants during the study. The 
percentage of excretion of SMCSO is based on the assumptions of the levels of SMCSO 
consumed prior to heating the soup; it does not take into account thermal degradation of 
SMCSO thus potentially under-estimating the percentage of excretion. Although a gold 
standard trial design was employed in this study, there were some limitations including 
absence of faecal collection and 48-72-hour urine sample collection. Even though Waring et 
al. reported only ˂2% of [35S] excreted via faeces following intake of [35S]-SMCSO ingestion 
in the form of a capsule [84], collection of faecal samples would have given an insight into the 
percentage of SMCSO excretion following soup consumption, a different matrix. The 
inclusion of faecal collection as part of the BOBS study protocol would have also provided 
useful information regarding excretion of GR and SF. Furthermore, one of the most 
challenging aspects of undertaking in vitro studies is choosing the concentration of the test 
compounds that are physiologically relevant. Whilst this study provides information on SF, 
GR, and SMCSO levels achievable in vivo, it does not reflect the concentrations that reach the 
liver prior to first-pass metabolism. A hepatic cell line (HepG2) was used for investigating the 
biological activity of SMCSO at the concentrations measured in vivo following consumption 
of the broccoli soups. However, the concentrations measured in the plasma reflect the levels 
distributed around the body following first-pass metabolism. The ideal sample collection to 
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gain such information would involve collection of blood samples from the hepatic portal vein 
which would give a representation of SMCSO concentrations achieved in the liver. However, 
such study has a high level of complexity and ethical issues would require serious 
consideration. Pharmacokinetic mathematical models to determine liver levels could be 
explored in future studies. 
Additionally, there were drawbacks from the in vitro studies. The main limitation of the caco-
2 studies in Chapter 4 was the use of Lucifer yellow as an independent integrity marker. In 
this particular case, Lucifer yellow with higher permeability than the test compounds may have 
not been a suitable paracellular marker. However, this information was not available prior to 
the study. This has limited the comparison of the data obtained from the current study with 
published data. In contrast, the main issue in Chapter 5 was not further exploring the potential 
thermal degradation of SMCSO that would inform the experimental design in terms of the 
appropriate concentrations to be tested in HepG2 cells. Perhaps, the lack of activity of SMCSO 
in modulating Nrf2-regulated gene expression could be due to the SMSCO degradation during 
the incubation time. 
 
 Future research 
The main outcome of this thesis is the discovery that SMCSO appears to be bioavailable in 
humans. This has led to further questions beyond the scope of this thesis, notably the question 
of how SMCSO is metabolised in humans and whether its biological activity could lead to 
significant health benefits. To date, there is very little experimental evidence which might 
contribute to a better understanding of the data reported in this thesis. A previous report has 
provided some information on the bioavailability of SMCSO by administrating radiolabelled 
SMCSO in humans, and measuring its recovery as 35S and sulphate [84]; however the endpoint 
of radioactivity implies that SMCSO underwent metabolism. Although there is some 
speculation that either the gut microbiota or human cysteine β-lyase can catalyse SMCSO, 
neither has been previously demonstrated in humans. In addition, it may undergo thermal 
degradation either during the cooking process or at body temperature. At present, we know 
that (i) cruciferous vegetables have high levels of SMCSO, which is bioavailable in humans 
and (ii) it does permeate across the enterocytes to reach the systemic circulation. 
The first question concerns whether SMCSO breaks down during the cooking process or at 
physiological temperatures. It has been demonstrated that SMCSO with the addition of a 
purified cysteine lyase undergoes degradation at 35ºC [41] or at 80ºC without the addition of 
the cysteine lyase [190]. However, further stability studies will need to be undertaken to 
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measure the levels of SMCSO at different time-points throughout the cooking process. In 
addition, it would be informative to investigate the effect of incubating synthetic SMCSO at 
various temperatures and monitor its stability. 
The second question is whether the gut microbiota can metabolise SMCSO and what are the 
metabolic products. Dr Lee Kellingray demonstrated reduction of SMCSO to S-
methylcysteine by an E.coli strain which also reduced GR (unpublished data). Further work 
will provide information on whether other gut bacteria can metabolise SMCSO. This could be 
achieved by adding a cocktail of gut microbiota, especially those known to have presented 
with cysteine β-lyase activity [42] to a sample of homogenised soup to the colon gut model 
described by Macfarlane et al. [193], which could be a suitable method in combination with 
analytical techniques for the analysis SMCSO end-products such as pyruvate and other known 
metabolites (Figure 6-4). Target metabolites can be analysed using LC-MS/MS or GC-MS, 
whereas unknown metabolites can be measured using NMR. Furthermore, the target 
metabolites such as MMTSO and MMTSI and other metabolites indirectly derived from the 
metabolism of SMCSO in plants could be measured in the samples collected from the BOBS 
study. This will give an idea of whether MMTSO and MMTSI are formed from the metabolism 
of SMCSO in humans. However, the development of novel analytical methods will be 
required. 
The third question is what metabolic pathways are modulated by SMCSO or its metabolites. 
While the current study demonstrated that SMCSO did not up-regulate Nrf-2 regulated genes, 
its potential biological activity cannot be dismissed. Perhaps SMCSO influences protein 
expression or the activity of enzymes rather than the expression of genes. Kumari and Augusti 
has previously reported a significant reduction in G6PD enzyme activity in rats on a SMCSO 
diet [137]. To follow on from the current work presented in this thesis, the protein expression 
of Nrf2-regulated genes can be investigated, or the enzyme activity of G6PD can be assessed 
using an assay kit following treatment with SMCSO. In addition, other researchers have shown 
that MMTSO and MMTSI are able to inhibit proliferation of cells, implying that biological 
activity associated with SMCSO may be due to its secondary metabolites [130,131]. The same 
experimental design as described in Chapter 5 can be undertaken with MMTSO and MMTSI 
to investigate whether these metabolites can influence Nrf2-regulated genes in liver cells. 
The experimental work on transport mechanisms (Chapter 4) has demonstrated interesting 
outcomes regarding the permeability of sulphur compounds in the gut. While the data is not 
conclusive, with GR and SMCSO potentially permeating via ‘gaps’ in the monolayer, there 
was a considerable difference in the transport of these compounds when incubated at 37ºC and 
4ºC, indicating transport through cells via active transport. In addition, there is a possibility 
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that these compounds may diffuse through the tight junctions. To further elucidate this, 
inhibitors of active transporters and tight junctions may be used. In the case of GR, it was 
hypothesised that, due to the presence of a glucose moiety, it may permeate through either 
GLUT2 or SGLT1, both present on the apical side of the intestinal membrane [194]. Inhibition 
of either GLUT2 with phloretin (Figure 6-5 A) or SGLT1 with phlorizin (Figure 6-5 B) may 
provide further insight into whether GR permeated across these specific transporters 
[157,165]. With regards to SMCSO, given its structural similarity with amino acids, it was 
suggested that SMCSO may use an amino acid transporter. This is a potentially complex 
avenue of research because of the wide range of amino acid transporters [195,196]. It was 
reported that mercury bound to cysteine permeated across intestinal cells using amino acid 
transporters b0,+ and B0,+ [196]. Further investigation of whether SMCSO uses either amino 
acid transport systems or others could be investigated by knocking out the transporters using 
siRNA [196]. Finally it is important to highlight that the use of inhibitors such as quinidine 
and carbenoxolone or silencing the tight junctions [197] could be an effective experimental 
route in order to exclude the possibility that SMCSO and GR permeability reported in the 





Figure 6-5: Inhibition of glucose transporters on the AP and BL membrane of 
enterocytes. SGLT1, a sodium-glucose transporter found on the apical membrane is 
inhibited by phlorizin (A) whereas GLUT2 found on the apical and basolateral 
membrane is inhibited by phloretin. 
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 Future impact 
Whilst the production of sulphur compounds in these novel broccoli varieties was already 
known in the field, their bioavailability in humans following consumption of soups made from 
the varieties was unknown. This study has provided the first evidence for dose-dependent 
bioavailability of beneficial sulphur compounds from novel broccoli soups.  
There are still many unanswered questions regarding the epidemiological findings and the 
underpinning mechanisms of SF. The current study has provided valuable information on the 
physiological concentrations of SF that are achievable, following consumption of the novel 
broccoli varieties. Further work is being undertaken in the Mithen group using the 
concentrations of SF from the current study to understand the underlying mechanisms.  
Currently the novel broccoli variety Myb28B/V, which is commercially available as 
‘Beneforte®’, does not have any health claims associated with the product as there is not 
currently enough evidence from long-term studies to legally make such claims. Whilst this 
study is not sufficient for any health claims, it is an important step in the right direction. 
Companies currently selling ‘Beneforte®’ would see this research as progress. A product with 
associated health claims may be more attractive to consumers and by extension more attractive 
to retailers.  
If the novel broccoli varieties were widely adopted, they could have wider positive 
implications on public health.  The consumption of the enriched glucoraphanin soups would 
enable the population to get beneficial amounts of the bioactives investigated within this thesis 
without requiring the consumption of unreasonably large amounts of broccoli. A portion of 
the Myb28V/V soups (300g) is equivalent to five portions of broccoli florets. One can 
speculate that you would therefore get the same benefits from eating one portion of the soup 
per week as you would get from eating five portions of broccoli florets. In comparison to other 
similarly sized meals (in terms of calorific value), the broccoli soups would provide substantial 
quantities of the bioactives whilst not affecting the nutrient composition. A portion of the novel 
broccoli soups provides 9% energy, 16% fat, 22% saturated fats, 4% sugars, 16% salt based 
on the reference intake (Section 6.6, Annex 2, p286), which is comparable to commercially 
available broccoli and stilton soups. 
 
 Conclusion 
In conclusion, the data presented in this research emphasises the use of the novel broccoli-rich 
product as a suitable intervention diet. There is ongoing research showing the potential health-
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benefit of consuming broccoli-rich diets against prostate cancer [92]. The broccoli soups tested 
in the current study could be an effective interventional strategy in a long-term trial recruiting 
men with organ confined prostate cancer to investigate whether this dietary approach may 
reduce cancer progression. Currently, two human intervention studies (ESCAPE study, 
clinical trials.gov: NCT01950143 and SAP study, clinical trials.gov: NCT02821728) 
recruiting prostate cancer patients are looking at the effect of broccoli-derived bioactives by 
using the soups well-characterised as part of this PhD project. Data obtained from this study 
will be very informative for the ongoing trials and will help the interpretation of their findings. 
Further, this study demonstrates another approach for delivering high levels of the bioactives, 
glucosinolates and SMCSO without unrealistic intake of cruciferous vegetables through our 
habitual diet. Further, this demonstrates that the soups with increasing GR levels results in 
increasing plasma levels and urinary excretion of SF and GR, and very importantly SMCSO 
is bioavailable. This is the first intervention study to report to bioavailability of intact GR and 
SMCSO. While it has been demonstrated that glucosinolates including GR do not exert 
biological activities in their form but only after conversion to ITCs, further research is needed 
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Executive Summary 
ABSTRACT: There is a large body of evidence suggesting that the consumption of 
cruciferous vegetables such as broccoli is beneficial to our health and is associated 
with a reduced risk of different types of cancer. Cruciferous vegetables are able to 
deliver in our body a group of compounds called isothiocyanates (ITCs) that are 
thought to be responsible of their health-promoting effects. Sulforaphane (SF) from 
broccoli is one of the most studied ITCs and its anticancer properties have been 
extensively investigated in in vitro and in vivo models. We are currently undertaking 
a 12- month intervention to determine whether a diet rich in SF will result in changes 
in genes and metabolites within prostate tissue in a way that could reduce the 
progression of prostate cancer (ESCAPE, REC Ref Number 13/EE/0110). The 
ESCAPE intervention involves weekly consumption of broccoli + stilton soups made 
with standard broccoli and two high-glucoraphanin (SF precursor) broccoli varieties 
able to deliver different levels of SF. We now propose to undertake an intervention 
study to measure the bioavailability of SF from the soups used in the ESCAPE 
study in terms of rate and extent to which SF reaches the systemic circulation and is 
excreted in urine. We will measure SF and its metabolites in plasma and urine 
samples collected from apparently healthy subjects after consumption of the three 
types of broccoli + stilton soups. 
PRIMARY AIM:  
To measure the total excretion of SF in urine collected for 24 hours after 
consumption of one pot (300g) of three types of broccoli + stilton soup containing 
different concentrations of glucoraphanin, SF precursor. 
SECONDARY AIMS:  
To measure SF and its metabolites in plasma following consumption of one pot 
(300g) of three types of broccoli + stilton soup containing different concentrations of 
glucoraphanin. 
To determine whether the glutathione S-transferase Mu 1 (GSTM1) genotype or 
other associated genotypes (e.g. GSST1) influence SF plasma pharmacokinetic 
parameters (Cmax, Tmax, area under the curve) and its total urinary excretion.  
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STUDY POPULATION: This study will recruit apparently healthy subjects aged 
18-65 years with a BMI between 20 and 35 kg/m2 (men and women). Recruitment 
will continue until ten participants have completed the study.  
OUTLINE STUDY DESIGN: 
The study outline is presented in Figure 1. This study will be a randomized, double-
blinded, three-phase crossover trial which will investigate the bioavailability of SF 
following consumption of broccoli + stilton soup containing different concentrations 
of glucoraphanin. The following soups will be tested in the three phases:  i) 300g 
standard broccoli + stilton soup, ii) 300g Beneforte® broccoli + stilton soup, iii) 300g 
Beneforte Extra broccoli + stilton soup. Participants will undergo three phases 
separated by a minimum of two weeks (wash-out period). Each phase will consist of 
a 48 hour pre-intervention diet restriction, a study day involving an 8 hour 
cannulation at the Human Nutrition Unit (HNU) of the Institute of Food Research 




Study protocol Version 3-BOBS 10th November 2014 
























Figure 1: Study outline  






Quantification and profiling of ITC 
11 Blood samples 
6 Urine samples 
11 Blood samples 
6 Urine samples 
11 Blood samples 









Participants will be allocated to one of the following soups 
for each phase: 
- Standard broccoli + stilton soup 
- Beneforte ® broccoli + stilton soup 
- Beneforte Extra broccoli + stilton soup 
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1. Scientific background  
There are many epidemiological studies that have reported reduction in the risks of 
cancers such as ovarian, pancreatic, breast and prostate with the consumption of 
cruciferous vegetables. Epidemiological studies from US, Singapore and China 
suggest that diets rich in cruciferous vegetables, e.g. broccoli, may reduce the risk of 
prostate cancer [91,92]. Studies have shown that an intake of one or more portions 
of broccoli per week can reduce the incidence of prostate cancer and also the 
progression from localised to aggressive forms of cancer. 
 
1.1. Metabolism of glucosinolates 
Cruciferous vegetables accumulate a group of compounds called glucosinolates 
which are sulphur containing phytochemicals. As well as containing glucosinolates, 
the broccoli florets also contain the thioglucosidase, myrosinase. The myrosinase is 
spatially separated from the glucosinolates, however when the plant structure is 
mechanically compromised, the plant thioglucosidase, myrosinase  comes into 
contact with the glucosinolates [198] and catalyses the hydrolysis of the 
glucosinolates to isothiocyanates (ITCs) [Figure 2].  In addition to the myrosinase, 
the glucosinolates can be hydrolysed by human gut microbiota with myrosinase-like 
activity [Figure 3].Glucoraphanin is the main glucosinolate naturally found in broccoli, 
which is catalysed to the ITC sulforaphane (SF).  
 
Figure 2: Structure of the main glucosinolate in broccoli, Glucoraphanin and its 
isothiocyanate Sulforaphane  
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Figure 3: Glucosinolate metabolism [37] 
 
1.2. Metabolism of sulforaphane 
ITCs such as sulforaphane (SF) are bioactive compounds that exhibit anti-cancerous 
activity associated with cruciferous vegetable consumption. Overcooking of broccoli 
denatures the myrosinase enzyme so the glucoraphanin enters the gut where it is 
hydrolysed to SF by gut thioglucosidase. SF is then absorbed by the enterocytes, 
conjugated with glutathione via glutathione-S-transferases (GSTs) and transported 
into the systematic circulation to be metabolized by the mercapturic pathway [Figure 
3]. It is then excreted as N-acetylcysteine conjugates in the urine [37,38].Glutathione 
transferases (GSTs) are dimeric enzymes that catalyse the conjugation of glutathione 
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(GSH) to xenobiotics, e.g. ITCs or endogenous compounds, to facilitate their 
metabolism and excretion. There are three mammalian GSTs: cystolic, mitochondrial 
and microsomal. It is the GSTM1-1 and GSTP-1 class of GSTs that usually catalyse 
the conjugation between glutathione and SF [38].Approximately 45% of consumed 
SF occurs as free SF in the plasma with the rest occurring as thiol conjugates. The 
peak concentration of SF and its thiol is 2µm, which decreases within one hour [37]. 
 
1.3. GSTM1 Genotype 
The protective effects of SF appears to be linked with the GSTM1 (glutathione S-
transferase mu 1) genotype. One major GSTM1 polymorphism refers to the presence 
or absence of the gene. Individuals with a homozygous deletion in the GSTM1 gene 
(GSTM1 -/-), termed as GSTM1 null, do not have a functional GSTM1 protein 
accounting for 39-63% of the population. On the other hand those with two GSTM1 
intact alleles or a heterozygous deletion in the GSTM1 gene (GSTM1 -/+ or GSTM1 
+/+) are classified as GSTM1 positives [38]. Epidemiological studies reported that 
broccoli consumption provides greater protection for GSTM1 positive individuals than 
GSTM1 null individuals. It is thought that the GSTM1 enzyme may catalyse the 
dissociation of the SF-thiol conjugates [38]. 
 
1.4. Beneforte® development 
Broccoli contains approximately 6-9 µmol g-1 dry weight of glucosinolate in their florets 
[18]. A new variety of broccoli has been developed over the last twenty years by our 
research group delivering a threefold higher concentration of SF than standard 
broccoli because it accumulates 2.5-3 fold higher levels of glucosinolate in its florets 
[18]. This specific broccoli is now marketed under the trademark name Beneforte® 
broccoli which is also known as super broccoli. It is the F1 hybrid formed from the 
cross-breeding between a standard broccoli and a wild species broccoli known as 
B.villosa [17,18] that contains gene segments from B. villosa introgressed into the 
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1.5. Bioavailability studies 
Bioavailability is a term which describes the amount of a nutrient that is absorbed 
into the systemic circulation and becomes available at target tissues from the 
consumption dose. 
 
In this project we propose to undertake a bioavailability study looking at the 
bioavailability of sulforaphane from three types of broccoli + stilton soups. This 
study design is based on two other similar bioavailability studies: a study by 
Gasper et al 2005 and a study by Saha et al 2012.  
 
One of the studies was a randomised, two-phase crossover study undertaken to 
measure the bioavailability of SF from fresh versus frozen broccoli. The study 
consisted of two 5-day test phases with a washout period of 7 days (LREC 2003/082). 
Blood and urine samples were collected from 18 apparently healthy participants after 
they were fed 100g of fresh broccoli and 100g of frozen broccoli over the two phases. 
Participants were recruited based on their GSTM1 genotype in order to achieved 
balanced groups [68].The other study was a randomised, three-phase crossover 
study with a washout period of 21 days, which recruited 16 participants. This study 
fed participants broccoli soup, super broccoli soup and water (reference E/10/2003). 
This study also recruited an equal number of participants with GSTM1 positives and 
nulls [38]. 
 
In this proposed study, the design will be that of a three-phase crossover similar to 
Gasper et al (reference E/10/2003) with the blood and urine collection timepoints 
similar to that of Saha et al. One of the main differences between the proposed study 
and the two studies listed above is the study soup. Saha et al 2012 used 100g of 
fresh or frozen broccoli with 150g of water, microwaved for 75s and blended to create 
a soup.  Gasper et al 2005 cooked 100g of florets with 150mL of water, microwaved 
for 90s then blended to create a soup. The light cooking of the broccoli in the Gasper 
study ensured that the activity of myrosinase enzyme was still preserved. In the study 
by Saha et al, the activity of the myrosinase enzyme was still preserved in the lightly 
cooked fresh broccoli. However, the myrosinase was inactivated in the lightly cooked 
frozen broccoli due to the process of blanching first before freezing the broccoli 
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florets. The soups used in this study are made and frozen by a food company so the 
myrosinase is inactive. Also the soups are in a form that can be made commercially 
available and thus more palatable than blended luke warm broccoli in water.   
 
The studies also differ in the concentration of SF and glucaraphanin delivered by the 
soups. In the Gasper study 15 μmol and 52 μmol of SF; in the Saha study 23.5 μmol 
of SF and no glucoraphanin in the fresh broccoli soup and 42.5 μmoles of 
glucoraphanin in the frozen broccoli soup.  
In this current study, the concentrations of glucoraphanin are: 
 43 μmoles in standard broccoli + stilton soup, 
 180 μmoles in Beneforte® broccoli + stilton soup 
 442 μmoles in the Beneforte Extra broccoli + stilton soup.  
 
The proportion of glucoraphanin per frozen weight of broccoli soup in the Saha study 
is similar to that in this cannulation study (42.5 μmoles per 236g soup and 43 μmoles 
per 300g in the standard broccoli +stilton soup respectively). Following consumption 
of the soup made from frozen broccoli, SF conjugates were not detected in plasma 
until 1 hour after consumption and peaked at 6 hours and rate of excretion peaked 
during the 4-6 hours urine collection. Because the SF conjugates appeared later, 
participants will be cannulated in this study for 8 hours and blood will be collected at 
the following time points post soup consumption: 0, 30, 45, 60, 90, 120, 180, 240, 
360, 480 mins and 24 hours. In addition, urine will be collected at the following 
timepoints: 0, 0-2, 2-4, 4-6, 6-8, 8-24 hours even though the rate of excretion peaked 
during the 4-6 hours. The early timepoints will be necessary for the additional sulphur 
analyses and for the other two soups that will deliver a higher concentration of 
glucoraphanin.  
Due to the results from the study by Saha et al 2012, where there were no significant 
difference in the plasma levels or total urinary excretion between GSTM1 nulls and 
GSTM1 positives, participants will not be selected for this criteria. However, 5ml from 
the 15ml blood sample that will be collected from each participant at the eligibility 
screening will be used for genotyping purposes, which will be used to justify any 
outliers that may be seen in results from this study. 
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1.6. Use of broccoli soups in studies 
In our research group, we are currently undertaking two intervention studies to 
investigate the beneficial effects of a diet rich in SF on prostate cancer (ESCAPE, 
REC Ref Number 13/EE/0110; ESCAPE-ING, IFR HRGC Ref Number IFR02/2014). 
The ESCAPE and ESCAPE-ING studies are double-blinded dietary interventions 
recruiting patients with early prostate cancer on active surveillance. Participants are 
asked to consume, for the duration of the study one portion per week of broccoli soups 
made with different broccoli varieties (standard, Beneforte® and Beneforte extra 
broccoli) delivering increasing levels of SF. Plant breeders at Seminis developed the 
Beneforte® broccoli cultivar, which is subject to very stringent quality control and is 
now widely commercialised in US and several European countries, including the UK. 
The breeders have developed another broccoli cultivar, Beneforte extra, which has 
almost double the amount of glucoraphanin compared to Beneforte® broccoli. 
Beneforte® and Beneforte extra have been developed by conventional breeding. 
Data obtained by analysing the study soups used in the ESCAPE and ESCAPE-ING 
studies have shown that one pot of the Beneforte extra broccoli soup (300g) contains 
approximately 442µmoles of glucoraphanin 
 
In this study, we propose to undertake an intervention with standard 
broccoli + stilton, Beneforte® and Beneforte extra broccoli + stilton 
soups to measure the bioavailability of SF in apparently healthy 
subjects. Data obtained from this study will provide valuable information 
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2. Hypothesis 
 
Consumption of the Beneforte Extra broccoli + stilton soup will result in a higher 
excretion of SF and its metabolites in urine compared to Beneforte® and standard 




 To measure the total excretion of SF in urine collected for 24 hours after 
consumption of one pot (300g) of three types of broccoli + stilton soup 
containing different concentrations of glucoraphanin, SF precursor. 
 
 To measure SF and its metabolites in plasma following consumption of one 
pot (300g) of three types of broccoli + stilton soup containing different 
concentrations of glucoraphanin. 
 
 To determine whether the glutathione S-transferase Mu 1 (GSTM1) genotype 
or other associated genotypes (e.g. GSST1) influence SF plasma 
pharmacokinetic parameters (Cmax, Tmax, area under the curve) and its total 
urinary excretion. 
 
4. Study design 
This study will be a randomized, double-blinded, three-phase crossover trial [Figure 
4] to assess the bioavailability of SF after consumption of (i) 300g standard broccoli 
+ stilton soup (providing 43 μmoles/300g  glucoraphanin), (ii) 300g Beneforte® 
broccoli + stilton soup (providing 180 μmoles/300g  glucoraphanin), (iii) 300g 
Beneforte Extra broccoli + stilton soup (providing 442 μmoles/300g of glucoraphanin). 
The reported levels of glucoraphanin in the three types of soups come from recent 
analysis undertaken in February 2014.The study will be carried out at the Human 
Nutrition Unit (HNU) of the Institute of Food Research (IFR). Blood and urinary 
samples will be collected from participants following consumption of the broccoli + 
stilton soups with the aim of detecting plasma and urinary metabolites of SF, which 
are surrogate markers of bioavailability.  
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Each phase will consist of a 48 hour pre-intervention diet restriction, a study day 
(study day 1) comprising of approximately a nine hour stay at the HNU which will 
involve cannulation. The following morning participants will visit the HNU for up to 1 
hour for collection of a single blood sample at 24 hour post-dose followed by 
breakfast. During study day 1, eleven 10ml blood samples will be collected over the 
course of the day from participants at the following timepoints: 0, 30, 45, 60, 90, 120, 
180, 240, 360, 480 mins and a 24 hour blood sample. Six urine samples will be 
collected at the following timepoints: 0, 0-2, 2-4, 4-6, 6-8, 8-24 hours. 
The three phases will be separated by a minimum of a two week washout period. This 
is to ensure that the veins recover from the 8 hour cannulation period for re-
cannulation during the next phase. For the duration of the study, participants will be 
required to follow a glucosinolate-free diet for a total of nine days which will be three 
days per phase. The three days are split into 48 hours (2 days) prior to the study day, 
24 hours (1 day) on the study day as well as the following morning until the 24 hour 
blood and urine sample have been collected. After the 24 hour urine and blood 
samples have been collected, participants can resume their normal diet for a 
minimum of two weeks until 48 hours prior to their next study day. This will reduce 
the contribution of glucosinolate from other foods having an impact on the results of 
the study. The involvement of the participants will last approximately 11-12 weeks. 
The study will be led by Professor Richard Mithen. The study team members are Miss 
Tharsini Sivapalan, Dr Antonietta Melchini and Dr Charlotte Armah. Study talks, 
screening and study days will be carried out by the study team which includes by Miss 
Tharsini Sivapalan (a first year PhD student at the IFR) with the assistance of Dr 
Antonietta Melchini. Additional assistance with study talks, screening and study days 
will be provided by Dr Charlotte Armah in the absence of Dr Antonietta Melchini. All 
the biochemical analysis will be performed by Miss Tharsini Sivapalan with the 
assistance of Dr Antonietta Melchini under the supervision of Dr Shikha Saha, an IFR 
analytical expert. Screenings and cannulation will be performed by an appropriately 
trained and experienced HNU research nurse. 
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 Consume broccoli soup 




Start of study day 1 





Visit 3- Study Day 1 
4. 15 ml Blood sample – 10ml will be 
for full blood count, urea, electrolytes 
and HbA1c analysis, 5 ml for 
genotyping 
Diet Restriction 48 
hours prior to study 
day 




8 hours  
Cannulation  
-Baseline blood sample 
9 Blood Samples: 30, 45, 60, 90, 120, 
180, 240, 360, 480 mins from 
consumption of soup 
4 Urine Samples: 0-2, 2-4, 4-6, 6-8 
hours 
Diet Restriction 
End of phase 1 
3b. Measurements 
for BP, Pulse, Height, 





Figure 4: Detailed outline of study design 
Each study phase will follow the same pattern as study phase after a minimum of 2 week washout 








Annex 1- Invitation letter from HNU database         Version 2-BOBS 29th July2014 
 
4.1. Recruitment  
The aim will be to recruit apparently healthy participants aged 18-65 years old. 
Recruitment will continue until ten participants have completed the study. Potential 
participants will be recruited from the Human Nutrition Unit (HNU) volunteer database 
and the HNU senior research nurse will be responsible for this process. The database 
contains the names and contact details of local people who have previously registered 
an interest in participating in research studies at the IFR.  Those individuals whose 
details are currently held on the database and who meet the basic inclusion criteria 
will be sent the study information pack. This will consist of a letter of invitation to take 
part in the study (Annex 1), the Participant Information Sheet (PIS) (Annex 2) with a 
response slip and pre-paid envelope to return the response slip.  
In addition to using the database for recruitment, advertisements (Annex 3) will be 
placed around the Norwich Research Park (University of East Anglia (UEA), John 
Innes Centre (JIC), The Genome Analysis Centre (TGAC) and IFR), and other 
appropriate locations for example, supermarkets and social clubs within an approx 40 
miles radius of IFR.  
If required, advertisements will be placed in the local newspapers; radio (and 
television) coverage will be obtained. Either the advertisement or a link to an IFR 
website containing the study advert will be placed on internet sites such as gumtree, 
social networking sites such as Facebook/ Twitter. The advertisement will contain 
contact details of members of the study team. It will be highlighted that in order to be 
eligible to take part in the study, participants need to live within a 40 mile radius of 
IFR. Those responding to the adverts will be sent an information pack consisting of a 
letter of invitation (Annex 4), PIS, a response slip and pre-paid envelope. 
Potential participants, who are interested in taking part in the study, after having read 
the PIS, will be asked to register their interest either by returning the PIS response 
slip or by contacting a member of the study team by telephone or email. When 
participants have registered their interest they will be contacted by a member of the 
study team to book an appointment to attend the HNU at IFR for a study talk.  
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 Potential participants identified by the HNU database and advertisements are sent a 
Participant Information Sheet (PIS)
Potential participants contact a member of the study team to book study talk  
Visit 1: STUDY TALK at the HNU
Potential participants come to meet a member of the study team to discuss 
the study and a urine sample pot provided to potential participants for 
eligibility screening appointment 
After a minimum 72 hours consideration period , potential participants contact  
a member of the study team to book a screening appointment at the HNU
Visit 2: ELIGIBILITY SCREENING APPOINTMENT at the HNU 
- Consent form & medical declaration form signed and copy given to participant
- Urine dip stick test - undertaken by HNU nurse 
- Screening questionnaire completed with participant by HNU nurse; measurements taken and recorded 
for blood pressure, pulse,  height, weight, body mass index 
- If above screening procedures are successful: A blood sample (15ml) taken by HNU nurse 10 ml for 
FBC,  U's + E's and HbA1c and 5ml for genotyping at IFR
Urine container provided to participants for study day
Random allocation of one of the three broccoli soups
Diet Restriction prior to the study day 
Participants eliminate foods high in glucosinolates, alcohol and spicy food for 48 hours
Participants will fast for 10 hours overnight prior to the study day and advised to drink 
plenty of plain water
Visit 3:  STUDY DAY 1 at the HNU 
Baseline urine sample is collected by participants in urine pot
Participant comes to the HNU, CRF completed by nurse
Nurse measures BP to check it is below 160/100  or above 90/50 or 95/55 if symptomatic prior to 
cannulating participant and  baseline blood sample is taken
Partipant consumes broccoli soup 
10ml of blood samples are collected at: 0, 30, 45, 60, 90, 120, 180,  240, 360, 480 mins
Urine samples collected at: 0-2, 2-4, 4-6, 6-8, 8-24 hours
Lunch (5 hours after soup consumption) provided and unlimited water
Study lasts approximately 8 hours, and participant can leave after the last blood sample of the day  
is collected and  a drink (tea/coffee) and biscuits offered   
Diet restriction is required to be maintained overnight
Urine pot provided for 24 hour urine collection
Visit 4:  24 hour samples
24 hour urine sample collected by participants
Participants returns to HNU for 24 hour blood sample (10ml) taken by HNU nurse
Standard HNU breakfast provided (cereal, toast, coffee/tea)
Participants are booked for phase 2 of the study and reminded about diet restriction 48 hours 
prior to study day  
PHASE 2 and 3 STUDY DAYS
Same procedure as Study Day 1 and 24 hour samples of Phase 1
24 hour blood collection of Phase 3









Figure 5: Study flowchart describing the involvement from the participants 
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4.2. Study Talk (HNU-Visit 1) 
 
During the study talk, a member of the study team will go through the PIS and explain 
the study fully including discussing all aspects of the participant’s involvement [Figure 
5]. The participant will be encouraged to ask any questions they have at the time. The 
participant will be able to speak to the HNU senior research nurse if they have any 
questions relating to cannulation, venepuncture or any of the clinical measurement 
prior to making any commitment.  After the talk, potential participants will be given a 
minimum period of 72 hours (3 days) to consider whether they wish to participate in 
the study. During this period the potential participants will not be contacted. If after 
the 72 hour period, they still wish to participate in the study, they will be asked to 
contact a member of the study team to book an appointment at the HNU for an 
eligibility screening. At the study talk, potential participants will be provided with a 
container for their urine collection on the morning of the eligibility screening visit (Visit 
2).  If they do not wish to participate they will be told to discard the container. 
If after the study talk the potential participant has decided to take part and request to 
book their eligibility screening appointment before leaving the HNU an appointment 
can be booked. However, this appointment will be scheduled for after a minimum of 
3 days from the study talk. Any potential participants who book their eligibility 
screening appointment at the study talk will not be contacted during this time. 
Potential participants who respond positively after the study talk will be invited to the 
HNU for an eligibility screening (Visit 2). They will be sent appointment cards with 
their appointment date and time and a reminder of what they need to do and bring 
with them for the eligibility screening (Annex 5). Participants will also be reminded to 
bring with them details of any prescribed medication, herbal remedies or dietary 
supplements (i.e. name of medication, dose taken). For validity of the urine dipstick 
test the urine has to be tested within 2 hours of collection and therefore potential 
participants will be asked to collect a fresh midstream urine sample within 2 hours of 
their screening appointment. If the potential participant forgets to bring their urine 
sample or the urine sample provided is more than 2 hours old they will be provided 
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4.3. Eligibility Screening (HNU-Visit 2) 
 
Potential participants are assessed for eligibility based on a set of specific inclusion 
and exclusion criteria, an eligibility questionnaire, anthropometric measurements 
(Blood pressure, pulse, weight, height and Body Mass Index (BMI)) and results of 
clinical laboratory tests (Combur 9 urine dipstick test and screening blood results 
(FBC,U/E and HbA1c)).  
On the day of the eligibility screening at the HNU, potential participants will arrive at 
the HNU. They will be met by a member of the study team and taken into a confidential 
room where a member of the study team (Tharsini Sivapalan and Dr Antonietta 
Melchini) or the HNU senior research nurse will go through the consent form (Annex 
6). Potential participants will be encouraged to ask any questions they have at this 
stage about the study and their involvement after which they will be asked to sign the 
consent form agreeing to participate in the study and to all their clinical results being 
sent to their GP. In addition they will be asked to sign a medications declaration form 
(Annex 7) agreeing to inform a member of the study team of any medication they may 
have to take, or if they become unwell or pregnant whilst on the study. A member of 
the study team (Tharsini Sivapalan or Dr Antonietta Melchini) or HNU senior research 
nurse will also sign the consent form and the participants will be given a copy to keep 
for their records. Each participant will be assigned a unique eligibility screening code 
number which will be used on their eligibility screening paperwork and samples. 
Once the consent form has been signed by the participant, the HNU nurse will test 
the urine sample using Combur 9 urine dipstick test (Roche Diagnostics). The nurse 
will then complete an eligibility screening questionnaire with the participant (Annex 
8), a case report form (CRF) (Annex 9), measure and record blood pressure (BP), 
pulse (P), height (cm) and weight (kg) and calculate Body Mass Index (BMI, kg/m2).  
If the BMI is ≤20 or ≥35 kg/m2, the participant will be excluded from the study. If blood 
pressure is less than 90/50 or 95/55 mmHg if symptomatic, or greater than 160/100 
mmHg they will be excluded from the study and advised to speak to their GP. 
The urine dipstick test results will be known immediately. If any of the results for the 
urine dipstick test are flagged the nurses will refer to the HNU Protocol ‘For the referral 
of abnormal urinalysis results at screening’ which provides advice on exclusion or re-
screening of the participant. This protocol has been authorised by the HNU medical 
advisor. In the event of a flagged urinalysis the HNU senior research nurse will speak 
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to the participant and they will be advised whether a re-screen or exclusion is 
appropriate. 
In the event of a flagged urinalysis indicating re-screen is appropriate the HNU 
research nurse will speak to the participant regarding their results and they will be 
advised to visit their GP/practice nurse prior to returning for a re-screen. If the 
urinalysis results are flagged on the second occasion the participant may be excluded 
depending on the tests flagged. No blood sample will be taken until the re-screen 
appointment and then only if the urine test is satisfactory. 
If blood is flagged in the urine sample of female participants they will be asked if they 
are menstruating or have just finished menstruating, if they answer yes to either they 
will be asked to provide a second urine sample for testing 5 days after finishing 
menstruation. In the event of a flagged urinalysis on the second occasion, which 
indicates they may be re-screened, the HNU research nurse will speak to the 
participant and they will be advised to speak to their GP regarding their results prior 
to coming back to the HNU for a re-screen. No blood sample will be taken until the re-
screen appointment and then only if the urine test is satisfactory 
In the event of a flagged urinalysis indicating exclusion is appropriate the HNU 
research nurse will speak to the participant regarding their results and they will be 
advised to visit their GP to discuss the results. 
Although participants will be given a copy of their flagged urine results to take with 
them to their GP, a member of the study team will send a copy of all the eligibility 
screening results including urinalysis to the GP (Annex 10) within the timescale 
advised by the HNU senior research nurse, and this will be supported with a letter to 
their GP detailing their screening results (urine dipstick test, screening blood results 
(FBC,U/E and HbA1c), blood pressure, pulse, weight, height and BMI) (Annex 11). 
The letter will also indicate whether the participant is included or excluded from the 
study. 
As this study requires the participants to undergo an eight hour cannulation, plus a 24 
hour blood sample over three phases, the vein status of the potential participants will 
be assessed by the HNU senior research nurse who is experienced at undertaking 
cannulation/phlebotomy procedures to ensure the veins are suitable and therefore 
minimising the risk of damage to the vein or to prevent putting participants through 
unnecessary attempted cannulation. Those who do not have suitable veins for 
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cannulation as assessed by the HNU senior research nurse will be excluded from the 
study. 
If the result of the urine dipstick test is satisfactory and the participant is happy to 
continue, a 15ml blood sample (approximately 3 teaspoons) will be taken by the HNU 
nurse via venepuncture using a butterfly needle. 10ml (approximately 2 teaspoons) of 
the blood will be sent to the SPIRE Hospital for analysis of Full Blood Count (FBC), 
Urea and Electrolytes (Us + Es) and HbA1c (glycated haemoglobin). In addition, 5ml 
(approximately one teaspoon) of the blood sample will be used for genotyping which 
will be stored and subsequently analysed at IFR. After obtaining the blood sample the 
participants will be free to leave the HNU. Participants will be provided with a urine 
container for their urine collection the morning of study day 1 of phase 1 and a list of 
foods that will need to be eliminated from their diet (Annex 12) 48 hours prior to the 
study day, the study day itself and the following morning.  
 If any of the individual results from the screening blood tests analysed at the SPIRE 
Hospital falls outside the standard reference ranges, they will be assessed by the 
HNU medical advisor or in their absence a doctor from the UEA medical centre, who 
provides emergency cover for the HNU. They will consider whether the results could 
affect the study data or have implications for the health of the participant, and 
therefore, whether inclusion, re-screen or exclusion is appropriate. It may be that even 
though results are outside the standard reference ranges, either a re-screen or 
inclusion may be appropriate. Since some minor deviations will not warrant a re-
screen and will neither affect the study data nor have health implications for the 
participant. If the participant may be included in the study the medical advisor will write 
‘satisfactory for study’ on the blood results form indicating that inclusion onto the study 
is appropriate.   
If a re-screen is considered appropriate, the participant will be given the option of 
returning for another blood test after an appropriate period of time, as advised by the 
HNU medical advisor. Participants who do not wish to be re-screened will be excluded 
from the study. Participants who display screening parameters outside the standard 
reference ranges for the study on the second occasion (rescreen) may be excluded 
from the study depending on the individual results flagged. This decision will be made 
by the HNU medical advisor.    
By signing the consent form, the participant has agreed to clinical information being 
sent to their GP. Copies of all eligibility screening results from fresh samples (not 
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stored), which have been analysed by an accredited laboratory (SPIRE Hospital) will 
be sent to the participant’s GP.  
Participants will be informed of flagged blood results by a telephone call or an e-mail 
initially, followed by a letter (Annex 13) advising them to speak to their GP to discuss 
the results and/or to inform them that they will not be able to take part in the study. As 
the scientist in charge is not medically trained, they will not advise the participants 
which results are flagged or any other course of action. If the blood test results indicate 
a problem that requires immediate attention, the HNU medical advisor will advise the 
HNU senior research nurse to contact the participant by telephone to inform them of 
the results and advise them to make an appointment with their GP. In some cases the 
HNU medical advisor may ask the HNU senior research nurse to contact the 
participant’s GP directly and results may be faxed to the GP. The participant will be 
advised by the HNU senior research nurse that their GP has been/will be contacted 
directly.  
Participants that successfully pass the eligibility screening will be invited to commence 
the study within one month of the screening visit. They will be sent an appointment 
card with their study day 1 appointment. Participants are free to withdraw from the 
study at any time without giving any reason. Re-screen will be necessary if the period 
between screening and  starting on the study is more than one month. A letter (Annex 
14) will be sent to the GPs of the participants that are successfully recruited onto the 
study to inform them of their patient’s involvement in the study. This letter will be 
accompanied with a summarised description of the study (Annex 15). The GPs will 
also be sent a copy of all clinical results taken at the eligibility screening (blood 
pressure, pulse, weight, BMI, dipstick urine test, FBC, U+Es and HbA1c) and any 
clinical results collected during the study deemed significant by the HNU medical 
advisor.  
If the participants that have passed the clinical screening experience any illness or 
change in their medication (between the period of passing the clinical screening and 
starting the study), they should immediately notify a member of the study team either 
by telephone, letter or email to ensure that they will still be eligible to participate in the 
study or whether they will need to be re-screened or any booked study days 
postponed/ rescheduled or excluded. This will be decided by the HNU senior research 
nurse and HNU medical advisor. 
Once recruited onto the study, the participant’s code number assigned to them at 
screening will be used on all their samples. This is to ensure the blood samples for 
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genotyping and the other samples collected during their involvement in their study all 
have the same code number and to ensure anonymity and confidentiality. Only the 
members of the study team named in the approved documentation will be able to link 
the codes to participant’s names however, the code may be broken in the event of a 
medical emergency as deemed appropriate and necessary by the HNU senior 
research nurse, the HNU medical advisor or a UEA doctor who may provide cover in 
cases of emergencies.  All personal information will be kept confidential and known 
only to the chief investigator, members of study team, HNU nurses, HNU medical 
advisor, UEA doctor and the participant’s GP.   
As recruitment approaches the required number of participants for this study, those 
who subsequently express an interest will be asked if they would be happy to be 
placed on a stand-by list in the event of participants dropping out or being withdrawn. 
At the study talk they will be reminded that they may not get the opportunity to take 
part in the study. If it turns out that they are not required then they will be notified by 
phone and letter (Annex 16). If participants on the waiting list are required, they will 
be contacted to book an eligibility screening appointment. If participants from the 
waiting list no longer wish to participate in the study, they will be removed from the 
waiting list and will play no further part in the study. Further individuals from the waiting 
list will then be approached if required. 
 
4.3.1. Basic inclusion criteria 
 
 Men and women  
 Aged 18-65 years 
 Non-smokers  
 Those that live within 40 miles of IFR  
 Those who like broccoli + stilton soups 
 
4.3.2. Basic exclusion criteria 
 Those unwilling/unable to provide urine and blood samples 
 Results of the clinical screening indicate, or are judged by the HNU medical 
advisor to be indicative of a health problem which could compromise the well-
being of the participants if they participated, or which would affect the study 
outcome. 
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 Those whose vein status is assessed by HNU senior research nurse as 
unsuitable for cannulation 
 Known history of fainting when blood samples are taken, feel unwell or faint 
during any clinical study day procedures at the HNU 
 Women who are or have been pregnant within the last 12 months or who are 
breast feeding. 
 Those diagnosed with any long-term medical condition (e.g. diabetes, 
haemophilia, cardiovascular disease, glaucoma, anaemia) or requiring 
medication that may affect the study outcome.  
 Smokers (if smoked within 6 months prior to the study or during the study). 
 Those taking dietary supplements or herbal remedies which may affect the 
study outcome - unless the participant is willing to discontinue taking them for 
1 month prior to starting study. Please note that some supplements may not 
affect the study and this will be assessed on an individual basis 
 Those allergic to any of the ingredients in broccoli + stilton soups  
 Participants allergic to members of the Brassica family, e.g. mustard allergy 
(often combined with sensitivity to mugwort pollen, cabbage and peach) or to 
Brassica pollens (mustard or rapeseed).  
 Those taking any prescribed or non-prescribed medication (short or long 
term), which may affect the study data or participant’s wellbeing. This will be 
assessed by the HNU medical advisor on an individual basis. 
 Those on an anti-coagulant therapy or have had anti-coagulant therapy in the 
past 3 months. 
 Parallel participation in another research project that involves dietary 
intervention  
 Any person related to or living with any member of the study team 
 Participation in another research project, which involves blood sampling within 
the last four months unless total blood from both studies does not exceed 
470mL (unless the participants are willing to wait 4 months and then be re-
screened). 
 Those unwilling to provide GP’s contact details  
 Those unable to provide written informed consent 
 Those not suitable to take part in this study because of the screening results 
 Those who have donated or intend to donate blood within 16 weeks prior to 
the study or during the study 
 Those with a body mass index (BMI, kg/m2) ≤20 or ≥35 kg/m2 
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 Depressed or elevated blood pressure measurements (<90/50 or 95/55 if 
symptomatic or >160/100) 
 Those that have used antibiotics within the previous one month or on long-
term antibiotic therapy. 
 Those who are unable to completely finish the 300g portion of broccoli + stilton 
soup on any of the study days as this will affect study data. 
 
5. Study Procedures 
 
5.1. Randomisation 
The randomization will be undertaken by a third party with the use of an electronic 
randomization generator (www.randomization.com). This uses a method called 
‘second generator’, that creates random permutations of treatments for human 
intervention studies where participants are to receive all of the treatments in random 
order. 
 
5.2. Study Day Preparation (Diet Restriction): 
Participants successfully recruited onto the study will be provided with a list of all the 
cruciferous vegetables to be eliminated from their diet at the eligibility screening (visit 
2). This will involve elimination of ITC-containing foods including all cruciferous 
vegetables, spicy foods and alcohol 48 hours (2 days) prior to the study day and for 
24 hours (1 day) on the study day until the 24 hour blood and urine samples have 
been collected on the following morning. This will mean three days of diet restriction 
per phase and a total of nine days of diet restriction for the duration of the study. This 
diet restriction will continue until the participant’s involvement on the study is 
complete. Based on previous studies, by avoiding food containing ITC precursors for 
at least 24 hours, we can ensure that ITCs will not be found in circulation [38].  
Participants will also be provided with a urine container at the eligibility screening 
(visit 2) to collect their baseline urine sample for study day 1.  
One week before study day 1, participants will be sent a letter or email to confirm the 
study day appointment (Annex 17) and reminding them that they will be in HNU for 
approximately nine hours, to wear comfortable loose clothing and to collect the first 
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urine sample on the morning of study day 1 in the container provided. In addition they 
will be reminded to maintain a diet restriction 48 hours before the study, and asked to 
fast for 10 hours overnight prior to the study day, but will be advised that it is important 
to drink as much plain water as they need during the period of fasting. 
 
5.3. Study Day 1 (HNU-Visit 3)- Phase 1: 
Participants will be asked to come to the HNU between 7:30 am and 8:00am having 
fasted for 10 hours overnight (except for plain water). This is to ensure the cannulation 
is completed while medical cover from the UEA medical service is available. During 
the study day, participants will be provided with the broccoli + stilton soup with two 
slices of bread and lunch. They will also be offered a drink (tea/coffee) and biscuits 
before they leave the HNU at the end of the day. All the meals will maintain the 
glucosinolate restriction. Participants will be given food choices for the lunch (Annex 
18). 
Prior to cannulation, the HNU nurse will complete a CRF (Annex 9) with the 
participant to assess whether there have been any changes in health or medications 
since screening that would affect their ability to continue; and importantly to check if 
they are happy to continue with the study. If participants have consumed ITC 
containing foods, the study day will be postponed. The participant’s blood pressure, 
pulse, weight, height and BMI will be measured and recorded on the CRF. If the 
participant’s blood pressure is <=90/50 or 95/55 (if symptomatic) or 160/100 or above, 
three successive measurements will be taken at 15 minutes intervals as per the HNU 
‘Protocol for action to be taken for hypotensive/hypertensive participants at screening 
and study interventions’. If the blood pressure measurements remain outside the 
inclusion criteria and HNU’s protocol then it will result in the participant being excluded 
from the study. Participants will also be advised to speak to their GP to discuss their 
blood pressure. The nurse will give the participant a copy of the blood pressure 
measurements to take to their GP. The participant’s GP will be sent a letter (Annex 
19) with the BP results notifying them of the exclusion and informing them that the 
participant has been asked to discuss their results with them.  
 
The ITC metabolites will be measured in the blood and urine therefore if female 
participants are menstruating or have just finished menstruating, their study day 
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appointment will be rescheduled 7 days after their periods has ended, as blood in the 
urine will affect the study data.  
 
 Baseline Urine Sample 
A baseline urine sample will be collected by the participant at home on the morning 
of the study day in the urine container provided prior to the study day. If the 
participant has forgotten to bring the sample with them, they will be offered the 
opportunity to provide a urine sample at the HNU. This urine sample will be counted 
as the baseline urine sample (timepoint 0). 
 
 Baseline Blood Sample 
The baseline blood sample will be taken after the CRF has been completed and the 
participant is deemed eligible to proceed in the study. The HNU nurse will cannulate 
the participant using a sterile intravenous cannula of appropriate gauge for the vein 
(as assessed by HNU senior research nurse). A tube fitted with an integral 3-way tap 
will be flushed with approximately 0.2ml normal saline for injection to eliminate the air 
before attaching it to the cannula. The connection tube will allow blood samples to be 
taken using the 3-way tap, thus minimising risk of contamination to the iv site and risk 
of infection. Once the cannula has been checked, it will be fixed in place using a 
transparent sterile dressing to enable the nurse to observe the cannulation site for 
swelling/redness during the study day. Prior to the baseline sample being taken, the 
saline will be drawn back using a syringe and discarded. The baseline blood sample 
(time point 0) of 10ml will then be taken. The i.v.cannula will be flushed with a 
minimum of 5ml of normal saline to clear the line and maintain patency of the cannula. 
Occasionally, more than 5ml is required to clear the cannula therefore, up to 10ml of 
sterile normal saline may be used to clear the line. Flushing of the cannula will 
continue after each subsequent blood sampling and as required between sampling 
during the study day to maintain patency of the cannula. Occasionally, it is not 
possible to cannulate at the first attempt or the cannula may become blocked during 
the study day, and therefore the cannula may need to be re-sited.  In the event that 
either of these situations arises one further attempt will be made to cannulate a vein. 
The cannula may need to be re-sited either initially or during the study day if patency 
is not maintained. However, if it is not possible to re-site the cannula and if there are 
only two blood samples left to take, the HNU senior research nurse will assess the 
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situation and if the participant is in agreement the last two samples may be taken as 
individual blood samples using a butterfly needle. If there are more than two samples 
that remains to be taken and the cannula cannot be resited then the study day will be 
stopped and the participant will be withdrawn from the study. The HNU senior 
research nurse is experienced at performing cannulation and the relevant techniques 
associated with maintaining patency and blood sampling via a cannula. 
 Consumption of Study Soup 
One pot (300g) of broccoli + stilton soup will be heated and two slices of bread 
(brown/white) with 20g or 2 portions of butter or margarine will be provided to 
participants to consume once the baseline blood sample has been taken. The 
participants will be permitted to consume up to 250 ml of water over the next 2 hours.  
After 2 hours, they will be allowed to drink as much water as they like, which will be 
measured and recorded.   
A member of the study team will record the time after consumption of the soup. 
Throughout the study day, participants will be advised to drink plenty of plain water to 
stay hydrated. Ten 10ml blood samples will be collected at the following time points: 
0, 30, 45, 60, 90, 120, 180, 240, 360, 480 mins. 
Total blood volume collection per study day 1= 100ml [10ml × 10 (including baseline 
blood sample)] 
Participants will be provided with 4 containers, with powdered ascorbic acid as a 
stabilising agent to collect their urine samples over the 24 hours labelled as: 0-2, 2-4, 
4-6 and 6-8 hours.  
Participants will be provided with a study specific glucosinolate-free lunch 5 hours 
after the consumption of the soup. The lunch will consist of approximately 130g of 
tuna, or 80 g of cheese made into sandwiches using 2 or 4 slices of brown/white 
bread, with or without butter/margarine and/or mayonnaise (2 tsp or 10 g each). In 




























Figure 6: Schematic diagram of timepoints for breakfast and lunch 
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Following the last blood sample the cannula will be removed and the cannulation site 
dressed with a sterile gauze dressing. Participants will be offered a drink (tea/coffee) 
and biscuits before they leave the HNU. A container will be provided for the 24 hour 
urine collection (8-24 hours). Participants will be reminded to maintain their 
glucosinolate diet restriction until after their 24 hour urine and blood sample have 
been collected the following morning. 
The participants will be required to attend the HNU the following morning (visit 4) to 
provide a 24 hour blood sample and hand in their 24 hour urine sample, which would 
have been collected up to the morning.  
5.4. 24 hour samples (HNU-Visit 4)- Phase 1: 
Having fasted again overnight for 10 hours (except for plain water), participants will 
be required to attend the HNU within 24 hours of consumption  of the broccoli + stilton 
soup to have their 24 hour blood sample (10ml) taken. This appointment where the 
24 hour samples will be collected will last approximately up to 1 hour at the HNU and 
will include breakfast. The 24hr blood sample will be taken by venepuncture using a 
butterfly needle from a suitable vein in the participant’s arm. The procedure will be 
carried out by an appropriately trained HNU nurse. Their 24 hour urine sample will be 
handed over to a member of the study team. Following the blood sample, participants 
will be offered and encouraged to have a standard HNU breakfast. This will signify 
the end of study phase 1. Participants will be free to leave after they have finished 
their breakfast (cereal/ 2 slices of bread or toast with 20g (or 2 portions) of 
butter/margarine, coffee/tea) and will be booked in to attend study day 1 for phase 2 
after a minimum of a two week washout period. Participants will be reminded to start 
a glucosinolate free diet 48 hours prior to phase 2 (study day 1). A list of all the foods 
that need to be excluded will be provided if necessary. 
5.5. Study Days(HNU-Visit 5-8)-Phase 2/Phase 3: 
Study day procedures for phase 2 and phase 3 will be the same as phase 1. The only 
exception is that participants will be given a different broccoli + stilton soup for each 
phase. 
5.6. Completion of the study 
After the 24 hour blood sample collection and urine collection of phase 3, participants 
will have completed the study. They will be informed that they no longer need to follow 
a glucosinolate-free diet. Participants who were recruited through advertisements will 
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be asked if they would consent to be contacted about future studies on broccoli (or 
similar) that may be undertaken at IFR (Annex 20).  
 
6. Adverse Events (AE) and Serious Adverse Events/Suspected 
Unexpected Serious Adverse Reactions (SAEs/SUSARs) 
The IFR complies with the National Research Ethics Service (NRES) and International 
Conference on Harmonisation –Good Clinical Practice (ICH-GCP) rules and the 
appropriate NRES form will be used to report the occurrence of serious adverse 
events and suspected unexpected serious adverse reactions. All adverse 
events/reaction and SAEs will be reported in the participant-specific case report form 
(Annex 9). The report will include, the nature of the event, severity (mild, moderate 
or severe), and relationship to the study (definitely, probably, possibly, not related). 
Advice will be given by the HNU medical advisor as to the cause, relationship and any 
required further action (depending on the type of reaction); duration (dates and times), 
interventions and outcomes. 
According to ICH GCP a serious adverse event (SAE) is defined as an untoward 
occurrence that: 
 Results in death 
 Is life threatening 
 Requires hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability or incapability 
 Is otherwise considered medically significant by the investigator 
 
Any adverse event/reaction or a serious adverse event/reaction will only be recorded 
if they have occurred whilst the participant is on the study. The Chief Investigator will 
report all SAEs to the research ethics committee (REC) and human research 
governance committee (HRGC) as soon as they become aware, using the standard 
NRES form. Reports of SAEs will be provided to the REC within 15 days of the event 
being reported to a member of the study team. Once the incident has been resolved, 
both REC and HRGC will be informed of the outcome. The participants are asked 
questions relating to allergy at the eligibility screening to minimise the risk of any 
adverse events or reactions. 
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7. Study soup 
The order in which the participants will consume their soups over the three phases 
will be decided randomly. All participants will consume all three soups containing: 
 standard broccoli + stilton providing 43 μmoles/300g  glucoraphanin,  
 glucoraphanin-enriched broccoli + stilton- Beneforte® providing 180 
μmoles/300g  glucoraphanin) 
 Beneforte extra broccoli + stilton providing 442 μmoles/300g of glucoraphanin 
The reported levels of glucoraphanin in the three types of soups come from analysis 
undertaken in February 2014 [Figure 7]. 
As mentioned in section 1.4 Beneforte® and Beneforte extra have been developed 
by conventional breeding. Standard broccoli, Beneforte® and Beneforte extra all have 












Figure 7: Bar graph showing levels of Glucoraphanin in the three types of soups 
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7.1. Supply of study soup 
Three types of broccoli soups: (i) standard, (ii) Beneforte® and (iii) Beneforte Extra 
will be prepared by Bakkavor, a leading international producer of fresh prepared foods 
[Figure 8]. The standard, Beneforte® and Beneforte extra broccoli soups we will have 
one recipe (+ stilton cheese). Ingredient declarations, nutritional information and 
allergy statements for the three broccoli + stilton soups have been provided from the 
producer (Annex 21). Bakkavor will make the soup, freeze them and then arrange for 
them to be delivered directly to the IFR. On arrival at IFR, the temperature of the 
soups will be checked and recorded by a member of the study team before they are 
unloaded and placed in the freezer. The soups will be stored in a dedicated food 
freezer at the HNU and member of the study team will monitor and record the 
temperature of the freezer on a daily basis to comply with HACCP (Hazard Analysis 
Critical Control Point).  
 
 
Figure 8: Broccoli + stilton soups provided by Bakkavor will be packed in a carton 
designed to freeze soups in individual portions. 
 
7.2. Preparation of study diet 
The broccoli + stilton soups will be heated by the study scientist using a microwave in 
the HNU kitchen, using instructions provided by Bakkavor then given to participants 
for consumption. Participants are expected to finish the whole portion of soup. Two 
slices of bread with butter or margarine spread will be provided. The time taken by 
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each participant to consume the soup will be noted by a member of the study team. 
Once the soup is finished the time will be noted, which will commence the 24 hour 
period.  
7.3. Preparation of food 
The study soups, HNU standard breakfast and study specific lunch will be handled or 
prepared in the HNU diet kitchen by study team members who have completed formal 
Level 2 training in food safety and the IFR in-house food hygiene training module 
included in the IFR Human Studies Training Program. All food preparation is carried 
out in the HNU diet kitchen in compliance with Environmental Health Guidelines. The 
HNU diet kitchen is registered with the local Environmental Health Office. All foods 
used in the breakfast and lunch are commercially available foods purchased in local 
supermarkets. 
 
8. Experimental method 
 
8.1. Blood sampling and processing 
All venepuncture blood samples will be collected using a butterfly needle at the 
screening (15ml) and the 24 hour blood samples (10ml). Blood samples (10ml) 
collected on the study days will be collected via an intravenous cannula unless the 
last two samples are taken by venepuncture due to the cannula needing to be 
removed. 
Total blood volume collection for whole study= (110ml × 3 phases) + 15ml from 
screening 
       = 345ml (unless participant is re-
screened thus up to 355ml of blood could be collected) 
Blood samples will be transferred to tubes containing EDTA anticoagulant, mixed well 
by inversion and the tubes will be centrifuged (1000 x g, 15 minutes, room 
temperature) for plasma separation. Aliquots of plasma will be stored at -80 °C and -
20°C until analysis of SF and its metabolites are performed. 
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8.2. Urine sampling and processing 
Participants will be given appropriately labelled specimen containers for their mid-
stream morning urine samples. For their collection over 24 hours (0, 0-2, 2-4, 4-6, 6-
8 and 8-24 hours), a number of pre-labelled containers containing 1g of powdered 
ascorbic acid as a stabilising agent will be provided. The participants will be advised 
to keep the containers containing urine samples they collect at home away from 
children and pets. If they accidentally get powder on their skin they  will be told to 
wash it off as soon as possible.  
The total volume of urine collected will be recorded, from which 10ml sub-samples 
will be taken and stored at –80 °C until analysis. The remaining urine will be discarded. 
8.3. Genotype determination 
From the 15ml of blood sample collected at the participant’s eligibility screening visit, 
5 ml will be used for genotyping. The genomic DNA will be extracted from the blood 
sample using the QIAamp DNA Mini kit protocol (Qiagen Inc.) prior to genotyping for 
GSTM1 and other associated genotypes (e.g. GSST1)  using real-time PCR 
according to the method of Cotton et al. [146], and others. These blood samples will 
be stored at IFR. All genotyping analysis will be carried out at IFR. 
8.4. Quantification and profiling of ITC levels in blood and urine 
 
8.4.1. Cyclocondensation Assay 
Total SF and it conjugates (glutathione, cysteine-glycine, cysteine and N-acetyl 
cysteine) will be measured in plasma and urine samples using a method called 
cyclocondensation assay [61]. SF and its metabolites will be then identified by LC-MS 
analysis (as described below).  
 
8.4.2. LC-MS 
SF and its conjugates (glutathione, cysteine-glycine, cysteine and N-acetyl cysteine) 
in the urine and plasma sample will be measured by a validated liquid 
chromatography-mass spectrometry method in Gasper et al [38].  
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8.4.3. ICP-MS 
Plasma will be sent to the University of Nottingham for analysis of plasma sulphur and 




All participants will be assigned a unique code number at screening. A lockable filing 
cabinet or cupboard will be used to keep paper documents and participants’ personal 
data. The file that links the participant to the code and personal information will also 
be kept in a locked filing cabinet but separately to all the other documents. All 
electronic data will be stored on a password protected shared data file between the 
study team on IFR computers. The main computer storage will be on one main IFR 
computer, but as part of a password protected shared network. All IFR computers are 
individually password protected and the shared network access is limited to those 
working within the research area. Manual files/folders will consist of coded files for 
each participant. No data with the participants’ name will be filed in the numbered file. 
Confidential data will be accessed only by the members of the study team, HNU 
nurse, HNU medical advisor, UEA doctor providing emergency cover, participant’s 
GP and CI. The participant’s GP will have access to personal data. The samples sent 
to the SPIRE hospital for biochemical analyses (full blood count, U’s + E’s and other 
laboratory facilities) will be known only by their code number. All data collected will 
also be identified by code only.  
Data will be stored for at least 15 years after completion or discontinuation of the 
study. The data will be stored in the IFR human studies archive. Access to archived 
data will be limited to the members of the study team and CI or the CI's successor. 
The quality assurance auditors may also be allowed access to data with the 
permission, and in the presence, of the CI however they will not have access to the 
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10. Statistical Analysis  
 
10.1. Sample size calculation 
To detect a significant (P<0.05) difference in mean total urinary thiol excretion of 18 
μmol between consumption of normal broccoli + stilton soup and Beneforte® broccoli 
+ stilton soup, the study requires ten participants giving a power of 80%. The SD of 
the differences between the two groups was estimated to be 17 μmol. The basis for 
this calculation was preliminary unpublished data from 65 subjects on the ENGAGE 
study (12/EE/0483). 
 
10.2. Data analysis 
Data will be analysed using mixed effects models. These are linear models that 
account for the non-independence of the type of data that will be generated in this 
cross-over study (i.e. data that come from the same participants after different 
interventions). Some variation in the outcome measures will come from the genotype 
of the participants and allowances will be made for that by including it as an 
explanatory variable in the model. The aim of the analysis will be to examine whether 
the intervention(s) have any effect on the various outcome measures (e.g. urinary 
excretion of total thiol conjugates, pharmacokinetic parameters generated from the 
time course of plasma samples). 
 
11. Ethical considerations 
 
Food safety: IFR follows Environmental Health Guidelines for the storage and delivery 
of all food to IFR. These guidelines will be adhered to when processing and handling 
all food items. 
 
Toxicity: There is no evidence from animal or human studies that broccoli is harmful.  
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The level of glucoraphanin that will be consumed in the broccoli + stilton soups with 
the highest concentration will be similar to that being consumed in the current 
intervention study (ESCAPE, REC Ref Number 13/EE/0110). 
 
Cannulation/Phlebotomy: As with all procedures involving venepuncture the 
participants may feel a little discomfort on initial insertion of the intravenous cannula 
needle on the study day or the butterfly needle for single blood sampling, however, 
once the cannula/needle is in the vein there should be minimal or no pain. A small 
bruise may develop at the venepuncture/ cannula insertion site but, as with all bruises, 
this should fade after a few days. The HNU nurses are experienced in undertaking 
these procedures, therefore, the risks associated with these procedures are minimal. 
The well-being of the participants will be monitored by the HNU nurses throughout the 
study day and they are trained to deal with medical emergencies. A doctor from the 
UEA Medical Centre will also be contactable to provide medical support if the 
participant becomes unwell on the study day. 
 
Allergies/sensitivity/dietary requirements: The participants are asked about any 
known allergies/dietary requirements they may have at the study talk and by the nurse 
at the eligibility screening and on each study day. This information is documented on 
their screening questionnaire and the CRFs. Anyone who has a known 
allergy/sensitivity to any of the contents of the broccoli + stilton soups will be unable 
to participate in the study. If any participant demonstrates any signs of possible 
allergy/sensitivity to the soup whilst on the study, they will be withdrawn from the study 
at that point. Information regarding the contents of the soup will be given to 
participants in the PIS. 
 
12. Participants’ expenses/payments 
 
Each participant will receive a pro rota inconvenience payment for their participation 
in the study. The breakdown of the payment is outlined below: 
Screening appointment: 
Mid stream Urine sample                                                                            £2.00 
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Single venous blood sample                                                                      £5.00 
Total per screening = £7.00 (This could be £12.00 if a blood re-screen required and 
£9.00 if a urine re-screen is required) 
Each phase of the Study: 
Three days of a restricted diet (no GSL and ITCs)                                  £15.00 
Morning urine sample (Day 1)                                                                    £2.00 
24 hour urine collection (Day 1-2)                                                            £10.00 
Insertion of cannula                                                                                  £15.00 
£3 per hour cannulated (x 8 hours )                                                         £24.00 
Single venous sample (1 sample at £5)                                                     £5.00 
Inconvenience payment                                                                           £94.00 
Total per phase =                                                                                   £165.00 
The total expenses for each participant per 3 phase study will be =      £495.00 
Total expense for whole study including screening (excluding re-screens) = 
£502.00  
Participants will be reimbursed travel expenses to and from the HNU (at IFR). This 
will be reimbursed at the IFR's current mileage rate which is currently 45p per mile or 
by reimbursing public transport costs on production of a ticket or receipt. If participants 
require transport, this is provided by IFR as a taxi and is paid for by the study. 
 
13. Study partners 
The study will be funded by a Biotechnology and Biological Sciences Research 
Council (BBSRC) institute strategic programme grant (BB/J004545/1), BBSRC 
Doctoral Training Patnership grant (BB/J014524/1) and an award by the Prostate 
Cancer Foundation. 
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Annex 1- Invitation letter from HNU database         Version 2-BOBS 29th July2014 




Thank you for your interest in 
The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
at the Institute of Food Research 
I have sent you details of this study which is in progress at present as your details 
currently held on the database indicate that you may fit the criteria. If you are 
interested in participating, please complete and return the reply slip on the enclosed 
participant information sheet (PIS). If you have any further questions about the 
study, please contact, Tharsini Sivapalan on 01603251425 
(tharsini.sivapalan@ifr.ac.uk ) or Dr Antonietta Melchini on 01603 255030 
(antonietta.melchini@ifr.ac.uk) or as stated on the enclosed participant information 
sheet. 
If, however, any of your details have changed or change in the future, or you would 
prefer to no longer remain on the database, please could you inform the Human 
Nutrition Unit on 01603 255305. 
Thank you.  
Yours sincerely, 
Mrs Aliceon Blair 
HNU senior research nurse 
Norwich Research Park, Colney, Norwich NR4 7UA, UK  
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723 
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You are being invited to take part in a research study. Before you  decide it is important 
for you to understand why the research is being done and what it will involve for you. 
Please take time to read the following information       carefully. Talk to others about the 
study if you wish. 
 Part 1 tells you the purpose of this study and what will happen if you take part 
 Part 2 gives you more detailed information about how the study will be    
conducted 
Please ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
This information sheet is yours to keep. 
Thank you for reading this. 
Study scientist contact details: 
Miss Tharsini Sivapalan                          Dr Antonietta Melchini                                                                                                       
 (0)1603 251 425                                                    (0)1603 255 030                                                             
tharsini.sivapalan@ifr.ac.uk                          antonietta.melchini@ifr.ac.uk 
Chief investigator (CI) 
Professor Richard Mithen 
(0) 1603 255 259 
richard.mithen@ifr.ac.uk 
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PART 1 of the information sheet  
What is the purpose of this study? 
There is current evidence that suggests eating cruciferous vegetables like broccoli, 
cauliflower, cabbage is beneficial to our health as they contain compounds which are 
thought to reduce the risk of diseases such as cancer and    cardiovascular diseases. 
These compounds are called glucosinolates (GSLs) and more than 100 different 
GLSs are known to occur naturally in  cruciferous vegetables. 
 
Broccoli is a rich source of a GSL called 
glucoraphanin. When we eat broccoli, the bacteria in 
our gut break down the glucoraphanin to another 
natural compound called sulforaphane (SF). It is 
thought that broccoli is good for our health because of 
the effect of SF in our body.  We rely on our bacteria to 
do this even though the vegetable itself has proteins 
called Myrosinase which can convert GLS to SF. This 
myrosinase is however, destroyed when the broccoli is cooked. 
What we aim to do? 
We want to find out how SF is absorbed and metabolised by our bodies after    
eating three types of broccoli + stilton soups.   
We would like participants to eat one portion (300g) of broccoli + stilton soup on 
three separate days. We will then collect blood and urine samples over the course of 
the three days to measure the levels of SF and its metabolites. 
The three types of soups are: 
 Standard broccoli + stilton 
 Beneforte® broccoli +stilton - glucoraphanin-enriched broccoli  
 Beneforte extra broccoli + stilton- higher levels of glucoraphanin than 
Beneforte®  
The Beneforte® and Beneforte extra have been developed by conventional 
breeding so they are not genetically modified.  
The Beneforte® broccoli contain 2-3 times higher levels of the glucoraphanin. 
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This study will be a cross-over, double-blinded, randomised study and will be 
carried out at the Human Nutrition Unit (HNU) of the Institute of Food       Research 
(IFR).  
Cross-over trial: means that each participant will have a different broccoli + stilton 
soup in each phase. There are a total of three phases (three study days) in this study 
which will be separated by a minimum of two weeks (washout   period).  By the end 
of the study you would have consumed all three soups.  
Randomised trial: This means that the order in which you eat the soup will be 
randomly allocated. A computer program is used for the random allocation of the 
broccoli + stilton soup. Thus neither the scientist nor you can choose in which order 
you eat the three types of broccoli + stilton soups.   
Double-blinded trial: This means that the scientist nor you will know which of the 
three broccoli +stilton soups you will be eating at each study day. 
To investigate the aim of our study, we will need to collect: 
 urine samples  
 blood samples              
From the blood and urine samples, we will analyse the SF concentrations to 
understand how it is metabolised over 24 hours after eating the three types of broccoli 
+ stilton soups. 
 
Genotyping 
We all have about 25,000 genes.  Many of these genes have subtly 
different versions, which is why we all look slightly different to each other. 
The term genotype is used to describe which version individuals have. 
How beneficial certain vegetables may be for   different people may 
depend upon what genotype they have.  
This study will involve genetic analysis of your blood to see what genotype you have 
for two specific genes from the group of genes called GST (glutathione-S-
transferases). This analysis may help us understand how the body absorbs and 
excretes SF in the plasma and urine changes between different people.   
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It is important to stress this genetic analysis has no clinical relevance to you 
or your family nor will we be able to tell you whether you have the genes. 
 
Who can take part in the study?  
We are aiming to recruit: 
Women and men aged 18-65 years 
Non-smokers 
Those who live within 40 miles of IFR 
Those who like broccoli + stilton soup 
 
Who cannot take part in the study?  
You cannot take part in this study if: 
You are unwilling/unable to provide urine and blood samples 
Results of the clinical screening indicate, or are judged by the HNU medical 
advisor to be indicative of a health problem which could compromise your well-
being if you participated, or which would affect the study outcome. 
Your vein status is assessed by HNU senior research nurse as unsuitable for 
cannulation 
You have a known history of fainting when blood samples are taken, feel unwell or 
faint  during any clinical study day procedures at the HNU 
You are or have been pregnant within the last 12 months or you are breast 
feeding. 
You have been diagnosed with any long-term medical condition (e.g. diabetes, 
haemophilia, cardiovascular disease, glaucoma, anaemia) or requiring medication 
that may affect the study outcome. 
You smoke (or have smoked within 6 months prior to the study or during the 
study)  
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You are allergic to any vegetables of the Brassica family, e.g. mustard allergy 
(mugwort pollen, cabbage and peach) or to Brassica pollens (mustard or rapeseed).  
You are allergic to any of the ingredients of the broccoli +stilton soups  
You are taking dietary supplements or herbal remedies which may affect the study 
outcome - unless you are willing to discontinue taking them for 1 month prior to 
starting study. Please note that some supplements may not affect the study and this 
will be assessed on an individual basis. 
If you are taking any prescribed or non-prescribed medication (short or long term), 
which may affect the study data or your wellbeing. This will be assessed by the HNU 
medical advisor on an individual basis. 
You are on an anti-coagulant therapy or have had anti-coagulant therapy in the 
past 3 months. 
You are participating in another research project, that involves dietary intervention  
You are related to or living with any member of the study team 
You are participating in another research project, which involves blood sampling 
within the last four months unless total blood from both studies does not exceed 
470mL (unless you are willing to wait 4 months and then be re-screened). 
You are unwilling to provide GP’s contact details  
You are unable to provide written informed consent 
You are not suitable to take part in this study because of the screening    results 
You have donated or intend to donate blood within 16 weeks prior to the study or 
during the study 
You have a body mass index (BMI, kg/m2) <20 or  >35 kg/m2 
You have depressed or elevated blood pressure measurements (<90/50 or 95/55 
if symptomatic or >160/100) 
You have used antibiotics within the previous one month or on long-term antibiotic 
therapy. 
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You are unable to completely finish the 300g portion of broccoli + stilton soup 
portion on any of the study days as this will affect study data 
 
Why have I been invited?  
You have been invited to take part either because: 
 your details are currently registered on the IFR Human Nutrition Unit (HNU)    
database suggest that you may be able to take part in the study or, 
 you responded to an advertisement for the study    
 
Do I have to take part?  
Taking part in this study is completely up to you. If after reading this information 
sheet, you would like to take part then you should send in the response slip (page 21) 
using the pre-paid envelope and if you wish you can also contact a member of the 
study team named on the front page. If you do not wish to take part in the study, then 
please ignore the letter sent to you and no one will contact you about joining the study. 
Expressing an interest in the study does not mean that you are obliged to take part. 
You are free to withdraw from the study at any time, without giving a reason. A 
decision to withdraw or not to take part will not affect your participation in future 
studies or being contacted to take part in other IFR studies if you are on the HNU 
volunteer database.  
 
What next?  
When you have sent in your response slip, a member of the study team will contact 
you to book an appointment for you to come to the HNU for the study talk. You will 
be asked to come to the HNU for 8 visits (see flowchart on p12): 
VISIT 1- Study talk ~  approximately 1 hour  
VISIT 2- Eligibility screening ~ approximately 1-1½ hours including breakfast 
VISIT 3- Study Day 1- Phase 1 ~ approximately 9 hours at the HNU 
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VISIT 4– 24 hour samples- Phase 1 ~ approximately up to 1 hour including 
breakfast 
VISIT 5-8- Study Days- Phase 2-3 will be the same as visit 3 and 4 
 
We will try to book the screening and study day appointments at a time that is as 
convenient as possible for you but they will take place on weekdays. On the study 
days you will be required to come to the HNU between 7:30am and 8:00am and 
you will have to stay at the HNU for approximately 9 hours. 
 VISIT 1-Study Talk 
A member of the study team will contact you to book an 
appointment to invite you to the HNU for a talk about the study. 
The study talk will last approximately 1 hour. At the talk a member 
of the study team will go through this information sheet, the 
procedures and your involvement in this study.  You will be 
encouraged to ask any questions that you may have at the time. You will be able to 
speak to the HNU senior research nurse if you have any questions relating to 
cannulation, venepuncture or any of the clinical measurement prior to making any 
commitment. 
After the talk you will be given a minimum of 72 hours (3 days) to decide whether you 
wish to take part in the study. During this time we will not contact you. If you wish, you 
can talk to your family, friends or GP about the study. After 3 days if you decide to 
take part then you will need to contact a member of the team to book a screening 
appointment. At the end of the study talk we will give you a container which will be 
used for the collection of the urine sample on the morning of the eligibility screening 
visit should you decide to take part in the study.   
If you do not want to take part then you will not need to contact us, we will not contact 
you and you can dispose of the container given to you at the talk. 
Not taking part will not affect you being approached for future studies at IFR if you are 
registered on the HNU database.  
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 VISIT 2- Eligibility Screening 
This appointment will last approximately 1-1½ hours.  
You will need to bring a fresh midstream urine sample with you in the container 
provided at the study talk. This sample has to be produced within 2 hours of your 
appointment as this is required for the urine test to work. It is important for the urine 
dipstick test results and study analysis that you do not use any containers other than 
the ones given to you during the study to collect your urine. If you lose the container 
or forget to bring your urine sample, you will have another opportunity to produce a 
sample at the HNU. 
What will happen at the screening?  
On arrival at the HNU you will be met by a member of the study team 
and taken to a confidential room where we will ask you to sign a consent 
form to say that you have understood what the study involves and that 
you agree to take part in the study. If you were recruited through adverts, 
then you will be asked to sign another consent form on completion of the 
study to ask if you would agree to be contacted about future studies on 
broccoli or similar. Completion of this consent to contact form is optional.  
Please note: Participants already registered on the HNU volunteer database will 
be automatically contacted for future broccoli studies if your details fit the 
inclusion criteria. 
A member of the study team or the HNU senior research nurse will also sign the 
consent form and you will be given a copy to keep. After signing the consent form, 
you are still free to withdraw at any time without giving a reason.  
In addition, you will also be asked to sign a medications declaration form agreeing to 
inform a member of the study team of any medication you may have to take, or if you 
become unwell or pregnant whilst on the study. You will be given a copy to keep. 
After consent is signed, the HNU nurse will carry out the urine dipstick test on your 
sample.  The results will be known immediately and if any of the urine test results are 
‘flagged’ the HNU nurse will explain this to you. Flagged means that the results do not 
match one or more of the standard test results and may mean you need to come back 
for a re-screen or may be excluded from the study.  If any of the urine results are 
flagged the nurses will refer to the HNU Protocol ‘For the referral of abnormal 
urinalysis results at screening’ which provides advice on exclusion or re-screening of 
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the participant. This protocol has been authorised by the HNU medical advisor. You 
will also be advised to speak to either the nurse at your surgery or your GP to discuss 
the results and you will be given a copy of your urine results to take with you to the 
surgery. 
The HNU nurse will complete an eligibility questionnaire and a case report form with 
you. 
The HNU nurse will measure and record your: 
 -  Blood pressure (BP) 
 -  Pulse 
 -  Height (cm)  
 -  Weight (kg) 
 -  Calculate BMI (kg/m2) using your height and weight 
Your BMI indicates whether you are a healthy weight for your height; if your BMI is 
below 20 or above 35, you will be excluded from the study. 
As we need to insert a cannula into one of your veins in your arm for the study day 
and take a blood sample the day after is important that your veins are suitable for 
these procedures. Before taking the screening blood sample the HNU nurse will 
assess the veins in your arms to see whether they are suitable for cannulation. If the 
nurse does not find a suitable vein for cannulation, you may be excluded from the 
study. 
If the eligibility screening results (dipstick urine, screening questionnaire, blood 
pressure, pulse and BMI) are within the range for the study and you are happy to 
continue, the nurse will take a 15ml (approximately 3 teaspoons) blood sample from 
a vein in your arms. 10ml (equivalent to 2 teaspoons) of the blood will be sent to the 
SPIRE Hospital for analysis of full blood count (FBC), urea and electrolytes (Us + Es) 
and HbA1c. The HbA1c test will provide us with a picture of your average blood 
glucose levels over a period of about 3 months. 
In addition, 5ml (equivalent to 1 teaspoon) will be stored at IFR to be used for genetic 
analysis.   
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The HNU nurses are trained and experienced in carrying out the clinical procedures. 
Please ask them if you have any questions about the tests or procedures. 
Your GP will be notified of your participation in the study and will be sent all copies of 
your clinical screening results (urine results, blood results, blood pressure, BMI and 
weight). You are agreeing to this when you sign the consent form. 
If any of your clinical results are outside the standard reference ranges we may 
recommend that you speak to your GP about the results. All results outside the 
reference ranges are checked by the HNU medical advisor. The medical advisor will 
decide whether we may include you in the study, offer you the opportunity of a second 
screening (re-screen) or exclude you from taking part in the study.  
If you do return for a re-screen and your results fall outside the standard reference 
ranges on the second occasion, you may be excluded from the study depending on 
the results flagged. We cannot tell you what your results may mean as we are not 
medically qualified to do so. You should not worry if your results are flagged as it may 
be a one off result or it may be perfectly normal for you, but your GP will be able to 
explain them to you. Please remember these tests are performed to determine if you 
are suitable for the study, not to find out if you are healthy.  
You will be excluded from the study if the results of any of the screening tests are 
judged by the medical advisor to be unsuitable for your participation.  
If the results of your screening indicate that you are eligible to take part in the study 
you will be contacted by a member of the study team to arrange a date for your first 
study day. You will be provided with a urine container at the screening to collect your 
urine sample for the study day and a list of foods that will need to be eliminated from 
your diet for 48 hours (2 days) before the study day and throughout the study 
intervention phase until the 24 hour blood sample has been collected the following 
morning. 
Before study day: 
 Eliminate all foods high in glucosinolates (list of food to avoid on page 19), 
spicy food and alcohol from your diet 48 hours prior to the study day. We 
understand it is not easy to remember everything therefore, if you have 
accidentally consumed any food high in glucosinolates during the 48 hour 
restriction period please tell us as we will postpone the study day.  
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 Fast for 10 hours prior to the study day and drink plenty of plain water 
during the fast. 
 
 
 VISIT 3- Study Day 1 
A study day will approximately last for 9 hours and you will be required to stay in the 
HNU for the duration of the study day. 
-Morning of study day: 
On the morning of the study day, collect a sample of urine in the container that was 
provided at the screening. This sample will be used as your baseline. If you forget to 
bring your sample, you will have an opportunity to collect a sample at the HNU. 
Once you arrive at the HNU, you will hand your sample over to a member of the study 
team. The HNU nurse will then complete a case report form with you to check that 
you have not had any health problems or change of medication since your screening 
appointment. The nurse will also measure and record your blood pressure, height, 
weight and calculate your BMI. If your blood pressure measurement is outside the 
range for the study the nurse will take three further measurements at ten minute 
intervals. If your blood pressure measurement remains outside the range for the study 
you will be withdrawn from the study or if there are indications that your well-being 
maybe affected by any of the clinical procedure. If female participants are 
menstruating or have just finished menstruating, their study day appointment will be 
rescheduled 7 days after their period has ended. 
If your blood pressure measurement is satisfactory for the study the HNU nurse will 
insert a cannula into a vein in one of your arms. A short clear tube will be attached to 
the cannula to allow the nurse to take the blood samples from the cannula throughout 
the day. Once in place the nurse will flush via the connecting tube with sterile normal 
saline to check it is in position and check that you are comfortable. The normal saline 
will then be withdrawn back through the tube attached to the cannula and discarded, 
the first study blood sample will be collected. This first blood sample is called the 
baseline sample (0 hours). After the first blood sample and all other blood samples 
taken through the cannula during the day, the HNU nurse will flush the tube and 
cannula with sterile normal saline to stop it becoming blocked.  
If the cannula blocks during the study day the nurse may have to remove it and insert 
another cannula into a different vein in your arms. However, if there are only two blood 
samples left to take, the HNU nurse will assess the situation and if you agree the 
Annex 2-Participant Information Sheet  Version 4-BOBS 10th November 2014 
277 | P a g e  
nurse may be able to take them as individual blood samples using a butterfly needle 
the same as the way the blood was taken for your screening. The cannula site will be 
covered with a sterile dressing to protect it during the day. If there are more than two 
samples that remain to be taken and the cannula cannot be resited, then the study 
day will be stopped and you will be withdrawn from the study. 
After the baseline blood sample has been taken you will be given one 300g pot of 
broccoli + stilton soup to eat with two slices bread (brown/white) with butter or 
margarine. You will also be able to drink up to 250ml of water over the next 2 hours. 
After 2 hours, you will be allowed to drink as much water as you like which will be 
recorded. After 5 hours, you will be provided with a study specific lunch consisting of 
tuna or cheese sandwiches made with 2-4 slices of brown/white bread, with or without 
butter/margarine and/or mayonnaise in addition to the offer of a banana and a natural 
yoghurt.  
You will need to eat the study specific lunch on each of the study days. 
During the whole study day, a total of ten blood samples will be collected at the 
following time points: 0, 1/2, 3/4, 1, 1.5, 2, 3, 4, 6, 8 hours.  
You will also be asked to provide five individual urine samples during the study day 
at 0, 0-2, 2-4, 4-6, 6-8 hours. It is important that you drink enough water throughout 
the day so you can produce all five samples. 
After the last blood sample has been collected the HNU nurse will remove the cannula 
from your arm and cover the puncture site with a sterile gauze pad. You will be offered 
a drink (tea/coffee) and biscuits. You will be provided with a urine container and asked 
to collect all of your urine (8-24 hours) until the following morning (before your 
appointment at the HNU). After which, you will be able to leave the HNU provided the 
HNU nurse has checked that you are well. 
You will also need to eliminate food high in glucosinolates, spicy food and alcohol until 
you have had your 24 hour blood sample taken on the morning (list of foods to avoid 
at page 19). 
 VISIT 4– 24 hour samples 
The appointment that you attend at the HNU for sample collection 24 hours after 
consuming the broccoli soup, will last approximately up to one hour. 
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 You will have fasted overnight again for 10 hours (except for plain water) 
 You will need to bring the 8-24 hour urine collection with you to the HNU 
 You will need to arrive at the HNU within 24 hours of eating the soup to have 
your 24 hour blood sample taken. After this sample has been taken you will 
be offered and encouraged to have a standard HNU breakfast (cereal, toast, 
tea/coffee)  
After breakfast, you will be able to leave the HNU. You will be able to follow a normal 
diet for a minimum of two weeks until your 48 hours prior to your phase 2 appointment. 
 
 VISIT 5-8- Study Days for phase 2-3 
The study procedure for phase 2-3 will be exactly the same as phase 1 consisting of 
a study day 1 and 24 hour sample. The only difference is that you will be given a 
different broccoli + stilton soup for each phase. 
You will need to eliminate foods high in glucosinolates, spicy food and  alcohol 
48 hours prior to study day 1 until the 24 hour samples are collected the 
following morning in each phase. 
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Access to your personal information 
During the screening visit, you will be given a code number. This code number is 
unique to you and will be used to protect your identity and make your samples 
anonymous. Only the study team, HNU nurses, the HNU medical advisor, your GP, 
UEA doctor providing medical cover in the event of an emergency and CI will have 
access to any information about you. There is more information about this in Part 2 of 
this information sheet. 
 
Expenses and payments 
Participating in these studies is on a voluntary basis. However, we do recognise that 
taking part can cause some inconvenience and there are associated travel costs. 
Thus, you will receive £502 as an inconvenience payment on completion of the study; 
if you withdraw or are excluded from the study payment will be pro-rata. Travelling 
expenses to and from the HNU will be reimbursed on presentation of a receipt for 
buses or trains or at the current IFR mileage rate for private cars. If you require 
transport to and from the HNU, please let us know as we will organise and pay for a 
taxi.  
All payments are liable to tax and you are responsible for declaring your own 
payments for tax purposes. If you are in receipt of benefits this payment may 
affect your benefits. 
Members of staff at IFR are free to participate in this study; however we would 
like to point out that their inconvenience payment will be taxed at source in 
accordance with BBSRC and IFR rules and HM Revenue and Customs 
(HMRC). 
 
What are the risks or side effects of participating in this study? 
You may experience some discomfort on insertion of the needle for the screening 
blood test and the cannulation, which affects some people more than others. You 
should not experience pain during the procedure or afterwards. You may develop a 
small bruise at the site of the blood sample or cannula, but this will fade like any 
bruise. The nurses in the HNU are experienced at taking blood and cannulation. 
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As with any pressure measurement (like blood pressure) the inflation of the cuffs may 
cause slight discomfort.  
The HNU nurses will be happy to answer any questions you may have about any of 
the procedures involved. 
 
What are the potential benefits of taking part? 
There will be no direct benefit for you by taking part in this study. However, the results 
that we get from this study will provide us with more information on how the natural 







PART 2 of the information sheet 
 
What if relevant new information becomes available or changes to the 
study are made? 
If this happens we will tell you. If changes to the study have to be made you may be 
asked to sign another consent form. 
 
What happens if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without giving a reason. 
You will receive payment pro rata for samples given up to the point of withdrawal.  
 
This completes Part 1 of the information sheet 
If the information in Part 1 has interested you and you are 
considering taking part, it is important that you read the additional 
information in Part 2 before making any decision 
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Samples collected will need to be kept until the study has been finished and any data 
collected until the point of withdrawal will still be used unless you decide otherwise. 
 
What if there is a problem? 
If you have a concern about any aspect of the study, you should ask to speak to the 
researchers who will do their best to answer your questions. You can telephone Miss 
Tharsini Sivapalan on (0)1603 251 425 or Dr Antonietta Melchini on (0)1603 255 030. 
If you have any questions about any of the clinical procedures then we can arrange 
for the HNU senior research nurse to talk to you. 
If you remain unhappy and wish to complain formally, you can do this through the 
chairperson of the Human Research Governance Committee at IFR- Dr Linda Harvey 
(01603 255191). IFR accepts responsibility for carrying out trials, and as much will 
give consideration to claims from participants for any harm suffered by them as a 
result of participating in the study, with the exception of those claims arising out of 
negligence by the participant. Like all publically funded bodies, the Institute is unable 
to insure and thus cannot offer advance indemnity cover for participants. 
Please note that the Institute will not fund any legal costs arising from any 
action unless awarded by a court. 
 
Will my taking part in the study be kept confidential? 
We will only collect personal information or samples from you that are needed for the 
study. Your personal information and samples will be stored in the strictest confidence 
with access only by members of the study team, the HNU nurses, HNU medical 
advisor, UEA doctor providing medical cover in the event of an emergency, your GP 
and CI. All personal information is kept in locked cupboards/filing cabinets at IFR. 
During the eligibility screening you will be assigned a participant code number. This 
number is unique to you and it is this number that will be used to identify samples to 
protect your personal information.  The document linking the code to your personal 
information is kept locked up. Study samples and data generated from this study will 
be stored at the Institute of Food Research for up to fifteen years after the end of the 
study. 
Annex 2-Participant Information Sheet  Version 4-BOBS 10th November 2014 
283 | P a g e  
All research is subject to inspection and audit and although your records may be 
accessed for this purpose any personal information remains confidential. 
Please note that IFR has CCTV cameras in use for security purposes however, 
provision has been made so that volunteers attending the HNU will not be identified. 
 
Will my GP be informed? 
It is our policy to inform your GP that you are taking part in a study at IFR. All clinical 
screening results (blood tests-full blood count, urea and electrolytes and HbA1c, urine 
dipstick test, blood pressure, pulse, weight and BMI measurements) and any 
significant clinical results will be sent to the GP. This is one of the things you are 
agreeing to when you sign the consent form. 
You will be advised to discuss your blood results with your GP if any of the blood 
results are outside the standard references ranges as the members of the study team 
are not medically qualified to discuss this with you. Sometimes the HNU medical 
advisor will discuss your results with your GP. 
 
What happens to my samples? 
Samples given at screening: 
 the urine sample will be tested immediately using a urine dipstick test and 
then discarded. 
 10ml (2 teaspoons) of the blood sample will be sent to the SPIRE        
Hospital for full blood count, HbA1c, urea and electrolytes. 
 5ml (1 teaspoon) of blood sample will be stored at IFR for the genetic test 
described in Part 1 of this information sheet.  
Samples given at study days: 
 The blood and urine samples collected during the study days will be stored 
at IFR and analysed for SF concentrations.  
This will be done using a liquid chromatography/mass spectrometry (LC/MS) and 
cyclocondensation method.  
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LC/MS uses a method that can separate components of a  mixture. It will allow us to 
work out which compounds from the broccoli + stilton soup your body has absorbed, 
metabolised and/or excreted.  
The cyclocondensation method is a specific chemical reaction and will help us to 
find out the amounts of total SF and related compounds in your blood and urine 
samples.  
Some plasma samples from the blood samples will be sent to the University of 
Nottingham for analysis of sulphur and other elements. This will be done by a 
method called ICP-MS. 
 
What will happen to the results of the study? 
Unfortunately, we are unable to tell you any of your individual results. However, we 
will be able to report back the results of the study in the form of a basic   summary. 
The data resulting from the study may be published in scientific    journals or presented 
at meetings with our funders. 
Any data presented is anonymous and your name will not appear in any results 
presented or published.  
 
Who is funding this study? 
This study is being funded by Biotechnology and Biological Sciences Research 
Council (BBSRC, UK). This study is part of an educational project and Miss Tharsini 
Sivapalan is a research student at the University of East Anglia (UEA) and IFR which 
is also funded by the BBSRC. 
 
Who is performing this study? 
This study will be run by Miss Tharsini Sivapalan, a research student at IFR and will 
form part of her research studies at UEA. The chief investigator and PhD supervisor 
is Professor Richard Mithen. Dr Antonietta Melchini and Dr Charlotte Armah who have 
experience of running trials will also assist where necessary. The analysis of plasma 
and urine samples will be performed by Miss Tharsini Sivapalan at IFR laboratories 
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under the supervision of an analytical expert at IFR. The clinical procedures and 
screening will be undertaken by the HNU research nurses. 
Who has reviewed the study? 
Human studies research carried out at IFR is reviewed by the Institute of Food 
Research Human Research Governance Committee (HRGC) and an independent 
group of people called a Research Ethics Committee (REC) to protect your safety, 
rights, wellbeing and dignity. 
This study has been reviewed, and approved by HRGC and East of England Norfolk 
REC committee. 
 
What you need to tell us? 
We need you to tell us some things for your safety and for the success of the study. 
You need to tell us if you are taking ANY MEDICATION whilst on the study as some 
medication may affect the information we are collecting. 
This includes anything you may have bought from the chemist. You will be asked to 
bring details of any medication i.e. name of medication and the dose you are taking 
when you come for your screening.  
You will need also to tell us if you become unwell during the study or after a visit to 
the HNU. It is also important that you inform us if you think you may be pregnant or 
you become pregnant whilst on the study. 
Thank you very much for reading this information sheet and considering 
whether or not to participate in this study.  
Taking part in the research is entirely voluntary! You are free to withdraw from 
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For further information or to arrange a study appointment, please contact:  
 
Miss Tharsini Sivapalan    or          Dr Antonietta Melchini                                
 (0)1603 251 425                 (0)1603 255 030 
tharsini.sivapalan@ifr.ac.uk                                    antonietta.melchini@ifr.ac.uk 
 
Alternatively you can complete the attached response slip on page 21 and return 
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A list of foods that are high in glucosinolates and have to be avoided 48-hours 
before and during the study days: 
Garlic 
Mustard: all types including Ethiopian mustard, Indian mustard, Chinese mustard, 
red giant mustard, wrapped heart mustard cabbage, yellow mustard, black mustard, 
broad beak mustard, purple stem mustard, mustard spinach. 
Broccoli: all types including rapini or broccoli raab, alboglabra kai-ian (Chinese 
broccoli), romanesco broccoli, broccoli, broccoflower. 
Sprouting broccoli  
Brussels sprouts 
Cauliflower  
Cabbage: all types including white cabbage (drum), head cabbage, Savoy cabbage, 
red cabbage, green cabbage. 
Kale: all types including curley kale, Chinese kale, sea kale, pabularia siberian kale, 
acephala Kale. 
Kohl rabi 
Turnip and turnip tops 
Spring greens and Collard greens 
Chinese cabbage; Pak Choi;  Bok choy and other Chinese brassica vegetables   
Radish 
Salad rocket 
Horseradish: sauces and vegetables 
Cress: all types, including watercress and garden cress 
Papaya seeds, Wasabi  
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Soup ingredient information 
 










Annex 2-Participant Information Sheet  Version 4-BOBS 10th November 2014 
289 | P a g e  
 
 Cut along the dotted line 
Bioavailability Of sulforaphane from Broccoli Soups 
(BOBS) 
I am interested in taking part and/or finding out more information about this 




Daytime telephone no.: …………………………………………….. 
Evening telephone no.:……………………………………………... 
Mobile no.:..................................................................................... 
I am happy for a message to be left via my daytime/evening number: YES/NO 
*please circle as applicable 
Preferred time to call:................................................................... 
E-mail address: ……………………………………………………… 
Where did you hear about the study? 
  HNU database                        Study adverts  
  Media (TV/newspapers)   Social networks( facebook/twitter/gumtree) 
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Please return this form in the FREEPOST envelope provided to: 
Miss Tharsini Sivapalan/Dr Antonietta Melchini/ 
Institute of Food Research 
FREEPOST NC 252 





Expressing an interest does not commit you to taking part in the study
Annex 3- Advertisement poster  Version 2-BOBS 29th July 2014 






Annex 4- Invitation letter from advertisement         Version2-BOBS 29th July2014 




Thank you for your interest in. 
The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
at the Institute of Food Research 
I have sent you details of this study which is in progress at present as you have 
responded to the advert and you may fit the criteria. If you have any further 
questions about the study, please contact, Tharsini Sivapalan on 01603251425 
(tharsini.sivapalan@ifr.ac.uk ) or Dr Antonietta Melchini on 01603 255030 
(antonietta.melchini@ifr.ac.uk) or as stated on the enclosed participant information 
sheet. 
If you are interested in taking part or getting more information, fill out the reply slip of 
your participant information sheet, return it to the Institute of Food Research in the 
freepost envelope provided and a member of the study team will be in touch. 
Thank you.  
Yours sincerely, 
 
Miss Tharsini Sivapalan  
On behalf of the BOBS study team 
 
Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723
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The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
APPOINTMENT CARDS 
Visit 2: Screening / Rescreening: 
For screening bring with you a mid stream urine sample 





Preparation for Study days                                                                
Avoid eating foods high in glucosinolates,spicy food and 
alcohol for 48 hours (2 days) prior to study day             
Visit 3: HNU Cannulation                                                       
Fast for at least 10 hours & drink as much plain water as 
you need during the fast period.  Bring with you a mid-
stream urine sample from that morning.  
Avoid eating foods high in glucosinolates, spicy food and 
alcohol throughout the day. 
Visit 4: HNU 24 hour blood                                                 
Fast for at least 10 hours & drink as much plain water as 
you need during the fast period. Bring with you the 24 
hour urine collection. 
 
Day 1           











Day & Date ________                   
Start 
Time___________ 
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Preparation for Study days                                                                
Avoid eating foods high in glucosinolates,spicy food and 
alcohol for 48 hours (2 days) prior to study day             
Visit 5: HNU Cannulation                                                       
Fast for at least 10 hours & drink as much plain water as 
you need during the fast period.  Bring with you a mid-
stream urine sample from that morning.  
Avoid eating foods high in glucosinolates, spicy food and 
alcohol throughout the day. 
Visit 6: HNU 24 hour blood                                                 
Fast for at least 10 hours & drink as much plain water as 
you need during the fast period. Bring with you the 24 
hour urine collection. 
 
Day 1           














Preparation for Study days                                                                
Avoid eating foods high in glucosinolates,spicy food and 
alcohol for 48 hours (2 days) prior to study day             
Visit 7: HNU Cannulation                                                       
Fast for at least 10 hours & drink as much plain water as 
you need during the fast period.  Bring with you a mid-
stream urine sample from that morning.  
Avoid eating foods high in glucosinolates, spicy food and 
alcohol throughout the day. 
Day 1           








No diet restrictions between the phases 
No diet restrictions between the phases 
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Visit 8: HNU 24 hour blood                                                 
Fast for at least 10 hours & drink as much plain water as 
you need during the fast period. Bring with you the 24 




Day & Date ________                   
Start Time__________ 
 
If you are unable to make the appointment please contact Human Nutrition Unit on 
01603 255305. Thank you.
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Consent Form for Research Study 
Study Title: The Bioavailability Of sulforaphane from Broccoli Soups study 
(BOBS) 
Chief Investigator: Prof Richard Mithen 
Volunteer please initial each box 
I confirm that I have read and understand the information sheet dated ………….; 
version no. ………….; for the above study, and I have had the opportunity to 
consider the information, discuss the study and ask questions.    
I confirm that I have received satisfactory answers to my questions.   
I have been informed about the purpose of the genetic test and that it has no clinical 
significance for me or my family and I will not receive the results of this test.  
I agree and consent to having a blood sample taken for this test.    
I understand that my participation is voluntary, and I am free to withdraw from the 
study (1) at any time without giving a reason and (2) without my withdrawal affecting 
future participation in other research studies at IFR      
With who have you discussed the information for this research study? 
Name:  ………………………………………………………………………….. 
Role:  BOBS Study Scientist / Nurse 
I understand that any of my personal information and data collected during the study 
may be looked at by individuals at IFR, where it is relevant to participation in this 
study.            
I give permission for these individuals to have access to my information and data.  
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I understand that my personal information and data will be held confidentially at IFR 
and that it will be destroyed after 15 years.        
I agree to my GP being informed of my participation in the study, and for my clinical 
results to be sent to my GP  







I understand that all research is subject to inspection and audit.    
NB: although your records may be accessed for this purpose your personal 
information remains confidential 
I agree to take part in the above study. 
Signed:  ………………………………………………………………………….. 
(Name in BLOCK letters)…………………………………………………… 
Date:  ………………………………………………………………………….. Date of 
Birth: ………………..…………………………………………… 
I confirm that the participant above has been given a full verbal and written 
explanation of the study. 
Signed: ………………………………………………………………………… 
(Name in BLOCK letters)……………………………………………………  
Role:  ………………………………………………………………… ( BLOCK letters) 
Date: ………….………………………………………………… 
 
If you are unable to make the appointment please contact Human Nutrition Unit on 
01603 255305. Thank you. 
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Study Title: The Bioavailability Of sulforaphane from 
Broccoli Soups study (BOBS) 
MEDICATION/ MEDICAL CONDITIONS 
DECLARATION AGREEMENT 
 
Certain illnesses and medication may affect the outcome of research studies. 
Therefore, we would like you to inform the study organisers if you 
start taking medication 
suffer from any illness 
Please sign below to confirm that you have agreed to this request. 
I……………………….consent to inform the study organiser of the commencement of 
any medication/medical changes whilst participating in the study 
Signature of volunteer……………………………………………. 
Date……………………….. 





If you are unable to make the appointment please contact Human Nutrition Unit on 01603 
255305. Thank you.
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Study Title: The Bioavailability Of sulforaphane from 
Broccoli Soups study (BOBS) 
CONFIDENTIAL Participant Eligibility Screening Questionnaire  
Participant code number…………………   Sex: Male / Female 
Date of birth: ………………………………      
Age: …………………………………years 
Height:……………………Metres   
Weight: ………………………Kg  
Body Mass Index (BMI, kg/m2)……………  
Blood Pressure: Right arm…………..         Left arm……………. Pulse: ……… 
Urinalysis: see page 4 
Have you ever had any of the following?  If yes give details below each 
relevant section. 
 
Angina/heart disease: Y N  Thrombosis: Y N 
……………………………………  …………………………………… 
……………………………………  …………………………………… 
High Blood Pressure: Y N   High cholesterol: Y N 
……………………………………  …………………………………… 
……………………………………  …………………………………… 
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Chest problems: Y N   Diabetes:Y N 
……………………………………  …………………………………… 
……………………………………  …………………………………… 
Depression or anxiety:  Y N           Gastrointestinal disorder/surgery: Y  
N 
……………………………………  …………………………………… 
……………………………………  …………………………………… 
Skin conditions: Y N   Liver problems: Y N 
……………………………………  …………………………………… 
……………………………………  …………………………………… 




……………………………………   
…………………………………… 
Are you currently on any of the following? 
If yes, give details below each relevant section of brand, dosage, frequency, 
when started etc. 
Prescribed medication:     Y         N   
……………………………………………………………….…………………………….… 
……………………………………………………………….…………………………….… 
Dietary Supplements: Y N  Herbal remedies:  Y N 
……………………………………  …………………………………… 
……………………………………  …………………………………… 
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If taking broccoli and/or an ITC supplement, participant will have to 
discontinue use for at least 1 month before starting the intervention.  If 
participant not happy to do so, please exclude from study. 
 
WOMEN ONLY SECTION 
Are you/could you be pregnant?                                      Y         N          
Have you been pregnant within the last 12 months?      Y         N 
Are you breast-feeding?        Y         N 
End of women only section 









Are you currently a: Non-smoker / Current smoker / Ex-smoker / Lifelong 
smoker (circle appropriate) 
What do/did you smoke? (E.g. cigarettes, roll ups, cigars, pipe 
etc.)………………………………………….…… 
If a non-smoker, have you ever smoked? Y N   If yes, how long since you 
stopped smoking?................... 
If an ex-smoker: How long since you stopped smoking:……….….……How many 
did you smoker each day?.................... 
If currently a smoker/lifelong smoker: How many years have you been 
smoking?……………………………………………….…... 
Annex 8- Eligibility Screening Questionnaire   Version 2-BOBS 29th July 2014 
302 | P a g e  
 
DRINKING:  
Do you drink alcohol:            Y          N           How many units do you drink per 
week? ………………….…………………………… 
A unit of alcohol is approximately half a pint of beer or lager, a single pub 
measure of spirit e.g. gin/vodka or a small glass of wine (125mL).   
DIETARY QUESTIONS: 
Are you a vegan or vegetarian?                             Y N 
Do you have any special dietary requirements:  Y N 
If yes state:………………………………………………………………………………… 
………………………………………………………………………………………………… 







Are you a regular blood donor?  Y N 
If yes, when did you last donate blood? 
…………………………………………………………………………………………………. 
If within 16 weeks months, suspend screening until 16 weeks has elapsed 
since last donor session 
Are you happy not to donate blood while participating in this intervention study?  
Y N 
If no, exclude from study. 
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GENERAL PRACTITIONER: 
Do you agree to us informing your General Practitioner of your participation in the 
study or of any results found?  
Y N 
If you have answered NO to this question then we are unable to accept you on 
this study. 




Form completed by (print):………………Signature:…………………Date:…………… 
As far as you know are you related to or living with any member of study team? 
Y                 N 
Are you currently participating in another research study? 
Y                 N 
If yes check with participant whether involves dietary intervention/blood 
sampling – refer to HNU Senior Research Nurse or scientist 
Are you currently undergoing any GP/Hospital investigations? 
Y                 N 
(Add any other required information as per study exclusion criteria) 
Form completed by (print):……………………………Signature:…………………… 
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URINE DIPSTICK TEST RESULTS 
Attach to screening questionnaire to be kept at Study centre 
Study Title:     
Participant code number (NOT NAME):………………Date of Birth:…………………Male/Female (circle) 
Date of sample:……………………………………………    Time of sample:………………………………. 
URINE DIP STICK TEST RESULTS: 
pH:………………………… Protein:………………. Glucose:…………………… 
Ketones:……………….Urobilinogen:………………. 
Bilirubin: ………………. Blood:……………….. Leucocytes:……………….Nitrites:………………Specific 
Gravity: ……………….  
Test performed by:…………………………………. 
Signature:……………………………………………………………. 
Date:……………………………………………………Time:……………………………………………………………………. 
N.B.  If positive for blood and participant is female please ask if they are menstruating, if 
answer is yes, repeat the test once volunteer has ceased menstruating. 
Menstruating:          Y           N  Date due to finish menstruating:…………………..     
URINE DIP STICK TEST RESULTS REPEAT TEST RESULTS:      Y           N 
pH:……………….  
Protein:……………….Glucose:……………….Ketones:……………….Urobilinogen:………………. 
Bilirubin: ……………Blood:………Leucocytes:………Nitrites:…………Specific Gravity: ………  
Date of repeat test:……………………………………………Time:…………………………………………… 
Repeat test performed by:………………………….……  Signature:……………………………………… 
Abnormal results referred to HNU protocol ‘for the referral of abnormal urinalysis results at 
screening’:            Y             N 
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Please note a copy of these results must be sent to the participant’s G.P on the Clinical 


















If you are unable to make the appointment please contact Human Nutrition Unit on 01603 
255305. Thank you.
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CASE REPORT FORM 
Study Eligibility Screening 
 
The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
 
PARTICIPANT STUDY ID: 
 
Chief Investigator Prof Richard Mithen  
Study Manager/Study Coordinator      
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INSTRUCTIONS FOR COMPLETION OF CRFS 
The Case Report Forms (CRF) are to be completed in black ballpoint pen only.  All entries 
must be printed and legible. 
Ensure that the subject ID is consistent throughout the document. 
Each part of the CRF is to be completed as indicated. 
Dates are to be written as follows:  01 /01/2013  
      dd mm yyyy 
     Day Month Year 
Times are to be written using the 24h 00    :    00       (Midnight) 
 clock configuration as follows:-  Hours   Minutes 
When an answer to a question is required, mark the box corresponding to the response: 
Example:  “YES”  YES  NO  
Example:  “NO”   YES   NO 
The following abbreviations are to be used:- 
ND = Not Done, NA = Not Applicable, NK = Not Known 
If comments are required, print them clearly and briefly in English using capital letters. 
Corrections are to be made by striking out the erroneous data with a single line in such a 
way that the original entry remains legible.  The correct datum is then written clearly 
alongside the erroneous datum.  Do NOT use correction fluid. 
All corrections are to be datedand initialled.  A reason must be given for each correction 
or missing datum. 
If a whole page is to be changed, the page is to be struck out with a diagonal black line 
and a copy inserted in the CRF, dated and initialled. 
Ensure that all boxes are completed.  If a subject discontinues early, ensure that the Header 
information for all of the remaining pages is completed and a single line drawn through each 
uncompleted page. 
The Chief/Principal Investigator/Study Manager/Study Coordinator must sign and date the 
Study Completion page to certify completeness of the CRF.Only those members of staff 
trained and responsible for completing the specified duties may complete the CRF. 
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     dd   mm   yyyy 
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INFORMED CONSENT 
Has the participant given signed Written 
Consent to be included in this study? 
Yes  No If no, please do not 
    continue 
 
Date consent obtained 
____/_____/____ 
  dd   mm   yyyy 
Has the participant kept a copy of the 
information sheet and the consent form? 
Yes  No  
 
INCLUSION CRITERIA This should fit study inclusion criteria Examples below 
If the answer to any of the criteria below is NO, the participant does not qualify for the 
study 
Is the participant male/female? Yes  No  
Is the participant18-65years of age? Yes  No  
Is the BMI within ≤20 or ≥35kg/m2 range Yes  No  
Does the participant live within 40 miles of IFR? Yes  No  
Is the participant a non-smoker?  Yes  No  
Does the participant like Broccoli and Stilton soup? Yes  No  
Is the participant able to provide written informed consent? Yes  No  
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EXCLUSION CRITERIA 
If the answer to any of the criteria below is YES, the volunteer does not qualify for the 
study 
Is the participant related to or living with any member of the study 
team? 
Yes  No  
Does the participant have an intolerance / allergy to any member of the 
Brassica family, Brassica pollens or any of the constituents of the test 
meal/study food? 
Yes  No  
Is the participant a smoker or have they smoked within the last six 
months? 
Yes  No  
Has the participant been diagnosed with any long term medical 
condition(e.g. diabetes, cancer, cardiovascular disease) requiring 
medication that may affect the study outcome? 
Yes  No  
Is the participant pregnant, have they been pregnant in the last 12 
months or are they breast feeding? 
Yes  No  
Is the participant willing to provide blood and urine samples? 
Yes  No  
Does the participant have a known history of fainting when having blood 
samples taken? 
Yes  No  
Does the participant take any prescribed or over the counter (self-
prescribed) medications which could affect the study data? 
Yes  No  
Is the participant receiving any anti-coagulant therapy or has received 
any anti-coagulant therapy in the last 3 months? 
Yes  No  
Is the participant taking part in another study which involves dietary 
intervention and/or blood sampling? 
Yes  No  
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Has the participant participated in another research study in the last 4 
months which involves blood sampling? If yes exclude unless total 
blood from both studies does not exceed 470 ml or participant is willing 
to wait 4 months and be re-screened. 
Yes  No  
Is the participant’s blood pressure greater than 160/100 or less than 
90/50 or 95/55 if symptomatic? Either systolic or diastolic or both 
Yes  No  
Does the participant have any special dietary requirements which may 
affect the study data?  
Yes  No  
Does the participant agree to their GP being informed of their 
participation in study and to provide details of GP? 
Yes  No  
Is the participant on long term antibiotic therapy or used any antibiotics 
within the last month?   
Yes  No  
Is the participant a regular blood donor?       
If yes Date of last donation   Date: ____/_____/_______ 
                                 dd    mm    yyyy 
If less than 16 weeks postpone screening until after 16 
weeks 
Yes  No  
Does the participant agree not to donate blood for the duration of their 
involvement on the study?  
Yes  No  
Print Name ______________________   
Signed______________________     
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URINE DIPSTICK TEST RESULTS 
Combur 9 urine dipstick test used Time urine voided: 






Urobilinogen  Biliruben  






Urine should be tested within 2 hours of voiding for manufacturer’s validity. If more than 2 
hours has elapsed ask participant to collect another sample and discard first sample. 
 
ANTHROPOMETRIC MEASUREMENTS 
Blood pressure Pulse 
 











BP Cuff used 
(circle as appropriate) 
 
Small / Large 
 
Weight (kg)  BMI (kg/m2)  
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SUBJECT ELIGIBILITY 
Are the participant’s veins suitable for 
cannulation? 
Yes    No    
Is the subject eligible for the study 
according to screening questionnaire and 
 anthropometric measurements? 
Yes     No    
If No, what was the reason for decision? 
 
Print Name ______________________     
Signed  ______________________    Date: ____/_____/_____ 















    
 ____/_____/____ 
 dd       mm   yyyy 
 
 
    
 
____/_____/____ 
 dd       mm   yyyy 
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____/_____/____ 
 dd       mm   yyyy 
 
 
    
 ____/_____/____ 
 dd       mm   yyyy 
     
 
____/_____/____ 
 dd       mm   yyyy 
     
____/_____/____ 
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Need to stop for 
study 
          













    
 
____/_____/____ 
 dd       mm   yyyy 
 
 
    
 
____/_____/____ 
 dd       mm   yyyy 
 
 
    
 
____/_____/____ 
 dd       mm   yyyy 
     
 
____/_____/____ 
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SUBJECT ELIGIBILITY SCREENING BLOODS 
Has blood been taken for: 
Full Blood Count (FBC) 
Urea & Electrolytes (Us&Es) 
HbA1c 
Yes           No     
If No state reason: 
Were there any problems when taking 
blood? 
Yes     No    
If Yes state what problems? 
 
If participant felt unwell/faint/fainted during or after blood sampling exclude from study 
Blood sample taken by:   
Print Name______________________   
Signature:_____________________________ 
Role:______________________            Date:     ____/_____/_____ 
                                                       dd    mm    yyyy 
  
Were the screening blood results satisfactory for study inclusion? Yes  No   
If NO which results were flagged?   
FBC                                                                                                         Yes     No  
Us&Es                                                                                                     Yes     No    
HbA1c                                                                                                     Yes     No                                                                                                      
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Were flagged blood results referred to HNU Medical Advisor?       Yes     No  
If NO state 
why:__________________________________________________________________ 
Referred by: Print Name:______________________ 
Signature:____________________________ 
Date referred:                                                                Role: 
Has the participant been referred for a re-screen?                            Yes     No  
Re-screen blood?         Yes      No           Re-screen urine?  Yes     No  
Date re-screened:_____________________________      





Do you menstruate regularly? 
 
 
How long is your typical menstrual cycle? 
Yes           No     
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COMMENTS 
Any comments to record? Yes       No   
Please record any additional information relevant to the study.  Date and initial. 




Item Comment Date & Initials 
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PROTOCOL VIOLATIONS OR DEVIATIONS 
Were there any protocol violations or deviations during the Screening process? Yes   No  If Yes, please detail below: 

















dd   mm  yyyy 
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Annex 8- Eligibility Screening Questionnaire   Version 2-BOBS 29th July 2014 
320 | P a g e  
STUDY STATUS 
Did subject complete the screening process?     Yes   No   If No complete box 
below. 
Date of withdrawal:                           ____/_____/201 
    dd    mm    yyyy 




 Subject’s GP 
 Other (specify) _____________________________________ 
Primary Reason for withdrawal due to (please tick one): 
 Failure to meet inclusion criteria  
   Failure to provide a screening blood sample 
 Failure to comply with other requirements of the protocol (record on the 
comments page) 
 Failure to meet Blood Pressure criteria 
 Withdrawal of Consent 
 Other (specify) ______________________________________ 
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Was any Re-screen procedure necessary? 
 
Yes  No  
 







To the best of my knowledge, I confirm that I have made every reasonable effort to ensure 
that the data presented in this Case Record Form are a true, accurate and complete report 
and accurately reflect the study conduct during the screening process. 
Print Name ______________________     
Signed  ______________________    Date: ____/_____/201 
   Investigator                                     dd    mm    yyyy 
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CASE REPORT FORM 
Study Phase 1-3 
The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
 
PARTICIPANT STUDY ID: 
Chief Investigator Prof Richard Mithen  
Study Manager/Study Coordinator      
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INSTRUCTIONS FOR COMPLETION OF CRFS 
The Case Report Forms (CRF) are to be completed in black ballpoint pen only.  All entries 
must be printed and legible. 
Ensure that the subject ID is consistent throughout the document. 
Each part of the CRF is to be completed as indicated. 
Dates are to be written as follows:  01 /01/2013  
      dd mm yyyy 
     Day Month Year 
Times are to be written using the 24h 00    :    00       (Midnight) 
 clock configuration as follows:-  Hours   Minutes 
When an answer to a question is required, mark the box corresponding to the response: 
Example:  “YES”  YES  NO  
Example:  “NO”   YES   NO 
The following abbreviations are to be used:- 
ND = Not Done, NA = Not Applicable, NK = Not Known 
If comments are required, print them clearly and briefly in English using capital letters. 
Corrections are to be made by striking out the erroneous data with a single line in such a 
way that the original entry remains legible.  The correct datum is then written clearly 
alongside the erroneous datum.  Do NOT use correction fluid. 
All corrections are to be dated and initialled.  A reason must be given for each correction 
or missing datum.If a whole page is to be changed, the page is to be struck out with a 
diagonal black line and a copy inserted in the CRF, dated and initialled. 
Ensure that all boxes are completed.  If a subject discontinues early, ensure that the Header 
information for all of the remaining pages is completed and a single line drawn through each 
uncompleted page. 
The Chief/Principal Investigator/Study Manager/Study Coordinator must sign and date the 
Study Completion page to certify completeness of the CRF.Only those members of staff 
trained and responsible for completing the specified duties may complete the CRF. 
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                                                          STUDY DAY CRITERIA 
Has the participant given signed Written 
Consent to be included in this study? 
Yes  No   If no, do not 
continue 
Is the participant happy to continue on 
study?          
Yes          No   If  no, do not 
continue 
Is the participant well today?   If No postpone study day and 
inform scientist 
Yes  No  
Has the participant been well over previous five days? If No 
postpone study day and inform scientist. List any illness on 
comments page with date and duration of illness. 
Yes  No  
Does the participant have any known allergies? If Yes state 
below and exclude if allergic to any content of the study 
foods/soups/Brassica family or pollens 
Yes  No  
Allergies:   
Has the participant fasted for a minimum of 10 hours? If No 
postpone study day and inform scientist 
Yes  No  
When was the last time the participant consumed any of the 
foods below and which: 
Date Time 
Foods in high glucosinolates Yes     
Alcohol Yes    
Spicy food   Yes  
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Female participants only: 
Are you menstruating or just finished menstruating? If 
menstruating or just finished then postpone study day 7 days 
after menstruating and inform scientist 
When did your last period end? If no menstrual cycle for 2 
months or more ask ‘could you be pregnant?’ 
Yes  No  
 
Did the participant have any problems when screening blood 
taken? If participant felt unwell/faint/fainted during or after blood 
sampling exclude from study 
Yes  No  
Has the participant take any prescribed or over the counter (self-
prescribed)    
medications since their last visit? If Yes list on medications sheet 
of CRF and postpone study day/exclude from study as advised 
by HNU medical advisor 
Yes  No  
Has the participant received/taken any anti-coagulant therapy 
since last visit? 
If Yes list on medications sheet of CRF and postpone study 
day/exclude from study as advised by HNU medical advisor 
Yes  No  
Has the participant used/taken any antibiotics since last visit?  If 
Yes list on medications sheet of CRF and postpone study 
day/exclude from study as per study protocol 
Yes  No  
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Is the participant a blood donor?     
If yes Date of last donation                    Date: ___/___/___ 
                                                          dd   mm   yyyy 
Has the participant donated blood since their screening? 






Print Name ___________________   Signed______________________    
Date: ____/_____/_____ (dd mm yyyy)      
Role:_______________________________________ 
 
URINE DIPSTICK TEST RESULTS 
Combur 9 urine dipstick test used Time urine voided: 






Urobilinogen  Biliruben  






Urine should be tested within 2 hours of voiding for manufacturer’s validity. If more than 2 
hours has elapsed ask participant to collect another sample and discard first sample. 
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ANTHROPOMETRIC MEASUREMENTS 
Blood pressure Pulse 
 











BP Cuff used 
(circle as appropriate) 
 
Small / Large 
 
Weight (kg)  BMI (kg/m2)  
 
SUBJECT ELIGIBILITY 
Are the participant’s veins suitable for 
cannulation? 
 
Yes    No    
Is the subject eligible for the study 
according to screening questionnaire and 
 anthropometric measurements? 
 
Yes     No    
If No, what was the reason for decision? 
 
Print Name ______________________     
Signed  ______________________    Date: ____/_____/_____ 
  HNU Senior Research Nurse                         dd    mm    yyyy 
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 ____/_____/____ 
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____/_____/____ 
 dd       mm   yyyy 
 
 
    
 
____/_____/____ 
 dd       mm   yyyy 
 
 
    
 ____/_____/____ 
 dd       mm   yyyy 
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COMMENTS 
Any comments to record? Yes       No   
Please record any additional information relevant to the study.  Date and initial. 
Each comment should be completed by the appropriate Study Staff member. 
CRF Page 
Number 
Item Comment Date & Initials 
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                                        STUDY DAY BLOOD PRESSURE MEASUREMENTS (Pre-cannulation)     
Measured by:                
                                       Print Name___________________________Signature:__________________ 
                                                                                                                                                                    
                                       Role:__________________________________________ 
Arm with highest reading at screening to be used 
          Left arm         Right arm       
            (circle as appropriate)    
         If BP >160/100 or <90/50 or <95/55 (if symptomatic) repeat x 3 at 15 minute 
intervals   
 If BP remains above 160/100 or below 90/50 or 95/55 (if symptomatic) exclude participant 
from study 
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            Initial             
     Measurement  






           
                BP                





   
 













Yes   No  
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CANNULATION 
Type of  cannula used: 
 
           Size (Gauge):                             Name of nurse cannulating:________________________ 
Cannulation site :     
1)______________(2)______________ 
Length of time cannulated:__________                                    
 
                                Time Cannulated:     (1)___________________(2)________________  
 Time cannula removed:__________________ 
Sterile normal saline for injection used 
to flush cannula:  
Batch No:___________________  Exp. Date:____________________________________ 
 
Total amount of saline used during study day:___________________________________ 
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Any problems during cannulation:   
 Yes   No  
If YES give details: 
 
Was the cannulation site assessed by 
HNU nurse before leaving HNU?  
 
Yes   No  
 
Was the participant well on leaving HNU?    Yes   No     Time left HNU:______________ 
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24 HOUR SAMPLES (URINE AND BLOOD) 
 
Has the participant fasted for a minimum of 
10 hours?         Yes   No  
                          
  
                     
                 Is the participant well?     Yes   No  
Venepuncture site 
used:_______________   
                  
                 Has the 24hour blood sample been taken?  Yes   No  
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                 Any problems taking blood sample?              Yes   No  
           If YES state:_________________________________________________________ 
 
URINE                Has the participant handed urine sample to member of study team?    Yes   No  
Did the participant comply with study 
diet restrictions during Phase 1? 
 
Yes   No  
 
Was the participant able to eat the whole portion of soup?      Yes   No   
If No – exclude from study and give reason for not finishing the soup: 
______________________________________________________________________________ 
_____________________________________________________________________________ 
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PROTOCOL DEVIATIONS 
Were there any protocol violations or deviations during Phase 1? Yes  No  If YES, please detail below: 





















dd   mm  yyyy 
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CONCOMITANT MEDICATIONS 
Were there any medications taken during Phase 1?  













 Date ____/____/____ 
           dd    mm   yyyy 
     
 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
 Start 
 Date ____/____/____ 
           dd    mm   yyyy 
     
 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
 Start 
 Date ____/____/____ 
           dd    mm   yyyy 
     
 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
 Start 
 Date ____/____/____ 
           dd    mm   yyyy 
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 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
 Start 
 Date ____/____/____ 
           dd    mm   yyyy 
     
 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
 Start 
 Date ____/____/____ 
           dd    mm   yyyy 
     
 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
 Start 
 Date ____/____/____ 
           dd    mm   yyyy 
     
 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
 Start 
 Date ____/____/____ 
           dd    mm   yyyy 
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 Stop 
 Date ____/____/____ 
           dd    mm   yyyy 
 
NON-SERIOUS AND SERIOUS ADVERSE EVENTS 
Categorisation of Severity 
The grading of adverse events by the Investigator will take into consideration the 
following 3-point scale: 
Mild: 
For example, an adverse event that is easily tolerated by the volunteer, causing 
minimal discomfort and not interfering with everyday activities. 
Moderate: 
For example, an adverse event that is sufficiently discomforting to interfere with 
normal everyday activities. 
Severe: 
For example, an adverse event that prevents normal everyday activities. 
Relationship to Study Procedures 
The relationship of the clinical adverse events to the study procedure will be 
categorised as follows: 
Not related: 
This category includes such adverse events that, after careful medical consideration 
at the time of such evaluation, are judged to have clearly and incontrovertibly no 
relation with the study procedures.  Adverse events must have a definite extraneous 
cause (disease, environmental reasons, etc.).  Criteria listed under "remote", 
"possible", and "probable" must not apply. 
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Remote: 
This category includes such adverse events for which, after careful medical 
consideration at the time of evaluation, a remote possibility for a relation with the study 
procedures is taken into consideration, but which are judged with a high degree of 
certainty to have an unlikely relation. 
An adverse event is classified as "remote" if the following conditions apply: 
1. It does not follow a reasonable temporal sequence from the performance of the 
study procedures. 
2. It can very easily be explained by the subject's general condition, 
environmental conditions, toxic factors, or other kinds of therapy or treatment 
administered to the subject. 
3. It does not follow a known response pattern to the study procedures. 
Possible: 
This category includes such adverse events for which, after careful medical 
consideration at the time of evaluation, a possible relation with the study procedures 
must be taken in consideration or cannot be ruled out with certainty, but which is 
judged to have more likely no relation. An adverse event is classified as "possible" if 
the following conditions apply: 
1. It follows a reasonable temporal sequence from the performance of the study 
procedures. 
2. It can also easily be explained by the subject's general condition, 
environmental conditions, toxic factors, or other kinds of therapy or treatment 
administered to the subject. 
3. It follows a known response pattern to the suspected procedures. 
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Probable: 
This category includes such adverse events which, after careful medical consideration 
at the time of evaluation, are related to the study procedures with a high degree of 
certainty.  An adverse event is classified as "probable" if the following conditions apply: 
It follows a reasonable temporal sequence from administration of the study 
procedures. 
2. It cannot be reasonably explained by the subject's general condition, 
environmental conditions, toxic factors, or other kinds of therapy or treatment 
administered to the subject. 
3. It follows a known response pattern to the suspected procedures. 
 
ADVERSE EVENTS  
Did the subject experience any adverse events during the study? Yes No   
 
If Yes, please complete ALL sections below: 
Event Diagnosis  
Start Date 
___/____/201 
dd   mm  yyyy 
Start Time :  
Stop Date 
___/____/201 
dd   mm  yyyy 
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Stop Time :  
Frequency 
1 = Constant 
2 = Intermittent 
 
If Intermittent (i.e. > 1 
episode) please provide 
number of episodes 
 
Severity 
1 = Mild 
2 = Moderate 





1 = Not Related 
2 = Remote 
3 = Possible 




1 = None 
2 = Referred to   
       Subject’s GP 





If Other, please specify 
Outcome 
1 = Resolved 
2 = Ongoing 
3 = Lost to Follow Up 
4 = Death 
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Serious 
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Did subject complete Phase 1? Yes  No   If No complete box below. 
Date of withdrawal:                           ____/_____/201 
    dd    mm    yyyy 




 Subject’s GP 
 Other (specify) _____________________________________ 
Primary Reason for withdrawal due to (please tick one): 
 Blood pressure  (record on comments page) 
 Failure to comply with other requirements of the protocol (record on the 
comments page) 
 Serious Adverse Event/Reaction/ Adverse Event (record on the adverse event 
page) 
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 Withdrawal of Consent 
 Other (specify) ______________________________________ 
Was any Follow up procedure necessary? 
 
Yes  No  






To the best of my knowledge, I confirm that I have made every reasonable effort to 
ensure that the data presented in this Case Record Form are a true, accurate and 
complete report and accurately reflect the study conduct for the Phase. 
Print Name ______________________     
Signed  ______________________    Date: ____/_____/201 
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CLINICAL TEST RESULTS FORM- TO BE SENT TO THE 
PARTICIPANT’S GP 
Study Title: The Bioavailability Of sulforaphane from 
Broccoli Soups study (BOBS) 
Study Title ……………………………………………………………………… 
Participant’s Name:………………………………………………………………   
Date of Birth:………….                                                 Male/Female:………….. 
                           
Dipstick urine test results: Combur9  dipstick test strips used. Test areas 
compared after 60 seconds as per manufacturers guide. 
pH……  Protein:……… Glucose:……… Ketones:…… Nitrites:…… Bilirubin:…… 
Urobilinogen:………    Blood: (ERY)………. (Hb):….. ….  Leucocytes……… 
Menstruating:  Y   N   N/A (circle as appropriate)   
Test performed by (print name): ……………..       Signature:……………………  
Date:………      Time:………     
Repeat test required at surgery prior to re-screen:  Y   N   N/A (circle as appropriate)   
Repeat urine dipstick test results (HNU).  Tested using urine dipstick test 
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Urobilinogen:……….    Blood: (ERY)………  (Hb):…..……       Leucocytes………… 
Test performed by (print name): ……………..       Signature:……………………  
Date:………      Time:………     
 
Observations: 
Blood Pressure: Right arm:…………… Left arm:……………. Pulse:   Rt…… Lt……. 
Weight(kg): ……….  BMI(kg/m2):…………Reference range for study:  > 20 - <35 
kg/m2 
Copy of screening blood results attached: Yes   No   Not applicable   (circle as 
appropriate) 
The …………………….(insert as appropriate) result(s) will / will not exclude your 
patient from this study. 
Date:………………………………………..   Signature:………………………………… 
Abnormal results are referred to the HNU Medical Advisor for comments regarding 










If you are unable to make the appointment please contact Human Nutrition Unit on 01603 
255305. Thank you.
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Date 
Dear Doctor (insert name of participant’s GP) 
RE: (insert name of participant and home address) I am writing to inform you that 
your patient has consented to take part in a research study at the Institute of Food 
Research (IFR) in Norwich.  
The study is led by Professor Richard Mithen and is entitled: 
The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
The study has been approved by the IFR Human Research Governance Committee 
(HRGC) and (to add REC name after gaining approval). 
I have enclosed a copy of the Patient Information Sheet for your reference. 
Following consent, it is our standard practice to screen the volunteers to exclude 
any health factors that may affect the study data or indicate an issue which may 
require further investigation.  We are looking for healthy people who have no chronic 
illness and are not taking any prescribed medication that may affect the study data.   
Some/none of your patient’s results fell outside the standard reference range on this 
occasion.   
These results will/will not affect the study data. 
Your patient   will/will not be able to participate in the study. 
If you require any further information about the study then please do not hesitate to 
contact the study scientists Miss Tharsini Sivapalan on (0)1603 251425 (email 
Tharsini.sivapalan@ifr.ac.uk), Dr Antonietta Melchini on (0)1603 255030 (email 
antonietta.melchini@ifr.ac.uk) or Dr Charlotte Armah on (0)1603 255000 . 
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Thank you for taking the time to read this letter.  
Yours sincerely, 
 
Miss Tharsini Sivapalan 
On behalf of the BOBS study team 
Encs: Participant Information Sheet, version (insert version number) dated (insert 
date) 
Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723
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The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
A list of foods that are high in glucosinolates and have to be avoided 24-hours 
before and during the study days: 
Garlic 
Mustard: all types including Ethiopian mustard, Indian mustard, Chinese mustard, 
red giant mustard, wrapped heart mustard cabbage, yellow mustard, black mustard, 
broad beak mustard, purple stem mustard, mustard spinach. 
Broccoli: all types including rapini or broccoli raab, alboglabra kai-ian (Chinese 
broccoli), romanesco broccoli, broccoli, broccoflower. 
Sprouting broccoli  
Brussels sprouts 
Cauliflower  
Cabbage: all types including white cabbage (drum), head cabbage, Savoy cabbage, 
red cabbage, green cabbage. 
Kale: all types including curley kale, Chinese kale, sea kale, pabularia siberian kale, 
acephala Kale. 
Kohl rabi 
Turnip and turnip tops 
Spring greens and Collard greens 
Chinese cabbage; Pak Choi;  Bok choy and other Chinese brassica vegetables   
Radish 
Salad rocket 
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Horseradish: sauces and vegetables 
Cress: all types, including watercress and garden cress 
Papaya seeds 
Wasabi  
Please have a look at the photos that can help you in recognising all foods in the list:  
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The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
Date 
Dear…………………….. 
I am writing to inform you that one or more of the results from your blood tests fell 
outside the standard reference range. 
As you are aware from your interview it is our policy to refer such results to our 
medical doctor for a decision on whether you should participate in the study, as the 
results may affect the study data. 
The doctor has advised that the results flagged could affect this particular study’s 
data; therefore we are unable to accept you on this study.  However, these results 
do not necessarily exclude you from taking part in future studies. 
There may be no cause for concern about your health and copies of your results 
have been sent to your GP, therefore, we would suggest you contact your GP to 
discuss your results. Please find enclosed your expenses form for your screening 
samples.  Please complete the form with your name, address, bank details and 
mileage (if appropriate) and enclosing any public transport receipts.  Please make 
sure that you sign the form and return it to us in the freepost envelope provided.  
We would like to thank you for your interest and willingness to participate. 
Yours sincerely, 
Miss Tharsini Sivapalan 
On behalf of the BOBS study team 
Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723
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Dear Doctor (insert name of patient’s GP) 
RE: (insert name of patient and home address)  
I am writing to inform you that your patient has consented to take part in a research 
study organised by the Institute of Food Research in Norwich.  The study is led by 
Professor Richard Mithen and is entitled ‘The Bioavailability Of sulforaphane 
from Broccoli Soups study (BOBS)’. The study has been approved by the 
Institute of Food Research (IFR) Human Research Governance Committee (HRGC) 
and the (insert committee name) NRES Research Ethics Committee (REC).  
The study will investigate the isothiocyanate excretion following consumption of 
broccoli soups with different doses of glucoraphanin on three occasions. Twenty-
four hour urine samples and blood samples, before and after consumption of one 
pot (300g) of broccoli soup, will be collected from participants. Following consent it 
is our standard practice to screen the volunteers to exclude any health factors which 
may affect study procedures or indicate an issue which may require further 
investigation. It is our policy to forward copies of all results (normal or abnormal) 
during the study to the volunteer’s GP. 
Thank you for taking the time to read this letter. If you require any further information 
about the study then please do not hesitate to contact Professor Richard Mithen at 
the Institute of Food Research 01603 255259 (email richard.mithen@ifr.ac.uk or  
the study scientists, Dr Antonietta Melchini on 01603 255030 (email 
antonietta.melchini@ifr.ac.uk) or Tharsini Sivapalan on 01603251425 (email 
tharsini.sivapalan@ifr.ac.uk). 
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Thank you for taking the time to read this letter.  
Yours sincerely, 
Miss Tharsini Sivapalan 
On behalf of the BOBS study team 
Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723
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The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
Study description 
This will be a randomized, three-phase, double-blinded crossover study that will 
investigate the bioavailability of sulforaphane (SF), following consumption of three 
broccoli + stilton soups with different doses of glucoraphanin. The study will take 
place in the Human Nutrition Unit (HNU) at the Institute of Food Research. 
PRIMARY AIM:  
To measure the total excretion of SF in urine collected for 24 hours after 
consumption of one pot (300g) of three types of broccoli + stilton soup containing 
different concentrations of glucoraphanin, SF precursor. 
SECONDARY AIMS:  
To measure SF and its metabolites in plasma following consumption of one pot 
(300g) of three types of broccoli + stilton soup containing different concentrations of 
glucoraphanin. 
To determine whether the glutathione S-transferase Mu 1 (GSTM1) genotype or 
other associated genotypes (e.g. GSST1) influence SF plasma pharmacokinetic 
parameters (Cmax, Tmax, area under the curve) and its total urinary excretion.  
STUDY DESIGN: 
Participants will be asked to attend the HNU for a total of 8 visits during the study. 
Their involvement is expected to last 11-12 weeks. The following soups will be used 
as a test meal:  i) 300g standard broccoli + stilton soup, ii) 300g Beneforte® broccoli 
+ stilton soup and iii) 300g Beneforte Extra broccoli + stilton soup. The study will 
consist of three study phases separated by a minimum of two weeks washout 
period. Each phase will consist of a 48 hour pre-intervention diet restriction, a study 
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day (study day 1) consisting of approximately a 9 hour stay at the HNU and will 
involve the participant being cannulated for an 8 hour period to allow multiple blood 
samples to be taken. A 24 hour urine and blood sample will also be collected from 
the participants the following morning. During each study day 1, participants will also 
collect their urine in containers provided.  
Participants will be asked to eliminate foods high in glucosinolates, spicy food and 
alcohol 48 hours prior to each study day 1 and during each study phase until the 
collection of the 24 hour blood and urine samples i.e. a total of 3 days per phase 
and a total of 9 nine days for the entire study (Phase 1-3). They will also be asked to 
fast for a minimum of 10 hours overnight, and advised to drink plenty of plain water 
prior to blood sampling days in each study phase.  
During each phase, six urine samples will be collected after consumption of each of 
the soups at the following time-points: 0, 0-2, 2-4, 4-6, 6-8 and 8-24 hours. Eleven 
blood samples will also be collected at the following time-points: 0, 30, 45, 60, 90, 
120, 180, 240, 360, 480 mins and 24 hours.  
The total blood volume collection during the study is (110 ml  3 phases) + 15 ml 
screening sample = 345ml or 355ml if participant is re-screened.
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The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
Date 
Dear…………………….. 
I am writing to inform you that the recruitment for the Bioavailability of sulforaphane 
from broccoli soups (BOBS) study is now complete. I would like to thank you for 
your interest in the study and for your willingness to be on a stand-by list. 
Unfortunately, on this occasion, you were not required and as such will not be able 
to participate in this study. 
This will not affect your involvement in any future studies at the Institute. 
Many thanks again for your interest. 
Yours sincerely, 
 
Miss Tharsini Sivapalan 






Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723 
 




The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
Date 
Dear…………………….. 
I am writing to remind you of your appointment on: 
 
 
You will be required to remain in the HNU for approximately 9 hours on the study 
days and you will have a cannula in your arm for 8 hours. The nurse has asked us to 
advise you to wear comfortable clothing, which you can easily remove for toilet 
purposes whilst cannulated.  
Please also remember to collect the first urine sample on the morning of study day 1 
in the container provided. You need to maintain a diet restriction 48 hours before the 
study and fast for 10 hours prior to the study day. It is advised that you drink as 
much plain water as you need during the period of fasting. 
If you are unable to make the appointment, please ring the HNU on 01603 255305. 
Yours sincerely, 
 
Miss Tharsini Sivapalan 
On behalf of the BOBS study team 
 
Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723
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The Bioavailability Of 
sulforaphane from Broccoli Soups study (BOBS) 
Food Choices for study days 
Lunch 
2 - 4 medium slices of white or brown 
20g or 2 portions Butter or Flora (optional) 
130g Tuna Chunks in spring water or 80g grated mature cheddar cheese 
10g Mayonnaise (optional) 
Natural Yoghurt (optional) 
Banana (optional) 
Unlimited Water
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Dear Doctor ………….. 
Your patient, …………………………………..,date of birth …………………………….. 
has consented to take part in a Human Nutrition study at the Institute of Food 
Research entitled,  
The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
 
Prior to cannulation on the study day, it is our practice to measure and record the 
participant’s blood pressure to ensure it falls within the HNU’s reference range for 
cannulation, and the inclusion criteria for the study.   
Your patient’s blood pressure measurement was outside the range for cannulation 
and study inclusion criteria. Therefore, your patient will be excluded from the study. 
Please find a copy of the blood pressure measurements attached with this letter. 
You will already have received a copy of the eligibility screening blood results and 
blood pressure measurements. Your patient has been advised to discuss these 
results with you. 
Yours sincerely, 
Miss Tharsini Sivapalan  
On behalf of the BOBS study team 
Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723
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Consent to contact form for future research 
studies 
Study Title: The Bioavailability Of sulforaphane from Broccoli Soups 
study (BOBS) 
Chief Investigator: Prof Richard Mithen  
For participants who were recruited through advertisements  
Please sign below if you agree to be contacted about future studies on 
broccoli (or similar) that may be undertaken at IFR. 
Signed:  ………………………………………………………………………….. (Name in BLOCK 
letters)…………………………………………………… 







Contact telephone number:_______________________________________ 
E-mail address:________________________________________________ 
Norwich Research Park, Colney, Norwich NR4 7UA, UK 
www.ifr.ac.uk Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723
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* Standard broccoli or Beneforte broccoli or Beneforte extra broccoli  
 
 
The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
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Ms Tharsini Sivapalan 
Food and Health Programme  
Institute of Food Research  









HRGC ref: IFR06/2014 
Short title: Bioavailability of sulforaphane from broccoli soups (BOBS Study) 
 
The above protocol was discussed at  a meeting of the IFR Human Research 
Governance Committee (HRGC) held on Friday 4 July 2014. Following discussion, 
the committee’s decision was that the proposal could be submitted to an NHS 
Research Ethics Committee, once minor changes have been made. 
 
I list the main changes the committee requests and comments to consider. Please 
use the electronic version of the relevant text of this letter to detail your response to 
each of the points (eg. “Done”, or any argument for not agreeing with any point) and 
highlight the changes in your revised documents. This will hasten our review. 
 
General comments: 
1. The committee felt that further justification for undertaking the cannulation 
aspect of the study is required. The study has been powered on urinary sulforaphane 
excretion, so further justification is needed to confirm that the glucoraphanin doses 
you plan to use will elicit a statistically significant plasma response. Please confirm 
the glucoraphanin doses that you will be using for the study. Please discuss with Jack 
Dainty (institute statistician). 
2. Please justify the time points that you have chosen for blood sampling, there 
should be a scientific justification. 
3. It appears that the study has been powered on a comparison of the low and 
high glucoraphanin broccoli rather than the low versus medium content. In order to 
obtain useful data from the latter group the committee felt that the study should be 
powered on this comparison. Please discuss with Jack Dainty (institute statistician). 
4. The stated glucoraphanin content of the three types of broccoli used in this 
study is different from that stated in other submissions previously reviewed by the 
committee. Please clarify and amend. 
5. Throughout the documentation you use the terms ‘bioavailability’ and ‘plasma 
and urinary sulforaphane’ interchangeably. The latter are surrogate markers of 
bioavailability and it is important to make the relevant distinction and use the 
appropriate terms when describing the study. 
 
The Institute of Food Research is a registered charity (No. 1058499) 
and a company limited by guarantee (registered in England and Wales No. 03009972). 
VAT registration No. GB 688 8914 52 
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IFR receives strategic funding from the Biotechnology and Biological Sciences Research Council 
 
6. The committee felt that genotyping such a small number of participants would 
not provide any statistically significant data and this aspect should be removed from 
the study design. Please discuss with Jack Dainty (institute statistician). 
7. In the eventuality that the majority of participants do not take up the 
opportunity to provide an optional faecal sample, the likelihood is that collection of 
such a small number of samples (maximum 8) will not provide any useful data. The 
collection of the samples also does not appear to be relevant to the aims of the study 
and it is unclear how they would be used. Please discuss with Jack Dainty (institute 
statistician). 
8. Dr Charlotte Armah (HRGC committee member) has offered to provide further 
guidance and advice on the preparation of the general aspects of your submission. 
Please discuss with Charlotte. 
9. Mrs Aliceon Blair (HNU senior research nurse) has offered to provide advice 
on the clinical and HNU related aspects of your study. She has prepared appropriate 
wording that will be helpful. Please discuss with Aliceon. 
10. As this is the first study that you will be undertaking at IFR, the committee 
presumes that you will be fully supported by the study research team during the initial 
study talks and screening and study days? 
11. The soups you plan to use in the study are variously referred to throughout 
the documentation as broccoli soup, broccoli and stilton soup, and broccoli and stilton 
flavoured soup.  Please confirm which type of soup you plan to use and amend the 
documentation accordingly. 
12. The title of the study is inconsistent in the submitted documentation. Please 
check and amend as appropriate. 
13. Please note: the protocol is a standalone document and all the annexes are 
an annex to the protocol. The protocol is not an annex. 
14. Please provide a copy of the letter confirming insurance details for the study 
from Ian Bartlett. 
15. Please resubmit an HRGC registration form including the signature of the 
senior research nurse. 
16. There are several typos and grammatical errors throughout the 
documentation. Please amend. 





Protocol (version 1, dated 26 June 2014) 
 
18. Why is the study single-blinded? Could it be a double-blinded? Please clarify. 
19. As your eligibility screening does not include glucose measurements there is 
no need for the participants to be fasted as HBA1c analysis does not have this as a 
requirement. Therefore, this will allow slightly more flexibility in the timing of screening 
appointments (please note: all blood samples need to be at SPIRE Hospital by 3pm). 
Please speak to Aliceon for further clarification and amend documentation as 
appropriate. 
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20. The washout period between study days should be stated as a minimum of 2 
weeks throughout the documentation. Please amend. 
21. Pg 4, scientific background, 3rd line: Gasper et al (2005) is not an 
epidemiological study. 
Please amend. 
22. Pg 17, eligibility screening: There is some repetition in this section. Please 
amend. 
23. Pg 17, eligibility screening: Who is taking written informed consent form the 
study participants? Please clarify and include details. 
24. Pg 27/28: Do participants really need a breakfast of two slices of toast two 
hours after they have had soup with two slices of toast? They may be quite full, 
especially as they are also having sandwiches etc. at the five hour time point. 
However, on page 32 it states that the participants will be having bread rather than 
toast. Please clarify and amend. 
25. Pg 28, 31 and 32: The information relating the HNU kitchen etc. is repeated 
on these pages. Please amend. 
  
26. Pg 29, last para: What do you mean by ‘linked studies’? It is better to ask 
participants if they would consent to be ‘contacted’ (rather than recalled) about future 
studies on broccoli (or similar) that may be undertaken at IFR. You will also need to 
amend the wording on the consent from to reflect this, or you could consider a 
separate consent form for this aspect of the study. Please discuss with Aliceon the 
process for keeping a list of participants for future studies to make sure that they are 




27. Clinical aspects of study details on this form need amending. Please discuss 
with Aliceon. 
28. A6-2 suggests that you are going to pay participants for loss of wages if they 
take the day off work to participate in study days. The committee presumes that this 
is incorrect. Please clarify and amend. 
 
Annex 3: PIS (version 1, dated 26th June 2014) 
29. Whilst the committee was not against the booklet format for the PIS, it felt that 
it needed to be reformatted. Currently the font is quite large and text rather spaced 
out, which means that at almost 40 pages, the booklet is very long. This format would 
also benefit from an index because it is much harder to find your way around the 
information contained within, due to lots of pages of solid text. This booklet format will 
also be more difficult (although not impossible) to upload electronically to NRES for 
review. It is essential that it is submitted in the format that you will be presenting it to 
study participants i.e. two pages of text per A4 sheet. It will also be necessary to have 
a standard A4 version of the PIS for the purposes of 
e-mailing it to potential participants. The booklet edition must also contain a version 
number and date. 
30. Some of the clinical and HNU aspects of the study need rewording. Please 
discuss with Aliceon who will advise accordingly. 
31. There are several sections of text in the PIS that need re-writing in lay 
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language. Please amend as appropriate. 
32. Pg 2, 2nd para: It is arguable that the health benefits of broccoli are purely 
due to sulforaphane. Please amend. 
33. Pg 2, 3rd para: There is some text missing. 
34. Pg 3: The aim of the study is not worded appropriately. Please amend. 
35. Pg 3: The soup is described variously, see earlier comment. Please clarify and 
amend. 
36. Pg 8: It would be helpful to state on which page the flow chart is located 
when it is referred to here. 
37. Pg 16: It reads as though participants will receive £250 for the faecal 
samples alone. Please amend. 
38. Pg 18: The flow chart needs simplifying, it is too wordy. Please also remove 
the references to the types of analysis as participants will not know what U’s and E’s 
are etc. Please also remove the reference to a CRF for the same reason. 
39. Pg 25: Please remove the word ‘ladies’ in reference to pregnancy as it is not 
necessary. 
40. Pg 28: The soup ingredients sheet should refer to three types of broccoli 
soup, not just two? Please clarify and amend. 
 
Annex 4 Poster (version 1, 26 June 2014) 
41. You should give an example and explain the ‘natural compounds’ you refer 
to in the first sentence of the advert. 
42. Some of the text needs rewording e.g. potential participants will not 
necessarily understand what is meant by a ‘glucosinolate free diet’, and 
‘recompensate’ is used incorrectly in this context. It would be better to ask if 
potential participants like broccoli and stilton soup, as they may like cheese and 
broccoli separately, but maybe not together in a soup. Please amend. 
 
Annex 5, invitation letter (version 1, 26th June 2014) 
43. This letter needs re-wording to reduce the over-use of the word ‘study’. 
 
Annex 7, consent form (version 1, 26th June 2014) 
44. Please refer to earlier comment regarding the consent form and amend as 







Linda Harvey PhD, cert CRGCP 
Vice chair, IFR Human Research Governance Committee cc. HRGC members 
 
cc. HRGC members 
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HRGC ref: IFR06/2014  
Short title: Bioavailability of sulforaphane from broccoli soups (BOBS Study) 
 
Please find responses to all points discussed at the meeting of IFR Human Research 
Governance Committee (HRGC) held on Friday 4th of July 2014. 
 




1. The committee felt that further justification for undertaking the cannulation 
aspect of the study is required. The study has been powered on urinary sulforaphane 
excretion, so further justification is needed to confirm that the glucoraphanin doses 
you plan to use will elicit a statistically significant plasma response. Please confirm 
the glucoraphanin doses that you will be using for the study. Please discuss with Jack 
Dainty (institute statistician 
 
The documentation has been amended taking into account this comment. 
 
2. Please justify the time points that you have chosen for blood sampling, there 
should be a scientific justification. 
 
The documentation has been amended taking into account this comment. The 
time points selected for this study have been based on the same time points used in 
the study by Shikha et al 2012. Eventhough in the study by Shikha et al 2012 the SF 
peaks were seen after 1 hour post soup consumption and peaked at 6 hours, the 
earlier timepoints will be necessary for the additional sulphur analyses and for the 
other two soups that will deliver a higher concentration of glucoraphanin. 
 
3. It appears that the study has been powered on a comparison of the low and 
high glucoraphanin broccoli rather than the low versus medium content. In order to 
obtain useful data from the latter group the committee felt that the study should be 
powered on this comparison. Please discuss with Jack Dainty (institute statistician). 
 
The documentation has been amended taking into account this comment. 
 
4. The stated glucoraphanin content of the three types of broccoli used in this study 
is different from that stated in other submissions previously reviewed by the 
committee. Please clarify and amend. 
 
The stated glucoraphanin content of the three types of broccoli + stilton soups 
that will be used in this study are from a recent analysis on the broccoli and 
stilton soups carried out in February 2014. The stated Glucoraphanin content 
 Institute of Food Research 
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in previous submissions are from broccoli florets instead of broccoli + stilton 
soups which has resulted in the difference.  
 
5. Throughout the documentation you use the terms ‘bioavailability’ and ‘plasma 
and urinary sulforaphane’ interchangeably. The latter are surrogate markers of 
bioavailability and it is important to make the relevant distinction and use the 
appropriate terms when describing the study.  
 
The documents were checked to ensure that the relevant disctinction has been 
made. In addition, on p11 of the protocol the following phrase has been added 
‘Blood and urinary samples will be collected from participants following 
consumption of the broccoli + stilton soups with the hope of detecting plasma 
and urinary metabolites of SF which will be surrogate markers of 
bioavailability’.   
 
6. The committee felt that genotyping such a small number of participants would 
not provide any statistically significant data and this aspect should be removed from 
the study design. Please discuss with Jack Dainty (institute statistician). 
 
This aspect was discussed with Jack Dainty and was agreed that even though 
genotyping the small number of participants will not provide statistically 
significant data, it can be used to justify any outliers that could be seen from 
the results. Therefore, the study team have decided to genotype the participants 
in this study. 
 
 
7. In the eventuality that the majority of participants do not take up the opportunity 
to provide an optional faecal sample, the likelihood is that collection of such a small 
number of samples (maximum 8) will not provide any useful data. The collection of 
the samples also does not appear to be relevant to the aims of the study and it is 
unclear how they would be used. Please discuss with Jack Dainty (institute 
statistician). 
 
The collection of the faecal samples will no longer be part of this study. This 
aspect has been removed from the study. 
 
8. Dr Charlotte Armah (HRGC committee member) has offered to provide further 
guidance and advice on the preparation of the general aspects of your submission. 
Please discuss with Charlotte. 
 
The general aspects of the submission were discussed with Dr Charlotte Armah 
and feedback provided by Dr Charlotte Armah was taken into account in 
amending the documents. 
 
9. Mrs Aliceon Blair (HNU senior research nurse) has offered to provide advice on 
the clinical and HNU related aspects of your study. She has prepared appropriate 
wording that will be helpful. Please discuss with Aliceon. 
 
The clinical and HNU aspects of the study were discussed with Mrs Aliceon 
Blair and feedback provided by Mrs Aliceon Blair was taken into account in 
amending the documents. 
 Institute of Food Research 
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10. As this is the first study that you will be undertaking at IFR, the committee 
presumes that you will be fully supported by the study research team during the initial 
study talks and screening and study days? 
 
The study research team which includes Dr Antonietta Melchini and Dr 
Charlotte Armah (in the absence of Dr Antonietta Melchini) will provide 
assistance in the initial study talk, screening and study days. A paragraph on 
the roles of the members of research team has been added to the protocol on 
p 11/12. 
11. The soups you plan to use in the study are variously referred to throughout the 
documentation as broccoli soup, broccoli and stilton soup, and broccoli and stilton 
flavoured soup.  Please confirm which type of soup you plan to use and amend the 
documentation accordingly. 
 
The documentation has been amended taking into account this comment. 
 
12. The title of the study is inconsistent in the submitted documentation. Please 




13. Please note: the protocol is a standalone document and all the annexes are an 




14. Please provide a copy of the letter confirming insurance details for the study 
from Ian Bartlett. 
 
A copy of the letter confirming insurance details for the study from Ian Bartlett 
has been enclosed with the documents. 
 
15. Please resubmit an HRGC registration form including the signature of the senior 
research nurse. 
 
The HRGC registration form including the signature of the senior research 
nurse has been enclosed with the documents. 
 
16. There are several typos and grammatical errors throughout the documentation. 
Please amend. 
 
All documents were checked and have been amended taking into account this 
comment. 
 
17. Please ensure that the information in the submission is consistent between 
documents. 
 
All documents were checked and have been amended taking into account this 
comment. 
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Specific comments: 
 
  Protocol (version 1, dated 26 June 2014) 
   
18. Why is the study single-blinded? Could it be a double-blinded? Please clarify. 
 
Members of the study have decided that the study will be a double-blinded 
study. 
 
19. As your eligibility screening does not include glucose measurements there is no 
need for the participants to be fasted as HBA1c analysis does not have this as a 
requirement. Therefore, this will allow slightly more flexibility in the timing of screening 
appointments (please note: all blood samples need to be at SPIRE Hospital by 3pm). 
Please speak to Aliceon for further clarification and amend documentation as 
appropriate. 
 
This clinical aspect was discussed with Mrs Aliceon Blair. Participants will not 
need to fast for the HbA1c analysis and all documents have been amended 
appropriately. 
20. The washout period between study days should be stated as a minimum of 2 




21. Pg 4, scientific background, 3rd line: Gasper et al (2005) is not an 









23. Pg 17, eligibility screening: Who is taking written informed consent form the 
study participants? Please clarify and include details. 
 
The written consent form will be taken by the HNU senior research nurse or by 
members of the study team. 
 
24. Pg 27/28: Do participants really need a breakfast of two slices of toast two hours 
after they have had soup with two slices of toast? They may be quite full, especially 
as they are also having sandwiches etc. at the five hour time point. However, on page 
32 it states that the participants will be having bread rather than toast. Please clarify 
and amend. 
 
Participants will no longer have breakfast. They will have the study soup with 2 
slices of bread then lunch. All documents have been appropriately amended. 
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25. Pg 28, 31 and 32: The information relating the HNU kitchen etc. is repeated on 




26. Pg 29, last para: What do you mean by ‘linked studies’? It is better to ask 
participants if they would consent to be ‘contacted’ (rather than recalled) about future 
studies on broccoli (or similar) that may be undertaken at IFR. You will also need to 
amend the wording on the consent from to reflect this, or you could consider a 
separate consent form for this aspect of the study. Please discuss with Aliceon the 
process for keeping a list of participants for future studies to make sure that they are 




There are now two consent forms (Annex 6 and Annex 20) produced having 
taking this comment into account. The wording has been amended and a 
separate consent form  (Annex 20) consent form will be given to participants 
who were recruited through adverts upon completion of the study to ask 
whether they would be happy to consent to be contacted for future studies by 




27. Clinical aspects of study details on this form need amending. Please discuss 
with Aliceon. 
 
  The clinical aspects of the submission were discussed with Mrs Aliceon 
Blair and feedback provided by Mrs Aliceon Blair was taken into account in 
amending the IRAS. 
 
28. A6-2 suggests that you are going to pay participants for loss of wages if they 
take the day off work to participate in study days. The committee presumes that this 
is incorrect. Please clarify and amend.  
 
The IRAS has been amended taking into account this comment. 
 
 
Annex 3: PIS (version 1, dated 26th June 2014) 
29. Whilst the committee was not against the booklet format for the PIS, it felt that 
it needed to be reformatted. Currently the font is quite large and text rather spaced 
out, which means that at almost 40 pages, the booklet is very long. This format would 
also benefit from an index because it is much harder to find your way around the 
information contained within, due to lots of pages of solid text. This booklet format will 
also be more difficult (although not impossible) to upload electronically to NRES for 
review. It is essential that it is submitted in the format that you will be presenting it to 
study participants i.e. two pages of text per A4 sheet. It will also be necessary to have 
a standard A4 version of the PIS for the purposes of e-mailing it to potential 
participants. The booklet edition must also contain a version number and date.  
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The booklet format has been reformatted. The font and text space has been 
reduced. The booklet is now 25 pages. An index has also been included. For 
the online upload, the booklet created on publisher (two pages of text per A4) 
will be converted to a PDF file then uploaded which will be in the same format 
that will be presented to participants. 
 
30. Some of the clinical and HNU aspects of the study need rewording. Please 
discuss with Aliceon who will advise accordingly. 
 
The clinical and HNU aspects of the study were discussed with Mrs Aliceon 
Blair and feedback provided by Mrs Aliceon Blair was taken into account in 
amending the documents. 
 
31. There are several sections of text in the PIS that need re-writing in lay language. 
Please amend as appropriate. 
 
The documentation has been amended taking into account this comment. 
 
32. Pg 2, 2nd para: It is arguable that the health benefits of broccoli are purely due 
to sulforaphane. Please amend. 
 
The documentation has been amended taking into account this comment. 
 
33. Pg 2, 3rd para: There is some text missing. 
 
The documentation has been amended taking into account this comment. 
 
34. Pg 3: The aim of the study is not worded appropriately. Please amend. 
 
The documentation has been amended taking into account this comment. 
 
35. Pg 3: The soup is described variously, see earlier comment. Please clarify and 
amend. 
 
The documentation has been amended taking into account this comment. 
 
36. Pg 8: It would be helpful to state on which page the flow chart is located when 
it is referred to here. 
 
  The page of the flowchart is added on p5 of the PIS in the section ‘What 
next?’ which introduces the HNU visits. 
 
 
37. Pg 16: It reads as though participants will receive £250 for the faecal samples 
alone. Please amend. 
 
This has been amended as faecal sample collection is no longer part of this 
study.   
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38. Pg 18: The flow chart needs simplifying, it is too wordy. Please also remove the 
references to the types of analysis as participants will not know what U’s and E’s are 
etc. Please also remove the reference to a CRF for the same reason. 
 
Flowchart has been amended into a simplified version p12 of the PIS. 
 





40. Pg 28: The soup ingredients sheet should refer to three types of broccoli soup, 
not just two? Please clarify and amend. 
 
The documentation has been amended taking into account this comment. 
 
 
  Annex 4 Poster (version 1, 26 June 2014) 
41. You should give an example and explain the ‘natural compounds’ you refer to 
in the first sentence of the advert. 
 
Examples of the natural compounds have been included. 
 
42. Some of the text needs rewording e.g. potential participants will not necessarily 
understand what is meant by a ‘glucosinolate free diet’, and ‘recompensate’ is used 
incorrectly in this context. It would be better to ask if potential participants like broccoli 
and stilton soup, as they may like cheese and broccoli separately, but maybe not 
together in a soup. Please amend. 
 
The document has been amended taking into account this comment. 
 
  Annex 5, invitation letter (version 1, 26th June 2014) 
43. This letter needs re-wording to reduce the over-use of the word ‘study’. 
 
The document has been amended taking into account this comment. 
 
  Annex 7, consent form (version 1, 26th June 2014) 
44. Please refer to earlier comment regarding the consent form and amend as 
appropriate. 
 
There are now two consent forms (Annex 6 and Annex 20) produced having 
taken the earlier comment regarding the consent form into account. Annex 20 
consent form will be given to participants who were recruited through adverts 
upon completion of the study to ask whether they would be happy to consent 






Miss Tharsini Sivapalan 
 Institute of Food Research 
Norwich Research Park 
Colney 
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Miss Tharsini Sivapalan 
Food and Health Programme  
Institute of Food Research  
Norwich Research Park  
Norwich 
NR4 7UA 
15 August 2014 
Dear Tharsini, 
HRGC ref: IFROG/2014 
Short title: Bioavailability of sulforaphane from broccoli soups (BOBS Study) 
The revised documentation you have provided has been reviewed by Dr Sian Astley, 
Dr Jack Dainty, Mrs Aliceon Blair and myself and we are happy to take Chair's Action 
on behalf of the Human Research Governance Committee (HRGC) to give approval 
for this proposal (Protocol version 2, dated 2910712014) to be submitted  to  an  East  
of  England NHS Research Ethics Committee. This approval means that the HRGC 
is satisfied both with the originality and quality of the science proposed and considers 
that adequate expertise and resources are available to undertake the research. 
Please enclose this letter, along with the previous correspondence from the HRGC 
(dated 0810712014) and your response (dated 2910712014) with your ethics 
submission. 
May I take this opportunity to remind you that (i) all staff involved with the project must 
complete the relevant modules of the HRGC Human Studies training course prior to 
starting work on the study, and (ii) your study should be registered on a publicly- 
accessible database such as www.clinicaltrials.gov. 
The HRGC general conditions of approval are appended.  
Yours sincerely, 
 
Linda Harvey. PhD, certCRGCP 
Chair, IFR Human Research Governance Committee  
cc: HRGC members 
 
 Institute of Food Research 
Norwich Research Park 
Colney 
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29th July 2014 
REC ref 14/EE/1121 
Short title: Bioavailability of sulforaphane from broccoli soups (BOBS Study) 
Dear Tracy, 
I would like to apply for SSA exemption for the above study.  
Please see the exemption request from the sponsor of this study below. 
Kind regards, 
 
Miss Tharsini Sivapalan 
 
SSA exemption request  
 
Dear Tharsini, 
Following our earlier conversation regarding the requirement for SSA for the above 
study, I can confirm that as sponsor’s representative for this study, I consider that 
the Institute of Food Research would be SSA exempt in accordance with sections 
4.4 - 4.6 (Requirement for site specific assessment) of the Standard Operating 
Procedures for Research Ethics Committees (version 5.1, March 2012). The SOPs 
can be found at the following link: www.hra.nhs.uk/documents/2013/08/standard-
operating-procedures-for-research-ethics-committees-sops.pdf 









NRES Committee East of England - Norfolk 
The Old Chapel Royal Standard Place 
Nottingham NG1 6FS 
 
Telephone: 0115 883 9525: 
 
18 September 2014 
 
Prof Richard Mithen 
Associate Director (Nutrition) and Head of Plant Natural Products and Health 
Programme and Chair of the Graduate Studies Committee 







Dear Prof Mithen 
 
Study title: An intervention study to assess the 
bioavailability of sulforaphane delivered 
by glucoraphanin-enriched broccoli soups 
in healthy subjectsREC reference: 14/EE/1121 
Protocol number: N/A 
IRAS project ID: 157660 
 
The Research Ethics Committee reviewed the above application at the meeting 
held on 15 September 2014. Thank you to Miss Tharsini Sivapalan and Dr 
Antoinetta Melchini for attending to discuss the application. 
 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details, unless you expressly withhold 
permission to do so.  Publication will be no earlier than three months from the date 
of this favourable opinion letter.  Should you wish to provide a substitute contact 
point, require further information, or wish to withhold permission to publish, please 





The members of the Committee present gave a favourable ethical opinion of the 
above research on the basis described in the application form, protocol and 
supporting documentation, subject to the conditions specified below. . 
 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start 
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of the study. 
 
1. Please ensure that it is clear on page 11 of the Participant Information 
Sheet that the 24 hour testing may take up to an hour. 
 
 
You should notify the REC in writing once all conditions have been met 
(except for site approvals from host organisations) and provide copies of any 
revised documentation with updated version numbers.  The REC will 
acknowledge receipt and provide a final list of the approved documentation 
for the study, which can be made available to host organisations to facilitate 
their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites (“participant identification centre”), guidance 
should be sought from the R&D office on the information it requires to give 
permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance 
with the procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host 
organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on question 2 of the IRAS filter 
page) must be registered on a publically accessible database within 6 weeks of 
recruitment of the first participant (for medical device studies, within the timeline 
determined by the current registration and publication trees). 
 
There is no requirement to separately notify the REC but you should do so at the 
earliest opportunity e.g. when submitting an amendment. We will audit the registration 
details as part of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact 
Catherine Blewett (catherineblewett@nhs.net), the HRA does not, however, 
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It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site (as 
applicable). 
 
Summary of discussion at the meeting 
 
Ethical issues raised by the Committee in private discussion, together with 
responses given by the applicant when invited into the meeting 
 
Recruitment arrangements and access to health information, and fair 
participant selection 
 
The Committee agreed the randomisation process would need to be clarified and 
asked the applicants to explain how this would be done.  The applicants advised 
randomisation will  take place before the participants enter the study room by 
another member of the team and participants will be randomised into the study by 
the other member of the team to ensure that the applicants are unaware which 
group they are allocated to. 
 
The Committee queried why the applicants had opted to set the upper age limit at 
65.  The applicants advised once a person passes a certain age, their metabolism 
and taste can change which may skew the results of the study. The applicants 
went on to advise that cannulation in older people can also carry a higher risk. 
 
The Committee asked the applicants why they had opted to exclude smokers from 
the study. The applicants advised in smokers, the metabolism can be affected, 
which could skew the results of the study. 
 
Favourable risk benefit ratio; anticipated benefit/risks for research participants 
(present and future) 
 
The Committee considered and discussed the length of time participants would be 
cannulated. The Committee asked the applicants whether this could be reduced 
as other reports have indicated that participants would only need to be cannulated 
2-6 hours after ingesting the broccoli to detect the levels of glucoraphanin and 
sulforaphane.  The applicants advised that other studies had not sought the same 
levels of sulforaphane and glucoraphanin for analysis and by cannulating 
participants earlier in the study a wider reporting range would be achieved. 
 
Informed consent process and the adequacy and completeness of participant 
information 
 
It was noted that on page 11 of the Participant Information Sheet (PIS), it states 
“the 24 hour sample will last up to 1 hour” which the Committee considered 
confusing. The Committee asked the applicants to clarify this sentence.  The 
applicants confirmed the sentence means when participants attend for their 24 hour 
screening, the appointment is expected to take an hour. 
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The Committee asked the applicants what was meant by the “unexpected 
disclosures” detailed in the paperwork.  The applicants advised this means if a 
Research Nurse is made to feel uncomfortable by something the participant says 
during the study, they may ask another member of the team to remain present in 
the room. 
 
The Committee commented on the format of the PIS and noted that the index made 




The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Copies of advertisement materials for research 
participants 
2 29 July 2014 
Evidence of Sponsor insurance or indemnity 
(non NHS Sponsors only) [Insurance letter] 
 24 July 2014 
GP/consultant information sheets or letters 
[Annex 15- Study Description for GP] 
2 29 July 2014 
IRAS Checklist XML [Checklist_18082014]  18 August 2014 
 
IRAS Checklist XML [Checklist_20082014]  20 August 2014 
Letters of invitation to participant [Annex 1- 
Invitation letter from HNU database ] 
2 29 July 2014 
Other [Annex 5-Appointment card] 2 29 July 2014 
Other [Annex 12- List of high glucosinolates] 2 29 July 2014 
Other [Annex 19- GP letter with study day 
exclusion] 
2 29 July 2014 
Other [HRGC response letter]  29 July 2014 
Other [Annex 7- Medical Declaration Form] 2 29 July 2014 
Other [Annex 13- Exclusion Letter] 2 29 July 2014 
Other [Annex 20- Consent form on completion of 
study] 
2 29 July 2014 
Other [HRGC approval letter]  15 August 2014 
Other [Invitation letter from advertisements] 2 29 July 2014 
Other [GP letter with clinical results] 2 29 July 2014 
Other [Annex 18- Food choices for study day] 2 29 July 2014 
Other [HRGC minor changes letter]  08 July 2014 
Other [Annex 9- Case Report Form] 2 29 July 2014 
Other [Annex 16- Apology letter for not 
participating] 
2 29 July 2014 
Other [CV for study scientists]  24 April 2014 
Other [Annex 10-Clinical Results] 2 29 July 2014 
Other [Annex 17- Appointment Letter] 2 29 July 2014 
Other [CV for study scientists]  24 April 2014 
Other [Annex 8- Eligibility Screening 
Questionnaire] 
2 29 July 2014 
Other [Annex 14- Letter to GP involvement of 
study] 
2 29 July 2014 
Other [Annex 21- Soups information sheet] 2 29 July 2014 
Participant consent form [Annex 6-Consent form] 2 29 July 2014 
Participant information sheet (PIS) [Annex 2- 
Participant information sheet] 
 29 July 2014 
REC Application Form [REC_Form_18082014]  18 August 2014 
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REC Application Form [REC_Form_20082014]  20 August 2014 
Research protocol or project proposal [Study 
Protocol] 
2 29 July 2014 
Summary CV for Chief Investigator (CI) [CV for 
CI] 
 24 April 2014 
Summary CV for student [CV for student]  29 July 2014 
Summary CV for supervisor (student research) 
[CV for supervisor] 
 24 April 2014 
 
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed 
on the attached sheet. 
 
Dr Linda Harvey is the Sponsor representative for this study. The Committee 
agreed that this was a conflict of interest and Dr Harvey was not present during 
the discussion and decision for this study. 
 




The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in 




The Health Research Authority is continually striving to provide a high quality 
service to all applicants and sponsors. You are invited to give your view of the 
service you have received and the application procedure. If you wish to make your 





We are pleased to welcome researchers and R&D staff at our training days – see 



















Enclosures: List of names and professions of members who were 
present at the meeting and those who submitted written comments 
 
“After ethical review – guidance for researchers” 
 
Copy to: Linda Harvey, Institute of Food Research 
14/EE/1121 Please quote this number on all correspondence 
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NRES Committee East of England - Norfolk Attendance at Committee meeting 




Name Profession Present Notes 
Mr Ron Driver Retired Lecturer/Statistician Yes  
Miss Sheila Ginty Tissue Viability Specialist Nurse No  




Mrs Janette Guymer NHS Ad inistrator Yes  
Dr Linda Harvey Senior Research Scientist No  
Dr Peter Langdon Senior Lecturer in Clinical 
Psychology and Disability, 
Honorary Consultant Clinical 
and Forensic Psychologist 
Yes  
Dr Elizabeth Lund Independent Consultant, 
Nutrition and Gastrointestinal 
Health 
Yes  
Mr George Mak-Pearce Psychological Therapist Yes  
Dr Michael Sheldon (Chair) Retired Clinical Psychologist Yes  
Dr Robert Stone Retired General Practitioner Yes  
 
Also in attendance: 
 
Name Position (or reason for attending) 
Miss Tracy Leavesley REC Manager 
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Norwich Research Park 
Colney 
Norwich NR4 7UA 
UK 
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10 November 2014 
Miss Tracy Leavesley 
REC Manager NRES Committee East of England-Norfolk 
The Old Chapel 




REC reference: 14/EE/1121 
Short title: Bioavailability of sulforaphane from broccoli soups (BOBS Study) 
 
I would like to submit a substantial amendment to the NRES Committee East of 
England - Norfolk. The amendment covers some changes to the BOBS study  
protocol. 
Please find a revised copy of the following documents enclosed with changes 
highlighted and in bold: 
• The substantial IRAS amendment form 
• Study protocol version 3  
• Annex 2- PIS version 4  
• Annex 9- Case Report Form version 3  
 





Miss Tharsini Sivapalan 
 
 Institute of Food Research 
Norwich Research Park 
Colney 
Norwich NR4 7UA 
UK 
www.ifr.ac.uk 
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10 November 2014 
Dr Linda Harvey, 
Chair, IFR Human Research Governance Committee 
 
REC reference: 14/EE/1121 
Short title: Bioavailability of sulforaphane from broccoli soups (BOBS Study) 
 
I would like to submit a substantial amendment to the NRES Committee East of 




Please find a revised copy of the following documents enclosed with changes 
highlighted and in bold: 
• The substantial IRAS amendment form 
• Study protocol version 3  
• Annex 2- PIS version 4  
• Annex 9- Case Report Form version 3  
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We request an amendment to the BOBS study protocol. The amendment covers three parts 
of the protocol. 
 
Exclusion criteria 
We are requesting an amendment to one of the exclusion criterion (IRAS form: A6-2, A17-2, 
A32; Study protocol version 2: Exclusion criteria- p 21; Annex 2_PIS_version 3: p 3; Annex 9 
case report form_version 3: Screening day-exclusion criteria-p 3).  
 
In the current protocol version 2, the exclusion criteria include:  
Smokers 
The exclusion of smokers was decided because smoking affects metabolism which would 
affect the study data. However, if smokers have stopped smoking for the last 6 months prior 
to the start of the study then it would not affect our study data. Therefore we would like to 
change the previous exclusion criterion to the following exclusion criterion to increase the 
number of potential participants: 
 
Smokers (if smoked within 6 months prior to the study or during the study). 
Study day procedure 
We are requesting an amendment to the study day procedures which applies to females only 
(IRAS form: A6-2, A13,A32; Study protocol version 2: Study day-p 24; Annex 2_PIS_version 
3: p 10; Annex 9 case report form_version 3: Screening day- p 8, Phase 1- p 14, Phase 2- p 
28, Phase 3- p42).  
 
In the current protocol version 2, there is no consideration on the collection of urine from 
females during study days if they are menstruating. Therefore we would like to make an 
amendment to the study day procedures so that if females are menstruating or have just 
finished menstruating then the study day will be rescheduled to after 7 days of having finished 
menstruating. This is because blood in the urine sample will affect the study data as we are 
measuring the ITC metabolites in the urine samples. This will also minimise inconvenience 
caused to female participants to attend a cannulation day where blood samples and urine 
samples will be collected for 24 hours whilst menstruating. 
 
Inconvenience payment (IRAS form: A46; Study protocol version 2: p 37; Annex 
2_PIS_version 3: p 13) 
 
The current financial compensation the volunteers receive for taking part in the study is £220. 
This sum was calculated on the basis of standard compensation paid for cannulation, obtaining 
blood and urine samples and dietary restriction. However, no compensation was included for 
the time requirement to be at the Human Nutrition Unit, equivalent to three whole days. 
Following a review of other studies of a similar nature, we would like to increase the total 
Substantial Amendment-1 
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compensation to £500. This has been discussed with Dr Linda Harvey, Chair of IFR HRGC 
who agrees this revised compensation sum is appropriate. 
 
Note: Annex 9 case report phase 3 was missed out in the original ethics submission. 
The phase 3 case report is exactly the same as phase 1 and phase 2 that were approved. 
The only difference is the mention of phase 3.
Substantial Amendment-1 








26 November 2014 
NRES Committee East of England - Norfolk 
The Old Chapel Royal Standard Place 
Nottingham NG1 6FS 
Tel: 0115883939
 
Prof Richard Mithen 
Associate Director (Nutrition) and Head of Plant Natural Products and Health 
Programme and Chair of the Graduate Studies Committee 
Institute of Food Research Norwich Research Park Colney 
NR4 7UA 
 
Dear Prof Mithen 
 
Study title: An intervention study to assess the bioavailability of 
sulforaphane delivered by glucoraphanin-enriched broccoli soups in healthy 
subjects 
REC reference: 14/EE/1121 
Protocol number: N/A 
Amendment number: Substantial amendment 1 Amendment date: 12 
November 2014 
IRAS project ID: 157660 
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Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form 
and supporting documentation. 
 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document Version Date 
Notice of Substantial Amendment (non-
CTIMP) [Signed by Richard Mithen] 
Substantial 
amendment 1 
12 November 2014 
Other [Case Report Form - Annex 9] 3 10 November 2014 
Participant information sheet (PIS) 4 10 November 2014 
Research protocol or project proposal 3 10 November 2014 
Substantial Amendment-1 
391 | P a g e  
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it 
affects R&D approval of the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
We are pleased to welcome researchers and R & D staff at our NRES committee 






Dr Michael Sheldon Chair 
E-mail: NRESCommittee.EastofEngland-Norfolk@nhs.net 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to:  
Linda Harvey, Institute of Food Research 
14/EE/1121: Please quote this number on all correspondence 
 Institute of Food Research 
Norwich Research Park 
Colney 
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NRES Committee East of England - Norfolk 





Also in attendance: 
Name Position (or reason for attending) 
Mr Tad Jones REC Assistant 
 
Name Profession Present Notes 
Dr Michael Sheldon (Chair) Retired Clinical Psychologist Yes  
Dr Robert Stone Retired General Practitioner Yes  
 Institute of Food Research 
Norwich Research Park 
Colney 
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26th August 2016  
Georgia Copeland 
REC Manager NRES Committee East of England-Cambridgeshire and Hertfordshire 
The Old Chapel 




REC reference: 14/EE/1121 
Short title: Bioavailability of sulforaphane from broccoli soups (BOBS Study) 
 
I would like to submit a substantial amendment to the NRES Committee East of 
England - Cambridgeshire and Hertfordshire. The amendment covers changes in 
the sample storage after notification of the end of the study. We will notify the end of 
the study when the last participant has signed the consent form agreeing for 
samples to be stored at the Norwich biorepository or declined sample storage or we 
have been unable to contact the last participant 6 months after sending out the letter 
(Annex 22). 
 
Please find the following documents enclosed: 
Letter to participants- Annex 22 version number 2 (01/06/16) 
Biorepository REC approval letter 
Tissue  bank participant information sheet and consent form- Annex 24 version 
number 15 (21/02/14) 
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We request an amendment to the BOBS study in regards to the storage of samples 
after notification of the end of the study. We would like to notify the end of the study 
after we have attempted to contact each of the study participants to ask for consent 
to store their remaining blood and urine samples in the Norwich Biorepository. We will 
declare the end of study when either the last participant has signed the consent form 
agreeing for samples to be stored in the Norwich Biorepository, or has declined 
sample storage in the Biorepository, or alternatively we have been unable to contact 
them within 6 months of sending the letter.  
 
Use of biological samples after research 
We would like to request an amendment to transfer the remaining of blood and urine 
samples to the local Human tissue bank (The Norwich Biorepository) of the Norfolk 
and Norwich University Hospital (Annex 23 Biorepository REC approval letter) at the 
end of the study to help future research studies. The proposed banking will be done 
exclusively after obtaining appropriate consent from study participants (Annex 24 
Version 15, 21 February 2014, Biorepository information sheet/consent form). 
In the current IRAS form it is stated that the urine and blood samples will be discarded 
according to the Human Tissue Authority’s Code of Practise at the end of the study. 
However, the analysis of these samples has provided novel information about the 
absorption of bioactive compounds from broccoli. This was the first study that has fed 
volunteers with a special variety of broccoli (Beneforte extra) for measuring the 
bioavailability of sulphur-containing compounds. The use of these samples for the 
research purposes approved by the current ethics approval has provided valuable 
data about sulphur compounds that can now be further investigated using in vitro 
models. These findings have not been previously reported in literature and are 
extremely valuable to inform our research group, which is currently undertaking 
parallel human intervention studies at the Norfolk and Norwich University Hospital 
using the same broccoli-rich diet (ESCAPE, REC NRES Committee East of England-
Cambridge South 13/EE/0110; ESCAPE-ing, REC NRES Committee East of 
England-Cambridge South 14/EE/1149; SAP, REC NRES Committee East of 
England-Cambridge East: 16-EE-0054). Furthermore, results obtained by analysing 
these samples were valuable for the recent submission of a grant proposal to the 
Prostate Cancer Foundation (PCF, USA) to seek additional financial support for future 
research at the Institute of Food Research. 
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We would like contact study participants and ask their written informed consent to 
bank their biological samples already collected as part of the study at the Norwich 
Biorepository according to the Norwich Biorepository procedures. Once the last 
participant has consented or declined sample storage at the Norwich Biorepository or 
we have been unable to contact the last participant 6 months after sending the letter 
we will notify the REC the end of the study. It is important to stress that we are not 
asking study participants to donate any additional samples but only to give permission 
for the storage and use of existing samples in the future in accordance with local 
policies of the Norwich Biorepository. In order to do this, we would like to contact the 
participants that took part in the study via a letter sent to their address and email 
address (in case either their postal or email has changed) (Annex 22  Version 2  1st 
June 2016, letter template) and follow this up with a telephone call if we don’t receive 
a reply from them one month after sending out the letter. We will attempt to call no 
more than 3 times for a period of 6 months. Their contact details are up to date 
because we recruited subjects registered on the Human Nutrition Unit Volunteer 
Database at the Institute of Food Research. Participants will be provided with a copy 
the Biorepository information sheet for ‘The donation, collection, storage and use of 
samples of tissue and/or fluids and/or other material from a healthy adult donor for 
research’ (Annex 24 Version 15, 21 February 2014).  If participants do not wish to 
give consent for the proposed banking or the study team is not able to contact them 
after 6 months of sending out the letter, their biological samples will be disposed of in 
accordance with the Human Tissue Authority guidance after notifying the end of the 
study. If participants do not want their samples stored at the Norwich Biorepository 
then we will discard them in accordance to the Human Tissue Authority guidance and 
this will not accept their participation in future studies.  However, if they wish to give 
consent for their samples to be stored at the Norwich Biorepository we would request 
them to come to the Human Nutrition Unit for them to sign the appropriate consent 
form (Annex 24, The Norwich Biorepository consent form, Version 15, 21 February 
2014) to enable us to bank their samples in accordance with the local policy for tissue 
banking. Consent will be obtained by appropriately members of the study team or by 
a senior research nurse at the Human Nutrition Unit. Participants will be reimbursed 
travel expenses to and from the Human Nutrition Unit. This will be reimbursed at the 
IFR's current mileage rate or by reimbursing public transport costs on production of a 
ticket or receipt. If volunteers require transport by taxi, this will be arranged and pre-
paid by us. It is envisaged that the banking of the remaining of blood and urine 
samples at the end of the study at The Norwich Biorepository will be valuable for 
obtaining additional information for this study and for designing further studies. 
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However it is important to stress that any further analysis will be carried out in full 
compliance with ethical requirements. 
IRAS form Part B: Section 5 (14) 
In the IRAS form Part B: Section 5 (14), it is stated that the samples will be discarded 
according to the Human Tissue Authority’s Code of Practise at the end of the study. 
We would like to request an amendment to store at the tissue bank. 
To attach as supporting documents: 
Annex 22-Letter to participants to explain the reason of being contacted 
Annex 23- Biorepository REC approval letter 
Annex 24- Biorepository information sheet and consent for ‘The donation, collection, 
storage and use of samples of tissue and/or fluids and/or other material from a healthy 
adult donor for research’  
 
Annex 22 –Letter to participants                 Version 2-BOBS               1st June 2016 
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The Bioavailability Of sulforaphane from Broccoli 
Soups study (BOBS) 
1st June 2016  
Dear _________________, 
 
I would like to thank you again for taking part in this study. The study analysis has 
now come to an end and the data from the study has provided new information 
about the absorption of sulforaphane from the broccoli soups. This has provided 
new results that have not been previously reported in literature.  We will be sending 
out a summary of the study results shortly. 
 
We are contacting you by both letter and email (in case either your postal or email 
address has changed) to request your consent to store your urine and plasma 
samples at the Norwich Biorepository, which is based at the Norfolk and Norwich 
University Hospital. These samples may be used for any future analysis of 
compounds that we, or other researchers may do. We only want to store the 
samples that have already been collected from the study and you do not need to 
provide any more samples. Please see enclosed the information sheet/consent form 
about storage of samples at the Norwich Biorepository.  
 
If after reading the enclosed information sheet you might be willing for us to store 
your samples then please send the reply below in the provided pre-paid envelope or 
contact me on tharsini.sivapalan@ifr.ac.uk. I will then contact you to organise a visit 
it to the Human Nutrition Unit to go through the participant information sheet and 
consent form and answer any of your questions. You will be reimbursed for your 
travel expenses to and from the Human Nutrition Unit. This will be reimbursed at the 
IFR's current mileage rate or by reimbursing public transport costs on production of 
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a ticket or receipt. If you require transport by taxi, this will be arranged and pre-paid 
by us. This will be at a convenient time for you, within normal working hours. 
 
If you do not wish for your samples to be stored then please send the reply below 
and we will discard them according to the Human Tissue Act, 2004 as initially 
discussed when the study started. This will not affect your participation in any future 
studies at the Institute. 
 
If we haven’t heard back from you one month after sending out this letter then we 
will follow up with no more than 3 telephone call attempts for a period of 6 months. If 
after this we can’t get in contact with you then we will discard them according to the 
Human Tissue Act, 2004 as initially discussed when the study started. This will not 
affect your participation in any future studies at the Institute. 




Miss Tharsini Sivapalan 




 I will be willing to store my samples at the Norwich Biorepository for future research. I’m 
happy to be contacted to organise a visit to the Human Nutrition Unit. 
 I don’t want my samples to be stored at the Norwich Biorepository for future research. 
Please don’t contact me regarding this.
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East of England - Cambridgeshire and Hertfordshire Research Ethics 
Committee 
The Old Chapel Royal Standard Place 
Nottingham NG1 6FS 
 
 
16 September 2016 
Miss Tharsini Sivapalan  
Institute of Food Research  




Dear Miss Tharsini Sivapalan 
Study title: An intervention study to assess 
the bioavailability of 
REC reference: 14/EE/1121 
Protocol number: N/A 
Amendment number: 2 
Amendment date: 01 June 2016 
IRAS project ID: 157660 
The above amendment was reviewed by the Sub-Committee in correspondence. 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form 
and supporting documentation. 
Discussion 
There were no ethical issues raised. 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document Version Date 
Covering letter on headed paper  26 August 2016 
Letters of invitation to participant 2 01 June 2016 
Notice of Substantial Amendment (non-CTIMP) 2 01 June 2016 
Other [Biorepository REC approval letter ]  05 March 2014 
Other [Biorepository Information Sheet and Consent Form ] 15 21 February 2014 
Other [e-mail ]  31 August 2016 
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Membership of the Committee 
The members of the Committee who took part in the review are listed on the 
attached sheet. 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it 
affects R&D approval of the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
We are pleased to welcome researchers and R & D staff at our NRES committee 




Mr David Grayson Chair 
E-mail: nrescommittee.eastofengland-cambsandherts@nhs.net 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to:  
Professor Richard Mithen, Institute of Food Research Linda Harvey, Institute 
of Food Research 
14/EE/1121: Please quote this number on all correspondence 
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East of England - Cambridgeshire and Hertfordshire Research Ethics 
Committee Attendance at Sub-Committee of the REC meeting on 13 
September 2016 
Committee Members: 
Name Profession Present Notes 
Mr David Grayson (Chair) Retired Local Government 
Administrator 
Yes  
Dr Wassim Matta General Practitioner Yes  
 
Also in attendance: 
Name Position (or reason for attending) 
Miss Lindsey Wallace REC Assistant 
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Appendix II-Mineral elements graphs 
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Figure: Concentration of mineral elements in plasma measured by ICP-OES. 
